Mainstreamed genetic testing in ovarian cancer: A case study of BRCA1/2 tumour testing by Rahman, Belinda
1 
 
 
 
Mainstreamed genetic testing in ovarian cancer:    
A case study of BRCA1/2 tumour testing 
 
A thesis submitted for the degree of Doctor of Philosophy 
 
 
 
 
 
 
 
 
 
 
Belinda Rahman 
University College London 
2019 
  
2 
 
Declaration 
 
I, Belinda Rahman confirm that the work presented in this thesis is my own. Where 
information has been derived from other sources, I confirm that this has been 
indicated in the thesis.  
  
3 
 
Abstract 
 
Background 
With the advent of targeted therapies in ovarian cancer (OC), there is an impetus to 
identify patients with a BRCA1/2 mutation. Germline testing has already been 
integrated into the oncology setting using a mainstreamed model (MGT). Tumour 
testing is now available to detect the presence of somatic BRCA1/2 mutations.  
Aim 
To explore the introduction of mainstreamed BRCA1/2 tumour testing (MTT) in OC, 
focusing on clinical outcomes and patient experience.  
Methods 
A case study approach, using different research methods, was taken to gain an in 
depth understanding of the case (MTT) within its context. 
Results 
A service evaluation of the current state of MGT at UCLH found that in the 122 patients 
who were tested over 12 months, germline BRCA1/2 mutation prevalence was 14.8%. 
Developing the MTT pathway was feasible but challenging; delays were related to 
retrieval and review of archived tumour tissue. First-line MTT was provided for fifty 
patients; one somatic and eight germline mutations were identified. More than half 
this sample (52.6%) required follow-up germline testing. A prospective study using 
validated measures found no change in distress or quality of life scores before, during 
and after MTT. Patients reported low decisional conflict scores and no decision regret 
over MTT. After results disclosure patients with a genetic alteration had significantly 
more testing-related distress. Qualitative interviews revealed MTT was a brief, 
transient experience in the context of facing OC. Genetic misconception was 
common, with patients incorrectly attributing a hereditary component to tumour 
testing. Primary motivations for testing were related to clarifying genetic risk 
information for family, rather than personal benefit for treatment options.  
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Conclusion  
A more streamlined process of providing MTT is needed. While MTT appears to have 
little psychosocial impact, poor understanding of the distinction between germline and 
somatic mutations indicates the need for improved communication and information 
provision in OC.    
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Impact statement 
 
Up to 15% of ovarian cancer cases will be caused by inherited germline BRCA1/2 
mutations. An additional 5% of cases will have an acquired somatic BRCA1/2 
mutation. With the development of novel treatments that specifically target BRCA-
mutated ovarian cancer, it is becoming increasingly important to identify mutation 
status in patients with high grade serous disease. 
This research has demonstrated both the feasibility and challenges of developing a 
mainstreamed pathway of delivering BRCA1/2 tumour and germline testing (MTGT) 
in the oncology setting. With the NHS preparing to deliver this model of testing in 
ovarian cancer across the UK, these findings are particularly timely and have the 
potential to inform the development of this service. Suggestions for implementation of 
an efficient MTGT pathway, including potential pitfalls to avoid, could be invaluable. 
MTGT was also shown to have a small but significant impact on patient management. 
Eleven patients were found to carry a germline or somatic BRCA1/2 mutation from 
MTGT, six (54.5%) had subsequently been able to access targeted therapies. MGTG 
not only had a direct impact on treatment decisions, it also provides further evidence 
of the clinical utility of MTGT. In a disease which has historically shown poor survival, 
the hope of more treatment opportunities cannot be underestimated.  
MTGT also has wider implications for prevention of ovarian cancer; once germline 
mutation carriers are identified from MTGT predictive testing can be offered to 
unaffected at-risk relatives where effective risk-reducing interventions exist if mutation 
status is confirmed. In the case of somatic BRCA1/2 mutations, relatives can be 
reassured there is no inherited component.  
Studying the patient experience of MTGT has provided evidence that overall this 
approach is well tolerated and does not lead to poor psychosocial outcomes. Other 
ovarian cancer patients and their oncologists can proceed with testing in the 
knowledge that MTGT is manageable and does not lead to further burden in addition 
to cancer diagnosis and treatment.   
The finding of genetic misconceptions in relation to germline and somatic mutations 
has important implications outside the context of MTGT and ovarian cancer. Tumour 
testing in other cancers is becoming more common. Being aware of areas in the 
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testing process which need better communication and further information provision 
has the potential to significantly improve patient understanding.  
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Chapter 1 Introduction and background 
 
1.1 Ovarian cancer 
Ovarian cancer is the fifth most common cancer affecting women in the UK, but, 
despite a relatively rare age-standardised incidence of 17 cases per 100,000 females, 
it accounts for more deaths than all other gynaecological cancers combined [1]. As 
early stage symptoms are few and non-specific, such as bloating and/or abdominal 
pain, ovarian cancer is often only diagnosed at an advanced stage. Despite progress 
in surgical techniques and chemotherapeutic agents, five-year survival rates remain 
low at around 40% [2]. There is a recognised genetic component to ovarian cancer; 
germline mutations in the cancer susceptibility genes BRCA1 and BRCA2 confer risks 
of ovarian cancer up to 40% and 10% respectively [3]. 
Approximately 90% of ovarian tumours arise from the surface epithelium, and are 
known as epithelial ovarian cancer (EOC).  These tumours can be distinguished by 
histology type; for example, between mucinous or non-mucinous (serous, 
endometrioid, clear cell and transitional cell) tumours which are believed to have 
distinct aetiologies [4]. As tumours with mucinous histologies are rarely observed in 
BRCA1/2 mutation carriers, genetic testing is targeted to women with high grade non-
mucinous EOC, which accounts for up to 70% of all ovarian cancer cases. 
1.2 Genetic testing and ovarian cancer 
Currently the most effective measure for preventing ovarian cancer is to identify 
women at increased genetic risk for the disease. Once women with BRCA1/2 
mutations are identified, they can be offered prophylactic surgery to remove the 
ovaries and fallopian tubes, which has been shown to reduce the risk of cancer by up 
to 85% [5].  
Not only is knowledge of genetic status of benefit for preventing ovarian cancer, 
BRCA1/2 mutation status is already being used to make specific treatment 
recommendations for women diagnosed with cancer. In particular, there is evidence 
that BRCA-associated ovarian cancers have a more favourable prognosis than 
sporadic ovarian cancers [6], that they respond differently to chemotherapeutic 
regimens and that they are responsive to novel agents that specifically target BRCA-
associated tumours [7-10].  
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It is clear that there may be significant benefit to both the patient and her family for 
genetic testing to be made available. Historically women diagnosed with ovarian 
cancer were referred to a familial cancer clinic (FCC) for genetic counselling and 
consideration of BRCA1/2 genetic testing if they had a strong family history of breast 
and/or ovarian cancer or other high risk features such as Ashkenazi Jewish ancestry 
or early age of disease onset. Given these guidelines, BRCA1/2 genetic testing was 
only available to a minority of women with ovarian cancer.  
The traditional approach of using family history as the major selection criterion for 
genetic testing has been challenged, as many as 44% of BRCA1/2 mutation carriers 
do not have a potentially significant family history [11]. Reasons for this include: small 
family size, few female relatives (or few living to an age to have developed cancer), 
patrilineal inheritance, lack of knowledge of family history, lower than predicted cancer 
penetrance and/or non-disclosure of relevant family cancer diagnoses. A large study 
on BRCA1/2 mutation frequency in women with ovarian cancer concluded that 
germline BRCA1/2 testing should be offered to all women diagnosed with non-
mucinous EOC, irrespective of family history [12]. Therefore triaging for genetic 
testing using family history and/or age alone can no longer be recommended. 
Furthermore it may be beneficial if women are referred for genetic testing shortly after 
their diagnosis with primary or recurrent ovarian cancer to help guide their treatment 
options. 
1.2.1 BRCA1/2 germline vs tumour testing  
The vast majority of genetic testing in ovarian cancer has involved germline testing 
for inherited mutations in BRCA1 or BRCA2 genes. This type of germline mutation is 
commonly detected through testing of blood or saliva samples.  
In contrast, testing of tumour tissue can identify somatic mutations, mutations that are 
acquired and are non-heritable. Independent of any germline mutation, a tumour may 
have a somatic mutation not identifiable through germline testing. Studies have shown 
that testing ovarian tumour tissue enables identification of tumours with germline or 
somatic mutations and could identify up to 50% more patients with BRCA-mutated 
ovarian cancer compared to germline testing alone [13]. Thus tumour testing has the 
potential to expand the number of patients that may benefit from BRCA-targeted 
therapies.   
Tumour testing is now available as a genomic test designed to detect the presence of 
a BRCA1/2 gene mutation in ovarian tumour tissue. Patients with an identified somatic 
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mutation can then be offered germline testing to confirm whether it is an inherited 
mutation (which provides important information to blood relatives) or an acquired 
mutation present only in the tumour.  
1.3 Targeted treatments  
A new group of treatments targeting BRCA related cancers have been developed. 
Poly ADP-ribose polymerase (PARP) inhibitors are promising anti-cancer agents in 
ovarian cancer which act by blocking the DNA repair activity of PARP enzymes. In 
the absence of PARP activity cancer cells are sensitive to DNA-binding 
chemotherapeutic drugs and give in to cell death. 
In December 2014 the first PARP-inhibitor, olaparib, was licensed for use in Europe 
specifically for women with platinum-sensitive relapsed ovarian cancer who carry 
BRCA1/2 germline or somatic mutations. Olaparib is associated with a statistically 
significant improvement in progression-free survival for BRCA-related ovarian cancer 
[14]. This approval represents the first targeted treatment for ovarian cancer. Other 
PARP-inhibitors are undergoing evaluation in early phase clinical trials, exploring 
different treatment schedules and platinum-sensitive vs platinum-refractory ovarian 
cancer.  
As targeted treatments become increasingly available for BRCA-related ovarian 
cancer, providing genetic testing in the oncology setting offers the opportunity to 
determine BRCA1/2 mutation status for more patients . It also allows for testing to be 
offered along the cancer pathway; for example at ovarian cancer diagnosis, during 
treatment or after recurrence. Treatment decisions can then be made based on the 
results of testing. Women with recurrent ovarian cancer who are identified as 
BRCA1/2 mutation positive may be eligible to receive olaparib. 2 Mutation status can 
also indicate eligibility for participation in PARP-inhibitor clinical trials. 
1.4 Mainstreamed genetic testing 
In 2013 changes to the UK National Institute for Health and Care Excellence (NICE) 
clinical guidance, specifically guideline CG164, recommended lowering the pre-test 
BRCA1 and BRCA2 carrier probability risk from 20% to 10% or more [15]. A diagnosis 
of high grade non-mucinous ovarian cancer would reach the 10% threshold, 
regardless of family history or age at diagnosis, making significantly more patients 
eligible for BRCA1/2 testing.  
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With advances in genetic testing technology it is becoming increasingly faster and 
more cost-effective to conduct large scale mutation testing, thereby making it 
available to more women. Coupled with the advent of targeted treatment, integrating 
genetics in mainstream medicine is a key strategy in response to the increasing 
demand for genetics services in conditions such as ovarian cancer where there is a 
substantial element of inherited disease. 
As a result, systematic genetic testing for all women with high grade non-mucinous 
ovarian cancer is rapidly increasing. To adapt to the increasing number of patients 
who require BRCA1/2 genetic testing, streamlined approaches to providing testing 
and counselling have been developed. Mainstreamed genetic testing (MGT) is one 
such model, where BRCA1/2 testing is embedded within the oncology service; 
oncology health professionals directly provide genetic testing to their patients, with 
referral to clinical genetics service only as and when required.  
MGT after ovarian cancer diagnosis thus has a number of purposes: BRCA1/2 
mutation status can provide clinical information about risk of recurrence, response to 
treatment, prognosis and future cancer risks, it can guide treatment decisions 
including targeted therapy options and eligibility for clinical trials, and it can also inform 
family members of their own cancer risks. 
1.4.1 Mainstreamed BRCA1/2 tumour testing  
Genetic testing of tumour tissue is already an important part of clinical care in 
diseases such as non-small cell lung cancer, where testing can help inform prognosis 
and is important for treatment decisions. Tumour testing of the EGFR gene and ALK 
gene has no hereditary implications and as a result rarely involves clinical genetics 
services. In contrast, BRCA1/2 tumour testing is just emerging as a part of ovarian 
cancer clinical care, and although its aim is to identify somatic mutations, it may still 
have implications for family members. If a mutation is identified on tumour testing, 
without follow-up germline testing it is unclear if the mutation is somatic or germline 
in nature.  
With olaparib already licensed for use for patients with somatic BRCA1/2 mutations 
in the UK and increasing numbers of PARP-inhibitor trials available for eligible 
patients, there is added incentive to identify those with a somatic mutation. Like MGT, 
BRCA1/2 tumour testing can follow a mainstreamed model; both tumour and germline 
testing can largely be provided within the oncology setting with limited or no clinical 
genetics input unless requested.  
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If both germline and tumour BRCA1/2 testing will be available for ovarian cancer 
patients, there are some advantages to offering tumour testing as a first-line test 
compared to germline testing. It is likely to increase the number of patients eligible for 
new treatments and/or clinical trials targeting BRCA-mutated ovarian cancer by 
approximately 50%. It may reduce the number of patients facing the decision whether 
or not to undergo germline genetic testing to only those in which a somatic mutation 
is identified. This allows for the ‘staggering’ of genetic testing and testing results. In 
this way patients can consider somatic testing to guide their treatment decisions 
without learning of the inherited nature of their disease, thus removing the potential 
added distress of learning of cancer risk implications for family members.   
1.5 MGT at UCLH 
Previously at UCLH, women diagnosed with ovarian cancer were referred to the North 
East (NE) Thames Regional Genetics Service, Great Ormond Street Hospital (GOSH) 
if they had features which suggested an inherited basis to their disease; for example, 
young age at diagnosis, Ashkenazi Jewish ancestry or strong family history of breast 
and/or ovarian cancer (HBOC). Given these criteria, only a small number of women 
were referred annually for genetic testing and counselling. There are reported barriers 
to referral and uptake of genetic counselling for both clinicians and patients [24-27], 
which could have further impacted the number of ovarian cancer patients who actually 
proceeded to testing.  
MGT was implemented at UCLH in April 2015; BRCA1 and BRCA2 germline testing 
was offered to all high grade non-mucinous ovarian cancer patients who had not 
previously had BRCA1/2 germline or tumour testing. Genetic testing and testing 
results were provided by oncologists in the gynaecology oncology outpatient clinics. 
Patients who received BRCA1/2 mutation positive results or variant of unknown 
significance (VUS) were then referred to their local clinical genetics service for genetic 
counselling. Unaffected members of the wider family could be offered predictive 
genetic testing through the clinic as per standard procedure. 
In July 2016 the NE Thames Regional Genetics Laboratories at GOSH introduced 
germline testing for three additional ovarian cancer susceptibility genes: BRIP1, 
RAD51C and RAD51D. 
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1.6 Psychosocial impact of MGT 
There is a wealth of data available on the psychosocial implications of BCRA genetic 
testing in unaffected individuals. It is encouraging that overall there are rarely adverse 
long-term impacts as a result of genetic testing [16]. However, there may be significant 
differences between genetic testing in an unaffected high risk cohort compared to a 
cancer patient sample. Ovarian cancer is already a disease associated with significant 
emotional burden. It is often diagnosed at an advanced stage and the risk of recurrent 
disease is relatively high, both of which can exacerbate patient distress. As a result, 
psychological distress is not uncommon. Studies have shown that between 20-33% 
of ovarian cancer patients have depression scores and 29%-38% have anxiety scores 
that warrant further clinical evaluation [17-19].   
MGT is available for patients at any point along the cancer pathway from diagnosis, 
treatment, relapse, remission and recovery. Thus patients may already be managing 
complex information relating to their surgical and treatment decisions, coping with 
side effects from chemotherapy, facing a recurrence or be in remission. If MGT leads 
to an added or unmanageable psychological burden for ovarian cancer patients, 
offering BRCA1/2 testing in the oncology setting may not be in patients’ best interests. 
With improvements in long-term survival rates and treatment options, the importance 
of identifying and addressing psychosocial functioning during and after cancer 
treatment is increasingly recognised. Screening for distress is becoming a standard 
of care in the UK and worldwide. The NICE guidelines for supportive and palliative 
care require the assessment of patients’ emotional as well as physical needs [20]. 
There is a need to evaluate the psychological outcomes of MGT to help inform the 
development of this clinical service and ensure the wellbeing of women with ovarian 
cancer.   
Much of the psychosocial genetic testing research has been within cohorts of healthy 
women currently unaffected with cancer. It is important to describe the clinical 
experiences of ovarian cancer patients and the context in which MGT will take place 
as these may be factors that influence responses to psychological measures.  
1.7 Genetic counselling and MGT 
Genetic counselling has been an important component of the genetic testing process. 
Working in a multi-disciplinary setting with clinical geneticists, clinical scientists and 
nurses, genetic counsellors are an essential part of the clinical genetics service 
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provision. Genetic counsellors are somewhat unique in their role as health 
professionals responsible for addressing and managing not only the clinical and 
informational needs of patients, but also their emotional and psychosocial needs. One 
definition of genetic counselling is: 
 …the process of helping people understand and adapt to the medical, 
psychological and familial implications of genetic contributions to disease. 
This process integrates the following: 
• Interpretation of family and medical histories to assess the 
chance of disease occurrence or recurrence 
• Education about inheritance, testing, management, prevention, 
resources and research 
• Counselling to promote informed choices and adaptation to the 
risk or condition (p.79) [21]. 
 
Over the last few decades, clinical genetic testing has moved from sequencing of 
single genes to next generation sequencing (NGS) of gene panels and whole genome 
sequencing. These continuing advances in genomic technology and the integration of 
genomics into mainstream medicine are leading to rapid changes in service delivery, 
with the UK Association of Genetic Nurses and Counsellors recently publishing a 
vision statement describing the role genetic counsellors now play. This includes: 
• Applying genomic information to overall future healthcare for an 
individual and family 
• Providing practical and psychosocial support or those with, and 
at risk from, genetic disease 
• Navigating the ethical challenges surrounding the disclosure and 
sharing of genetic information 
• Interpreting and explaining complex, incidental or uncertain 
genomic information. 
• Providing education for the wider healthcare workforce on the 
clinical application of genomics (p661) [22]. 
 
Despite the evolution of genetics in medicine, the core competencies of genetic 
counselling remain largely the same, and can be adapted to different settings [23]. 
Furthermore what remains central to the role of genetic counsellors is the process of 
communication. When considering BRCA1/2 genetic testing this may include but is 
not limited to, implications and outcomes of testing, risks and limitations, risk-reducing 
interventions and other medical management, or facilitating the decision-making 
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process. In the model of MGT described in this thesis, the process of information 
provision and communication now falls to the patient’s treating oncologist.   
One of the key tenets of genetic counselling has been non-directiveness, described 
by Kessler as where the counsellor ‘…tries to persuade the counsellees to think that 
they have the capacity and ability to make and carry out their own decisions’ (p.11) 
[24]. Over the years the criticisms of non-directiveness include how and if it can be 
measured, and whether it can actually be achieved. An early empirical study by Michie 
et al which coded transcripts of genetic counselling consultations as well as rating 
scales completed by counsellors and counsellees reported that all interactions had 
elements of directiveness [25]. In an editorial piece commenting on Michie’s findings, 
Bernhardt foresaw a shift in practice where ‘Genetic counselling and testing will 
increasingly… be provided by non-geneticists’ (p.18), where the ethos of the patient-
doctor relationship is unlikely to have a basis in non-directiveness [26]. Elwyn et al felt 
that an approach of shared decision-making and clinical recommendations better 
reflected both the realities and the nuances of genetic counselling [27]. This approach 
would also be more applicable to genetic testing encounters that take place outside 
of the clinical genetics context, which is becoming increasingly common with MGT.  
Perhaps the most critical difference to a mainstreaming model of delivering genetic 
testing that is oncology-led, is the lack of genetic counselling. Non-genetic medical 
specialties can be provided with training programmes and educational resources in 
order to ‘upskill’ their genetics expertise; however, it may be more challenging to 
replicate the counselling expertise and psychosocial focus that genetic counsellors 
bring.  
1.8 Justification for research  
Ultimately, providing germline testing and identifying a BRCA1/2 mutation in a woman 
with ovarian cancer not only provides important information regarding treatment and 
outcome, but is crucial for cancer prevention in relatives. There is also a potential 
psychological benefit to at-risk relatives; a recent study has shown that women at 
increased risk of ovarian cancer who did not know their genetic status significantly 
overestimated their own risk of cancer [28]. Relatives who are found not to carry the 
same mutation can be reassured that their risk of developing cancer is the same as 
that of the general population. For patients who have tumour testing and are found to 
have a confirmed somatic BRCA1/2 mutation, this alleviates concerns for relatives 
while potentially providing clinical benefits with access to targeted therapies.  
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Despite the benefits and increasing availability of MGT, the impact of moving testing 
from the specialised service of clinical genetics and genetic counselling to the 
oncology setting remains unknown. Although genetics in medicine is rapidly 
progressing towards a mainstreamed approach, it is important to identify if this is both 
feasible and acceptable to patients. In particular, little is known about ovarian cancer 
patients’ interest or attitudes towards mainstreamed BRCA1/2 germline or tumour 
testing, their intentions to accept an offer of testing, the decision making process, or 
outcomes from testing. From a clinical perspective, the outcomes of BRCA1/2 tumour 
testing in this patient group and if or how the results are used for clinical management 
will also be of interest. Lastly it is also important to explore the logistics of introducing 
a new mode of genetic testing into the oncology setting, particularly when it involves 
different clinical departments and testing pathways.   
1.9 Thesis chapter plan  
This thesis begins with a closer look at the clinical aspects of ovarian cancer and 
genetic testing in Chapter Two, before leading into Chapter Three and a review of 
previous research into the psychosocial aspects of ovarian cancer and genetic 
testing. Chapter Four covers the research methodology and outline of the studies 
undertaken. Chapter Five reports findings from a service evaluation of the first year 
of MGT at UCLH. Chapter Six details the implementation and clinical outcomes of 
mainstreamed BRCA1/2 tumour testing in ovarian cancer. In Chapter Seven, 
quantitative findings from the patient experience of mainstreamed BRCA1/2 tumour 
testing is described while Chapter Eight focuses on the qualitative findings. In my final 
chapter, Chapter Nine, I discuss my overall research findings and future directions in 
this field. 
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Chapter 2 Ovarian cancer and genetic testing – clinical 
perspectives 
 
2.1 Introduction  
This chapter expands on two key areas of this PhD thesis: (i) ovarian cancer and (ii) 
genetic testing in ovarian cancer, both of which are critical to the context in which this 
research was undertaken. The first section is an overview of ovarian cancer from 
diagnosis to treatment, to describe the clinical background of my patient group. The 
next two sections describe both germline and tumour testing in ovarian cancer. This 
chapter finishes with a summary of the new targeted treatments available for ovarian 
cancer.  
2.2 Ovarian cancer  
2.2.1 Incidence  
Ovarian cancer is still classified as a ‘rare’ cancer, although the incidence is rising 
[29]. England has an age standardised incidence of 17.5 ovarian cancer cases per 
100,000 females [30]; recent data from the Office of National Statistics (ONS) reported 
6430 cases were recorded in 2016 [31].  
2.2.2 Pathway to diagnosis 
2.2.2.1 Symptoms  
Although ovarian cancer has historically been referred to as a ‘silent killer’ due to the 
perception that women are only symptomatic with advanced disease [32], data from 
retrospective, prospective and case control studies refute this [33-35]. For example, 
a survey of more than 1700 ovarian cancer patients found that 95% reported 
symptoms prior to diagnosis, including 89% of women with early stage disease [36]. 
However, the symptoms of ovarian cancer are often described as ‘non-specific’ and 
can be mistaken for other or existing medical conditions such as irritable bowel 
syndrome (IBS) [37]. NICE guidance reports four symptoms that are suspicious of 
ovarian cancer, particularly in women over the age of 50 and/or if the symptoms are 
persistent: 
 
30 
 
• ‘Abdominal distension (women often refer to this as 'bloating') 
feeling full (early satiety) and/or loss of appetite 
• Pelvic or abdominal pain 
• Increased urinary urgency and/or frequency’ (p.10) [29].  
 
2.2.2.2 Presentation 
If ovarian cancer is suspected, the NICE guidance recommendations for primary care 
are sequential testing of biomarker CA125 followed by ultrasound if CA125 is above 
35 IU/L [29]. Clinical findings that would require urgent referral for a two week wait 
appoint to specialist care include ascites and an abdominal or pelvic mass. Nearly 
one third of women with ovarian cancer will be diagnosed via acute presentation to 
emergency departments while an additional one third from other specialty 
departments [38].  
2.2.2.3  Establishing a diagnosis 
Further testing in secondary care includes ultrasound and CA125 (if not already 
undertaken). CT scan of abdomen and pelvis may be indicated. A risk of malignancy 
score (RMI) calculated from CA125 level, menopausal status and ultrasound score; 
women with an RMI score above 250 or more are referred to a specialist 
multidisciplinary team (MDT) [29]. Other investigations such as laparoscopy, 
hysteroscopy or radiologically guided biopsy may be requested by MDT to establish 
diagnosis [39].  
2.2.3 Stage 
Cancer Research UK data from 2014 reported on stage at diagnosis of ovarian cancer 
cases in England, with 31% of patients diagnosed with stage I disease, 5% stage II, 
31% stage III and 18% stage IV; in 15% of patients stage was unknown [40].  
Ovarian cancer is surgically staged following the International Federation of 
Obstetrics and Gynaecology (FIGO) system [41].   
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Table 2.1 FIGO ovarian cancer stages 
STAGE I: Tumour confined to the ovaries  
IA 
Tumour limited to one ovary, capsule intact, no tumour on surface, negative 
washings  
IIB Tumour involves both ovaries otherwise like 1A 
IC Tumour limited to one or both ovaries 
IC1 Surgical spill 
IC2 Capsule rupture before surgery or tumour on ovarian surface 
IC3 Malignant cells in ascites or peritoneal washings 
STAGE II: Tumour involves one or both ovaries with pelvic extension (below the 
pelvic brim) or primary peritoneal cancer 
IIA Extension and/or implant on uterus and/or Fallopian tubes 
IIB Extension to other pelvic intraperitoneal tissues 
STAGE III: Tumour involves one or both ovaries with cytologically or histologically 
confirmed spread to the peritoneum outside the pelvis and/or metastasis to the 
retroperitoneal lymph nodes 
IIIA Positive retroperitoneal lymph nodes and/or microscopic metastasis beyond the pelvis 
IIIA1 
Positive retroperitoneal lymph nodes only 
IIIA1(i) Metastasis ≤ 10 mm 
IIIA1(ii) Metastasis > 10 mm 
IIIA2 
Microscopic, extrapelvic (above the brim) peritoneal involvement ± positive 
retroperitoneal lymph nodes 
IIIB 
Macroscopic, extrapelvic, peritoneal metastasis ≤ 2 cm ± positive 
retroperitoneal lymph nodes. Includes extension to capsule of liver/spleen. 
IIIC 
Macroscopic, extrapelvic, peritoneal metastasis > 2 cm ± positive 
retroperitoneal lymph nodes. Includes extension to capsule of liver/spleen. 
STAGE IV: Distant metastasis excluding peritoneal metastasis 
IVA Pleural effusion with positive cytology 
IVB 
Hepatic and/or splenic parenchymal metastasis, metastasis to extra- abdominal 
organs (including inguinal lymph nodes and lymph nodes outside of the 
abdominal cavity) 
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2.2.4 Treatment and management  
As up to 60% of women with ovarian cancer are diagnosed with advanced stage 
disease (stages III and IV) [1], this section will focus on the treatment and 
management aspects of these stages.  
2.2.4.1 Surgery 
The NICE guidance for surgical treatment of ovarian cancer describe the objective as 
‘complete resection of all macroscopic disease’ (p.19) [29]. Primary and interval 
debulking (after neo-adjuvant chemotherapy) involves bilateral salpingo-
oophorectomy, total abdominal hysterectomy, omentectomy and lymphadenectomy 
[42]. Optimal cytoreduction is the resection of all macroscopic disease; increasingly 
this may involve ultra-radical surgical resections which can include stripping of the 
diaphragm, multiple bowel resections, cholecystectomy and/or splenectomy [42]. 
These procedures require specific expertise or undertaken in collaboration with other 
surgical specialties. Studies have shown that more aggressive surgical efforts aiming 
for complete cytoreduction lead to longer survival times [42-44] although it may also 
impact morbidity and quality of life.  
If primary debulking is unlikely to result in optimal cytoreduction due to extensive 
disease, three cycles of neo-adjuvant chemotherapy followed by interval debulking 
has comparable survival outcomes [45].   
2.2.4.2 Chemotherapy 
Taxane- and platinum-based combination chemotherapy, typically six cycles of 
adjuvant paclitaxel and carboplatin, are the standard first-line treatments for advanced 
ovarian cancer. CA125 biomarker and CT scans are used to monitor treatment 
response both during and after chemotherapy. Response rates for first-line 
chemotherapy are high, up to 70-80%, although the majority of women subsequently 
relapse [46].  
Ovarian cancer patients who relapse receive several more lines of treatment. Patients 
who relapse within six months, up to 25%, are described as having ‘platinum-resistant’ 
disease. Within this patient group the aim of ongoing treatment is to maintain quality 
of life by preventing and controlling symptoms [46]. Patients with ‘platinum-sensitive’ 
disease continue to receive platinum-based therapies individually or in combination. 
Many patients will ultimately develop platinum resistance, limiting treatment options. 
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The goal of ongoing chemotherapy treatments, for example third- or even fourth-line 
chemotherapy, is largely to manage symptoms and prolong life and is not intended to 
be curative. 
2.2.4.3 Other treatments  
Bevacizumab (Avastin) is a biological therapy which acts by anti-angiogenesis, 
targeting vascular endothelial growth factor proteins thereby inhibiting tumour growth. 
It is often referred to as a ‘maintenance’ treatment and used in addition to first line 
chemotherapy until disease progression, unacceptable toxicity or for up to 18 cycles.  
Bevacizumab has UK marketing authorisation, however it does not currently have 
NICE approval for use within the National Health Service (NHS) due to concerns 
about cost-effectiveness [47], although patients in England may access this therapy 
through the Cancer Drugs Fund. 
2.2.5 Histology  
The histology of ovarian cancer is important in the context of genetic testing. Distinct 
histological types have different epidemiological and gene expression profiles and this 
may influence treatment regimens and prognosis. Ovarian cancer was previously 
thought to arise from the epithelial surface of the ovary, but recent evidence indicates 
that the distal end of the fallopian tube is involved in the development of serous 
carcinomas, whereas endometrioid and clear cell carcinomas develop from ectopic 
endometrium [48]. Invasive mucinous cancers are not ovarian in origin but 
metastases from other solid tumours [49].  
High grade serous ovarian cancer is the most common subtype. Germline BRCA1/2 
mutations are typically found in high grade serous disease, and patients with 
mucinous or low grade histology types are not routinely offered BRCA1/2 genetic 
testing unless there are other risk factors to consider such as family history or 
ethnicity.  
2.3 Germline testing in ovarian cancer 
2.3.1 BRCA1 and BRCA2 germline testing  
Clinical genetic testing for BRCA1 and BRCA2 mutations has been available following 
the isolation of gene loci on chromosomes 17 and 13 respectively in 1994 and 1995 
[50, 51]. The cancer susceptibility risks are well established for mutation carriers; the 
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average cumulative risk of developing ovarian cancer by age 70 for BRCA1 mutations 
is 39% (18-54%) and 11% (2.4-19%) for BRCA2 mutations [3].  
The prevalence of germline BRCA1/2 mutations within an ovarian cancer cohort can 
vary by patient factors such as disease histology and ethnicity. BRCA1/2 mutations 
are less common in mucinous and non-high grade serous ovarian cancer, whereas 
Ashkenazi Jewish ancestry and founder mutations can inflate BRCA1/2 mutation 
prevalence. As a result, reported mutation rates range from 5.8 to 30.6% [12, 52-58]. 
One of the largest cohorts of population-based ovarian cancer patients (n=1001) 
reported a BRCA1/2 mutation frequency of 14.1% overall, and 17.1% in high grade 
serous cases [12]. The authors report that the majority of cases with endometrioid 
and clear cell histology with BRCA1/2 mutations were later reclassified as serous or 
unspecified adenocarcinoma.   
BRCA1 and BRCA2 genes are known as tumour suppressor genes. BRCA1/2 
proteins play an important role in maintaining chromosomal stability in response to 
DNA damage, specifically in the homologous recombination DNA repair process of 
double strand breaks (DSB) [59]. Germline and somatic BRCA1/2 mutations result in 
homologous recombination deficiency (HRD) and inability to repair DSB, leading to 
additional mutations accumulating, loss of genetic information, chromosomal 
instability and eventually cell death [60].  
Data from The Cancer Gene Atlas (TCGA) reported that up to half of high grade 
serous ovarian cancers demonstrated HRD [61]. Other genes and their encoded 
proteins that are recognised to contribute to homologous recombination repair include 
ATM, CHEK2, BRIP1, RAD51C, RAD51D and PALB2 [10]; these are often referred 
to as HRD genes.   
Genetic testing for HRD gene mutations are already being incorporated into clinical 
practice. At NE Thames Regional Genetics Service which provides BRCA1/2 testing 
for ovarian cancer patients at UCLH, a five gene panel including BRCA1, BRCA2, 
RAD51C, RAD51D and BRIP1 genes was introduced in July 2016. A recent position 
statement from the UK’s national Cancer Genetics Group agreed to also include 
mismatch repair genes associated with Lynch syndrome (MLH1, MSH2, MSH6) in 
gene panels for ovarian cancer [62].  
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2.3.2 Genetic testing for ovarian cancer patients 
Until MGT was introduced at UCLH, ovarian cancer patients were referred to the NE 
Thames Regional Genetics Service at GOSH by their oncologist if he/she suspected 
there may be an inherited basis to the diagnosis. Factors which may have triggered 
referral included family history of cancer, age at diagnosis, Ashkenazi Jewish 
ancestry, amongst others. Clinical genetics staff would then assess the patient for 
eligibility for BRCA1/2 testing based on the current testing criteria and offer testing if 
appropriate.  
Identifying ovarian cancer patients who may be eligible for testing relied on 
oncologists recognising features which could indicate a hereditary basis to their 
patient’s diagnosis, for example asking and recording a sufficient family history. Data 
from three UK gynaecological oncology centres showed that up to 12% of patients 
had no family history recorded [63]. Of 22 patients where a significant family history 
which met criteria for referral to clinical genetics was recorded, no action was taken 
for 68%.     
Health professionals without specific genetics expertise or training may find it difficult 
to identify the clinical features, ‘red flags’, associated with inherited cancer 
predispositions. Low genetic testing referral rates for ovarian cancer patients have 
been identified across Europe, USA and Canada. A 2016 survey conducted of 
medical and gynaecological oncologists from Europe and USA found that 45-73% of 
their ovarian cancer patients had been tested for BRCA1/2 mutations, citing the 
absence of family history or other risk factors for not offering testing [64]. A review of 
BRCA1/2 genetic testing referral rates for ovarian cancer patients across America and 
Europe found rates varied between 7-100% [65].  
Several factors have driven changes to guidelines for genetic testing in ovarian 
cancer. Firstly there is accumulating data on the high prevalence of germline 
BRCA1/2 mutations amongst patients [12, 53-58]. Secondly, one of the major 
selection criteria for genetic testing, family history, is now recognised to be a poor 
predictor of mutation status. Alsop et al reported 57% of mutation carriers had no 
family history [12]. Furthermore, a systematic review found in 78% of studies, a 
substantial proportion of ovarian cancer patients with a BRCA1/2 mutation had no 
significant family history of breast and/or ovarian cancer [66]. Thirdly, BRCA1/2 
mutation status is of increased clinical significance thanks to new therapies that 
specifically target BRCA-mutated ovarian cancer.  
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Guidelines from Europe, in particular the European Society for Medical Oncology 
(ESMO) recommend patients with high grade ovarian tumours are tested for germline 
BRCA1/2 mutations [67]. After revisions to the NICE guidance were published in 2013 
lowering the threshold at which BRCA1/2 testing could be offered, the UK Genetics 
Testing Network (GTN) developed consensus testing criteria to include germline 
BRCA1/2 testing for all women with high grade serous ovarian cancer [68]. 
As more centres adopt these recommendations and move to systematically offering 
genetic testing to women diagnosed with ovarian cancer, one approach to 
accommodate the growing number of patients who require BRCA1/2 testing is to 
streamline the testing process and embed testing within the oncology setting, 
otherwise known as ‘mainstreamed genetic testing’ (MGT).  
2.3.3 Mainstreamed genetic testing (MGT) 
Genetic testing when used in the clinical setting, is performed to ‘…determine the 
genetic cause of a disease, confirm a suspected diagnosis, predict future illness, 
detect when an individual might pass a genetic mutation to his or her children, and 
predict response to therapy’ [69]. Genetic counselling is a clinical service typically 
delivered alongside genetic testing, to provide information and support to individuals 
with or at risk of genetic disease. The tenants of genetic counselling, non-
directiveness and informed decision-making, ensure patients have sufficient and 
appropriate information to reach a decision, whilst being supported in their choice(s).  
Until recently, genetic testing has been provided in a stepped approach of multiple 
appointments with clinical geneticists and/or genetic counsellors. The focus of testing 
was largely on identifying future cancer risks and the prevention strategies available 
for unaffected individuals at high risk and their family members. The introduction 
chapter of this thesis has touched on the changes that are influencing the traditional 
approach to BRCA1/2 genetic testing; family history is no longer advocated as the 
main selection criteria and there is increased recognition of the opportunity genetic 
testing can provide to guide treatment decisions in both breast [70] and ovarian cancer 
[66].  
The model of MGT in ovarian cancer is a significant departure from how BRCA1/2 
genetic testing has previously been provided. Instead of genetic counsellors and 
clinical geneticists, health professionals specifically trained in human genetics and 
communication skills, genetic testing is provided by oncologists. Testing takes place 
within the ovarian cancer patient’s oncology appointment, and is discussed alongside 
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other treatment and medical decisions. If a patient consents to BRCA1/2 testing, she 
will receive her results from her oncologist. Where a BRCA1/2 mutation or VUS has 
been identified, the patient will then be referred to her local clinical genetics service 
for genetic counselling, which will also provide predictive testing for at-risk relatives.  
 
Figure 2.1 Traditional model of genetic testing and counselling 
 
 
Figure 2.2 Mainstreamed genetic testing in ovarian cancer 
 
Genetic counselling and testing is adapting to the growing demand for genetic testing 
services within oncology. Although MGT provides more ovarian cancer patients 
access to testing and streamlines the approach to testing by incorporating it within 
their current oncology care, it lacks the opportunity for genetic counselling prior to the 
testing decision. As testing may be offered shortly after diagnosis, during cancer 
treatment, in remission or on relapse, considering the implications of genetic testing 
along the cancer pathway is also important. 
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Meiser described the importance of measuring not only the clinical but psychosocial 
outcomes of genetic testing, ‘Ethical practice requires that we are confident that 
information about genetic risk and test results can be provided without damaging 
psychological or behavioural consequences’ (p.1061) [16]. Thus there is a wealth of 
literature on the psychosocial impact of genetic testing, particularly within hereditary 
cancer. However the change in context, service provider and lack of genetic 
counselling in the mainstreamed genetic testing approach is a significant change from 
the settings in which much of this research was conducted. With the introduction of 
MGT at UCLH, understanding the implications for patients is necessary to ensure the 
clinical benefits are balanced against any possible psychosocial impact. 
2.3.4 Mainstreamed BRCA1/2 testing in UK 
When work for this PhD began in January 2015 there were three key programmes in 
the UK which had implemented and were exploring systematic genetic testing for 
ovarian cancer patients from a mainstreaming approach. These programmes and 
their published data are described below.   
The Mainstreaming Cancer Genetics (MCG) in ovarian cancer programme was 
introduced at the Royal Marsden Hospital in 2013 offering systematic BRCA1/2 
testing to women with non-mucinous ovarian cancer [71]. In this mainstreamed 
‘oncogenetic’ pathway, BRCA1/2 germline testing was discussed and offered to 
eligible ovarian cancer patients by an approved cancer team member as well as being 
provided with an information sheet. Written consent was taken for patients who 
wished to have testing and if further counselling was required patients were referred 
to the clinical genetics service [72]. Published data on the first 16 months of the MCG 
programme reported of the 207 patients offered BRCA1/2 testing, all chose to proceed 
with testing. Thirty three patients were identified as carrying pathogenic BRCA1/2 
mutations, leading to a prevalence of 15.9% [73]. Only 45% (n = 15) of these patients 
would have qualified for testing under previous guidelines. Genetic testing also had a 
significant impact on clinical management, with the results of BRCA1/2 testing 
deemed to be useful in treatment decisions in 64% of cases. George et al also tracked 
family management in the referral of unaffected at-risk family members to clinical 
genetics and the uptake of predictive testing. A patient experience survey found that 
all patients were pleased to have had testing with 98% glad testing was incorporated 
into their oncology care [73].  
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In East Anglia, the Genetic Testing for Epithelial Ovarian Cancer (GTEOC) study 
examined the feasibility and acceptability of BRCA1/2 germline testing [74]. Eligible 
patients had a diagnosis of high grade serous or endometrioid ovarian cancer in the 
prior 12 months. Using a ‘genetics coordinated’ delivery model, BRCA1/2 testing was 
initially offered and discussed by the treating oncology team, before the patient was 
referred to the study coordinator to provide more detailed information, take consent, 
organise testing as well as collect demographic and family history data. Between 2013 
and 2015, 232 (87%) of eligible ovarian cancer patients consented to testing; 18 
patients (7.8%) were identified as BRCA1/2 mutation carriers. Validated measures 
were used to explore the psychological impact of testing. Plaskocinska et al found 
overall genetic testing did not exacerbate distress already experienced as a result of 
receiving a diagnosis of cancer. Highest cognitive avoidance scores were reported for 
patients identified as carrying a BRCA1/2 mutation. The authors also reported that 
younger patients had significantly higher levels of intrusive thoughts and perceived 
stress post-testing. Similar to the MCG programme, patients’ responses 
demonstrated good acceptability of genetic testing, with sufficient time and 
information to make their testing decision [74].  
In Scotland, routine germline BRCA1/2 testing was introduced for non-mucinous 
ovarian cancer in 2012 following three different models of testing delivery [75]. In East 
Scotland (Edinburgh and Dundee), testing followed an oncology-led model, with pre-
test counselling provided and written consent taken by the medical oncologist who 
then organised blood draw for testing. In Aberdeen a similar approach was used 
although all patients were then referred to the clinical genetics service for telephone 
genetic counselling. In the West of Scotland BRCA1/2 testing was managed in a 
genetics-led model, with all patients referred to the clinical genetics service. Data 
reported here focuses on testing results after changes were made to the selection 
criteria for testing to include all women with a diagnosis of non-mucinous ovarian 
cancer who were classified as either ‘new criteria’ on first-line treatment (n = 236) or 
‘prevalent population’ patients who had not met previous testing criteria but were still 
under the care of the oncology department (n = 158). Across all sites rates of germline 
BRCA1/2 mutations were 13.1% in the new criteria patient group, and 12.7% in the 
prevalent population. Under previous testing guidelines, 48% (15/31) of BRCA1/2 
mutation carriers in the new criteria and 45% (9/20) in the prevalent population would 
not have been eligible for testing. In total, 10 patients (2%) actively declined testing 
while 21 patients (13%) passively declined testing by failing to respond to contact from 
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clinical genetics. Patient and health professional satisfaction was not assessed in this 
study.  
These three programmes of offering systematic genetic testing to ovarian cancer 
patients have shown that this is a feasible and successful method of delivering 
BRCA1/2 testing to more patients in the UK. In the MCG and GTEOC programmes, 
and mainstreaming models used in Edinburgh and Dundee, no formal pre-test genetic 
counselling was provided to patients. The lack of counselling appeared to have little 
impact on patients’ experiences of genetic testing in terms of satisfaction and 
acceptability with both the MCG and GTEOC study reporting high satisfaction [73, 
74]. 
The value of implementing universal BRCA1/2 testing for ovarian cancer patients is 
also reflected in the number of BRCA1/2 mutation carriers that would have been 
missed if previous testing guidelines and selection criteria were followed. Manchester 
scores were recorded for BRCA1/2 mutation carriers in Scotland and MCG 
programme; in both cases nearly half of patients had scores <15 and therefore would 
not have been eligible for testing [73, 75].  
Across these three publications, there were low rates of patients declining genetic 
testing. It appears a completely oncology-led model of BRCA testing delivery may 
lead to higher rates of patient testing. For example, no patients declined the offer of 
testing in the MCG programme [73]. In the east of Scotland only three patients 
declined testing when offered by their oncologist, compared to west Scotland where 
seven patients actively declined testing offered by clinical geneticists and a further 21 
who passively refused [75]. In the GTEOC study, where discussion of testing was 
initiated by the oncologist or specialist nurse and consenting and organising of blood 
draw was undertaken by the study team, from a sample of 281 eligible patients 87% 
consented to participate indicating there was a remaining 13% who declined study 
participation [74].  
2.4 BRCA tumour testing in ovarian cancer 
The focus of this chapter so far has been on germline testing in ovarian cancer for 
inherited mutations in BRCA1 or BRCA2 genes. Germline mutations are commonly 
detected through genetic testing of blood or saliva samples and should involve 
discussion of implications for family members as first degree blood relatives are at 
50% risk of carrying the same mutation. In contrast, genetic testing of tumour tissue 
can identify somatic mutations that are acquired and are non-heritable.  
41 
 
BRCA1/2 tumour testing involves NGS of BRCA1 and BRCA2 genes, typically from 
samples of tumour stored in formalin (formalin-fixed paraffin-embedded, FFPE) 
blocks which are used for histological examination and diagnosis [76]. Some patients 
may have multiple tumour blocks from extensive removal of tumour tissue during 
debulking surgery, while others only a single block, most commonly from an omental 
biopsy. A major technical challenge of BRCA1/2 tumour testing is ensuring there is 
both sufficient quantity and quality of DNA from stored tissue samples for genetic 
sequencing and analysis [77]. An additional challenge is DNA damage from the 
formalin fixation process which can lead to fragmentation of DNA and sequence 
artefacts [78]. Mutation artefacts can be false positives, and distinguishing true 
positive mutations from artefacts requires repeat analysis [76-78]. Despite these 
challenges, tumour testing for BRCA1/2 mutations by NGS is feasible and can be 
used to identify somatic mutations in ovarian cancer patients [79, 80]. In recent ESMO 
guidelines for ovarian cancer treatment recommendations, tumour testing for 
BRCA1/2 somatic mutations should be considered [67].  
This has led to a growing body of literature on the prevalence of somatic BRCA1/2 
mutations in ovarian cancer. As shown in the table below, from published data the 
reported rate of somatic mutations ranges from 3-9% [13, 61, 81-85]. Moschetta et al 
(2017) believe that the true rate of BRCA1/2 somatic mutations is likely to be between 
5-7%; that is for every four or five ovarian cancer patients where a germline BRCA1/2 
mutation is identified, one additional patient will have a somatic mutation [86].  
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Table 2.2 Published somatic mutation rates in ovarian cancer 
Study Country Cases Ovarian cancer histology 
Somatic 
BRCA1/2 
mutations  
Hennessey et al. 
2010 [13] 
USA 235 
Serous, non-serous, mixed, 
other 
7% 
The Cancer 
Genome Atlas 
Research Network 
2011 [61] 
International 316 High grade serous 3% 
Pennington et al. 
2014 [81] 
USA 367 
Serous, poorly differentiated 
not otherwise specified, clear 
cell, endometrioid, 
carcinosarcoma, other 
6.8% 
Yates et al. 2014 
[82] 
USA 88 
High grade (histology not 
otherwise specified) 
9% 
Chao et al. 2016  
[83] 
Taiwan 99 
Serous, endometrioid, clear 
cell 
4.0% 
Koczkowska et al. 
2016 [84] 
Poland 100 High and low grade serous 4.2% 
Dougherty et al. 
2017 [85] 
UK, USA 209 High grade serous 9.6% 
 
To classify mutations found on tumour testing as either somatic or germline in nature 
can only be achieved by germline testing. The majority of mutations found on 
BRCA1/2 tumour testing will be germline inherited mutations [13] which presents a 
challenge to how tumour testing is discussed with patients, what information is 
provided and how consent is taken [87].  
2.4.1 Mainstreamed tumour testing  
At the time this work was undertaken, routine molecular testing of tumour tissue was 
primarily undertaken to identify somatic mutations that could inform and guide 
treatment (e.g. EFGR in non-small cell lung cancer) but which has no hereditary 
implications. One area where this is changing is colorectal cancer. Lynch syndrome, 
also known as Hereditary Non-Polyposis Colorectal Cancer (HNPCC), is an inherited 
cancer syndrome associated with predisposition to not only colorectal cancer, but a 
range of other cancers including endometrial and ovarian [88]. Lynch syndrome 
accounts for 3% of all colorectal cases [89]. Previous tumour testing for Lynch 
syndrome in colorectal cancer patients was based on family history and other clinical 
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factors by using guidelines (e.g. Amsterdam II Criteria and Revised Bethesda) to 
identify those at high risk [90]. In 2017 NICE published guidance recommending 
immunohistochemistry (IHC) or microsatellite instability (MSI) testing at diagnosis for 
all patients with colorectal cancer, with the aim of identifying tumours with deficient 
DNA mismatch repair [91]. The results of MSI and/or IHC testing can then be used in 
turn to guide further testing for Lynch syndrome.  
Although results from MSI and IHC tumour testing require confirmatory germline 
testing using a blood or normal tissue sample, nevertheless it presents the first 
systematic tumour testing in cancer patients that has the potential to identify a 
hereditary basis to the disease. NICE guidance reports, ‘Healthcare professionals 
should ensure that people are informed of the possible implications of test results for 
both themselves and their relatives, and ensure that relevant support and information 
is available. Discussion of genetic testing should be done by a healthcare professional 
with appropriate training’ (p. 5) [91].  
This recommendation could also be extended to tumour testing in ovarian cancer. 
BRCA1/2 mutations identified on tumour testing may be germline and heritable in 
nature or may be somatic and non-inherited, and it is important that this is 
communicated clearly to patients.  
2.4.2 Mainstreamed BRCA1/2 tumour testing at UCLH 
With the feasibility of BRCA1/2 tumour testing in ovarian cancer established, it is worth 
considering whether this could be implemented following an MGT model which is 
oncology-led. There is already a precedent of mainstreamed tumour testing in other 
cancers, for example testing for EFGR mutations to guide treatment decisions in non-
small cell lung cancer [92]. MGT for BRCA1/2 germline testing has already been 
successfully implemented within the gynaecology oncology department (this is 
discussed further in Chapter 5); oncologists are familiar with discussing BRCA1/2 
testing with patients, completing genetic test request forms and referring patients to 
their local clinical genetics service if required. 
In terms of the process of tumour testing, there are existing links between UCLH 
gynaecological oncology and histopathology departments because of the importance 
of confirming histotype for ovarian cancer diagnosis. Patient tumour tissue is typically 
already available, either from debulking surgery or from a guided biopsy during the 
diagnostic pathway, and archived for up to seven years on site in the cellular 
pathology department. A genetic testing laboratory with validated methods of 
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BRCA1/2 tumour testing is also essential. At the time this research was undertaken, 
the NE Thames Regional Genetics Laboratories which provides BRCA1/2 MGT for 
UCLH patients did not offer this service.  
An important consideration for mainstreamed BRCA1/2 tumour testing is the timing of 
germline and tumour testing. As BRCA1/2 mutation status can influence treatment 
decisions, testing at diagnosis could be beneficial for clinical management. Ngeow et 
al described the ideal timeframe for tumour testing as patients receiving pre-test 
genetic counselling prior to surgery, although this requires prompt consultation with 
health professionals, cancer genetics expertise as well as sufficient tumour tissue 
from a pre-surgical biopsy [93].  
Using tumour testing as a first line genetic test for BRCA1/2 mutations has some 
potential benefits. This approach would provide genomic information upfront to guide 
treatment decisions; patients with an identified somatic mutation could then be offered 
germline testing to confirm whether it is an inherited mutation (which provides 
important information to blood relatives) or an acquired mutation present only in 
tumour [87]. Where there is no mutation identified in tumour, no further genetic testing 
is required. This approach could reduce the number of patients facing the decision 
whether or not to undergo germline genetic testing to only those in whom a mutation 
is identified on tumour testing. This would lead to focused germline testing, reducing 
the burden on clinical genetics services [80, 87]. Patients can consider tumour testing 
to guide their treatment decisions initially, without learning immediately of the inherited 
nature of their disease, thus removing the potential added distress of learning of the 
cancer risks for family members.   
2.5 BRCA1/2 mutation status and targeted therapies 
2.5.1 Olaparib, the first PARP-inhibitor 
Understanding the role and function of HRD genes and proteins has shed light on 
chemotherapeutic response in ovarian cancer as well as potential for targeted 
treatments. Poly(ADP-ribose) polymerases (PARP)-inhibitors are the first class of 
new treatments that are targeted towards BRCA-mutated ovarian cancers.  
As outlined earlier in this chapter, it is recognised that BRCA1 and BRCA2 are tumour 
suppressor genes which play an important role in the DNA repair process. PARPs are 
enzymes which are activated by DNA damage and facilitate DNA repair pathways. 
PARP inhibitors are believed to work by blocking PARP activity, thereby preventing 
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DNA repair and leading to synthetic lethality in BRCA-deficient tissues. Inhibiting 
PARP causes single strand DNA breaks to become DSBs. Due to HRD in BRCA-
mutated tumours, the DBSs are unable to be repaired and the cell is directed to cell 
death [10].  
Olaparib was the first PARP-inhibitor to be FDA approved in the treatment of platinum-
sensitive relapsed ovarian cancer for patients with germline BRCA1/2 mutations who 
have completed at least three courses of platinum-based chemotherapy [94]. In 
December 2014 the European Medicines Agency (EMA) gave market authorisation 
to olaparib for use in BRCA-mutated recurrent platinum-sensitive high grade serous 
ovarian and fallopian tube cancer [95]. In January 2016 NICE guidance published 
recommendations for olaparib as a maintenance treatment after three or more 
courses of platinum-based chemotherapy in patients with high grade serous ovarian 
cancer carrying either germline or somatic BRCA1/2 mutations [96].     
In February 2019 the EMA’s Committee for Medicinal Products for Human Use 
(CHMP) adopted a positive opinion supporting extension of olaparib authorisation for 
use as a maintenance treatment in high grade epithelial ovarian cancer for patients 
regardless of BRCA1/2 mutation status [97, 98]. As the request for extension awaits 
approval from the European Commission, this has yet to impact UK recommendations 
for the use of olaparib. However the potential to extend the use outside of a BRCA-
mutated cohort has potentially significant implications for tumour testing in ovarian 
cancer; if mutation status is no longer an eligibility criteria to access this novel therapy, 
could this lead to less genetic testing in this patient population?  
The most recent change to olaparib in the US has been FDA approval in December 
2018 for olaparib to be used as a maintenance treatment for ovarian cancer patients 
with germline or somatic mutations earlier in the treatment pathway; it can now be 
accessed following first-line platinum-based chemotherapy rather than after third-line 
treatment [99].  
Licensing of the first targeted therapy in ovarian cancer was an additional driver for 
genetic testing; there was clinical impetus to identify patients with germline or somatic 
BRCA1/2 mutations who could be eligible to receive olaparib maintenance treatment. 
This PhD began in January 2015, shortly after olaparib was approved for use in the 
USA and EU. In April 2015 pathways for germline testing were implemented and 
BRCA1/2 MGT introduced for ovarian cancer patients at UCLH. Recruitment of 
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ovarian cancer patients for mainstreamed BRCA1/2 tumour testing ran from 
November 2016 until the last patient was recruited at the beginning of 2018.   
2.5.2 The current state of PARP-inhibitors 
A number of other PARP-inhibitors have been licensed for use both in the US and 
Europe. In July 2018 NICE guidance recommended niraparib via the Cancer Drug 
Fund and a managed access program only as further evidence on clinical and cost-
effectiveness is needed [100]. Similar to olaparib, niraparib is also recommended for 
ovarian cancer patients with platinum-sensitive relapsed disease, either after two 
courses of chemotherapy if they carry a germline BRCA1/2 mutation or after three 
courses of chemotherapy for non-carriers.  
In May 2018 rucaparib was granted conditional marketing authorisation by the EMA 
as a monotherapy for women with germline or somatic BRCA1/2 mutations who have 
had two lines of platinum-based chemotherapy but are unable to tolerate any 
additional chemotherapy [101]. In the UK rucaparib is currently under NICE appraisal 
[102] but may be accessed directly from Clovis under a compassionate access 
scheme [103].  
Although olaparib was initially licensed for use only for ovarian cancer patients with 
BRCA1/2 mutations, clinical data is increasingly suggesting that PARP-inhibitors may 
also have clinical utility in other HRD-mutated cancers [104]. A recent systematic 
review reported significantly higher rates of progression free survival at six and 12 
months in a cohort of patients with HRD-mutated ovarian cancer compared to non-
HRD patients [105]. 
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gBRCA = germline BRCA mutation; sBRCA = somatic BRCA mutation, OC = ovarian cancer 
Figure 2.3 Timeline of key points in olaparib authorisation
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Chapter 3 Psychosocial aspects of MGT 
 
3.1 Introduction 
Since clinical genetic testing for HBOC became available for BRCA1/2 mutations in 
1996, a large body of literature has developed on the psychological impact of 
BRCA1/2 genetic testing. Much of this research has focused on the experiences of 
‘high risk’ individuals with a significant family history of cancer, but as yet unaffected 
by the disease. Overall, the literature shows that unaffected individuals show some 
psychological benefit from receiving mutation negative results (non-carriers), while 
those who are found to carry a BRCA1/2 mutation rarely show long-term adverse 
psychological effects [16]. Although these findings are encouraging, there are 
important differences between the approaches to genetic testing provided by the 
traditional genetic counselling model and that of MGT discussed previously in Chapter 
2. There are also differences between tumour and germline testing which may impact 
psychosocial outcomes, particularly in a two-step approach where initial tumour 
testing arguably has less implications compared to the hereditary nature of identified 
mutations.  
With more patients accessing tumour testing for somatic mutations, largely to inform 
treatment decisions or as part of clinical trial participation, there is a small body of 
literature exploring the patient experience. Qualitative interviews with advanced 
cancer patients (non-small cell lung, melanoma, colorectal, breast, ovarian, 
endometrial cancer) found that the majority understood testing was to guide treatment 
options, with half of participants describing tumour testing as DNA analysis for specific 
genetic mutations which could be targeted by novel drugs [106]. Motivations for 
testing were the personal benefit and hope offered via potential access to novel 
treatments based on genomic sequencing results [107]. Advantages of testing were 
personal benefits such as potential access to targeted therapies as well as informing 
cause of cancer [106, 108]. Some participants described advantages relevant only to 
germline testing such as motivation for behaviour change and improving earlier 
diagnosis. Participants felt disadvantages were associated with receiving mutation 
negative results which limited treatment options [107], as well as logistical challenges 
relating to biopsy and treatment delays [106]. Another study described disadvantages 
such as unwanted information, disclosure of incidental findings and potential 
psychological harm [108].  
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A quantitative survey of advanced cancer patients referred for genomic tumour testing 
for early phase clinical trials reported that 64% believed testing would significantly 
improve their cancer care [109]. Nearly half of participants felt they had sufficient 
understanding of testing to provide informed consent while a third wanted genetic 
counselling prior to testing.  
Where incidental inherited genetic information was available, almost all participants 
expressed interest in receiving this in order to help family members. This was 
perceived to be an additional burden, while for others it was inconsequential in the 
context of their diagnosis and treatment [107]. In two studies a number of participants 
misinterpreted tumour testing as germline testing, describing concern about heritable 
risks to relatives, cancer prevention, as well as other concerns relating to insurance 
discrimination and psychological impact [106, 108].  
In this emerging field of tumour testing in cancer, these papers provide some insight 
into patients’ attitudes and experiences. However there is an important distinction 
between BRCA1/2 tumour testing and other somatic testing, as it has the potential to 
provide hereditary information.  
As mainstreamed tumour testing in ovarian cancer is an emerging approach to 
BRCA1/2 genetic testing, to date there is no published literature exploring the 
psychosocial experiences of patients. As most mutations identified on BRCA1/2 
tumour testing will be germline mutations [87], it is relevant to consider outcomes from 
MGT which is typically germline testing. Genetic testing in other contexts can also 
provide insight into the cancer patient’s experience of genetic testing: rapid or 
treatment-focused genetic testing (TFGT) in the acute oncology setting where its 
purpose may be to guide treatment, and genetic testing for HBOC offered to 
individuals with a current or previous diagnosis of breast and/or ovarian cancer. 
Reviewing the literature on BRCA1/2 testing for women with cancer will inform our 
knowledge on the potential psychological impact of tumour and germline testing in 
both a patient and survivor cohort.   
3.2 Psychological impact of MGT  
3.2.1 Methods 
3.2.1.1 Eligibility criteria 
 
50 
 
Inclusion 
Studies were included if: (i) the focus of the study was on breast/ovarian cancer 
patients taking part in BRCA1/2 genetic testing, with our without genetic counselling; 
(ii) psychological outcome measures were used assessing the impact of genetic 
testing; and (iii) were published in a peer-reviewed journal in English. Studies which 
reported a mixed cohort of both unaffected and affected individuals were included 
only if results are reported separately for those affected with cancer. Articles published 
from the year 1996 onwards were included in the review as BRCA1/2 genetic testing 
for HBOC was introduced at this time. Both qualitative and quantitative studies were 
included for this review. 
Exclusion 
This review excluded studies about uptake of genetic testing, prevalence of BRCA1/2 
mutations amongst breast/ovarian cancer patients, multi-gene panel testing, pre-
symptomatic genetic testing, genetic counselling interventions, books, lectures, 
reviews, single case reports, or conference abstracts. 
3.2.1.2 Psychological impact 
Psychological impact in genetic testing is a broad description encompassing the 
psychological effects and responses resulting from the experience of having genetic 
testing. Within the literature this includes anxiety, depression, cancer-specific 
distress, cancer worry and genetic testing-related distress. A range of validated 
psychometric quantitative questionnaires is typically used to measure psychological 
impact.  
3.2.2 Identification of studies 
A review of studies published between January 1996 and March 2016 was conducted. 
MEDLINE, EMBASE, PsycINFO and CINAHL databases were searched using the 
following key words individually and in combination: cancer [breast cancer, breast 
neoplasm, ovarian cancer, ovarian neoplasm, affected, cancer patient]; genetic 
testing [genetic testing, genetic counselling, diagnostic testing, mainstreamed genetic 
testing, mainstreaming, rapid genetic testing, treatment-focused genetic testing, 
symptomatic testing, mutation analysis, DNA analysis]; psychological outcomes 
[psychological impact, distress, anxiety, depression, worry, psychological stress].  
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3.2.3 Study selection 
Titles and, where available, abstracts were reviewed against inclusion criteria. For 
those that appeared to meet inclusion criteria, one researcher (BR) reviewed full texts.  
3.2.4 Data extraction 
Data were extracted using EndNote X7 and Microsoft Excel 2011. 
3.2.5 Data synthesis 
Each of the studies included in this review was described by summarising the same 
features for each study (e.g. design, participants, outcome measures and findings). 
As the focus of this review was the psychological impact for individuals with a cancer 
diagnosis, and genetic testing approaches similar to that of MGT, studies were 
grouped by cancer history status (e.g. affected, affected vs non-affected, newly 
diagnosed). Within these groups studies were then organised by study design 
(retrospective vs prospective).  
3.3 Results 
34 studies met the inclusion criteria and form this narrative literature review. Data 
extraction tables and flow diagram of the review can be found in the Appendix.   
3.3.1 Design of included studies 
Of the studies included in this review, 15 were retrospective in study design and the 
remaining 19 were prospective. Across the retrospective studies, time from genetic 
testing results disclosure to questionnaire completion ranged from 2-3 weeks post-
results disclosure to up to 10 years. Most prospective studies reported on short-term 
outcomes post-testing, although long-term data up to three years after genetic testing 
was available.    
3.3.2 Outcome measures of included studies  
A range of validated and self-developed measures were used to record psychological 
outcomes of testing. Distress was measured using Hospital Anxiety and Depression 
Scale (HADS) [110-113], Impact of Events Scale (IES) [110, 112, 114, 115], State-
Trait Anxiety Inventory (STAI) [114, 116, 117], Hopkins Symptom Check-list 25 [115], 
Irritability Depression and Anxiety Scale (IDA) [118], General Health Questionnaire 
(GHQ-28) [119], Centre for Epidemiological Studies Depression Scale (CES-D) [120]. 
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Cancer specific-distress or worry was typically measured using IES [119, 121] or The 
Cancer Worry Scale (CWS) [122]. Genetic testing-related distress used the IES [123] 
or the Multidimensional Impact of Cancer Risk Assessment (MICRA) [124, 125]. Other 
measures related to genetic testing included the Decision Regret Scale (DRS) and 
Satisfaction with Decision Instrument (SWD) [126].  
3.3.3 Psychological impact of genetic testing in women with a personal history of 
cancer (affected) 
There is a small body of literature examining the psychological impact of the genetic 
testing experience specifically of women with a current and/or previous history of 
cancer. The data described here are reported separately for qualitative and 
quantitative research.  
Six studies used qualitative methods to retrospectively explore the experiences of 
women with cancer undergoing genetic testing for hereditary cancer [111, 114, 127-
129]. In one-on-one semi-structured interviews with women affected by breast and/or 
ovarian cancer, Hallowell et al reported that most women did not experience 
emotional difficulties during testing [127], and it was not an experience that increased 
anxiety [128]. Compared to their experiences of cancer diagnosis and treatment, 
genetic testing was inconsequential [128]. This was echoed by the findings of Kenen 
et al, where participants described the effects of cancer as worse than genetic testing 
[129].  
Responses to genetic testing results varied; BRCA1/2 mutation carriers described 
both costs and benefits associated with their results [127]. Costs included anxiety for 
future cancer risks to self and relatives and/or responsibility of communicating results 
[114, 127-129] while benefits were described as relief from personal guilt attributed to 
developing cancer [129]. Although the majority were not surprised to learn their 
mutation positive status [111] or felt it was expected given their cancer history [114], 
a small proportion of women were distressed by their results [114], and felt as though 
they were reliving the trauma of their cancer diagnosis [111, 129]. Women receiving 
inconclusive results expressed positive responses such as relief [114] but also 
described disappointment, anger and disbelief [127].     
Six studies quantitatively assessed the psychological impact of genetic testing in 
cohorts of affected women. Three retrospective studies observed no significant 
differences between BRCA1/2 mutation carriers and non-carriers on anxiety, 
depression or cancer-related distress [110, 114, 118], although carriers showed 
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significantly higher genetic testing-related distress compared to non-carriers [110]. 
Hughes Halbert et al reported that at one month post-results disclosure, women who 
received BRCA mutation positive results had significantly more perceived stress 
related to genetic testing compared to women with BRCA1/2 negative results [116].  
Two prospective studies compared psychological outcomes pre- and post-genetic 
counselling and testing [112, 115].  In a large sample of breast cancer patients, no 
differences were observed between BRCA1/2 carrier status and distress, or between 
pre- and post-testing on anxiety and depression. There was a significant increase in 
cancer-related distress (intrusion) post-testing [112]. In contrast Wood et al 
demonstrated a significant decrease in anxiety from pre- to post-testing with no 
differences observed across carrier status [115].  
3.3.4 Psychological impact of genetic testing comparing women with and without 
personal history of cancer (affected vs unaffected) 
A total of fifteen papers using a mixed sample of affected and unaffected individuals 
measuring the psychological impact of genetic testing met the inclusion criteria and 
are reviewed here [113, 117, 119-121, 123-125, 130-136]. As some studies report the 
impact of BRCA1/2 test results (e.g. mutation carriers vs non-carriers) and/or personal 
cancer history on psychological outcomes, results of these papers are organised by 
two categories: carrier status and affected status.  
3.3.4.1 Mutation carrier status 
The impact of BRCA1/2 mutation carrier status on psychological outcomes for women 
with and without a personal history of cancer is mixed.  
BRCA1/2 carrier status was not associated with changes in anxiety or depression 
from pre-testing, to one and 12 months post-test disclosure for either affected or 
unaffected women [113, 117]. Similarly, no differences were found on distress 
measures (cancer-related and general distress) between those receiving BRCA1/2 
mutation positive and inconclusive results at six weeks, six months or 18 months after 
post-test disclosure [119, 121, 132].  In a sample of BRCA1/2 carriers, no differences 
were observed between affected and unaffected women at one and seven months 
post-testing on breast cancer-worry and distress [130]. Affected women with 
inconclusive results showed similar levels of worry and distress compared to affected 
women with BRCA1/2 mutation positive results [130].  
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Other studies report adverse effects related to receiving BRCA1/2 mutation-positive 
results in a mixed cohort of affected and unaffected women. Two weeks after 
receiving genetic testing results, BRCA1/2 mutation carriers had more test-related 
and general distress compared to non-carriers [123]. Post-results disclosure, 
BRCA1/2 mutation carriers were significantly more anxious than non-carriers across 
both affected and unaffected women [131]. This effect was seen long-term; five years 
post-results both affected and unaffected BRCA1/2 carriers had significant higher 
levels of genetic testing distress compared to individuals with inconclusive results 
[124].  
In a retrospective study of carrier status and personal cancer history, affected women 
with a BRCA1/2 mutation positive result were at significantly higher risk for global 
psychological distress compared to non-carriers. Unaffected BRCA1/2 carriers also 
showed elevated distress levels [133].  
A recent retrospective study examined long-term genetic testing outcomes across six 
groups approximately 12 months after receiving results: affected mutation carriers, 
affected VUS carriers, affected non-carriers, unaffected mutation carriers, unaffected 
VUS carriers and unaffected non-carriers.  Using a specialised measure for the impact 
of genetic testing (MICRA), Lumish et al found that unaffected mutation carriers had 
the highest MICRA total and distress scores compared to any other groups [126]. This 
group also had significantly higher intrusion, avoidance and hyper-arousal scores as 
measured by the IES, compared to any other groups. 
In another short-term retrospective study, women had received their results of 
BRCA1/2 genetic testing one month earlier [137]. Unaffected women had significantly 
higher anxiety and depression scores, but mutation status (i.e. carriers vs non-
carriers) was not associated with distress or poor mood states.    
3.3.4.2 Affected status 
A previous cancer diagnosis was associated with clinically significant levels of anxiety 
at 3 and 12 months post-test disclosure, regardless of BRCA1/2 testing result [113]. 
Affected women had significantly higher levels of cancer-related distress at baseline 
and after receiving results compared to unaffected women [119]. 
Personal cancer history influenced responses when receiving inconclusive results; 
affected women who received an inconclusive result had significantly higher levels of 
breast cancer worry and distress compared to unaffected women [130]. In a sample 
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of participants who all received BRCA1/2 mutation positive results, at one month post-
disclosure affected women had significantly higher levels of cancer-related distress 
compared to unaffected women [117].  
Time from diagnosis was shown to impact psychological outcomes; affected women 
who received a BRCA1/2 mutation positive result diagnosed within one year from 
genetic testing had significantly more anxiety and cancer-related distress compared 
to women diagnosed less recently [120].  
Some findings reported poorer outcomes for unaffected women. No differences were 
observed at other time points (baseline and post-results). Unaffected BRCA1/2 
mutation carriers showed greater test-related distress two weeks after results 
disclosure compared to affected carriers [123]. In a long-term follow-up study Hughes 
Halbert et al observed a non-significant association between genetic testing-related 
distress and personal cancer history, with unaffected women more likely to 
experience distress [125].  
In three studies, personal cancer history did not play a role in psychological outcomes. 
No significant differences were observed between affected and unaffected women 
pre- and post-results disclosure on anxiety or depression at both six weeks, 6 and 18 
months [119, 121, 132].  
3.3.5 Psychological impact of genetic testing at diagnosis 
There is a growing body of literature related to genetic testing at the time of breast or 
ovarian cancer diagnosis to inform treatment options. Seven papers were found 
examining the psychological outcomes of offering genetic counselling and testing to 
newly diagnosed cancer patients [122, 138-143] 
A pilot study of breast cancer patients offered rapid genetic counselling and testing 
(RGCT) used a self-developed scale to measure psychological impact. Half the 
sample reported that RGCT caused additional distress, while 19% found it reduced 
distress and 27% felt it had no effect. BRCA1/2 mutation carriers had significantly 
higher cancer-related distress scores compared to non-carriers [138].  
A larger prospective randomised-controlled trial of RGCT which compared cancer 
worries, cancer-related distress, anxiety and depression at pre-testing, six and 12 
months post-testing, found no significant differences between women receiving 
RGCT and those receiving usual care [139]. Similarly no change in psychological 
distress (anxiety, depression and cancer-related distress) was observed across 
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breast cancer patients approached for genetic during adjuvant radiotherapy who 
accepted testing, those who declined testing or patients who were not approached, at 
timepoints from baseline up to 12 months [140]. In a long-term follow-up study, ten 
years after breast cancer patients had been approached for genetic testing and 
counselling while receiving radiotherapy, participants had low levels of distress [122]. 
No differences were found between patients offered testing, and a control group of 
patients not eligible for genetic testing [122].   
Timing of genetic counselling and testing in newly diagnosed patients may influence 
psychological outcomes. Christie et al found women who received genetic counselling 
before their definitive treatment surgery showed a significant decrease in cancer-
related distressed from pre- to post-counselling, while no change was seen for women 
who received genetic counselling after definitive surgery [141].   
In a study of new breast and ovarian cancer patients who were offered BRCA1/2 
testing, anxiety decreased significantly from the time of test offer to six months after 
receiving genetic testing results, while there was no change in depression scores 
within the same time frame [143]. There were no differences in distress scores 
between patients identified as mutation carriers, and non-carriers.  
A qualitative study of TFGT for ovarian cancer described the experiences of receiving 
genetic test results shortly after diagnosis [142]. Women who learnt they were 
BRCA1/2 mutation carriers described feeling sad, attributing this to the implications 
their results had for family members, and relief for the increased treatment options 
now available and an explanation for their cancer development. Women who received 
inconclusive results expressed relief for their family members and were not 
disappointed at their ineligibility for BRCA-targeted treatments [142].  
A prospective study of newly diagnosed breast cancer patients who underwent TFGT 
examined test related outcomes by family history status [144]. Overall, mutation 
carriers had both significantly more test-related distress and decision regret when 
compared to non-carriers across time and family history.  Amongst mutation carriers, 
women with no family history had significantly higher test-related distress compared 
to women with a family history; no differences were observed amongst non-carriers. 
Similarly mutation carriers with no family history reported significantly more decision-
related regret compared to women with a family history whilst no differences were 
observed in the non-carrier group.  
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In a recent study of systematic BRCA1/2 testing in ovarian cancer, women completed 
validated psychological measures twice, once anchoring to their diagnosis of cancer 
and a further time to their genetic testing experience [74]. Plakoscinska et al found 
women had significantly lower scores on the measures anchored to genetic testing 
when compared to their cancer experiences with the authors concluding that genetic 
testing did not exacerbate distress already experiences by receiving a diagnosis of 
cancer. Mutation status was shown to impact psychological functioning, with women 
who were BRCA1/2 mutation carriers reporting significantly cognitive avoidance 
scores.   
3.4 Discussion 
Overall the large body of literature on the psychological impact of BRCA1/2 genetic 
testing in unaffected individuals indicates that non-carriers experience some 
improvement in psychological outcomes, while BRCA1/2 mutation carriers are largely 
unaffected [16]. However, the findings are inconsistent, with some studies 
demonstrating short-term adverse effects related to testing [145, 146]. Differences in 
findings may be attributed to differences in participant characteristics (e.g. number of 
affected relatives, awareness of family history, socio-demographic factors, 
perceptions of risk), genetic counselling practice across centres and countries, 
availability of risk management options for those identified as BRCA1/2 mutation 
carriers, and study methodology [16].  
In this literature review of psychological outcomes post-BRCA1/2 genetic testing in 
women with a current or previous history of cancer, reported findings were similarly 
varied. Changes in anxiety and depression were not associated with BRCA1/2 
mutation carrier status in affected women [110, 114]. However perceived stress and 
distress specific to genetic testing were increased in affected BRCA1/2 carriers 
compared to non-carriers [110, 112, 116].  
Studies which included a mixed sample of both affected and unaffected women had 
similar findings; BRCA1/2 mutation carrier status had no impact on anxiety, 
depression or cancer-related distress [113, 117, 119, 121, 132]. However both short- 
and long-term increases in genetic testing-related and/or general distress were 
reported in affected and unaffected BRCA1/2 carriers [123, 124, 133]. Only one study 
reported differences in anxiety between carriers and non-carriers for a mixed sample, 
describing this as a ‘natural’ response’ in most individuals [131].  
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It appears that overall genetic testing, and in particular receiving BRCA1/2 mutation 
positive results, has little psychological impact for women with and without a personal 
history of cancer. For both groups of women, adverse outcomes were mostly for 
genetic testing-related distress. Standard psychosocial measures may not be 
sensitive to the subtle and specific changes associated with the experience of genetic 
testing, such as responses to test results, fears for future health, responsibility of 
communicating results to relatives and worries for children. For most of the studies in 
this review, the IES was used to measure cancer-related worries as the traumatic 
event, rather than genetic testing. Using more specific measures such as the 
Multidimensional Impact of Cancer Risk Assessment (MICRA) could provide more 
informative data relating to the genetic testing experience.   
Qualitative studies included in this review provide more insight into quantitative 
findings reported for affected women. Within the context of their cancer diagnosis and 
treatment, the experience and outcomes of genetic testing experience was 
comparatively insignificant [128, 129, 136]. Affected women who received BRCA1/2 
mutation positive results described both positive and negative responses, with 
benefits such as relief from self-blame while acknowledging difficulties related to 
future risks for self and family and challenges related to disseminating results [114, 
127-129]. A small number of women were distressed to learn their BRCA1/2 carrier 
status [114] describing this as exacerbating their previous cancer diagnosis [111, 
129].   
The role of personal cancer history on psychological outcomes in genetic testing is 
mixed; several studies report adverse psychological outcomes for anxiety and cancer-
related distress in affected women post-testing [113, 117, 119], while others found 
anxiety or test-related distress was worse in unaffected women during testing, and at 
short- and long-term follow-up [123, 125, 134] .  
Although most affected women appear to cope well with genetic testing, there is some 
risk that genetic testing involves reliving the trauma related to their cancer diagnosis 
and/or treatment. Despite the acknowledgements of benefits related to genetic 
testing, it implies there is a risk of ‘overburden’. Given their previous experiences with 
cancer diagnosis and treatment, it is not unexpected that for some affected women, 
genetic testing has a negative impact on psychological wellbeing. Studies have 
reported higher baseline scores for anxiety, depression and cancer-related distress 
in women with a personal history of cancer [119, 147, 148]. The findings relating to 
poorer outcomes in unaffected women may reflect the negligible impact genetic 
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testing has for affected women in the context of their prior cancer experiences. 
Affected women may be better prepared to receive cancer risk information and reflect 
on predisposed genetic risk.  
The timing of genetic counselling and testing may be crucial; in a study comparing 
genetic counselling before or after definitive surgery for breast cancer treatment, 
women who received pre-test counselling before surgery had improvements in 
cancer-related distress. In contrast no change was observed for women who received 
counselling after their surgery [141]. Genetic counselling may have been perceived to 
be informative to the treatment decision. In the period prior to surgery counselling may 
have provided reassurance for concerns related to diagnosis, surgery and future 
cancer risks. Studies specifically evaluating the effects of genetic counselling have 
shown it to improve knowledge [149], perceived risk [150] and cancer-related 
concerns [151].  
Genetic testing closer to diagnosis may have an adverse impact on psychological 
wellbeing. Affected BRCA1/2 carriers diagnosed less than one year prior to receiving 
genetic test results had worse outcomes for anxiety and cancer-related distress [120]. 
Within a year of diagnosis patients may still be adjusting to their diagnosis and 
undergoing treatment. Cancer treatment is already associated with negative 
psychological responses [152] that may be exacerbated by genetic testing.   
These findings are particularly relevant given the growing interest in offering genetic 
testing to newly diagnosed cancer patients to inform and guide treatment decisions. 
With medicine increasingly taking a targeted approach, knowledge of BRCA1/2 
mutation status at diagnosis can inform decisions related to contralateral risk-reducing 
mastectomy in breast cancer [70], and eligibility for targeted therapies such as PARP-
inhibitors in ovarian cancer [66]. Although there are limited numbers of papers 
published in this area to date, it is encouraging that much of the literature reports no 
adverse outcomes from approach for genetic counselling and testing at diagnosis 
both in the short-term and long-term [122, 139, 140]. The potential for informing or 
expanding the treatment options available may ameliorate distress associated with 
genetic testing.  
New approaches to genetic testing such as RGCT, TFGT and MGT are a significant 
departure from the traditional model of genetic testing which was typically offered 
post-treatment to inform unaffected relatives about their cancer risks. This review not 
only informs our understanding of the outcomes for women who undergo genetic 
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testing who have a recent and past history of cancer, but also identifies areas where 
further research is needed.    
Many of the studies reviewed did not report on date from diagnosis in affected women. 
In some studies where this data was included, date from diagnosis was stratified to 
more or less than five or ten years making it difficult to draw conclusions on the 
influence of the cancer experience, in particular diagnosis and treatment, on genetic 
testing outcomes [124, 128]. For some studies, this data had a wide range from 
several months to decades post-diagnosis [110, 111, 129]. As discussed, timing may 
be an important influence on psychological outcomes during and after genetic testing 
[153]. Better reporting of diagnostic data, as well as current and/or past treatments, is 
needed for future research that includes individuals with a personal history of cancer.   
There was also significant variation in sample sizes across studies, from 35 [115] to 
464 [124]. Small study cohorts may only allow for the detection of large differences 
and can make generalisation difficult. However a number of studies with small cohorts 
did report significant differences between groups, even with low statistical power 
[110].  
Several studies used a retrospective design. Without a baseline comparison of 
psychological state, this provides only a ‘snapshot’ of time and limits the ability to 
comment on the actual impact of genetic testing. Furthermore, there is some risk of 
recall bias or reconstruction of past events [154].  
Despite these limitations, some of the reviewed studies had strengths which should 
be noted. A number of studies included comparative groups of affected women who 
were not referred or ineligible for genetic testing to control for effect of personal cancer 
history [122, 136, 139, 140]. Three quantitative studies incorporated a qualitative 
component [111, 114, 136]; qualitative data can be a rich addition to a study, helping 
to further explain or support quantitative findings.  
3.4.1 Implications for practice and research 
In MGT for ovarian cancer, patients may have testing at any stage along the cancer 
pathway: diagnosis, treatment, relapse and remission. The oncology clinical team 
provides follow-up care for ovarian cancer patients and survivors up to several years 
post-diagnosis [39]. This review includes cohorts of affected women from diagnosis 
to up to ten years post-diagnosis. In general there is little psychological impact from 
genetic testing across these timeframes for women with a personal history of cancer. 
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However women with cancer diagnosed more recently who learn they are BRCA1/2 
mutation carriers are at risk for psychological distress. The literature also 
demonstrates that there is a small sample of both affected and unaffected women 
who are at risk of psychological harm during or as a result of genetic testing.  
Given the variation in the literature for reported ages, date from diagnosis and period 
between diagnosis, counselling and testing, it is difficult to make specific 
recommendations for women with breast or ovarian cancer who are faced with the 
decision to have MGT. Further research is needed to identify which factors (e.g. age, 
prior cancer diagnosis, family history) may be detrimental to psychological outcomes 
during testing.  
High anxiety prior to testing has been reported as a predictor for poor outcomes in a 
number of studies. Psychological assessment before genetic counselling or the offer 
of testing is therefore essential to identify women who may be particularly affected by 
genetic testing and may find it difficult to cope with the process and/or outcomes. 
Vulnerable women could benefit from close monitoring during genetic testing and/or 
further psychological support. Integration of support services either via the oncology 
or psychology clinical team will ensure patients are referred promptly and 
appropriately if necessary.  
Validated measures which are more sensitive to the specific experience of genetic 
testing should be used in future studies alongside the psychometric scales typically 
used in psycho-oncology research. 
Studies that did not include receipt of genetic test results for participants, but involved 
the offer of genetic testing and/or genetic counselling were included in this review. For 
this PhD thesis, the genetic testing offer is in itself considered an important event. 
Genetic testing has not been part of the typical treatment pathway for ovarian cancer; 
cancer patients may be less aware of genetic testing, particularly if it is offered by their 
treating clinician or combined with other diagnostic tests [147]. Thus the offer of 
genetic testing may be unexpected and elicit a psychological response independently 
of test results.    
3.4.2 Implications for PhD design and methodology 
This literature review has highlighted that date from diagnosis can impact 
psychological outcomes after learning their BRCA1/2 mutation carrier status, with 
women less than one year from cancer diagnosis experiencing greater distress than 
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those diagnosed less recently [120]. This PhD project is aiming to sample the 
experiences of women across the whole cancer pathway, as mainstreamed genetic 
testing is offered in this way within the clinical service. It is essential that date from 
diagnosis data is collected for all participants. As newly diagnosed ovarian cancer 
patients may be particularly vulnerable, it is important that these patients are identified 
to the research team and can be closely monitored if they need further psychosocial 
support during their participation.  
The need for further research into factors predictive of poor psychological outcome 
during genetic testing is highlighted in the previous section. For this study clinical and 
self-report data will be collected to identify if disease (e.g. symptom burden, stage at 
diagnosis, treatment, date from diagnosis), or socio-demographic (age, education, 
parity) factors impact on psychological responses.  
High baseline levels of anxiety are a predictor of adverse psychological outcomes 
during genetic testing. The prospective quantitative study of this PhD research will 
include a baseline measure of distress prior to the offer of testing. This is a unique 
feature of this project; the vast majority of studies on the psychosocial impact of 
genetic testing have measured psychological functioning only after the offer of genetic 
testing.  This also allows for the genetic testing offer to be measured as a separate 
event to the results of genetic testing. Comparisons can be made for psychological 
responses at baseline, after consenting to testing and after receipt of genetic testing 
results to inform our understanding of the impact of the entire genetic testing process.  
Where possible, the psychological measures chosen for this project have been used 
in other psychosocial genetic testing research to allow comparison with previous 
research or have been developed specifically for the experience of genetic testing for 
hereditary cancer.  
3.5 Summary 
There is a growing body of literature examining the psychological impact of genetic 
testing amongst individuals affected with cancer, and in more recent years the focus 
has moved to the newly diagnosed patient group to reflect the developments in 
targeted therapies. Overall it appears that genetic counselling and testing can be 
offered to newly diagnosed breast and ovarian cancer patients without leading to 
psychological distress.  
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Chapter 4 Research methodology  
 
4.1 Introduction 
The provision of genetic testing for women with ovarian cancer has expanded rapidly. 
The most recent development to date has been the validation of BRCA1/2 genetic 
testing of ovarian cancer tumour tissue to identify somatic mutations [76, 79, 80]. In 
the UK there is currently limited access to BRCA1/2 tumour testing in ovarian cancer; 
at the time this research was undertaken could be accessed either as work-up for 
clinical trial eligibility, private payment or in collaboration with genetic testing 
companies (i.e. provision of free tumour tests). Such a collaboration led to an 
opportunity to explore the introduction of tumour testing for women with ovarian 
cancer at UCLH. Myriad Genetics provided fifty tumour tests (Tumour BRACAnalysis 
CDx®) for use in this PhD research.  This chapter describes the study design and 
research undertaken, as well as the methodological considerations which have 
underpinned this work. 
4.1.1 Research development 
In 2014 I began developing my PhD project; initial plans were to explore MGT at 
UCLH and conduct a mixed methods study to examine ovarian cancer patients, 
relatives and health care professionals’ attitudes and experiences of this new model 
of providing genetic testing. Reflecting the rapidly evolving field of clinical genetics 
and oncology, two large UK programmes looking at MGT and systematic genetic 
testing for ovarian cancer patients, including patient experience and outcomes, had 
begun in 2013.  
In 2015 once enrolled on my PhD programme I developed a three-arm study design 
to examine psychological distress in ovarian cancer and the impact of MGT. A cross-
sectional study would describe the levels of distress in patients with ovarian cancer 
from UCLH. This data would also provide a baseline measure of psychological state 
in this patient cohort. An observational prospective study would then explore the 
psychosocial impact of MGT. Lastly a qualitative study aimed to explore in depth the 
experiences of ovarian cancer patients who had undergone MGT.  
By 2016 further developments in BRCA1/2 genetic testing and a collaborative 
approach from Myriad Genetics provided me with an opportunity to focus my research 
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on tumour testing in ovarian cancer. At the time, this new mode of genetic testing was 
not available within the NHS, although patients could access it privately. Seizing on 
this excellent opportunity to be involved in a new approach to genetic testing, the 
focus of my research shifted once more. I considered carefully what aspects of 
BRCA1/2 tumour testing would be of most interest and relevance, as well as 
contribute to our understanding of novel genetic testing methods.  
With my background in psychosocial research in cancer genetics and having trained 
as a genetic counsellor, I chose to centre my research on the provision of BRCA1/2 
tumour testing to patients, the patient experience of testing and the clinical outcomes. 
I felt one of the most important factors to be considered was the context in which 
tumour testing would be provided, following a ‘mainstreamed’ pathway (much like 
MGT) within an oncology setting. Wanting to reflect the context, process and 
outcomes in my research design and findings I sought a methodology which could 
encompass a multi-faceted approach.   
4.2 Making a case for a case study approach  
The case study approach is particularly useful to employ when there is a 
need to obtain an in-depth appreciation of an issue, event or 
phenomenon of interest, in its natural real-life context. (p.1) [155] 
Case study research is an established approach with a long history across many 
disciplines, in particular social science domains. Although case study research has 
historically involved qualitative and ethnographic methods, increasingly the use of 
multiple methods of data collection and analysis is encouraged [156]. This flexible 
approach to case study design means the methodological nature is not compromised, 
while allowing for different methods to best elucidate the case under study.   
In the literature case study is referred to both as a method in itself, or as an 
overarching approach to research [157]. This PhD work follows the definitions of 
Simons, where case study is seen as an overarching approach with ‘…research intent 
and methodological purpose’, which in turn guides the various methods or ‘techniques 
of research’ which have been chosen to explore the current case or issues (p.3) [157].  
A case study approach allows for an in depth examination or exploration of a particular 
phenomenon (the ‘case’) that requires an understanding of the contextual situation of 
the case. Yin describes factors where a case study approach would be relevant: 
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• Form of research questions is How, or Why 
• Requires no control over behavioural events 
• Focuses on contemporary ‘real world’ events [158].  
Studying the introduction of mainstreamed BRCA1/2 tumour testing for ovarian 
cancer patients could have been undertaken as a series of quantitative surveys or 
qualitative interviews independently or as a mixed methods study, to explore patients’ 
experiences of this new testing strategy. However there are other aspects of this new 
mode of genetic testing that are of interest and relevance. For example, what is the 
context in which this new mode of testing will be introduced? Why has genetic testing 
become such a key part of ovarian cancer care? What genetic testing is already being 
undertaken in the context of ovarian cancer care? How would BRCA1/2 tumour testing 
be delivered, i.e. what are the logistics, pathways and people required? How will the 
results of testing be used to inform patient care? Furthermore the contextual situation 
of tumour testing is significant – this model of mainstreaming may have an important 
impact on how testing is utilised by health professionals, and accepted and 
understood by patients.  
A case study approach is multi-faceted, allowing for different research methods as 
well as the inclusion of other data sources to gain a better understanding of the case 
in its current context. For my PhD research, this approach enabled me to examine a 
number of elements related to introducing BRCA1/2 tumour testing in ovarian cancer. 
The emphasis on the ‘contemporaneous’ nature of a case study approach is 
particularly relevant to my research as the scientific, clinical, social and cultural 
landscape of genetic testing is ever evolving. As has been highlighted in earlier 
chapters, within the last five years there have been significant changes in the field of 
genetic testing for ovarian cancer starting with eligibility criteria for BRCA1/2 genetic 
testing expanding the number of patients who were able to access testing. Advances 
in targeted treatments in ovarian cancer have driven the need to identify more 
germline and somatic mutation carriers. There is also recognition that in order to keep 
pace with the growing number of patients where genetic testing is recommended, 
incorporating testing into mainstream medicine and within the cancer treatment and 
diagnostic pathway is essential.   
Although I have presented my argument for taking this approach for my research, 
there are criticisms of case study research. The flexibility of case studies is appealing 
to researchers (including myself), however this can lead to poorly articulated and 
methodologically weak studies where it has been adopted as a convenient label [159]. 
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Similarly the creativity of qualitative research still requires justification and adequate 
methodological description. Hyett et al emphasise the importance of including the 
research paradigm that has influenced study design, as well as clear methodological 
description, sufficient justification of why the case was selected and the context of the 
case [159].  
Some of what I perceive to be the advantages of case study methodology have also 
been used as its weakness. The ability of this approach to take a focused examination 
of a case means that criticisms often lie in its inability to be generalisable, and 
therefore is considered to be a poor scientific method [159, 160]. There are two issues 
raised here, generalisability and research quality. Flyvbjerg argues that ‘The goal is 
not to make the case study be all things to all people. The goal is to allow the study 
to be different things to different people’ (p.239) [160].  
The nature of case studies specifically and qualitative research more broadly, is that 
they differ markedly from hypothesis driven, experimental research and therefore their 
quality should not be measured by the same concepts [161]. Case studies, as with 
any other research methodology, can be conducted well if relevant steps to ensure 
rigour are undertaken. This is discussed further in this chapter.    
4.3 Case study strategy 
My case study approach has been informed by the work from a number of leading 
case study researchers: Yin [158], Simons [157] and Stake [162] in particular. My 
academic and research background has followed a biomedical model of learning, 
rather than anthropological or ethnographic training. Thus I was drawn to case study 
approaches which felt comprehensible and achievable within my scope of experience 
and skills. Published articles by Baxter and Jack [156] and Crowe [155] have also 
been helpful. This chapter addresses the key components of this research including 
the case study design, plans for collecting, analysing and interpreting the data, and 
reporting the findings [155].  
4.3.1 Defining the case 
Miles and Huberman define a case as ‘…a phenomenon of some sort occurring in a 
bounded context’ (p.25) [163]. A case can also be defined by the research question(s), 
existing literature and prior knowledge of the setting or context [155]. Simons takes a 
less prescriptive approach to defining the case, suggesting that the case can instead 
be identified be as a ‘specific statement of the research focus’ (p.28) [157]. She also 
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believes that cases can be chosen because of an inherent interest in the case and 
more simply, ‘a general intent to understand what is happening in the case’ (p.29) 
[157]. As Baxter and Jack wrote, when defining the case it may be helpful to ask 
yourself as the researcher, what aspect will be under analysis – is it the individual or 
a programme? Or is the process the main research interest? Or perhaps the 
difference between organisations is where the research should focus [156].  
A helpful starting place for defining my case was to firstly identify the ‘phenomenon’; 
this was mainstreamed BRCA1/2 tumour testing, then consider the overall context of 
the phenomenon, i.e. genetic testing in ovarian cancer. Lastly, who the phenomenon 
involves, from patients and health professionals to histopathology staff. Some 
relevant research questions for this work focused on specific aspects of the 
phenomenon such as: How is BRCA1/2 tumour testing implemented for clinical use? 
How do patients experience BRCA1/2 tumour testing? What are the clinical outcomes 
of mainstreamed BRCA1/2 tumour testing?  
Drawing these elements together, I defined the case under study as, ‘The introduction 
of mainstreamed BRCA1/2 tumour testing: patient experiences and clinical 
outcomes’.  
4.3.2 Binding the case 
Both Crowe and Simons use the boundaries of the case to help define it [155, 157], 
as it can clarify not only what or who is under study, but the timeframe of the case 
study and the type of data that is needed [155]. Therefore, establishing boundaries 
within a case study are imperative for not only managing the scope of the research 
but also for focusing and framing the research [164].  
A case can be bound by: (a) by time and place; (b) time and activity [162]; and (c) by 
definition and context [155]. It is necessary to be both selective and specific in defining 
the parameters, including the participants, location, process and timeframe [164].  
It was helpful that there were some clear boundaries to this case, the first of which 
was time. PhD projects, as with other research, are often constrained by time with a 
distinct period for research planning, data collection and analysis. The case timeframe 
was also dictated by its activity; there were a specific number of tumour tests available 
for patients (fifty tests) and the timeframe was dictated by the time required to recruit 
the necessary number of participants. These tests were also allocated solely for use 
at a specific place, in the UCLH gynaecological oncology outpatient clinic. Participants 
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were defined as ovarian cancer patients who would be eligible for BRCA1/2 tumour 
testing as specified by the testing criteria.  
4.3.3 Determining the type of case study 
This component of case study research is sometimes referred to as selecting the case 
[155, 164], however Baxter and Jack refer to this aspect as considering what type of 
case study you plan to conduct [156]. The type or selection of case study may be 
determined by factors such as where the cases are located or what cases might lead 
to the most understanding about the phenomena [157]. However, it will also be guided 
by the overall study purpose [156].  
Two key case study researchers use different terms to describe and define different 
types of case studies, although these terms are now use widely within the case study 
literature. In particular Yin identifies exploratory, explanatory or descriptive case 
studies [158], while Stake categorises case studies as intrinsic, instrumental or 
collective [162]. These case study types are shown in the table below.  
Although there are differences to the study types, a case study can be both intrinsic 
and instrumental and categorising a case into one specific type can be challenging 
[165]. The selection of the case study type should also be guided by the overall study 
purpose – is the aim of this case study to describe, explore or compare a case?  
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Table 4.1 Examples of different case study types 
 
Case study type Definition 
Explanatory Employed to ‘explain phenomena’ 
Can explain causal relationships  
Useful for complex phenomena where survey or experimental 
methods would be inappropriate [166] 
Exploratory Useful for studying new phenomena or where outcomes are 
unknown 
Can be initial step for explanatory research and used to refine future 
research questions [167] 
Descriptive Describe a phenomena and real life context 
Intrinsic Not representative of other cases, unique [155] 
Researchers with genuine interest in the phenomena; intent is to 
better understand the phenomena [156] 
Case itself is of primary interest, research is driven by wanting to 
know more about uniqueness of the case. Often leads to thick 
description of the case. More focus on interpreting meaning rather 
than generalisation. Aims to reflect richness and complexity of the 
case [165] 
Instrumental Specific case chosen less important than selecting a case that 
allows investigation of an issue or phenomenon [155] 
Focus on specifics related to research question 
Attempts to identify patterns and themes  
Comparison with other cases [168] 
Collective Multiple case carefully selected 
Allows comparisons and/or replication to be made across cases 
[155] 
Explore differences within and between cases [156] 
 
When reflecting on this case, it holds properties which were both intrinsic and 
exploratory. As I will discuss later in the chapter, my background in genetic 
counselling and psychosocial research in cancer genetics have meant my interests 
have long lain in the field of genetic testing, and have now focused on this specific 
context of BRCA1/2 tumour testing in ovarian cancer.  
‘The real business of case study is particularisation, not generalisation. 
We take a particular case and come to know it well, not primarily as to 
how it is different from others but what it is, what it does’ (p.7) [162].  
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As Stake emphasises, a case study should aim to explore in detail the phenomenon 
and embrace its unique features, rather than making comparisons or drawing 
generalisations. Tumour testing is a new approach to BRCA1/2 genetic testing, and 
at the time this PhD was undertaken, not part of standard care for ovarian cancer 
patients. Given rapid changes in genetic testing technology, service delivery and for 
whom and how targeted treatments can be used, BRCA1/2 tumour testing may not 
be available or used in the same way, in this same context, again. Thus many features 
of this case are unique. This was an opportunity to explore in depth, not only how 
tumour testing can be implemented a mainstreamed model in clinical practice, but 
how it is used by oncologists and experienced by patients.  
4.4 Case study design  
There is no specific research design to follow for a case study. Rather, the design can 
be seen as a ‘blueprint’ for your research, which can be guided by what questions to 
study and determine methods of data collection and analysis [158]. Simons echoes 
this approach, as she writes ‘In many types of case study the design is more emergent 
than preordinate. It provides a starting point’ (p. 31) [157].  
However, some structure or plan is needed to undertake any kind of research. There 
are some elements of case study research design which were considered, these are 
discussed below.  
4.4.1 Formulating research questions 
Simons recommends starting case study design with identifying or refining the 
research questions as they can provide a framework and/or focus for the case study 
[157]. These questions can be returned to throughout the course of the research 
which allows reflection on whether or how well they have been addressed.   
Referring back to the case, ‘The introduction of mainstreamed BRCA1/2 tumour 
testing: patient experiences and clinical outcomes’, I developed research aligning to 
my specific research interests and previous experience. Having spent several years 
researching psychosocial aspects of genetic testing, focusing on patient experience 
was a priority for me. An oncology-led model of MGT is gaining ground in cancer 
centres across the UK although there is still a dearth of literature around patient 
experiences and outcomes. This was also an opportunity to contribute to the literature 
on this topic. A driver for both tumour and germline BRCA1/2 testing has been their 
potential to impact patient management and treatment decisions. Examining the 
71 
 
clinical outcomes is an important part of linking the outcomes from genetic testing to 
the clinical care of patients.   
What is perhaps neglected in this case study is the experience of the oncologists who 
are involved in delivering germline and tumour testing. Although this is also an area 
of interest for me, I had already anticipated some of the logistical challenges 
associated with organising tumour testing and felt I may be limited with time. However 
this would be an important area of further research, particularly if an oncology-led 
model of MGT becomes part of clinical care more widely across the UK. In future, an 
ethnographic approach could be used to study how oncologists offer and discuss 
genetic testing, and the form, nature and content of these patient-facing encounters.  
I also drew upon several key aspects of the case to specify my research questions. 
The first key aspect was determining the current state of BRCA1/2 genetic testing for 
ovarian cancer patients at UCLH by asking, ‘How is BRCA1/2 germline testing in 
ovarian cancer currently used in the gynaecology oncology department?’. Referring 
to the people of the case, ‘How do patients experience mainstreamed BRCA1/2 
tumour testing?’. The last research question is descriptive, seeking to answer ‘What 
are the clinical outcomes of BRCA1/2 tumour testing and how do they impact ovarian 
cancer care?’.  
4.4.2 Type of case study design 
A key decision in determining the type of case study design is whether the research 
is best undertaken as a single or multiple case study. In a multiple or collective case 
study design, the researcher is able to examine the case within as well as across 
settings. Thus comparison is sought and a collective case study often looks for 
differences within a case.  
Yin describes two types of single case study designs; a single ‘holistic’ case design 
where the case can be examined as a whole, or an ‘embedded’ design with subunits 
of analysis [158]. In an embedded single case study design, the subunits provide an 
opportunity for a more complex or extensive analysis and have the potential to 
enhance insights into the case. It is crucial that focus remains on the original case, as 
neglecting this will shift the aims and orientation of the intended research [158]. Other 
key authors in case study research and referenced in this chapter do not make a 
distinction between holistic and embedded study designs. However their use of 
multiple methods (discussed further below) and examining different aspects within a 
single case are not dissimilar.  
72 
 
Returning to the defined case, the overall context is genetic testing in ovarian cancer 
while the case is the introduction of mainstreamed BRCA1/2 tumour testing at UCLH. 
The embedded subunits will be used to explore the research questions around the 
use of genetic testing, patient experience and clinical outcomes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Embedded single case study 
 
4.4.3 Multiple methods and data sources 
Using different or multiple methods to collect and analyse data is an approach that is 
encouraged in case study research. As noted by Baxter and Jack a case study 
approach ‘…facilitates exploration of a phenomenon within its context using a variety 
of data sources’ (p.544) [156]. In particular, case studies which explore programmes, 
hierarchies or institutions would find using multiple methods helpful in order to develop 
a comprehensive understanding of the issue under study. Simons identifies three 
commonly used qualitative methods which ‘…facilitate in-depth analysis and 
understanding’ as observations, interviews and document analysis (p.33) [157].  
There is a distinction between a case study using multiple methods, sometimes 
referred to as a mixed methods case study, and mixed methods research. In a case 
study, although different or multiple methods are used, these methods are integrated 
and share the same research question [158]. Yin argues that in comparison, mixed 
methods research uses different methods in separate studies which are then 
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combined [158]. Some case studies already represent mixed-methods research to 
some degree. In an embedded single case study, different research methods may be 
used between analysis of the main case and embedded subunits.  
Multiple data sources are typically found in case study research in comparison to other 
research methodologies such as experiments or surveys [158]. Use of multiple data 
sources from the same phenomenon is referred to as triangulation, and can be a 
method of increasing the validity of the research [155, 169].  What is key to using 
multiple methods and multiple data sources are that the findings are converged and 
considered together, with all data contributing to the researcher’s understanding of 
the phenomenon under study.  
Ultimately the methods and data sources that are chosen should reflect the research 
aims and questions. In this case study the overall case was the introduction of 
mainstreamed BRCA1/2 tumour testing at UCLH. To explore the activity of the case, 
I organised BRCA1/2 tumour testing for all patients who consented to testing. This 
gave me first-hand experience of what introducing a new mode of genetic testing 
entailed, from developing a new testing pathway within the clinical service, to 
retrieving tumour blocks and reviewing them with the consultant pathologist, and 
finally packaging tumour blocks to send to the Myriad laboratories in Germany. This 
is discussed further in Chapter 6.  
The embedded subunits address the research questions and are summarised in the 
table below. Each method and data source will be discussed briefly; a more detailed 
discussion of the methods, data collection and participants are provided in each 
chapter.  
Table 4.2 Research methods 
Research question Method to answer research question 
How is genetic testing currently used for 
ovarian cancer patients at UCLH? 
Service evaluation of existing MGT 
service 
How do patients experience mainstreamed 
BRCA1/2 TT*? 
Quantitative surveys and qualitative 
interviews  
What are the clinical outcomes of BRCA1/2 
TT? 
Provision of TT, reviewing TT results 
and medical records 
 
*TT = tumour testing 
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4.4.3.1 Service evaluation 
A service evaluation aims to define or judge the current healthcare service of interest, 
with the purpose of using the outcomes from the evaluation to inform the service and 
local decision-making [170]. It differs from a clinical audit which is a systematic 
assessment of resource use as well as the impact of care on patient clinical outcomes 
and quality of life. A service evaluation can be seen as an in-depth study of the service 
of interest at a discrete point in time, which is key to a case study approach where the 
specific context is crucial for shaping our understanding of the case.   
To begin my research, it was important to establish the context of my research and 
address the research question, ‘How is genetic testing currently used for ovarian 
cancer patients at UCLH?’. To answer this I conducted a service evaluation to review 
the current state of BRCA1/2 genetic testing for ovarian cancer patients at UCLH. 
BRCA1/2 germline testing for ovarian cancer patients with high grade non-mucinous 
disease was implemented in 2015 at UCLH using a mainstreamed model of testing 
delivery. The service evaluation focused on the first year of MGT and sought to define 
who was being tested, the outcomes of testing and how the results of testing were 
used by oncologists. This is discussed further in Chapter 5.   
4.4.3.2 Questionnaires 
Questionnaires are popular research instruments and are often used in health care 
based research as a method to generate large amounts of data. Validated 
questionnaires have been rigorously tested for reliability and validity during the 
development process [171]. They also allow comparison with published data where 
the same questionnaire has been used.  Although qualitative methods may be used 
more commonly in a case study approach, quantitative techniques can be of value; 
Baxter and Jack believe using quantitative survey data can facilitate a ‘holistic 
understanding of the phenomenon being studied’ (p.554) [156]. When used to 
supplement other data sources, questionnaires can provide empirical data for high-
quality case studies [172]. 
To explore the research question relating to how patients experience mainstreamed 
BRCA1/2 tumour testing, I decided to use both quantitative and qualitative methods. 
The aim was to collect quantitative data from each participant who consented to 
BRCA1/2 tumour testing. Questionnaires were completed by patients at three 
timepoints along the tumour testing pathway from the offer of testing to receiving 
results. Validated measures across topics such as quality of life, attitudes and 
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knowledge towards genetic testing, decision-making and psychological distress were 
used. Choice of measures and results of questionnaires are discussed further in 
Chapter 7.   
4.4.3.3 Interviews 
Qualitative methods, in particular interviews, are ideal for new or poorly understood 
topics, and when we wish to describe and understand experiences, ideas, beliefs and 
values from the perspective of the local population [173]. Interviews are one of the 
most common methods in qualitative research and have been a key element of case 
study research. Interviews can document the interviewee’s perspective on a topic, 
engage in dialogue with the interviewee, explore a topic in greater depth, and provide 
important insights into the phenomenon of interest [157].  
There are acknowledged limitations with interview data, such as bias from both the 
researcher in the articulation of questions, and response bias from interviewees [158]. 
There may be inaccuracies in interviewee stories due to poor recall particularly if the 
interview is retrospective in nature.   
In this research, interviews were a significant component of exploring how patients 
experience BRCA1/2 tumour testing. The interviews would overlap on some topics 
included in the questionnaires to develop a deeper understanding of the issues, as 
well as acting as a ‘check’ of the findings observed so far while allowing for new, 
emergent data.   
A number of patients who underwent BRCA1/2 tumour testing were interviewed after 
receiving their results. Development of the interview schedule, participant details and 
findings are discussed further in Chapter 8.  
4.4.3.4 Clinical data  
To collect data on the outcomes of genetic testing, testing reports for all patients who 
had undergone BRCA1/2 tumour testing, and in some case germline testing, via MGT 
were reviewed. Relevant clinical data such as diagnosis, date of diagnosis, disease 
histology and treatment history, was collected from hospital medical notes. This is 
discussed further in Chapter 6.  
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4.5 Philosophical underpinnings   
Reflecting on the philosophical paradigm which underpins research is an important 
part of developing a robust and rigorous study. In case study research, the way in 
which the case is approached and the research designed will be influenced by the 
philosophical position of the researcher. As Mills et al wrote, “To ensure a strong 
research design, researchers must choose a research paradigm that is congruent with 
their beliefs about the nature of reality’ (p.2) [174].  
Fossey et al believe that the philosophical paradigm is ‘…a system of ideas, or world 
view, used by a community of researchers to generate knowledge. It is a set of 
assumptions, research strategies and criteria for rigour that are shared, even taken 
for granted by that community” (p.718) [175].  
This system of ideas includes four key components: ontology, epistemology, 
methodology and methods [176]. Simply put, ontology is the study of reality or the 
fundamental nature of existence where an ontological question might ask ‘What is 
there?’. The role of ontology is to help researchers consider the certainty of nature 
and the existence of objects or subjects that we research. Epistemology is the study 
of knowledge, asking questions such as, ‘What do you know?,’ and, ‘How do you 
know it?’. An epistemological standpoint influences how we discover knowledge about 
that reality. Methodology is the strategy behind which methods are chosen and why, 
and asks, ‘How can we find out?’. Methodology will determine why, what, from where, 
when and how data is collected and analysed [176]. In turn the methods are the 
specific procedures to collect and analyse the data. The paradigms can use different 
methods to explore their research questions, using both or either quantitative or 
qualitative data.  
Table 4.3 below outlines different research paradigms and their corresponding 
ontologies and epistemologies. This is by no means an exhaustive list, but a summary 
of the paradigms that are most commonly found within a case study methodology. 
Although there are clear distinctions in assumptions of reality, truth and knowledge, 
there are also shared features between paradigms, with overlapping ontologies and 
epistemologies. By reviewing the various paradigms and their underlying 
philosophies, one is able to draw upon more than one paradigm or be informed by 
various epistemologies; Crowe believes this flexibility is particularly useful when 
conducting health services research [155].  
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Table 4.3 Research paradigms, ontologies, epistemologies and methodologies 
Paradigm Ontology Epistemology Methodology 
Positivism 
• Explain relationships, identify cause 
and effect 
• Seeks verifiable evidence  
• Basis for prediction and generalisation 
• Deductive approach 
• Impartial and value neutral 
• Focus on facts 
• Does not allow subjective opinion of 
researcher 
Realism 
• Objective 
• Objects exist independent 
of the knowledge of their 
existence 
• Reality exists independent 
of the researcher  
• Truths are absolute and do 
not change based on 
culture or history 
 
Objectivism  
• Impartial 
• Discovering absolute knowledge 
about an objective reality 
• Researcher and phenomena are 
independent entities 
• Removes all contextual factors 
• Phenomena is independent of 
human subjectivity and/or 
influence 
• Knowledge is discovered through 
impartial observation 
• Empirical studies, 
random samples, 
controlled variables 
and control groups 
• Large samples 
 
Post-positivism 
• Seeks to understand causal 
relationships  
• Unlike positivism, participants’ 
perspectives are sought 
• Knowledge is tentative and fallible 
• Knowledge can be shaped by 
contextual influences 
• Knowledge is not confined to what can 
be only be observed 
Critical-realism 
• Contemporary uptake of  
realism 
• Reality is interpreted 
through social conditioning  
• Knowledge is achieved by 
observation and reasoning  
Objectivism 
 
• Experimentation, 
correlational studies 
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Interpretivism 
• Multiple forms of reality, meanings and 
understanding 
• Reality is interpretations by individuals 
• Knowledge is subjective and relative to 
circumstances 
• Context affects experiences and 
meaning  
• Role of researcher is critical – beliefs 
and feelings guide research and 
influence interpretation  
• Focus on recognising and narrating the 
meaning of human experiences and 
actions  
Relativism 
• Reality cannot be separated 
from the subjective 
experience 
• Data and observations 
influenced by the observer 
• Multiple interpretations of 
experience lead to multiple 
realities 
• Aim is to understand the 
subjective experience of 
reality and multiple truths 
• Belief that reality is a finite 
subjective 
Subjectivism 
• Knowledge filtered through lenses 
of ethnicity, social class, 
language 
• Value laden 
• Observations influenced by 
observer, and vice versa 
• Aims to understand and be more 
sensitive to ethical and moral 
issues 
 
 
• Multiple methods to 
establish different 
views 
• Small samples 
researched in depth 
or over time 
• Qualitative 
• Case studies, 
phenomenology 
Constructionism 
• Knowledge is constructed 
• Truth is relative and dependent on 
perspective 
• Close collaboration between researcher 
and participant – meaning is created  
• Participant stories inform researcher 
understanding 
• Researcher is separate but not truly 
objective from phenomena under 
observation 
Critical realism Subjectivism • Qualitative 
• Interviews, 
document reviews, 
observations, case 
studies  
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Embracing the flexibility extolled by Crowe, there is more than one paradigm which 
has underpinned this work. Overall, the interpretivist paradigm best fits with my 
philosophical beliefs; that knowledge is relative and subjective and there are multiple 
meanings and ways of knowing. With a relativist ontology I accept that there is no 
single reality. As Corbin and Strauss wrote, ‘…I realise there is no one ‘reality’ out 
there waiting to be discovered’ (p.10) [177]. Acknowledging and recognising my 
influence on the research I conduct and analyse is key to a subjective epistemology. 
Again, Corbin and Strauss articulate this, as they believes it is not possible to 
‘…separate who I am as a person from the research and analysis that I do’ (p.11). 
There are also constructivist elements to my research, as I recognise that the 
collaboration between researcher and participant is where meaning is generated; 
research is a joint product of participants and the researcher. Furthermore reality can 
be socially constructed and dependent on the individual perspective. Meanings are 
generated within a particular social context, and it is likely that the same work 
undertaken by a different researcher will produce different knowledge and 
conclusions. By using quantitative methods in the form of questionnaires and 
validated measures, where the research is seen as confirmatory rather than 
exploratory, there are elements of a post-positivist paradigm. Although this data is 
considered collectively, I am aware of the individual and subjective way which the 
data was completed by participants and collected by myself.    
4.6 Analysis 
There are very different approaches to case study analysis which may be dependent 
on the aims and design of the research, but also on the researcher. Key authors in 
the case study field describe different analytic techniques, for example Yin describes 
five specific techniques: pattern matching, explanation building, time-series analysis, 
logic models, and cross-case synthesis [158], while Stake uses categorical 
aggregation and direct interpretation [162] and Crowe refers to the Framework 
approach [155]. Baxter and Jack emphasised the importance of reviewing various 
analysis types to determine which approach is not only appropriate for your research 
design, but that you feel most comfortable with using [156]. Regardless of the analysis 
chosen, clearly describing the analysis process and rationale is important for rigorous 
research.   
My research data includes clinical data such as genetic testing reports and medical 
records, quantitative data from questionnaires, and qualitative data from interviews. 
Using multiple and diverse methods in this research presented a challenge to 
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developing a cohesive analysis plan. Applying one specific analytic technique to the 
whole data set felt incongruous, as many of these techniques did not offer the 
flexibility to include quantitative data. Furthermore some of the techniques aim to be 
explanatory, looking for causal effects in the data. In contrast, this research is 
explorative and descriptive, and though there are specific research questions 
articulated, they act to focus the research into a discrete and comprehensible 
component.   
Thus what I found most helpful and methodologically sound, was to analyse my 
quantitative, qualitative and clinical data separately, whilst being clear about the 
analysis methods chosen and the procedures I followed (discussed further in each 
chapter). Simons’ position is that analysis cannot be discussed without also 
discussing interpretation; ‘...interpretation is the key process for making sense of what 
has been learned’ (p. 118) [157]. This echoes the interpretivist paradigm guiding my 
research, and it is with this approach in mind that I draw together the findings from 
each embedded subunit together in the final chapter of my thesis. 
4.7 Ethical processes 
4.7.1 Formal ethics procedures 
A service evaluation does not require Research Ethics Committee (REC) or Health 
Research Authority (HRA) approval. To ensure I approached this aspect of my 
research rigorously I felt it was important that the aims, data collection plan and 
intended outcomes of the service evaluation were reviewed by a relevant governance 
body. The UCLH Applied Health Research in Cancer Governance Group reviewed 
and gave approval for the service evaluation to be conducted. 
For the patient experience component of this research, ethical approval was granted 
by the Hampstead REC and HRA (REC reference: 16/LO/1226, IRAS: 199605). This 
included permissions to collect relevant clinical data from participants.   
Both approval documents can be found in the Appendix.  
4.7.2 Conducting research ethically 
Formal ethics procedures, as noted in the section above, help to ensure that the 
research is conducted in an ethical manner in terms of the study design, data 
collection, analyses and published outcomes of research. However, as Simon notes, 
‘It is not possible to govern ethical behaviour through forms and procedures’ (p. 100) 
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[157]. Reflecting on the nature of ethics and what it means to conduct research 
ethically, Simons’ definition resonated with me: ‘[Ethics] means establishing 
throughout the research process a relationship with participants that respects human 
dignity and integrity and in which people can trust’ (p. 96). This is particularly fitting 
for case study research, which can often involve prolonged periods observing and 
interviewing participants.  
Whilst my research did not involve formal observations, in the process of conducting 
the service evaluation, recruiting ovarian cancer patients, organising BRCA1/2 
tumour testing and reviewing clinical data, I spent 12 months embedded within the 
UCLH gynaecological oncology team. Inevitably this time spent interacting with 
patients, participants, clinicians and other researchers raised some ethical and 
reflexive issues around expectations of my role, of establishing and maintaining trust 
and researcher-participant relationships. I discuss and reflect on these experiences 
in the relevant chapters.   
4.8 Rigour and research quality 
Although ‘rigour’ is often referred to in mainstream science and research following a 
positivist paradigm, it is not a term that is typically used within case study research; 
neither Simons [157], Stake  [162] nor Yin [158] explicitly refer to rigour within their 
books. However the authors do discuss two key aspects of rigour, validity and 
reliability, as criteria for judging the quality of the research design. Yin believes that 
internal validity, the extent to which a study can rule out or make unlikely alternate 
explanations of the results, should not be used for descriptive or exploratory studies 
[158]. Simons adds that other forms of validity, such as construct validity and 
reliability, are not applicable to qualitative case study research [157].  
These discrepancies highlight the struggle within the qualitative research domain 
about how to define and determine ‘rigour’. Guba and Lincoln developed alternate 
criteria to measure rigour and judge the quality of research – striving towards an 
overarching goal of trustworthiness through credibility, transferability, dependability, 
and confirmability [as cited in 171]. More recently Morse evokes a return to the 
mainstream terminology of rigour, validity, reliability and generalisability [178]. In her 
paper she critiques the strategies currently used to achieve rigour, accepting some 
strategies with caveats, while actively suggesting to avoid others. Some strategies 
appropriate and relevant to use for achieving validity and reliability in qualitative 
research are suggested below, although Morse remains critical about most strategies: 
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• Prolonged engagement, persistent observation, and thick, rich description 
• Interrater reliability, negative case analysis 
• Peer review or debriefing 
• Clarifying researcher bias 
• Triangulation. 
In the development of an 8 point quality assessment for qualitative research, Tracy 
lists four questions as a guide to achieving rigour [179]: 
• Are there enough data to support significant claims? 
• Did the researcher spend enough time to gather interesting and significant 
data? 
• Is the context or sample appropriate given the goals of the study? 
• Did the researcher use appropriate procedures in terms of field note style, 
interviewing practices, and analysis procedures? 
Considering the suggestions provided by Morse and Tracy to achieving rigour, I found 
neither to be sufficiently comprehensive to encompass my research methods and this 
case study approach. Instead I found the guidance on rigour from Liamputtong and 
Ezzy to be informative, logical and inclusive. The authors believe that validity and 
reliability are important issues to be considered in research but need to be 
conceptualised differently for a qualitative framework [173]. They describe six criteria 
to ensure rigorous research which I chose to employ in my research, shown in the 
table below.   
Table 4.4 Criteria for conducting rigorous research  
Criteria Description 
Theoretical rigour 
Sound theoretical/conceptual argument and appropriate 
choice of methods 
Methodological or 
procedural rigour 
Explicit account of research process and analysis 
Interpretative rigour Clear demonstration and justification of interpretation  
Triangulation Use of multiple methods and/or data sources 
Evaluative rigour – ethics 
and politics 
Addresses ethical procedures and ethical conduct 
Rigorous reflexivity Examines role of the researcher  
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Not all aspects of rigorous research are achieved during the design phase, in fact 
Morse believes that rigour should be achieved during the process of data collection 
and analysis [178]. However, these criteria provide an important basis from which to 
conduct rigorous research and therefore are helpful to consider at this point. In this 
thesis I have tried to address each of the six criteria. In this chapter have described 
the philosophical paradigm that guides this research to reflect theoretical rigour. To 
address methodological rigour, in the following chapters the research process and 
analysis are detailed for each embedded subunit. By using different methods, in this 
case a service evaluation, clinical data, qualitative interviews and quantitative 
questionnaires, this will hopefully lead to a comprehensive understanding of the case 
under study. Triangulation also becomes key in the final chapter as I draw together 
the different methods and data sources in the subunits to present a cohesive account 
of the case in its context. The ethical procedures have been described earlier in this 
chapter while I address ethical conduct later in Chapter 6.  
4.9 Reflexivity 
I have purposefully chosen to present my research in first person to reflect reflexivity. 
As an instrument of the research, writing in the first person acknowledges my role in 
the research and the impact this has on the participants, analysis process and 
dissemination of findings. Reflecting the interpretivist paradigm, Webb believes that 
writing in first person is acceptable when the researcher has played an important role 
in shaping the data or ideas presented [180].  
Reflexive research requires an awareness of the researcher’s contribution to the 
research process and how this influences and informs the research. As Rice and Ezzy 
wrote: ‘Reflexive research acknowledges that the researcher is part and parcel of the 
setting, context and culture they are trying to understand and analyse. That is to say, 
the researcher is the instrument of the research.’ (p. 41) [173].  
Simon emphasises the importance of examining the ‘self’ in case study research, as 
‘You are the main instrument of data gathering; it is you who observes, interviews, 
interacts with people in the field’ (p.81) [157]. Declaring values, preferences and world 
view is an acknowledgement of these influences on your actions, decisions and 
interpretations of the research.  
I present some details about myself that may have had an impact on how I conducted 
and analysed the research. These characteristics may have influenced the way in 
which the participants responded and engaged with me in the research process. As 
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Webb states, participants ‘…make judgements about researchers’ backgrounds, 
motives, intentions, beliefs and preferences and respond as they judge appropriate’ 
(p. 749) [180]. 
In my professional background, I have been a researcher in psychosocial aspects of 
cancer genetics for nearly ten years. I am also a qualified genetic counsellor, having 
completed my Masters in 2009 from the University of Melbourne. These days I am 
much more likely to describe myself as a researcher, having gone straight from my 
Masters into a research role, than a genetic counsellor. However the influence of my 
training and experiences during this time means I remain at heart a genetic counsellor 
and this is the lens through which I view, interpret, communicate and conduct my 
research.   
In the introduction chapter I touched on some of the key components of genetic 
counselling, such as non-directiveness, informed decision-making and 
communication skills. These components influenced not only my approach to 
undertaking my research, participant recruitment and engaging with patients, but also 
my expectations of what the genetic testing process and experience ‘should’ be.  MGT 
is a significant departure from the traditional format of genetic counselling and testing 
which I’ve highlighted in the first two chapters of this thesis, where my experience and 
understanding of testing is drawn from. Throughout this thesis where relevant I 
acknowledge the influence of my preconceptions on my research conduct and 
interpretation of the data.  
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Chapter 5 Service evaluation of mainstreamed BRCA1/2 
testing in ovarian cancer at UCLH 
 
5.1 Introduction 
Chapter 1 and 2 of this thesis have provided both an introduction to and a more 
detailed description of MGT. To summarise, there have been a number of factors 
contributing to a move towards providing BRCA1/2 genetic testing to more ovarian 
cancer patients, including: 
• Recognition that family history is no longer the ‘gold standard’ for determining 
eligibility for genetic testing  
• Prevalence of germline BRCA1/2 mutations in ovarian cancer patients is high  
• Changes to national guidelines (NICE, Guideline CG164) recommending 
lowering the mutation detection threshold to 10%  
• The first PARP-inhibitor, olaparib, licensed for use in the UK.  
A mainstreamed model allows for a greater number of women with ovarian cancer to 
access BRCA1/2 germline testing, with the intention of identifying more patients who 
are able to access targeted therapies and unaffected relatives who may benefit from 
predictive testing and/or risk reducing interventions. This approach is becoming 
increasingly adopted by gynaecological oncology services in the UK; several centres 
across the UK have implemented systematic genetic testing for women with high 
grade non-mucinous or serous ovarian cancer, either via oncology or clinical genetics.  
This chapter presents the first embedded subunit of research and data collection of 
this thesis and was a key component of the case study, describing the context into 
which BRCA1/2 tumour testing would be introduced. It provided an opportunity to not 
only develop an understanding of how the MGT works as a clinical service, but how 
genetic testing, both the service and the outcomes, are used by clinicians. It was also 
an opportunity to familiarise myself with the gynaecological oncology department 
which was to be a key part of my remaining PhD research.   
5.2 MGT service at UCLH 
At University College London Hospital (UCLH), MGT was implemented as a clinical 
service in the gynaecological oncology department in April 2015, and is ongoing. At 
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the time of implementation, there was no core funding for systematic germline 
BRCA1/2 testing for ovarian cancer patients. I was involved in the development of a 
funding proposal to the UCLH Charity to provide BRCA1/2 germline testing to all 
UCLH ovarian cancer patients with a diagnosis of high grade non-mucinous disease. 
The UCLH Charity initially funded BRCA1/2 germline testing for 12 months which 
enabled the MGT service to begin.   
UCLH adopted an oncology-led approach to MGT; information and consent for 
genetic testing as well as return of results was managed by the patient’s oncologist 
during her standard outpatient appointments. Oncologists and other relevant staff 
such as clinical nurse specialists and registrars were provided with training on 
ordering, discussing and consenting for germline BRCA1/2 testing by the Royal 
Marsden Mainstreaming Cancer Genetics programme [181]. Oncologists requested 
germline testing using specialised test request forms, with blood samples for testing 
taken from the Macmillan Cancer Centre phlebotomy service and delivered to NE 
Thames Regional Genetics Laboratories, GOSH, where all BRCA1 and BRCA2 
germline testing was undertaken. Eligibility for MGT was a diagnosis of high grade 
non-mucinous ovarian cancer, with no age or family history restrictions. Testing was 
offered both prospectively to newly diagnosed patients, and retrospectively to patients 
who may have been many months and even years from diagnosis but still under 
follow-up at UCLH. Women who were identified as carrying a BRCA1/2 mutation or 
VUS were referred to their local clinical genetics service, typically North East or North 
West Thames Regional Genetics Service, for genetic counselling. 
5.3 Aims 
As the implementation of MGT was a new approach to providing BRCA1/2 germline 
testing to women with ovarian cancer at UCLH, a service evaluation was undertaken 
after 12 months. A service evaluation can define a current service, as well inform the 
development or improvement of a service.  
The primary aim of this service evaluation was to describe the patient cohort at UCLH 
who had undergone MGT and to determine the prevalence of BRCA1/2 mutations. 
Secondary aims included evaluating: procedural outcomes such as timing of testing, 
and clinical outcomes such as changes to treatment and referral to clinical genetics.  
Results from the evaluation were fed back to the gynaecological oncology 
department, as well as the hospital funding body.  
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5.4 Methods 
5.4.1.1 Governance approval 
The UCLH Applied Health Research in Cancer Governance Group granted approval 
for this service evaluation in January 2017. This document can be found in the 
Appendix. 
5.4.1.2 Germline testing results 
The first step of this service evaluation was to determine which patients had been 
tested in the first 12 months of MGT.  
There was no separate database for recording genetic testing activity for UCLH 
ovarian cancer patients who had testing via MGT. Instead, once testing was complete, 
genetic testing reports from NE Thames Regional Genetics Service were returned to 
the requesting oncologist at UCLH by post, and subsequently scanned into the 
patient’s online clinical files in the Clinical Data Repository (CDR). Not all reports were 
clearly labelled as genetic testing reports which made identification challenging. Some 
oncologists would note the patient’s BRCA1/2 mutation status in their clinic letter 
headers which were duplicated and then updated after each clinic, however this was 
also practiced inconsistently.      
NE Thames Regional Genetics Service provided a list of all UCLH patients who had 
BRCA1/2 germline testing via MGT from February 2015 to April 2016. Using this as a 
reference, clinical files on CDR were reviewed for all patients who had been tested 
via MGT. Information on current age, date of diagnosis, diagnosis, pathology, genetic 
testing result and treatment was collected from CDR. The two local clinical genetics 
services were contacted to review referral patterns and family history data of patients 
who were identified as BRCA1/2 mutation positive or with a VUS. 
5.5 Results 
5.5.1 Patient characteristics 
122 women with ovarian cancer had BRCA1/2 germline testing via MGT between 
February 2015 and April 2016. Most patients (100/122, 82%) had high grade serous 
cancer, with stage III or IV disease (95/122, 78%). The median age at diagnosis was 
62 years (range 28-88), with 68 (56%) aged younger than 60 years at diagnosis. 
Patient characteristics are presented in Table 5.1 below.  
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Table 5.1 Summary of patient characteristics 
 BRCA1/2 mutation 
(n=18) 
BRCA1/2 VUS 
(n=9) 
No mutation 
(n=95) 
Age (years), median 
(range) 
58 (42-74) 66 (55-70) 62 (28-88) 
BRCA1 mx, n  10  3  0 
BRCA2 mx, n  8  6  0 
Pathology, n    
    Clear cell 0 0 5 
    Carcinosarcoma 1 0 4 
    Endometrioid 0 0 9 
    High grade serous 17 9 74 
    Mixed 0 0 2 
    Other 0 0 1 
Stage, n    
    I 0 1 14 
    II 1 1 9 
    III 10 4 45 
    IV 7 2 27 
    Not classified 0 1 0 
 
 
5.5.2 BRCA1/2 mutation carriers 
18 pathogenic mutations were identified via MGT: 10 BRCA1 and 8 BRCA2. Nine 
VUS were also identified. Known Ashkenazi Jewish/Polish founder mutations 
comprised 11% of pathogenic mutations (2/18). 
The median age of BRCA1/2 mutation carriers was 57 years (range 42-74 years), 
compared to 66 and 62 years in the VUS and no mutation groups, respectively. There 
was no significant difference in age at diagnosis between women with a BRCA1/2 
mutation and those without (Mann Whitney U test U =1125, z=1.369, p=.171). BRCA1 
mutation carriers were significantly younger at diagnosis than BRCA2 carriers 
(t(16)=2.84, 95% CI (18.4, 2.7), p=0.012). Almost all BRCA1/2 mutation carriers 
(17/18, 94%) had high grade serous histology; one patient had a carcinosarcoma. 
Similarly, almost all were diagnosed with stage III or IV disease (17/18, 94%).  
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Overall, the prevalence of BRCA1/2 mutations in this cohort was 14.8% (18/122). A 
large cohort of epithelial ovarian cancer patients reported a similar prevalence rate of 
14.1% [12]. Data from three UK sites offering systematic BRCA1/2 testing to ovarian 
cancer patients reported a prevalence of 7.8% in East Anglia [74], 15.9% in South 
West London [73] and 12.9% in Scotland [75] (shown in Table 5.2 below).  
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Table 5.2 Prevalence of BRCA1/2 mutations from systematic genetic testing in the UK 
 
*Reporting data from the ‘prevalent population’ and ‘new criteria’ groups  
**One patient had mutations in both BRCA1 and BRCA2  
Site UCLH East Anglia Royal Marsden Scotland* 
Timeframe 14 months 12 months 17 months 18 months 
Patient group 
High-grade non-mucinous 
EOC 
High-grade serous or 
endometrioid EOC 
Non-mucinous OC  Non-mucinous EOC  
Context Clinical service Research Research Clinical service 
MGT strategy 
Testing offered and 
organised by treating 
oncologist; results 
disclosed by oncologist 
Recruited by clinical team; 
testing offered and 
organised by research 
genetic counsellor; normal 
results disclosed by clinical 
team, mx+ve results 
referral to clinical genetics 
Testing offered and 
organised by approved 
cancer team member, 
results sent by letter to 
patient from genetics team 
East Scotland: Testing 
offered and organised by 
oncologist; in Aberdeen 
also telephone counselling 
from clinical genetics 
West Scotland: patients 
referred to clinical genetics 
Patients tested 122 232 207 394 
BRCA1 mx 10 12 17 25** 
BRCA2 mx 8 6 16 27** 
VUS 9 15 Not reported 30 
Overall BRCA mx prevalence 14.8% 7.8% 15.9% 12.9% 
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2015-2016 
5.5.3 Testing process and timing 
All BRCA1/2 germline testing by NGS and multiplex ligation-dependent probe 
amplification (MLPA) was performed by NE Thames Regional Genetics Service 
Laboratories.  
The median time from request receipt to results delivered was 26 working days (range 
14-48 days). On average, 8 BRCA1/2 germline tests were performed each month. 
The number of tests and mutations identified per month is highlighted in the figure 
below.  
 
 
Figure 5.1 Mutation detection rate per month   
 
As MGT was not restricted to newly diagnosed patients, less than half of patients had 
been diagnosed within the 12 months prior to testing (56/122, 46%). Within the newly 
diagnosed group, 19 patients were offered BRCA1/2 testing within one month of their 
diagnosis (35%).  
Amongst BRCA1/2 mutation carriers, ten patients (56%) had been diagnosed within 
the last 12 months, six of whom were tested shortly after diagnosis (within one month). 
Eight patients had been diagnosed between 21 to 104 months prior to BRCA1/2 
testing. 
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5.5.4 Clinical genetics and family history 
At the time of this evaluation, from 18 BRCA1/2 mutation carriers, four patients (22%) 
had not been referred to their local clinical genetics service for genetic counselling. 
Two of these patients were subsequently referred, 98 and 127 working days from date 
of MGT results. Of the remaining patients, most were referred promptly between 12 
and 43 working days after their MGT results were reported. Only two patients (22%) 
who received a VUS result were referred to clinical genetics.  
Due to referral delays to clinical genetics or because referred patients had yet to 
attend their genetic counselling appointment, family history data was only available 
for 13 BRCA1/2 mutation carriers. Using the Manchester scoring criteria, nine patients 
had some or a strong family history; four patients had no significant family history and 
would not have met previous guidelines for BRCA1/2 genetic testing (i.e. Manchester 
score <15) [182]; this is shown in Table 5.4 below. For predictive testing amongst 
family members of BRCA1/2 carriers, 15 family members had been referred to clinical 
genetics services with 11 undergoing testing.  
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Table 5.3 Family history and testing eligibility by Manchester score 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
Family history 
MGT 
result 
Notes 
Manchester 
score >15 
Only patient affected BRCA1 Small pedigree No (13) 
Only patient affected BRCA2 Patient BC and OC Yes 
Only patient affected BRCA2  No (10) 
Only patient affected BRCA1  No (13) 
Sister cancer of unknown primary, daughter bowel cancer 33 BRCA1 Patient BC and OC Yes 
Daughter breast cancer 44 BRCA2  Yes 
Mother cervical and pancreatic cancer 70s BRCA2  No (14) 
Maternal grandmother breast cancer 40s, paternal uncle prostate cancer 70s, paternal aunt 
breast cancer 31 
BRCA1 AJ founder mutation Yes 
Mother ovarian cancer, maternal grandmother ovarian cancer BRCA1  Yes 
Daughter breast cancer 41, mother breast cancer 40s, brother colorectal cancer 60s BRCA2  Yes 
Mother ovarian cancer, sister cervical cancer 30s, maternal aunt ovarian/cervical cancer  BRCA1  Yes 
Father lung cancer 60s, brother oesophageal cancer, sister breast cancer 70s, maternal 
cousin breast cancer 65 
BRCA2  Yes 
Sister cervical cancer 25, mother breast cancer 57, maternal half-sister cervical cancer 33, 
maternal aunt gastric cancer 33, maternal uncle colorectal cancer 53, maternal uncle bladder 
cancer 38, maternal first cousin breast cancer 42, paternal grandmother ovarian cancer 61 
BRCA1  Yes 
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5.5.5 Clinical management BRCA1/2 mutation carriers 
Clinical outcomes were reviewed for the 18 patients identified as carrying pathogenic 
BRCA1/2 mutations. For 67% (11/18) there was no change to current treatment; four 
patients were undergoing first line chemotherapy, three patients had completed first 
line chemotherapy and were on maintenance treatment (bevacizumab), and four 
patients were undergoing or had completed second line chemotherapy treatment.  
Six patients (33%) had been able to access PARP-inhibitors due to their mutation 
carrier status. Four patients were taking olaparib, one patient had accessed rucaparib 
via a Clovis Oncology compassionate use programme and one patient was 
participating in an olaparib clinical trial. When family history data was reviewed, data 
was available for five of these patients; three did not meet previous criteria for 
BRCA1/2 genetic testing.  
One patient was deceased eight months after receiving MGT results without any 
change to her treatment plan. 
5.5.6 Germline vs tumour testing  
Within this cohort of patients who had mainstreamed BRCA1/2 germline testing, two 
patients who had received germline negative results from MGT were later found to 
carry somatic BRCA1/2 mutations on tumour testing as part of clinical trial 
participation.  
5.6 Discussion 
MGT at UCLH provided BRCA1/2 germline testing to 122 ovarian cancer patients, 
with 18 women identified as carrying a BRCA1 or BRCA2 mutation. This mutation 
prevalence of 14.8% is similar to international published data [12]. There is now data 
available on BRCA1/2 mutation prevalence in other UK ovarian cancer cohorts, as 
shown in Table 5.2. The variation in prevalence between the four UK sites may be 
due to a number of factors. The lower detection rate in East Anglia of 7.8% may be a 
result of prospective testing only newly diagnosed patients and a lack of ethnic 
variation; in particular no Ashkenazi/Polish founder mutations were identified [74]. The 
higher detection rate of 15.9% at the Royal Marsden may be due to a population 
enriched for younger patients, as an age cut-off of less than 65 years was used for 
the first 9/16 months of MGT [73]. The higher detection rates at UCLH, Scotland and 
the Royal Marsden may also be due to the retrospective nature of testing; some 
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patients offered MGT were several years from diagnosis, which could indicate 
selection based on treatment response and/or improved survival. Rust comments that 
in a truly unselected ovarian cancer population, BRCA1/2 mutation prevalence is 
likely to be slightly lower than rates currently reported in the literature [75]. There were 
also differences in how systematic BRCA1/2 testing was delivered across these four 
sites. East Anglia and the Royal Marsden initiated testing as research studies, while 
Scotland and UCLH implemented MGT as a clinical service directly. UCLH and the 
east of Scotland used an entirely oncology-led model where MGT is offered, 
organised and results disclosed by the patient’s treating oncology.  
Within MGT at UCLH, there was variation as to the point at which patients were 
offered BRCA1/2 testing, ranging from eight years after to around the time of 
diagnosis. Currently there is no consensus for the optimal time at which MGT should 
be offered to women with ovarian cancer for either patient outcomes or clinical 
decisions. One approach to MGT is to systematically offer BRCA1/2 testing to all 
newly diagnosed patients. However retrospective  testing of all eligible patients at 
UCLH, one of whom had been diagnosed eight years previously, identified 44% of 
BRCA1/2 mutation carriers. Some oncology clinicians at UCLH chose to offer MGT 
early in the treatment pathway i.e. during first line chemotherapy. Research has 
indicated that women diagnosed with breast or ovarian cancer less than one year 
prior to receiving BRCA1/2 mutation positive genetic test results had poorer outcomes 
for anxiety and cancer-related distress [120]. However breast cancer patients 
approached for genetic testing and counselling at diagnosis had no adverse 
psychosocial outcomes in both the short- and long-term [122, 139].  
 At UCLH, MGT was not recorded systematically therefore it was impossible to 
determine which patients had been offered but declined genetic testing. Both the 
Marsden and Scottish testing programmes had very high rates of uptake, at 100% 
and 98% respectively [73, 75]. Uptake was slightly lower in East Anglia, however 
genetic testing was offered as part of a research study which may have discouraged 
some patients. Nevertheless, these rates are significantly higher than genetic testing 
uptake rates in unaffected individuals, where interest in testing is generally high but 
not necessarily reflected in testing uptake. For example, in families with a known 
BRCA1/2 mutation, interest in undergoing genetic testing was high although actual 
uptake of testing was low, despite the existence of options to manage or reduce 
cancer risks in individuals identified as carriers [183]. From 14 studies examining real 
breast cancer genetic testing decisions, the average uptake rate was 59%, with rates 
ranging from 25% to 96% across these studies [184]. However, given the experiences 
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at the Marsden and Scotland, it is likely that overall the uptake of MGT would also 
have been high at UCLH.  
After learning their BRCA1/2 mutation status from MGT between six and 14 months 
earlier, six patients had been able to access a PARP-inhibitor either as part of NHS 
care, managed access programme or clinical trial. There was no change to current 
treatment for eleven patients. The lack of direct impact from MGT on clinical 
management may be attributed to the timing of testing. As olaparib is currently 
available only for relapsed ovarian cancer after three or more lines of treatment, 
patients who are still on first or second line chemotherapy would not be eligible to 
receive this treatment.  
Knowledge of BRCA1/2 status can provide important cancer risk information for 
patients’ relatives. Patients who are identified as carrying a BRCA1/2 mutation or VUS 
should be referred to their local clinical genetics service to discuss implications of their 
test results including communicating results with at-risk family members. First degree 
blood relatives are at 50% risk of carrying the same mutation. Predictive testing 
provides an opportunity to identify unaffected BRCA1/2 mutation carriers who can 
consider breast and ovarian cancer risk-reducing interventions. A lack of consistent 
referral to clinical genetics services was highlighted by this evaluation; 22% (4/18) of 
BRCA1/2 mutation carriers and 78% (7/9) who received VUS results were not 
referred. It is unclear how VUS results are used for ovarian cancer patient clinical 
management or how they are interpreted by oncologists. The inherent ambiguity of a 
VUS result and complex interpretation are also challenges for genetics and other 
areas of clinical medicine [185, 186]. However it is important for women with a VUS 
to be under the care of a clinical genetics service to discuss implications of such 
results for themselves and family members. Segregation analysis of the variant 
amongst cancer affected family members may be undertaken, and VUS results may 
also be reclassified as either deleterious or benign with ongoing review. 
Within this cohort of patients who had MGT, two patients who received germline 
negative results were later identified to carry somatic BRCA1/2 mutations during 
clinical trial participation. Identifying somatic mutations in patients who are germline 
negative is important as these results may influence treatment decisions; these 
patients would be eligible for olaparib or other PARP-inhibitor clinical trials. It is 
estimated 5-7% of women with high grade serous ovarian cancer will carry a somatic 
BRCA1/2 mutation [86], which calls for greater access to tumour testing for patients. 
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BRCA1 and BRCA2 have been the high penetrance genes primarily associated with 
hereditary breast and ovarian cancer. Research continues to identify other genetic 
mutations which contribute to epithelial ovarian cancer. It is recognised that moderate 
susceptibility genes RAD51C, RAD51D and BRIP1 could be offered alongside 
BRCA1/2 for clinical genetic testing [187, 188]. NE Thames Regional Genetics 
Service is now able to simultaneously test multiple genes using a ‘mini gene panel’ 
for BRCA1, BRCA2, RAD51C, RAD51D and BRIP1. How these results will influence 
ovarian cancer patient management is an area for future inquiry. 
5.7 Summary 
This service evaluation begins to inform our understanding of how BRCA1/2 genetic 
testing in ovarian cancer is being used by oncologists at UCLH, and what role it plays 
in expanding treatment options for patients. It appears MGT is a feasible process of 
providing BRCA1/2 germline testing to ovarian cancer patients although the lack of 
systematic recording of offers and acceptance of MGT makes it not possible to 
comment on uptake rates. Greater clarity of how oncologists review and use VUS 
results is needed, as is the improvement of referral pathways to clinical genetics for 
these patients. The impact of BRCA1/2 testing on clinical management may be 
delayed depending at which point in the treatment pathway the patient has had 
testing.   
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Chapter 6 Implementation of mainstreamed BRCA1/2 tumour 
testing and clinical outcomes  
 
6.1 Introduction 
The service evaluation in Chapter 5 described the current state of BRCA1/2 germline 
testing at UCLH and the context in which BRCA1/2 tumour testing would be 
introduced. Compared to the retrospective nature of the service evaluation, the 
prospective approach of being involved in the provision of tumour testing is an 
opportunity to work with key individuals from patients and oncologists, to pathology 
and laboratory staff, and become immersed in the context itself.    
PARP-inhibitors are known to be effective for patients with either germline or somatic 
BRCA1/2 mutations; in the UK olaparib is licensed for use in both cases. With 5-7% 
of ovarian cancer patients expected to carry a somatic mutation [86], there is impetus 
to identify more patients who may benefit from access to PARP-inhibitors. The first 
round robin trial of NGS-based BRCA1/2 tumour testing in ovarian cancer across 
Germany, Switzerland and Austria has demonstrated the feasibility of this approach 
[189], and BRCA tumour testing is increasingly being considered in the UK. There are 
no specific guidelines for BRCA1/2 tumour testing, although guidance statements 
have recently been published [76]. This research offers a unique opportunity to 
provide BRCA1/2 tumour testing within the clinical context using a mainstreamed 
model.  
The aim of this chapter is to describe the clinical outcomes of mainstreamed BRCA1/2 
tumour testing within our ovarian cancer patient cohort at UCLH. It also aims to 
understand the process of implementing a new testing pathway, including any pitfalls 
and challenges. The outcome of this work can be used in an academic sense to inform 
the case under study, as well as to inform future clinical practice for the development 
of an established tumour testing service.   
6.2 Context  
As described earlier in Chapters 1 and 2, the gynaecological oncology department at 
UCLH has been providing systematic BRCA1/2 germline testing using a 
mainstreamed model to patients with high grade non-mucinous ovarian cancer since 
2015. The previous chapter presented the findings from a service evaluation after the 
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first year of MGT which demonstrated that this was a feasible and effective way of 
identifying patients carrying a BRCA1 or BRCA2 germline mutation.  
Myriad Genetics provided 50 BRCA1/2 tumour tests, the Myriad Tumor 
BRACAnalysis CDx® test, for UCLH patients with high grade serous ovarian cancer 
for this research work. With BRCA1/2 germline testing already accepted and utilised 
by both oncologists and their patients, the gynaecological oncology clinical team was 
interested in this opportunity to provide BRCA1/2 tumour testing to their patients. Just 
like the MGT model, tumour testing would follow a mainstreamed approach and be 
incorporated into the patient’s oncology outpatient appointments. I would be 
responsible for organising tumour testing and liaising between the necessary 
departments and Myriad laboratories. One of my academic supervisors, an oncology 
consultant within the department, was the named consultant for all tumour tests 
requested, and all results were returned to her via a secure email portal.  
6.2.1 Gynaecological oncology department at UCLH 
I was embedded within the outpatient services provided by the gynaecological 
oncology department. UCLH is a large, tertiary teaching centre which provides 
specialist care across north-central London and West Essex. It is one of six hospitals 
which form the North London Gynaecological Cancer Network. Clinical trials are an 
important part of the clinical service provided which includes national and international 
clinical trials as well as a portfolio of translational research. A purpose built Clinical 
Research Facility (CRF) supports early phase clinical trials.  
The outpatient oncology services are based in the Macmillan Cancer Centre, a 
purpose built centre ‘…designed with the needs of patients, and modern cancer care 
in mind, with lots of natural light, open spaces and a rooftop garden that everyone is 
welcome to use. To ensure that the building is truly patient-focused, patients were 
involved in both the design of the building and how the services operate within it’ [190].   
The outpatient clinic is situated on the first floor of the centre, with the oncology and 
surgical clinics running concurrently. There are typically four medical oncologists, two 
clinical oncologists, specialist registrars and a nurse practitioner for the 
gynaecological cancer patients. Pharmacy services are also embedded within the 
outpatient clinic, as is a clinical psychologist. As a tertiary cancer centre, some 
patients have been referred from their local, general hospitals for more specialist care; 
some patients travel from as far as Bath and Brighton. The portfolio of clinical trials 
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that the service offers also draws in patients from other hospitals and geographic 
sectors.  
A typical clinic will have at least 100 gynaecological cancer patients scheduled for 
appointments, with the majority having a diagnosis of ovarian cancer. Chemotherapy 
services are provided in a dedicated chemotherapy suite on the second floor of the 
centre. A more detailed description of the outpatient clinic can be found in the 
Appendix. 
6.3 Patient cohort 
An embedded subunit of this case study was to explore the patient experience of 
mainstreamed BRCA1/2 tumour testing; this is described further in Chapters 7 and 8. 
By participating in this study, patients were offered mainstreamed BRCA1/2 tumour 
testing.  
The clinical eligibility criteria for patients were:  
• Patients aged >18 years (no upper age limit) 
• Patients diagnosed with high grade non-mucinous EOC and still under the 
clinical care of the Gynaecological Oncology Department at UCLH 
• Patients who have had a previous primary cancer diagnosis and subsequent 
treatment 
Exclusion criteria were: 
• Patients who lack mental capacity to decide to take part in the study and to 
participate in it (upon clinical team’s judgement in accordance with the Mental 
Capacity Act 2005 Code of Practice 2007) 
• Patients who have already had genetic counselling and/or genetic testing  
• Patients who are known BRCA1 or BRCA2 mutation carriers 
• Patients who are too unwell, either due to their treatment or disease (based 
on clinician and/or researcher judgement) 
Using this criteria, eligible patients were identified in the weekly pre-clinic meetings 
which I attended. In the outpatient clinic the patient’s oncologist would briefly discuss 
the study with his/her patient during her appointment and then introduce the patient 
to me to discuss the study further and provide study documents. Further details 
regarding the recruitment process are provided in Chapter 7.  
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6.4 Tumour testing specifications 
Ovarian cancer tissue specimens are typically taken from a diagnostic biopsy (i.e. of 
the omentum or pleural fluid) or from debulking (primary or interval) surgery. Tumour 
tissue is then preserved as FFPE blocks with adjacent haematoxylin and eosin (H&E) 
stained sections. At UCLH, tumour blocks and H&E sections are stored and managed 
by the UCLH Cellular Pathology department.  
Tumour testing for BRCA1/2 somatic mutations was performed by Myriad Genetic 
Laboratories. The Myriad Tumor BRACAnalysis CDx® test uses NGS for DNA 
sequencing and large rearrangement analyses using MLPA of BRCA1 and BRCA2 
genes. Technical specifications of the test can be found in the Appendix. For testing, 
DNA is isolated from FFPE tissue blocks of ovarian, fallopian tube or peritoneal serous 
carcinoma. Tissue blocks are required to contain a minimum of 5x5mm tumour and 
20% tumour cellularity which is determined using the adjacent H&E stained section.  
After discussion with one of my supervisors, who is a consultant clinical geneticist, a 
decision was made that a tumour test would be deemed ‘incomplete’ if the MLPA 
portion of the test failed. In these situations, to ensure large genomic deletions or 
rearrangements were not missed, patients were asked to undergo germline testing. 
Similarly, if tumour testing failed completely, as the tumour blocks best fitting the 
specified criteria had already been selected and sent for testing, the test would be 
reallocated to a different patient; germline testing would then be organised. If a 
mutation or VUS was reported, follow-up germline testing was organised.  
6.5 Tumour testing pathway 
For this component of my PhD, I wanted to understand and experience what is 
involved in the development of a new genetic testing pathway in a mainstreamed 
context within the oncology setting. As I discovered, there are a number of integral 
components within the tumour testing pathway, which are described further below. 
Overall, the logistics of tumour testing are more complex than germline testing; 
obtaining a blood sample, though a more invasive process for the patient, and 
ensuring it is delivered safely to the relevant laboratory for testing, is a relatively 
straightforward process. I found the complexities of tumour testing were largely 
around the retrieval and reviewing of pathology material.  
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6.5.1 Tumour testing as a first line genetic test 
The approach taken for the timing of mainstreamed BRCA1/2 tumour testing in this 
research was to provide it as a first line genetic test. Germline testing would then be 
offered if there was any indication for further testing, i.e. if a mutation or VUS was 
identified in tumour or if tumour testing failed. The rationale for this approach was two-
fold. Firstly a key aspect of this case study was to examine the patient experience of 
tumour testing, thus it needed to be the primary mode of genetic testing. Secondly 
this approach could lead to ‘focused germline testing’ which has potential time and 
cost savings. As Capoluongo (2017) described, tumour testing can detect both 
somatic and germline mutations, therefore potentially only one genetic test is needed 
to identify all patients who may benefit from PARP-inhibitors [76]. However, given the 
importance of clarifying the hereditary nature of mutations identified from tumour 
testing for the benefit of future cancer risk surveillance and predictive testing for 
unaffected relatives, in this study any mutation or VUS identified on tumour testing 
would proceed with germline testing.  
 
 
 
 
 
 
 
 
 
Figure 6.1 Components of tumour testing pathway 
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tumour testing process, timeframe and potential outcomes, and were also provided 
with the Myriad information leaflet on tumour testing (please refer to the Appendix).  
After each participant consented to testing, I would collect the completed Myriad TRF 
from the oncologist and begin the process of retrieving stored tumour specimens.  
6.5.3 Retrieving and reviewing pathological material  
At UCLH, all tumour specimens from diagnostic and surgical procedures are stored 
within the UCLH Cellular Pathology Department for up to seven years; after this time 
specimens are stored in a secure NHS archive site in Wales. To access necessary 
specimens for testing, I made Pathology Material Requests (PMRs) to the pathology 
archive clerks. Once the PMR was approved and processed, the archive clerk 
retrieved all pathology slides from the patient’s diagnostic biopsy or debulking surgery 
as well as the accompanying pathology reports. I then collected the pathology slides 
and reports to review with the consultant gynaecological pathologist.  
Selecting the appropriate tumour blocks required the consultant pathologist to review 
the available H&E slides for each patient and identify three slides of corresponding 
tumour tissue which best met the Myriad specifications described in Section 6.4. I 
then requested the corresponding tumour blocks from these slides, as well as new 
adjacent H&E slides to be cut by the Cellular Pathology department. Once the chosen 
tumour blocks and new slides were prepared, I would collect and package them using 
the Myriad test kits, including the pathology report and TRF, to be couriered to 
Germany for testing in the Myriad laboratories.  
This process was repeated for all participants who consented to tumour testing.  
As UCLH is a tertiary referral centre, some patients had undergone their initial biopsy 
and/or surgical procedures at other hospitals. PMRs were made to relevant cellular 
or histopathology departments with clear guidance on the specifications required for 
the tumour blocks.  
 Turnaround time from date of participants consenting to testing, to results reported 
by Myriad was estimated to take 8-12 weeks.  
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Figure 6.2 Tumour testing pathway 
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• New adjacent H&E slides 
cut 
Tumour blocks and slides – 
UCLH  
• PMR for all available H&E 
slides for each patient 
• Slides and pathology reports 
reviewed with consultant 
gynaecological oncology 
pathologist 
• Up to three tumour blocks 
chosen 
• New adjacent H&E slides 
cut 
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6.6 Results from mainstreamed BRCA1/2 tumour testing  
6.6.1 Turnaround time 
The mean time from consent for tumour testing to when results were reported by 
Myriad was 55 working days (approximately 11 weeks, range 24-82 days). The mean 
time taken from consent to when tumour blocks and sides were sent for testing was 
42 days; once samples arrived at Myriad Laboratories testing and reporting was swift 
and results were usually provided in 10 working days. Although the majority of patients 
received their results within the estimated 8-12 week timeframe, some patients waited 
up to 82 working days for the results of testing.  
6.6.2 Pathology material 
The tumour tissue used for testing for 20 patients were samples from primary 
debulking surgery, while 28 had samples from IDS after neo-adjuvant chemotherapy. 
For nine patients the only tumour samples available was a single diagnostic biopsy 
either from the omentum, fallopian tube or pleural fluid. In an additional four cases 
where patients only had a single tumour block from biopsy, the patient’s oncology 
consultant chose not to proceed with tumour testing where only limited tumour tissue 
was available. These patients proceeded directly to germline testing via the usual 
MGT pathway. Outcomes for these patients are reported in Section 6.6.4.   
6.6.3 Tumour testing outcomes  
In total 57 participants underwent first line BRCA1/2 tumour testing via MGT.  
After tumour testing, Myriad reported no mutation or VUS results for 38 participants. 
For 26 of these participants, no further testing was required. However for three 
participants, their oncologist requested further germline testing via the usual MGT 
pathway because of relevant ethnicity or clinical indications as panel testing for an 
additional three genes (BRIP1, RAD51C and RAD51D) was available. One patient 
was subsequently found to carry a RAD51C germline mutation. In 12 cases (31.6%), 
the Myriad report noted that the MLPA component of testing had failed; follow-up 
germline testing was undertaken in 11 cases only as one participant’s oncologist 
made the decision not to offer follow-up germline testing. On follow-up germline 
testing, no germline mutations or VUS were reported for nine patients, while two 
participants received a RAD51C VUS result.  
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For eight participants, Myriad reported BRCA1/2 mutations initially identified in 
tumour; five BRCA2 mutations and three BRCA1 mutations (including one BRCA1 
Ashkenazi Jewish founder mutation). In seven cases, participants proceeded with 
follow-up germline testing, with all confirmed to be inherited, germline mutations. One 
participant did not proceed with germline testing – due to an error at recruitment, she 
previously had BRCA1/2 germline testing in 2016. As the previous germline testing 
reported no mutations, this participant was the only case where a BRCA1/2 somatic 
mutation was identified. These results are shown in Table 6.1 below.   
For two participants, Myriad reported a VUS on tumour testing in BRCA1 and BRCA2, 
respectively. Targeted germline testing by NE Thames Regional Genetics 
Laboratories was undertaken; no evidence of the VUS was found in lymphocyte DNA 
for either participant suggesting that the VUS was not germline in origin.   
One ‘inconclusive’ result was reported by Myriad; a large rearrangement of BRCA1 
gene with an atypical pattern observed for BRCA1 exons 11(3’)-24 was deemed 
inconclusive. There was insufficient data to definitely determine the structure of the 
large rearrangement, its breakpoints and its location within the gene. The Myriad 
report specifically stated, ‘…this finding should not be used for clinical management’ 
and recommended follow-up germline testing. No mutation was identified on follow-
up germline testing.  
Tumour testing failed in six cases due to insufficient quantity or quality of DNA which 
likely reflected both issues with DNA extraction from FFPE samples and low tumour 
tissue yield. When the pathology material was reviewed retrospectively, tumour 
samples from five participants were taken from interval debulking which may indicate 
chemotherapeutic response and lack of viable tumour tissue for testing. For the other 
case where testing failed, the only tumour specimen available was a pleural fluid block 
which is likely to have had less tumour tissue compared to specimens from an omental 
biopsy or debulking surgery.  
Two tumour tests were cancelled by Myriad Laboratories as the pathology report 
indicated samples were not high grade serous disease, but clear cell and 
endometrioid ovarian cancer, respectively.  
One patient had two tumour blocks tested (counted as two separate tests) due to 
laboratory error. 
The outcomes from tumour testing are shown in Figure 6.3.  
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Table 6.1 Germline and somatic BRCA1/2 mutations from tumour testing 
 
Study ID Age at dx (yrs) Gene Genetic alteration Mutation/ VUS Tumour Germline 
MGT042 63 BRCA1 c.1505_1509del (p.Leu502Serfs*2) Mutation Yes Yes 
MGT023 44 BRCA1 c.547+1G>T Mutation Yes Yes 
MGT059 53 BRCA1 c.5266dupC (p.Gin1756Profs*74) Mutation Yes Yes 
MGT029 61 BRCA2 c.5073dupA (p.Trp1692Metfs*3) Mutation Yes Yes 
MGT064 58 BRCA2 c.4859T>G (p.Leu1620*) Mutation Yes Yes 
MGT048 67 BRCA2 c.6535_6536insA (p.Val2179Aspfs*10) Mutation Yes Yes 
MGT068 64 BRCA2 c.8756del (p.Gly2919Valfs*8) Mutation Yes Yes 
MGT072 55 BRCA2 c.1562c>A (p.Ser521*) Mutation Yes No 
MGT017 77 BRCA1 c.5569del (p.Gln1857Argfs*65) VUS Yes No 
MGT027 65 BRCA2 c.7553T>G (p.Leu2518Arg) VUS Yes No 
108 
 
6.6.3.1 Additional tumour testing outcomes 
Two participants had repeat BRCA1/2 tumour testing by Foundation Medicine as part 
of a PARP-inhibitor clinical trial. For one participant Myriad tumour testing had initially 
failed due to insufficient DNA. For the second participant, Myriad had reported an 
inconclusive result of a large BRCA1 rearrangement (exons 11(3’)-24). Both 
participants had follow-up germline testing within this PhD project and no mutations 
were identified. In both cases, Foundation Medicine reported BRCA1 somatic 
mutations. 
6.6.3.2 Summary of mainstreamed BRCA1/2 tumour testing outcomes  
In total 57 patients consented to first-line BRCA1/2 tumour testing. Thirty participants 
(52.6%) went on to have follow-up germline testing either because of clinical 
indications, mutation/VUS identified on tumour testing or process issues (MLPA 
failed, tumour test failed or test cancelled). Seven participants were found to carry a 
germline BRCA mutation for a prevalence of 12.3%, one participant with a germline 
RAD51C mutation (1.8%) while one participant was found to carry a somatic BRCA1/2 
mutation (prevalence 1.8%). An additional two participants from this cohort were 
found to have a somatic BRCA1/2 mutation on repeat tumour testing, bringing the 
total somatic mutation prevalence to 5.3%.  
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Figure 6.3 Outcomes for mainstreamed tumour testing
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6.6.4 First-line germline testing outcomes  
As described earlier, four patients who had initially consented to tumour testing did 
not proceed with testing due to their oncologist’s decision not to use the limited tumour 
samples available. These patients proceeded with first-line germline testing via the 
usual MGT pathway. One patient was found to carry a BRCA1 mutation.  
6.6.5 Clinical management for BRCA1/2 mutation carriers 
Of the ten participants with a germline BRCA1/2 or RAD51C mutation or VUS, nine 
were referred to the local clinical genetics service. In the case of one participant with 
a RAD51C VUS, the oncologist decided not to make this referral as she felt it would 
be of little benefit to her patient. 
In February 2019 I reviewed the medical records of all participants who had 
undergone tumour testing and been found to carry a mutation: seven patients who 
were found to carry a BRCA1/2 germline mutation, one patient with a germline 
RAD51C mutation and three patients with a BRCA1/2 somatic mutation. These 
outcomes are reported in the table below.  
Eight participants had tumour testing early in their cancer pathway, either during or 
after completing their first line of chemotherapy. Six of the eleven participants (54.5%) 
had been able to access PARP-inhibitors treatment after receiving either their 
germline or somatic mutation positive results, with four participants subsequently 
enrolled on a clinical trial, one patient receiving niraparib via the managed access 
programme and one receiving rucaparib via the compassionate access program. The 
remaining five patients were not currently receiving any treatment.  
Of the four participants who had first-line germline testing, the participant who was 
found to carry a BRCA1 mutation completed her third line chemotherapy shortly after 
receiving her results. Recently she was declared eligible for olaparib and commenced 
treatment in February 2019. 
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Table 6.2 Clinical outcomes for BRCA1/2 carriers 
g(germline)BRCA, s(somatic)BRCA, PARP-i = PARP-inhibitors
Patient ID 
When tested in 
pathway 
MGT result 
MGT result 
received 
Clinical outcomes  
First-line tumour testing and second line germline testing 
MGT013 First line gRAD51C mx Nov 2017 
Completed second line chemo Dec 2017. Rucaparib monotherapy 
(compassionate access) July 2018 ongoing 
MGT023 First line gBRCA1 mx Aug 2017 
PARP-i clinical trial Feb 2018. Progressive disease, stopped trial. Third line 
chemo Oct 2018 ongoing 
MGT029 Second line gBRCA2 mx Sept 2017 PARP-i clinical trial May 2018 ongoing 
MGT042 Second line gBRCA1 mx Nov 2017 Completed third line chemo Nov 2017. No further treatment, surveillance only 
MGT048 First line gBRCA2 mx Nov 2017 No further treatment since first line chemo. Surveillance only 
MGT059 First line gBRCA1 mx Mar 2018 Completed second line chemo Aug 2018. Niraparib Sept 2018 ongoing 
MGT064 First line gBRCA2 mx Mar 2018 
Completed second line chemo Aug 2018. No further treatment, surveillance 
only 
MGT068 First line gBRCA2 mx June 2018 No further treatment since first line chemo, surveillance only 
MGT072 Second line sBRCA2 mx June 2018 No further treatment since second line chemo, surveillance only 
Repeat tumour testing 
MGT007 Second line sBRCA1 mx Unknown 
PARP-i clinical trial May 2018. Progressive disease, stopped trial. Third line 
chemo Aug 2018 ongoing 
MGT056 First line sBRCA1 mx Apr 2018 
PARP-i clinical trial May 2018. Progressive disease, stopped trial. Third line 
chemo Sept 2018 ongoing 
First-line germline testing 
MGT032 First line gBRCA1 mx Nov 2017 Completed third line chemotherapy Dec 2018. Olaparib Feb 2019 ongoing 
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6.7 Discussion of mainstreamed BRCA1/2 tumour testing  
The most time consuming aspect of organising BRCA1/2 tumour testing was the 
logistics of accessing and selecting appropriate tumour blocks. As this testing was 
classified as research, clinical requests made to the UCLH Cellular Pathology 
department took priority, leading to delays in retrieval of the pathology material for this 
study. Staff shortages amongst archive clerks exacerbated delays, and in the end I 
was given permission to access and retrieve necessary pathology material myself. 
Given the pressures on the pathology department, classifying tumour testing as a 
clinical service may not have vastly improved turnaround times of retrieval of archived 
tumour material.  
At the time of tumour testing implementation and set up, there was no appointed 
gynaecological pathologist consultant for this project. Pathology expertise is critical to 
the tumour testing pathway; pathology reports and H&E slides of ovarian cancer 
tumour tissue need to be reviewed to select tumour blocks with appropriate diagnosis 
(e.g. high grade serous disease), sufficient tissue and cellularity for tumour testing. 
Fortunately shortly after the initial set up, a newly appointed consultant gynaecological 
pathologist volunteered to provide her expertise to this project. In total the consultant 
pathologist reviewed 62 cases (57 ultimately proceeded to tumour testing), while one 
case was reviewed by another consultant pathologist while she was on leave. As the 
consultant pathologist had no allocated academic or research time, this was 
undertaken in addition to her clinical workload.   
Despite some of the factors required for tumour testing already being in place or 
provided (e.g. cellular pathology department onsite, gynaecological pathology 
specialty, tumour testing kits) it was challenging to develop this pathway. A lack of 
staff and low prioritisation for research requests for pathology material led to 
significant delays in obtaining tumour blocks and adjacent slides. If this process could 
be streamlined by the provision of a dedicated archive clerk for BRCA1/2 tumour 
testing requests and access to more than one gynaecological pathologist consultant, 
this may reduce the time taken to retrieve and review tumour blocks for testing.  
Depending on when tumour testing is undertaken, the turnaround time is important. If 
testing is provided shortly after diagnosis or during first line treatment, there is less 
pressure to provide results in order to inform eligibility for PAPR-inhibitors as olaparib 
is licensed for use in the UK only after three or more courses of platinum-based 
chemotherapy [191]. However for post-relapse or second line treatment, the results 
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of tumour testing become more clinically urgent. Similar to Myriad, other validated 
centres in Europe that undertake diagnostic tumour testing in progressive, relapsed, 
high grade serous ovarian cancer have a turnaround time frame of 10 working days 
from date of tumour block(s) receipt [189] to ensure timely feedback of results to 
oncologists for treatment decisions. To provide tumour testing to a greater number of 
patients would require the development of an efficient timeline to source and review 
tumour blocks for testing. A guidance statement on BRCA1/2 tumour testing called 
for results to be available between 30-40 days from when testing is requested [76].    
It was an important, and unexpected, outcome that two participants were later found 
to have BRCA1/2 somatic mutations which were not identified in the BRCA1/2 tumour 
testing undertaken in this PhD project. In one case tumour testing had failed; as noted 
earlier, in cases where tumour testing failed Myriad would allow the test to be 
reallocated. The strategy taken in this study was that the test would be reallocated to 
another participant, rather than retrieving and sending additional tumour blocks from 
the initial patient. In the other case Myriad had reported an ‘inconclusive’ result, whilst 
repeat testing by Foundation Medicine reported a BRCA1 mutation. It is likely there 
are differences between the mutation classifications between Myriad and Foundation 
Medicine, as Myriad retains its own databases and platforms for annotation and 
classification of variants which are not publicly accessible [192].  
Classification systems and terminologies differ between reports and the complexities 
of creating a unified interpretation and reporting system are recognised [193]. 
Currently there is no single guidance for classifying, interpreting or reporting somatic 
mutations, with various databases and literature sources available [193, 194]. Efforts 
are being made to collaboratively develop expert consensus to collate current 
knowledge of genetic variants [11]. Variation around classification can have a 
significant impact in terms of clinical decision-making. As Spriggs and Longo 
comment, ‘Different classifications may put the patient at risk for inappropriate 
treatment’ (p.2568) [11]. In this case, Myriad issued an ‘inconclusive’ result for one 
participant and recommended that these results were not used for clinical 
management. As it stood, given the participant had no mutation or VUS identified on 
follow-up germline testing, she would not have had access to PARP-inhibitors. Repeat 
tumour testing by Foundation Medicine reported a BRCA1 somatic mutation and the 
patient was subsequently enrolled on a PARP-inhibitor clinical trial. Until there are 
both standardised and validated NHS-based laboratories as well as classification and 
reporting systems for BRCA1/2 tumour testing in the UK, there may be some variation 
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in reporting of somatic mutations which could have a significant impact on clinical 
decision-making.  
Molecular genetic analysis in ovarian cancer of tumour tissue has assumed that the 
sample reflects the DNA expression profile of the entire tumour [195]. However cancer 
cells within a tumour can exhibit different gene expression patterns known as 
intratumoural heterogeneity (ITH) [196]. ITH has been shown to exist in epithelial 
ovarian cancer, which has implications for the reliability of tumour testing; Khalique et 
al suggested that in order to obtain a true representation of the genetic profile of 
ovarian cancer, multiple samples of tissue from the tumour would require analysis 
[195]. Due to a laboratory error, one participant did in fact have tumour testing using 
two distinct tumour tissues; testing was undertaken in both tumour tissue from IDS in 
2012 and metastatic tissue from laparotomy and resection of a pararectal mass in 
2018. No mutations were identified in either sample.  
As reported earlier in this chapter, one somatic mutation was identified in the course 
of this research, and two additional patients were later found to carry somatic 
BRCA1/2 mutations after repeat tumour testing. The estimates of somatic mutations 
in ovarian cancer from the literature has been reported as 3% [61], 7% [13] up to 9% 
[82]. As described by Moschetta et al, we could expect to identify one somatic 
mutation for every 4-5 germline mutations [86]. The proportion of somatic mutations 
found in this cohort of participants (including the two somatic mutations later found on 
repeat testing) was similar, with a prevalence of 5.3% (3/57). 
Patient management was reviewed for the participants identified as carrying either a 
germline or somatic mutation. In 58.3% of cases (7/12), participants had been able to 
access a PARP-inhibitor, either via a clinical trial, managed access or compassionate 
use program. Most participants had tumour testing early in their treatment pathway, 
either during or after completing first line chemotherapy. Therefore it is likely more of 
the participants in this group will go on to access PARP-inhibitors as they continue on 
their treatment pathway, either by meeting the criteria for olaparib or enrolling in a 
clinical trial. If authorisation for olaparib moves in line with US approval for use as a 
maintenance treatment after first line chemotherapy, more patients will have access 
to this treatment much earlier in their treatment pathway. There will be an impetus to 
offer tumour testing shortly after diagnosis in order to identify those eligible.    
There has been some debate in the literature of MGT as to whether an age cut-off for 
testing should be implemented, in particular for germline testing [74]. In this study 
115 
 
there was no upper age limit in terms of participant eligibility, therefore there was no 
age limit for tumour testing. In this cohort there were two participants over the age of 
70 where mutations were identified; one germline mutation carrier was 73 years at 
diagnosis, and one participant with a somatic mutation was 77 years. Anecdotally 
there was some variation in the maximum age at which the gynaecology oncologists 
were prepared to offer genetic testing, with some choosing not to test patients over 
the age of 70. Our knowledge of the clinical factors associated BRCA1/2 germline 
mutations includes younger disease onset, with increased ovarian cancer risks from 
age 40 for BRCA1 and age 50 for BRCA2 mutations [197]. Whether tumour testing 
should have similar age restrictions is as yet unclear. Currently it is unknown whether 
somatic mutations have a similar biological and/or clinical effect as germline 
mutations [86].  
In the previous chapter, the service evaluation found that participants with a germline 
BRCA1/2 VUS result were under referred to clinical genetics for follow-up. The 
outcomes from this chapter suggest that this uncertainty amongst some oncologists 
about the value of clinical genetics management for VUS results has persisted. In the 
process of mainstreamed tumour testing, two participants were found to have a 
RAD51C VUS on follow-up germline testing. Only one participant was referred to 
clinical genetics. Despite a reminder for the other patient to be referred, the oncologist 
felt that this would be of little benefit given her clinical condition of a recent relapse 
and platinum-resistant disease (this encounter is discussed further in the clinical 
reflections section later in this chapter). The uncertainty related to interpreting and 
managing VUS results is not unusual in non-genetics medical specialties. A recent 
survey of breast cancer specialists in the UK found that the majority of the sample 
(71.0%) felt unprepared to interpret a genetics report [198]. Only 24.1% of clinical 
oncologists and 38.1% medical oncologists were confident in their perceived 
understanding of a BRCA1/2 VUS result. Furthermore clinical testing of RAD51C 
genes in ovarian cancer is still relatively new in the UK; this lack of familiarity may 
also contribute to poor understanding of these results, particulaly in the case of a 
VUS. Informing oncologists of how these results are managed by clinical genetics and 
what information and support this service can provide to patients may help to 
encourage more consistent referral of patients with VUS results.  
In this study, MLPA failed in 21.0% (12/57) of cases and participants went on to have 
germline testing to ensure any large intragenic deletions or rearrangements (LGRs) 
were not missed. LGRs are more difficult to detect in DNA from FFPE samples [76] 
and MLPA analysis can be unreliable in tumour testing because of the heterogeneous 
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nature of tumour samples containing both normal and tumour cells [199]. There are 
different approaches to detecting LGRs in tumour testing. In the context of research 
studies the use of a single platform to detect both point mutations and LGRs by an 
NGS strategy is increasingly common [77, 200]. Others are developing novel 
approaches such as single-molecule molecular inversion probe (smMIP)-based 
targeted sequencing to streamline workflows [201]. Taking these approaches into the 
clinical setting will require extensive validation [77].  
The rate of tumour test failing completely was 10.5% (6/57) and attributed to 
insufficient quality or quantity of DNA. This is not an uncommon finding; data from the 
100,000 Genome Project reported 30.9% of samples had insufficient quality DNA 
from FFPE samples [202]. The challenges of extracting DNA of sufficient quality from 
FFPE samples has been described extensively [76, 77, 199, 201]. Tumour samples 
which are fresh frozen (FF) offer superior DNA quality; however, as yet this is not a 
routine service and may not be available at all oncology centres [76].  
The approach for this research was to offer tumour testing as a first line genetic test, 
with germline testing as a follow-up when necessary. In this study, more than half the 
sample (30/57, 52.6%) who had first line tumour testing went on to have second line 
germline testing either due to issues with testing (e.g. MLPA fail, test fail) or because 
a BRCA1/2 mutation or VUS was identified. Another issue with taking a first line 
tumour testing approach is that if a mutation is identified, it is unknown if it is somatic 
or germline in nature and second line germline testing is always recommended. Thus 
the process of genetic testing for these participants became somewhat drawn out; 
after the 8-12 weeks for tumour testing results, it was an additional 8 weeks before 
germline results were reported. Research is now looking at methods to predict the 
hereditary nature of a mutation identified on tumour testing using computational 
models [203].  
An alternative approach is to offer tumour testing as a second line test after germline 
testing, restricted to patients where no germline mutation was found. In this scenario, 
approximately 85% of patients would continue on to have a second line tumour test. 
Again the majority of patients would require further testing and waiting for a second 
set of genetic testing results. A third approach would be to offer tumour testing and 
germline testing concurrently, rather than sequentially; this would allow for the 
sensitivity of tumour testing (i.e. correctly identifying the presence of a somatic 
mutation) to be established as well as being the most time efficient pathway. Consent 
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for both a blood sample and tumour tissue could be taken at diagnosis and both 
testing pathways initiated concurrently.    
 
 
 
 
 
 
 
 
 
Figure 6.4 Models of tumour and germline testing timing 
 
BRCA1/2 tumour testing in ovarian cancer is not currently NHS funded and is 
therefore not part of standard care. Cost as well as access to an accredited tumour 
testing laboratory may impact how testing is delivered, i.e. as a first line vs second 
line test vs simultaneous testing. Germline testing is currently cheaper costing 
approximately £307 compared to £564 for tumour testing, although the cost of tumour 
testing can exceed £2000 when undertaken privately.  
Currently there is inequitable access to tumour testing for ovarian cancer patients in 
the UK with only a few centres providing testing as part of clinical care. Furthermore 
there remains disparity in access to germline testing across the country, with different 
testing protocols and guidelines in place [75]. Although more genetics and oncology 
centres are moving towards systematic BRCA1/2 testing for ovarian cancer patients, 
family history and age are still being used to determine eligibility for testing [73]. For 
genetic testing, whether germline or tumour, to reach as many ovarian cancer patients 
as possible, a systematic and unselected approach needs to be taken. 
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6.8 Clinic(al) experiences and reflections 
Prior to starting my PhD research, I had spent brief periods recruiting cancer patients 
for different psychosocial research projects from the outpatient oncology clinics in the 
UCLH Macmillan Cancer Centre. I had some other previous clinical, professional and 
personal experience working with individuals with cancer. However these interactions 
were typically short lived and transient.  
Until I began patient recruitment, it was difficult to anticipate how much time would be 
needed to set up the tumour testing pathways and recruit 50 eligible patients. 
Ultimately I spent just over 12 months embedded within the gynaecological oncology 
department, spending 50 consecutive Tuesdays in the outpatient clinic. This was a 
significant amount of time, which enabled me to observe and experience the inner 
workings of the clinic. Importantly it also gave me many opportunities to interact with 
patients, those who became study participants as well as others, and offered insight 
into the ovarian cancer trajectory of treatment, response and relapse.  
There is a body of literature around the potential benefits of qualitative research to 
participants, in particular in depth interviews which have been described as having a 
cathartic, validating and self-empowering effect on participants [204, 205]. It is 
increasingly acknowledged that qualitative research, particularly when studying 
sensitive topics or working with vulnerable groups, may have a less positive effect on 
the researcher(s) [206]. Challenges range from research concerns about boundaries, 
researcher-participant relationships, the research footprint and leaving the research 
field. However other challenges relate to the emotional toll research can take [207]. 
Furthermore, what remains undervalued is how the embedded nature of qualitative 
research and the long periods of fieldwork within the study setting and/or with 
participants has the potential to impact not only the researcher, but also their research 
[208]. Although my research did not include a formal ethnographic component, I was 
nevertheless embedded within the ‘field’ for a prolonged period of time. In this section 
of the chapter I reflect on some of the challenges I encountered during my time in the 
clinic and how these challenges shaped my research practice.  
6.8.1 Emotions and empathy in research 
The cyclical nature of ovarian cancer where patients often respond well to treatment 
for several or many months initially, before progressing and requiring more treatment 
became very evident over the 12 months I spent in the outpatient clinic. During this 
time participants often shared with me their good news, that they were responding 
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well or finishing treatment, as well as their bad news, when disease returned or 
progressed. A small number of participants passed away during the course of my 
research. Whether they were my own study participants or other patients in the clinic, 
it was always upsetting to see patients who were very unwell, sitting and waiting in 
clinic, unable to hide their pain or discomfort. It was also distressing to see young 
patients, closer to my age, in clinic; although ovarian cancer is more commonly in 
post-menopausal women, it was a reminder that cancer does not discriminate in age. 
Compounding my distress was the feeling of helplessness – I had no clinical skills to 
offer these patients, nor any practical or logistical help; there was usually no available 
room to move a patient who was unwell or distressed. Even the water fountain was 
broken. Furthermore I felt anxious about overstepping the roles of the reception and 
nursing staff. The intensive nature of being in every clinic over a year meant that at 
times I was exposed to difficult situations, some of which have continued to stay with 
me.  
These emotions are not uncommon in qualitative research, particularly around 
sensitive topics such as cancer. As Watts wrote, ’The subject of cancer can be 
emotive, evoking as it does a sense of one’s mortality’ (p.7) [207]. Responding 
emotionally to situations or experiences is part of human nature. Emotions also play 
a role in the research process [209]. Taking an interpretivist stance, I cannot be 
disembodied or objective to what I observe. Instead it is my role to find meaning from 
these experiences and use them reflexively for both myself and my research practice.     
I found it very easy to build rapport with the patients I met and recruited for my 
research. Some of this ability harks back to my genetic counselling training; a key 
component of the genetic counselling consultation is building rapport with the 
counselee. When conducting research on sensitive topics, establishing rapport is key 
to building trust between the researcher and participant. Using empathy has been 
described as one strategy to develop real connections with participants; Dickson-
Smith et al believe ‘The ability to be empathetic is one of the main skills needed to 
undertake qualitative research’ (p.65) [209]. However being empathic can take its own 
emotional toll, and I found establishing rapport involved managing not only my own 
but also participants’ emotions. In contrast to the other people in the outpatient clinic, 
from the health professionals to the reception staff, I stood out as someone who had 
time to give. This meant I had time beyond discussing my research or going through 
study documents; I also had time to sit, talk and listen. With patients giving up so 
much of their time, sharing their stories and experiences with me, it was instinctive to 
respond in a similar manner. Often at the back of my mind was whether I had shared 
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too much of myself, and where the boundaries lay within the researcher-participant 
relationship. This is not uncommon in qualitative research where issues of self-
disclosure are entwined with a reciprocal desire to give something back to participants 
[206, 209]. Because of my good rapport with participants, and interactions which 
lasted over many months, it was difficult not to develop an emotional attachment to 
some patients. Even now, after data collection has finished, there are patients whom 
I still think of. This has also been described as significant issue for other researchers 
[206], blurring the boundaries in the researcher-participant relationship.  
Dickson-Smith et al describe the experiencing of emotions in research as ‘emotional 
work’, to encompass the face-to-face interactions with research participants which 
involves both dealing with one’s own emotions as well as that of others [209]. The 
importance of acknowledging the emotional work involved in both clinical and 
qualitative research means it can not only be addressed in terms of research planning, 
but also in how it impacts data collection and interpretation. Furthermore it highlights 
the need for more professional support for researchers where existing self-care 
techniques and informal support networks may be insufficient. Wray et al write about 
their experiences embedded in a gynaecological cancer unit, describing the 
psychological burden they felt during their fieldwork [208]. The authors recommend 
professional counselling to be available via the research or academic institutions as 
well as regular supervision and debriefing.  
I was fortunate to engage with formal support shortly after starting my research. After 
three months in the clinic, my primary supervisor recognised that I was struggling with 
some of the clinical aspects and emotional work of my research. She prepared regular 
clinical supervision sessions with the consultant clinical psychologist for the 
gynaecological oncology department, who was familiar not only with the health 
professionals and the patients, but had a good understanding of the nature of the 
clinic and how it operated. This provided me with a confidential, non-judgemental 
space in which to share my worries as well as practical suggestions about how to 
manage them. 
6.8.2 Burden of responsibility  
Unlike other case studies or qualitative research that largely draws from the research 
setting and participants, in my PhD I was providing a service, tumour testing, to 
selected patients who agreed to take part in this study. During the process of 
recruitment and completing the study documents, participants would often say, off-
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hand, that they hoped the results would ‘come back negative’. Inevitably, they would 
mention concern about risks to children and other family members.   
Two patients were particularly anxious about genetic testing and the implications for 
their children. Both were already worried that ‘the same thing could happen’ to their 
daughters and found it distressing to consider that there could be an inherited 
component to their disease. For one patient, I even (somewhat directively) suggested 
that a genetic counselling appointment and having genetic testing within their local 
clinical genetics service may be the best route for them, to ensure they had sufficient 
time and support to consider their testing decision.  
Despite having no control over their (or any) tumour testing outcomes, the 
expectations of both patients left me anxious. One of the patient’s partner emailed me 
prior to their upcoming clinic appointment, to tell me it was her birthday that day and 
he hoped the genetic testing results would be the good news they wanted. I felt I had 
a responsibility to deliver to the patient the result they desperately sought. Another 
patient who had responded very well to a trial drug understood the potential clinical 
benefit of having a somatic mutation, telling me frequently she hoped testing would 
‘find a mutation’.  
Hiller and Vears believe that to manage clinical expectations during patient-participant 
recruitment and data collection requires ways of communicating with patient-
participants about the researcher such that any confusion between research with 
clinical care is reduced [210]. The challenge I faced was that this research was 
intertwined with clinical care; the results of tumour testing could potentially be used to 
determine treatment options.  
These encounters also highlighted an additional issue I struggled with throughout my 
time in the clinic, which was being privy to clinical knowledge about patients (both my 
own study participants and others) despite not having a clinical role. It was difficult to 
avoid being exposed to clinical information particularly when attending the pre-clinic 
meetings where each patient and treatment plan is discussed; these meetings were 
a crucial part of identifying patients who would be eligible for my own research. But 
was this clinical information necessary for conducting my research? Given the 
logistical challenges of avoiding exposure to such information, I felt it was inevitable 
that I would learn about the treatment and clinical management of other patients, and 
focused more on how to treat this information ethically and sensitively. Regarding 
clinical information that related to patients who had consented and become study 
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participants, I felt that my access to this information was addressed by the signed 
consent forms which specifically included access to medical records. Furthermore it 
provided more insight into the diagnosis and treatment pathway that these women 
experience as ovarian cancer patients but from a different perspective, informing and 
shaping my understanding of the context in which genetic testing was taking place.  
6.8.3 Blurred boundaries 
As mentioned in Section 4.9, I have been a researcher for many years but my training 
as a genetic counsellor has had a significant influence not only on my research 
interests, but on my expectations and perceptions of how genetic testing should be 
discussed and provided.  
A mainstreamed model of delivering genetic testing is a departure from the traditional 
model of genetic counselling and testing. Inevitably the way in which testing is 
delivered needs to adapt to its environment. In the case of the oncology setting, 
discussions around genetic testing need to be incorporated into the patient’s usual 
clinic appointment with the likely outcome being that these conversations are much 
briefer than would typically occur in a genetic counselling context.    
In some ways I found it difficult to accept that the conversations about genetic testing, 
and more specifically tumour testing, in the context of this research study, between 
oncologists and their patients would be different. I felt anxious about whether 
participants were receiving sufficient information from their oncology consultant or 
myself to make a sufficiently informed decision about whether to have tumour testing 
or not; I found myself having to supress my desire to provide additional unsolicited 
information to participants.  
When a clinician assumes the dual role of a researcher this can lead to role confusion 
[211], which may be external requiring clarification of what role you hold to others or 
internal confusion resulting from conflicting feelings between the two roles [212]. I do 
not perceive myself to be a clinician, and although the gynaecological oncology 
clinical team was already aware that I have a background in genetic counselling, in 
general there was no expectation that I was fulfilling this role. Nevertheless it had an 
impact on my experience and interactions with participants during my time in the clinic.   
There were a number of occasions when a participant would ask what I termed a 
‘clinical query’, a question relating to genetic testing or their treatment. It was 
straightforward to decline answering questions related to treatment as I have no 
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training nor expertise in this area, although I was happy to act as a sounding board. 
As I was responsible for organising tumour testing, I was confident it was my role to 
answer any questions relating to the process, outcomes and logistics. However when 
questions moved more into the realm of germline testing, and in particular, queries 
about implications for children or future cancer risks, I was unsure of where my 
boundaries lay. Furthermore, as a component of this research is also interested in 
what oncologists communicate about genetic testing (further discussed in Chapters 7 
and 8), I was concerned about ‘muddying the waters’. This is not an uncommon 
challenge in research. In a systematic review of the typology of the researcher-
clinician role, feeling uncomfortable about answering a participant’s clinical query 
typically arose if the researcher wanted to respond to the query, but was concerned 
about blurring their role or potentially impacting the data [210, 212].  
Two participants received germline RAD51C VUS results after follow-up testing when 
the MLPA failed on their tumour tests. For both participants, I suggested to their 
oncologist that the patient should be referred to their local clinical genetics service to 
discuss the result further. In one case, the oncologist declined to do so as she felt it 
would be of little benefit to the participant who had progressive disease and was just 
starting on a new clinical trial. I struggled with what I felt was her paternalistic decision; 
on one hand genetic counselling could be beneficial clinically, perhaps not 
immediately but in the future, to the patient and her relatives. I also felt genetic 
counselling could potentially provide further clarity and psychosocial support to the 
patient around her VUS result. Nevertheless, in the end I chose to accept the 
oncologist’s clinical decision, feeling that insisting or interfering further would overstep 
my boundaries as a researcher.  
This scenario was the first ‘ethically important moment’ I encountered during my time 
in the clinic, what Guillemin and Gillam refer to as ‘…the difficult, often subtle, and 
usually unpredictable situations that arise in the practice of doing research’ (p.262) 
[213]. The authors describe these moments as ‘ethics in practice’, making a distinction 
between the procedural ethics involved in regulatory ethical processes and the 
interactions between researchers and participants.  
Guillemin and Hillers believe reflexivity plays an important role in managing the ethical 
tensions undertaken in research [210, 213], some of which I encountered during my 
clinical experience and have described above. Reflexivity can contribute not only to 
ensuring rigour and good research practice, but also a means to being aware of the 
ethically important moments and how to address ethical concerns when they arise.    
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Guillemin also discusses the importance of always being alert to ethical tensions 
[213]. The reflexive practice I took during my research was to be cognisant of the 
ethical moments, and take time to consider how and why these moments had arisen. 
In the case I described above, uncertainty of my role and where my responsibilities 
lay contributed to this particular ethical tension. I perceived the potential value of 
further genetic testing or counselling, but recognised that this was my motivation, 
acknowledging that the oncologist had a different priority. In the case of ethical 
moments with clinical implications, discussion with my academic supervisor, who is a 
consultant clinical geneticist, or during my clinical supervision sessions was a means 
to addressing these moments and developing strategies to respond.  
My experience in the clinic was an invaluable part of my research. It was critical to 
developing my understanding of the context in which tumour testing was occurring, 
and in identifying my own strengths and limitations as a researcher. It also highlighted 
that my choices, beliefs and actions are still influenced by my genetic counselling 
background.  
6.9 Summary 
BRCA1/2 tumour testing is becoming an increasingly important part of the clinical care 
for ovarian cancer patients. Mainstreamed tumour testing is feasible, however 
developing efficient pathology pathways and improved genetic testing platforms is 
essential to providing testing to more patients. Concurrent tumour and germline 
testing is likely to be the best approach to ensuring genetic testing results are 
delivered in a timely manner.     
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Chapter 7 Exploring the patient experience of BRCA1/2 
tumour testing in ovarian cancer: a quantitative approach  
 
7.1 Introduction 
The service evaluation in Chapter 5 demonstrated that taking a mainstreamed 
approach to genetic testing is a feasible and effective model to identify women with 
ovarian cancer who carry germline BRCA1/2 mutations. In turn this has the potential 
to provide greater treatment options for patients as well as opportunities for predictive 
testing and/or risk reducing interventions in at-risk relatives.  
Despite the benefits and increasing availability of MGT, the impact of moving testing 
from the specialised service of clinical genetics and genetic counselling to the 
oncology setting remains largely unknown. Currently little is known about how ovarian 
cancer patients experience MGT or the psychosocial impact of providing testing in 
this manner. In particular women’s attitudes towards BRCA1/2 testing, their intentions 
to accept an offer of testing, the decision making process, or outcomes from MGT are 
poorly understood.   
Although there is a wealth of literature on the psychosocial impact of genetic testing 
it largely relates to unaffected individuals at high risk of developing cancer, with a 
smaller body of research on the impact of testing in cancer patients. Furthermore 
much of this research is within the context of the traditional model of genetic 
counselling and testing for germline mutations.  
There are subtle differences between the two genetic testing approaches. 
Independent of any germline mutation, a tumour may have an acquired somatic 
mutation not identifiable through germline testing. As outlined in Chapter 6, tumour 
testing involves a two-step procedure; if a mutation is identified in the tumour, 
germline testing can then be offered to determine if this is an inherited or somatic 
mutation.  
At the time of writing, access to BRCA1/2 tumour testing for somatic mutations varies 
across the UK with some centres providing this as part of standard care, while at other 
centres tumour testing may only be available as part of clinical trial participation, other 
research studies or by private funding. Nevertheless there is a small but growing 
population of patients who are being offered both germline and tumour testing as part 
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of their ovarian cancer clinical care. As tumour testing can only provide non-hereditary 
genetic information initially, there may be less of the implications which have been 
typically associated with germline testing such.   
However as the clinical outcomes in the previous chapter have demonstrated, first-
line BRCA1/2 tumour testing is not always straightforward; more than half of 
participants required follow-up germline testing. One aspect of this work was also to 
consider if there are differences in the experiences and outcomes of patients who 
have first-line germline testing, and those who have first-line tumour testing. A cohort 
of patients who were offered germline testing, via MGT as per usual care at UCLH, 
would also be recruited. 
This chapter took a quantitative approach to explore how ovarian cancer patients 
experience MGT, either via tumour or germline testing. This is now referred to as 
mainstreamed tumour and/or germline testing, or MTGT. The focus of this study is on 
three key areas of the patient experience, reflecting key stages of the MTGT pathway:  
• Attitudes and knowledge of BRCA1/2 testing, prior to testing  
• Decision making, when consenting to genetic testing 
• Impact of BRCA1/2 testing, after receiving results.  
7.2 Aims 
In order to address the key areas of the patient experience, the aims of this study 
were:  
• To explore attitudes, intentions and knowledge about BRCA1/2 genetic testing 
• To explore experiences of decision-making, including decisional conflict, 
motivations and uptake for MTGT 
• To explore the impact of testing and receiving results.  
• To explore differences in patient experiences and outcomes between tumour 
and germline testing.  
7.3 Methods 
7.3.1 Study design  
This was a prospective observational study with three distinct parts. The study was 
designed to follow the MTGT testing pathway and to reflect the key areas of the 
patient experience and study aims described above.  
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Figure 7.1 Overall study design and genetic testing pathway 
 
7.3.1.1 Attitudes and knowledge of BRCA1/2 testing, prior to testing 
In the first part of the study, eligible patients were invited to participate prior to the 
offer of MTGT. At this point, those who agreed to participate were asked complete 
Questionnaire 1, which explored attitudes to and knowledge of BRCA1/2 testing and 
their intention to take up the offer of MTGT.  
7.3.1.2 Decision making, when consenting to genetic testing 
After completing Questionnaire 1, at their next clinic appointment participants were 
offered MTGT (either first-line tumour or first-line germline testing) by their oncologist. 
Tumour testing would be organised by myself, germline testing via the usual clinical 
pathway. After consenting to testing participants were provided with Questionnaire 2 
to complete, which explored the decision-making experiences of ovarian cancer 
patients offered MTGT. This included motivations for genetic testing, uptake or 
decline of MTGT offer and decisional conflict. 
7.3.1.3 Impact of BRCA1/2 testing, after receiving results 
Once reported, genetic testing results were disclosed to participants by their 
oncologist during their outpatient appointment. Participants were then provided with 
Questionnaire 3 which explored the outcomes of MTGT post-results receipt.  
7.3.2 Participants 
Approximately 350 ovarian cancer patients are seen annually in the Gynaecological 
Oncology Department at UCLH. Up to 75% of patients have clinical features which fit 
current guidelines recommending BRCA1/2 genetic testing, i.e. diagnosis of high-
grade non-mucinous EOC [214].  
Patients with high 
grade non-mucinous 
EOC  
MTGT offer MTGT results 
Questionnaire 3: 
Outcomes   
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From previous psycho-oncology research in genetic testing, typically 70% of patients 
approached agree to participate [215, 216]. As UCLH is a large tertiary hospital 
heavily involved in research and clinical trials, patients may be familiar with an 
invitation to participate in research. Similar participation rates were expected for this 
project.  
As 50 tumour tests were available, this study aimed to recruit 50 participants who 
would be offered first-line BRCA1/2 tumour testing. An additional 50 patients who 
would be offered first-line BRCA1/2 germline testing would also be recruited in order 
to explore any differences between mode of testing and patient experience.  
7.3.2.1 Identifying participants 
Eligible ovarian cancer patients were identified during weekly pre-clinic meetings. I 
was present in these meetings to identify eligible patients who could be offered MTGT 
and invited to this study.  
Patients from all stages of the cancer pathway were included, such as newly 
diagnosed patients, those on active treatment (e.g. pre- and post-surgery, 
chemotherapy, radiotherapy) or in remission. As disease relapse is common in 
ovarian cancer, patients on second or third line treatment were also included. If there 
was no relapse or recurrence, ovarian cancer patients were followed up for five years 
after primary treatment. As MTGT was offered both prospectively (i.e. at diagnosis) 
and retrospectively, some patients recruited could be many months or years from their 
initial diagnosis.  
7.3.2.2 Eligibility criteria 
The following criteria were used to identify eligible patients and those who would need 
to be excluded from participation.   
Inclusion criteria  
• Patients aged >18 years (no upper age limit) 
• Patients diagnosed with high grade non-mucinous EOC and still under the 
clinical care of the Gynaecological Oncology Department at UCLH 
• Patients who have had a previous primary cancer diagnosis and subsequent 
treatment 
• Patients who are able to understand spoken and written English 
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Exclusion criteria 
• Patients who lack mental capacity to decide to take part in the study and to 
participate in it (upon clinical team’s judgement in accordance with the Mental 
Capacity Act 2005 Code of Practice 2007) 
• Patients who have already had genetic counselling and/or genetic testing  
• Patients who are known BRCA1 or BRCA2 mutation carriers 
• Patients who are too unwell, either due to their treatment or disease (based 
on clinician and/or researcher judgement) 
7.3.3 Study timing 
As outlined above, eligible patients who were invited to take part could be at any point 
along the cancer pathway. Some patients may be invited shortly after diagnosis, while 
other patients may be many months or years post-diagnosis. For patients on active 
treatment, outpatient clinic appointments were typically spaced between two to four 
weeks apart, depending on their treatment schedule. Patients on follow-up may be on 
six weeks, three or six months between appointments. Occasionally patients were on 
annual follow-up.  
Wherever possible, this study attempted to fit within the participants clinical pathway 
in order to reflect the real-time process of genetic testing. Therefore no additional 
appointments were scheduled for study participants. Participants were met in the 
outpatient clinic, or during their chemotherapy treatment. Questionnaires were given 
in person at their clinic appointment or posted to the participant’s home address. If 
there were many weeks or months between clinic appointments, participants were 
followed up by telephone.  
7.3.4 Germline vs tumour testing 
For this research, 50 tumour tests were provided by Myriad Genetics for eligible UCLH 
ovarian cancer patients. To ensure equality to access oncologists would randomly 
allocate patients to either germline or tumour testing. BRCA1/2 germline testing was 
already NHS funded and testing was provided by the NE Thames Regional Genetics 
Laboratories.  
Random allocation would occur after participants had completed and returned the first 
study questionnaire, but prior to consenting to MTGT. Random allocation would follow 
that used by the department for other studies.    
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7.3.5 Recruitment and consent 
7.3.5.1 Invitation 
Eligible participants were identified during the departmental pre-clinic team meeting 
prior to the week’s gynaecology oncology outpatient clinic. The morning of the 
outpatient clinic, a coloured note was attached to the medical notes of each identified 
patient as a reminder for her oncologist. During her consultation, the patient’s 
oncologist (registrar or consultant) briefly introduced the study to the patient. If the 
patient was interested in hearing more about the study, the oncologist then introduced 
the patient to me after her appointment. Patients who were not interested or declined 
to meet me at that point were not approached further, unless requested at a later date 
by either the patient themselves or their oncologist.     
7.3.5.2 Consent process 
Once patients were introduced to me, we had a brief discussion about whether they 
wished to hear more about the study immediately, or whether they preferred to 
postpone this to a later date by telephone or face-to-face during another outpatient 
appointment or chemotherapy treatment. If patient preference was to discuss the 
study immediately, a quiet and private spot was found within the Macmillan Cancer 
Centre.  
During the consent process, I first outlined the purpose of the study, what was 
involved, key timepoints and a description of tumour testing. I then went through the 
study information sheet and consent form with the patient, answering any questions 
she had regarding her participation or the study itself. At this point, unless patients 
declined outright, potential participants were given a minimum of 24 hours to make a 
decision regarding participation, at which time I contacted the patient to ask if she was 
willing to participate. At the follow-up phone call or face-to-face meeting, if patients 
expressed a desire participate and gave verbal consent, they were enrolled in the 
study and provided with the first study questionnaire (Questionnaire 1), information 
sheet and consent form, as well as a reply-paid envelope. Each participant was 
assigned a study ID which would be used throughout the duration of the study.  
A number of patients wished to give consent immediately during the initial meeting; if 
I felt satisfied that the patient had read the information regarding the study and had 
sufficient understanding, the patient was enrolled immediately. The patient was 
131 
 
provided with the information sheet, consent form, Questionnaire 1 and reply-paid 
envelope.   
7.3.6 Data collection 
As described above, once participants had been enrolled into the study they were 
provided with Questionnaire 1. When participants consented to MTGT, they were 
given Questionnaire 2 to complete. After MTGT results had been reported and 
disclosed to participants by their oncologist, they were provided with Questionnaire 3 
to complete.   
Participants were asked to return the completed questionnaire and consent form 
within a week, to ensure it could arrive and be processed prior to the next timepoint 
in the study timeline. Participants were given the option of completing each 
questionnaire at home and returning the questionnaire by post in the reply-paid 
envelope or bringing it to their next outpatient appointment, or completing the 
questionnaire in the presence of the researcher if they wished to.   
7.3.6.1 Data completion 
To maximise the completion rate of participant questionnaires, if I had not received a 
completed questionnaire within 7 days after recruitment, the participant was followed 
up with a reminder telephone call. If a participant was returning to UCLH prior to her 
next gynaecology oncology outpatient appointment, I offered to collect the completed 
questionnaire in person.  
The questionnaires used in this study were chosen not only for their clinical validity 
and frequent use within the research setting but also for their brevity in order to 
minimise participant burden and maximise completion rates. It was also emphasised 
during the consent process that the participants could contact the researcher by 
telephone if they had difficulty completing the questionnaire or needed to clarify any 
items and a number of participants did take up this offer.  
7.3.7 Questionnaires and measures 
Participants completed three questionnaires over the course of this study. Each 
consisted of a number of core measures which were repeated within every 
questionnaire, as well as measures specific to the timing at that part of the testing 
pathway. Figure 7.2 shows the testing pathway questionnaires and measures. The 
questionnaires can be found in the Appendix.  
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7.3.7.1 Core measures 
As the average time from recruitment to receipt of MTGT results was estimated to be 
four months, within this time period there may be significant changes in a patient’s 
clinical status or treatment. For example, some patients may have just started 
treatment for a new diagnosis or for relapsed disease, while for others treatment may 
be ongoing. Some patients may be recruited after having completed treatment and 
are on clinical follow-up only. As treatment, performance and/or disease status (i.e. 
remission or relapse) as well as symptoms can impact quality of life and psychological 
wellbeing, at each key part of the MTGT pathway it was important to measure 
psychological distress, quality of life and symptomatology.  
Demographic and disease data: The questionnaires collected data on socio-
demographic variables such as age, parity, education, employment etc. Clinical 
information was gathered from participants’ medical records: date of diagnosis, FIGO 
stage and histological grade, type/date of surgery, tumour histology, past and current 
chemotherapy treatment. (See Appendix p.285) 
Hospital Anxiety and Depression Scale (HADS): The 14-item HADS is a widely used 
measure of emotional distress and has two subscales measuring anxiety and 
depression [217].  (See Appendix p.286) 
Functional Assessment of Cancer Therapy (FACT-G): This 27-item instrument is 
widely used to measure cancer-specific health-related quality of life (HRQOL). There 
are four subscales measuring wellbeing: physical, social/family, emotional and 
functional [218]. (See Appendix p.305) 
NCCN/FACT Ovarian Symptom Index-18 (NFOSI-18): The NFOSI-18 is a validated 
measure used for ovarian cancer symptomatology developed as part of the Functional 
Assessment of Cancer Therapy (FACT) series of questionnaires which shows good 
content validity [219]. (See Appendix p.287) 
7.3.7.2 Additional measures 
Measures differed in each part of the study to reflect the different key areas and study 
aims.  
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Questionnaire 1: Attitudes, Intention and Knowledge 
BRCA1/2 testing knowledge: This is an 11-item true-false measure of assessing 
knowledge of inheritance of breast-ovarian cancer susceptibility and genetic testing 
[220, 221]. (See Appendix p.289) 
Attitudes to BRCA1/2 genetic testing: Attitudes were measured with 12 items about 
the risks and benefits of testing on a 5-point Likert scale which has been used 
previously in a large cohort of breast cancer patients [221]. Responses to the four 
benefit items and nine risk items were combined to create an overall score for benefits 
or risks of testing, with an internal consistency of 0.82 and 0.76, respectively. One risk 
item on cost of BRCA1/2 testing was excluded as this was not relevant for this study. 
(See Appendix p.288) 
Genetic testing intention: Three items assessed participants’ intentions to have 
genetic testing. Similar items have been used in other studies measuring genetic 
testing intentions [222]. (See Appendix p.290) 
Questionnaire 2: Decision Making 
Motivations and expectations: This measure was adapted from the validated 
instrument Motivations And Concerns for GeNEtic Testing (MACGNET) [223]. Some 
items were excluded or rephrased as they were not suitable for this population of 
cancer patients; other items developed from the literature and clinical experience 
were included. Motivational factors are assessed using a 5-point Likert Scale and 
include two open-ended questions. Expectations of outcomes for genetic testing 
results were also included. (See Appendix p.298) 
Decisional Conflict Scale (DCS): This 16-item validated scale measured decisional 
conflict in relation to genetic testing choices, including uncertainty about alternatives, 
modifiable factors contributing to uncertainty and perceptions of effectiveness of 
decision-making. A DCS score <25 indicates no difficulties with decision-making. 
Internal consistency coefficients ranged from 0.78 to 0.92 [224]. (See Appendix p.300) 
BRCA1/2 testing knowledge (as above).   
Attitudes to BRCA1/2 genetic testing (as above).  
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Questionnaire 3: Outcomes of MGT 
Decision Regret Scale (DRS): This five-item scale was used to measure decision 
regret in relation patient’s decision regarding genetic testing. The scale showed good 
internal consistency (Cronbach’s = 0.81 to 0.92) [225]. (See Appendix p.310) 
The Multidimensional Impact of Cancer Risk Assessment (MICRA): This 25-item 
questionnaire measured the specific impact of result disclosure after genetic testing 
with three subscales: Distress (α = .86), Uncertainty (α = .77) and Positive 
Experiences (α = .75) [226]. (See Appendix p.308) 
Clinic evaluation: An in-house scale of items assessed the communication of genetic 
information by the clinicians, understanding of genetic information, satisfaction with 
offer, information and support. (See Appendix p.311) 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.2 MTGT pathway timepoints and questionnaires 
 
7.3.7.3 Choice of measures 
The HADS is a brief, validated measure which provides a useful overall screening tool 
of anxiety and depression. Since it was first published in 1983 it has been used 
extensively within the primary care and general population setting. It was also relevant 
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to this study because of its use in cancer patient samples [227]. It has been used 
extensively in genetic counselling and testing research [228], which may allow 
comparisons between our findings and the literature. However there are criticisms of 
the HADS, including a lack standardised cut-off points [229], issues relating to the 
measure’s sensitivity and specificity [230] and whether a single-, two- or three-factor 
model structure is best [230, 231]. For example, although the HADS was developed 
to produce two separate scores to measure anxiety and depression, there has been 
a tendency to use the total score as a single measure of psychological distress in 
oncology studies [232]. As the aim of this study was not to identify the number of 
‘cases’ but rather using the HADS as a descriptive tool for levels of patient distress, 
the HADS scores were considered as a whole, rather than the subscales anxiety and 
depression separately. Moreover, a meta-analyses of HADS data reported that it did 
not provide good separation between the two subscales [233].   
The FACT-G was designed as a HRQOL assessment for cancer patients and is used 
in clinical trials and descriptive studies. Another widely used HRQOL measure is the 
European Organisation of Research and Treatment for Cancer Quality of Life 
Questionnaire Core 30 (EORTC QLQ-C30) which has very similar psychometric 
properties and item numbers; choice between the two measures was guided by a 
decision tree [234].  
The FOSI-18 has several benefits over other measures of symptomatology; it is brief 
and easy to complete, has global application and interpretation and has been 
validated within a sample of advanced ovarian cancer patients [219]. 
Motivations for genetic testing in unaffected individuals are well described, with 
learning cancer risks for self and/or family members and relief from uncertainty 
commonly cited [220, 235, 236]. Little is known about the motivations for women with 
a current ovarian cancer diagnosis to learn their genetic status. Previously motivation 
for testing was measured using statements based on clinical experience and the 
literature, and a validated scale was not available. Some adaptations to the 
MACGNET have been necessary because of the nature of the participant group, 
which renders some items inappropriate or obsolete; e.g., ‘I want to know what my 
chances are of getting cancer’. Although this measure is quite lengthy and has not 
been used widely within the literature to date, it is a validated measure developed 
specifically for inherited cancer syndromes and genetic testing.  
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The two measures relating to decision making chosen for this study, DCS and DRS, 
have both been widely used as a measure for health care decisions, including genetic 
testing decisions. The DCS can discriminate between two groups, those who make 
and those who delay decisions. Both can be customised to specific health care 
decisions, in this case BRCA1/2 tumour or germline testing. 
To date few studies have used measures that specifically explore the outcomes of 
genetic testing for hereditary cancer, rather adapting or anchoring other existing 
measures (for example the Impact of Events Scale, IES). The MICRA was developed 
to measure the specific impact of result disclosure after genetic testing. Strengths 
include its specificity, and its ability to differentiate between BRCA1/2 mutation 
carriers and non-carriers, and has been validated in a sample both with and without 
a cancer diagnosis. Variability in subscale scores reflects the range of response to 
testing and individual differences within individuals who have testing. The clinical 
significance of elevated MIRCA scores remains to be evaluated.  
In the genetic counselling context knowledge is a construct that has been used to 
measure the ‘success’ of the communication process, although more recently there 
has been a shift away from using this for assessing outcomes [228]. However in a 
research context it may still provide some useful insight into what patients already 
know and understand about genetic testing, and whether this changes over the course 
of testing. This is the intention for including a BRCA knowledge measure, to explore 
any changes during the mainstreamed genetic testing process. Other researchers 
have also adopted this approach either by adapting validated scales or developing 
their own scales without undertaking a formal validation process. The BRCA 
knowledge questions were chosen as they have been used previously in BRCA 
genetic testing research, were brief and easy to score, and covered key items relevant 
to this research [220, 221].  
7.4 Statistical analysis 
Statistical analyses were conducted using SPSS for Windows (Version 25.0; SPSS 
Inc., Chicago, IL). A minimum of two methods were used to determine the normality 
of data: Shapiro-Wilk's test (p > .05 indicating normal distribution) and the visual 
inspection of a Normal Q-Q Plot and/or histogram. 
Demographic and clinical factors were summarised with counts (percentages) for 
categorical variables. For continuous variables that were normally distributed, means 
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and standard deviations (SD) were reported; for skewed data, medians, ranges and 
interquartile ranges (IQR) were reported. 
Three predefined sub-groups were identified a priori to investigate the effects of these 
variables on the outcome of interest for each questionnaire: participant age, time from 
diagnosis and treatment status. Due to the small sample size the sub-groups were 
divided into binary categories: participant age was categorised as ‘younger, up to 70 
years’, and ‘older, 70 years and over’; time from diagnosis ‘12 months or less’ versus 
‘more than 12 months’; treatment status as ‘active’ (chemotherapy, immunotherapy 
or other cytotoxic treatment) or ‘surveillance’ only.   
The independent sample t-test was used in the subgroup analyses to compare 
differences between two independent groups for normally distributed continuous data, 
and the non-parametric Mann-Whitney U test was used otherwise. A paired samples 
t-test was used to determine if there were differences in means between two related 
groups on the same continuous, dependent variable if the differences between pairs 
were approximately normally distributed. The non-parametric Friedman test was used 
to test for differences between groups on repeated measures otherwise ANOVA was 
used. The results of the hypothesis tests were regarded as significant at p < 0.05. 
I undertook the statistical analyses of this data. Dr Aviva Petrie (Biostatistics Unit, 
Faculty of Medical Sciences, UCL) reviewed this chapter and provided feedback.  
7.4.1 Loss to follow-up between questionnaires 
There was some loss to follow-up between Questionnaires 1 (n = 63) and 2 (n = 53), 
and then a significant loss to follow-up at Questionnaire 3 (n = 33).  
The dropout between Questionnaires 1 and 2 was due to participants not wishing to 
have genetic testing (n = 1), withdrawing due to illness (n = 1), genetic testing 
organised outside of the study (n = 3), consultant decision not to continue with tumour 
testing (n = 1), or non-completion/return of questionnaire (n = 4). The further dropout 
between Questionnaires 2 and 3 was due to participants not proceeding with either 
tumour or germline testing (n = 3), non-completion/return of questionnaire (n = 13), or 
questionnaires not yet given to participant (n = 6).  
As significant loss to follow-up may introduce biased results as well as a loss of 
statistical precision, repeated measures analyses were only conducted using data 
from participants who had completed all three questionnaires (n = 29).  
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7.4.2 Missing data  
Of the questionnaires that were completed and returned, overall there was a minimal 
amount of missing data. Missing data was typically missing not at random (MNAR), 
with participants tending to not respond to similar items. In some cases this was 
conditional; for example, the item was related to having children or a partner which 
depends on parity and relationship status. In other cases it perhaps reflected difficulty 
in responding to the item. For example, 13% of participants had missing data for the 
same MICRA item, ‘Feeling happy about my test results’.   
Participants with more than 5% of data missing within a measure were excluded from 
the analysis. For items with responses scored on a Likert scale (e.g. Attitudes to 
genetic testing scale), missing data was imputed as the mid-point value. Where data 
was missing on knowledge measures, this was taken as responding as ‘Don’t Know’ 
and scored accordingly.  
Missing data was felt to be as missing at random (MAR) if only one participant had 
missing data for that specific item within a measure, or if the item had been completed 
successfully by a participant in an earlier questionnaire. For MAR data, last 
observation carried forward (LOCF) was used.  
7.5 Results 
7.5.1 Adaptations to this research study 
As described above in Section 7.3.1, initial plans for this research were to offer either 
mainstreamed BRCA1/2 germline or tumour testing (MTGT) to eligible ovarian cancer 
patients. Germline testing for all women with high grade non-mucinous ovarian cancer 
had already been implemented in this centre in April 2015, as described in the service 
evaluation of Chapter 5 earlier in this thesis. Germline testing remains the ‘gold 
standard’ approach to BRCA1/2 genetic testing within the UK and is the most common 
genetic testing service provided across clinical genetics and oncology centres.  
The intention of including both testing modes was to draw out any differences in the 
experiences of patients offered germline testing to those offered tumour testing. Thus, 
the materials used in this research were designed to refer to ‘mainstreamed genetic 
testing’ or ‘genetic testing’ generically, rather than germline or tumour testing 
specifically, in order to capture both testing modes using one standardised set of study 
questionnaires.  
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As tumour testing was a finite resource of 50 tests, to ensure equality of access as 
well as limiting bias or inherent clinical differences between patients offered germline 
or tumour testing, the intention was to randomly allocate either mode of testing as 
patients were recruited into the study. However this approach of random allocation of 
testing mode was modified shortly after recruitment began, due to the slower than 
anticipated recruitment rate and the limited timeframe in which recruitment was 
planned (these issues are discussed further in this chapter). As a result, a decision 
was made to offer tumour testing to the first 50 patients recruited, as this would ensure 
all tumour tests would be allocated prior to the recruitment period ending. Once all 
tumour tests had been allocated, recruited participants would be offered germline 
testing as per standard practice within this centre.  
Again, modifications became necessary during recruitment. More than the full 
recruitment timeframe of 12 months was required to recruit, provide and ensure 50 
participants had tumour testing and received results. Difficulties recruiting patients 
having standard germline testing (described in the following section) and the limited 
timeframe remaining meant a decision was made to abandon this group and focus 
solely on the process, provision, clinical outcomes and patient experience of tumour 
testing.  
These adaptations did not impact the study aims nor methods, and the structure of 
this study remained the same.  
7.5.2 Recruitment 
Participant recruitment commenced in November 2016. Recruitment was first 
completed in December 2017 when all 50 tumour tests had been allocated. However 
due to earlier tumour tests failing and subsequent reallocation of tests to other eligible 
patients, there still remained four tumour tests available. Recruitment recommenced 
in February 2018 and continued until the final tumour tests were allocated and 
participants received their results.    
During recruitment in clinic, in total 73 patients gave verbal consent to participate and 
were enrolled in the study. These patients were provided with all the relevant study 
documents for the purpose of completing the first study questionnaire and 
accompanying consent form. Ten patients did not complete the initial consent form or 
other study documents and after further discussion, either actively withdrew or were 
withdrawn from the study for the following reasons:  
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• Issues with genetic testing: lack of interest in genetic testing, not wanting to 
know genetic testing results 
• Psychosocial issues: feeling too overwhelmed to participate 
• Clinical issues: becoming too unwell to participate 
• Issues with research: not interested in to taking part in a research project 
• Failure to complete initial study documents despite repeated prompting from 
researcher 
• Communication issues: two patients were offered and agreed to germline 
testing instead as their consultant was not aware they had consented to this 
PhD project.  
A number of these patients proceeded with germline testing via the usual clinical route 
at a later date.  
7.5.2.1 Challenges to recruitment  
As described earlier in this chapter, eligible participants were identified during the 
weekly pre-clinic meeting attended by clinical and medical oncology consultants, 
registrars, clinical nurse specialists and the clinical trials team. The model of 
participant recruitment used in this study relied on oncologists initially presenting this 
study to their patient, and taking verbal consent from their patient for an introduction 
to me. Thus who could be approached and when, was to some degree guided by the 
oncologists; recruitment was a collaborative process. 
The first challenge to recruitment was that there were fewer eligible patients than 
anticipated. As MGT for BRCA1/2 germline testing had already been implemented at 
UCLH in 2015, there was a large sample of ovarian cancer patients who had already 
undergone genetic testing and were therefore ineligible to participate. This limited the 
pool of patients who could be approached for this study to (a) newly diagnosed 
patients, and (b) a smaller pool of existing patients who had not been previously 
offered testing by their oncology consultant.  
Ovarian cancer patients have intensive chemotherapy regimens and are closely 
monitored both during and post-treatment, and may spend many months or years in 
and out of treatment. As a result the medical and clinical oncology consultants were 
very well acquainted with their patients. This was both a benefit and, at times, a 
challenge to recruitment.  
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All the oncologists involved in this study demonstrated a protective nature over their 
patients. There was a reluctance for me to approach patients who would be receiving 
bad news during their clinic appointment that day (for example, disease progression 
or relapse), preferring to delay recruitment to another clinic visit. At times the 
oncologists were keen to avoid ‘overloading’ their patients with additional information 
or decisions, particularly for those who were newly diagnosed and beginning systemic 
treatment for the first time. Additionally, oncologists felt some patients had existing 
psychosocial issues which were not part of the study exclusion criteria, but meant 
they should not be approached for participation.  
Although there was no maximum age criteria for participation, some oncologists felt 
less inclined to recruit patients over the age of 70. There is published data on genetic 
testing in ovarian cancer to indicate that the prevalence of BRCA1/2 germline 
mutations is lower in older patients [74]. However other research has identified 
mutations in patients older than 70 [73], including data from the service evaluation in 
this PhD (see Chapter 5) and the clinical outcomes from the previous chapter. As 
somatic mutations are driven by a different mechanism and do not reflect the age 
incidence related to germline mutations, arguably there should be no age restriction 
for tumour testing.  
Medical gatekeeping is defined as a process where clinicians restrict access to 
research recruitment, either on an ad hoc or systematic basis, and has been 
recognised to take place within cancer clinical trials and research [237]. In particular, 
there has been an underrepresentation of elderly patients [238]. Despite the potential 
impact on recruitment, clinicians’ concerns about the wellbeing of their patients are 
important and should not be devalued [237].   
In this study, to some degree gatekeeping may have biased the sample to patients 
who were demonstrating better psychological and physical resilience than others. In 
some cases, repeated deferral of either introducing genetic testing or this study led to 
missing eligible patients, who in turn became ineligible because of poor health, or 
were offered germline testing outside of the study in the meantime. However, 
gatekeeping also ensured that the recruitment process was unlikely to have been an 
additional burden to patients and protected their wellbeing. 
As recruitment rates and barriers to recruitment was not an aim of this research, there 
was no systematic procedure of recording the number of patients approached and the 
number who declined. However, the rate of recruitment (approximately 1.3 patients 
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per week) was significantly less than anticipated, particularly in reference to previous 
psychosocial research in genetic testing for women with breast or ovarian cancer 
[110, 139]. Another study which was recruiting both ‘new’ and ‘old’ ovarian cancer 
cases for biobanking of blood and tissues samples for genetic testing, found lower 
recruitment rates [239]. Barriers to recruitment were reported as patients being too 
unwell, lack of time because of medical appointments, wishing to focus on treatment 
as well as concerns about genetic research [239].  
7.5.2.2 First-line germline testing comparison group 
By the time this study was undertaken in 2017, germline BRCA1/2 testing in ovarian 
cancer had become standard of care; at UCLH it had been offered via MGT since 
2015.  
The challenges of recruiting participants for germline testing was two-fold. Firstly, 
because germline testing had been available for nearly two years for patients with 
high grade non-mucinous ovarian cancer, a large number had already undergone 
testing via MGT. As described on the previous page, this limited the pool of patients 
who would be eligible for this study.  
Secondly germline testing had become routine, not only for the clinical team, but to 
some extent also for participants. Anecdotal evidence from my experience in the 
outpatient clinic as well as from the qualitative data in Chapter 8 showed that many 
patients knew genetic testing was available, and some had requested BRCA1/2 
testing from their oncologist themselves.  
At the time of recruitment, tumour testing was only available to patients if they were 
participants of this research. Thus taking part was potentially advantageous not only 
for participants but also for their oncologists, given that PARP-inhibitors are licensed 
for somatic mutations. In contrast, germline testing was and is readily available for 
patients outside of this study, thus there was little additional incentive to participating.   
Once recruitment for first-line tumour testing was complete, recruitment then turned 
to participants who would be offered first-line germline testing. Over the course of 
several clinics, five eligible patients were approached and invited to take part in this 
research. Following the same process of recruitment described in above, after a 
conversation in person or by phone, the study documentation (information sheet, 
consent form, questionnaire) was provided. After one follow-up prompt, either in 
person or by phone, no consent forms or questionnaires were returned. As the 
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timeframe for recruitment had already expired, a decision was made not to pursue 
recruitment any further.  
Low recruitment rates have also been an issue for other psychosocial research in 
MGT that was undertaken in the sample ovarian cancer cohort at UCLH. In an MSc 
project which I helped to supervise, as a follow-up to the service evaluation a brief 
questionnaire on experiences of MGT was developed. Of the 170 ovarian cancer 
patients who had MGT between February 2015 and June 2017 (as recorded by the 
NE Thames Regional Genetics Laboratories), 64 patients were excluded for the 
following reasons: 34 (53.1%) were deceased, 9 (14.0%) required an interpreter, 5 
(7.8%) patients had no genetic testing report in their medical file, 2 (3.1%) patients 
had no medical file, 4 (6.3%) patients were too unwell and 10 (15.6%) at the 
oncologists’ discretion. The remaining 106 eligible patients were invited to take part 
in the study by letter (signed by their treating oncologist) in which was enclosed a 
study information sheet and an ‘opt-in’ form. Using an opt-in approach, a study 
questionnaire and consent form was then posted to the patient along with a reply-paid 
envelope. Only thirty-three (31.1%) patients returned their opt-in form, with 29 
questionnaires later returned by post leading to an overall response rate of 27.4%.  
7.5.3 Sample characteristics  
The sample characteristics were recorded from the first questionnaire which acted as 
a baseline questionnaire prior to testing (n=63); the characteristics are summarised 
in Table 7.1 below.  
The mean age of participants was 63.8 years (range 36-86) at diagnosis, and 65.7 
years (SD ±9.86) at study recruitment. The mean length of time between diagnosis 
and study participation was 22 months; this ranged from recruitment shortly after 
diagnosis (one month) to several years post-diagnosis (132 months).  
Most participants (73.0%) described their ethnicity as White British, with a further 
15.9% of any other White Background. At least 23.8% of participants had completed 
high school education at O level or GCSE equivalent. More than half of this sample 
(58.1%) were married or living with a partner, and the majority of participants (81%) 
had at least one child. Reflecting the mean age of participants, at least half of this 
sample had retired from employment (52.4%).  
  
144 
 
Table 7.1 Participant socio-demographic characteristics.  
 
 
Characteristic Sample (n = 63) 
Age, mean (SD)  
   Diagnosis 63.8 (9.96) 
   Recruitment 65.7 (9.86) 
Ethnicity, n (%)  
    White  57 (90.5) 
    Black 3 (4.8) 
    Mixed 2 (3.2) 
    Other 1 (1.6) 
Education, n (%)  
   Degree or higher degree 12 (19) 
   A-levels of higher 11 (17.5) 
   O level/GCSE equivalent 15 (23.8) 
   ONC/BTEC 4 (6.3) 
   Still studying 1 (1.6) 
   No formal qualifications 11 (17.5) 
   Other 9 (14.3) 
Living arrangements, n (%)  
   Own outright 33 (53.2) 
   Own mortgage 14 (22.6) 
   Rent from local authority 8 (12.9) 
   Rent privately 3 (4.8) 
   Other 4 (6.5) 
Marital status, n (%)  
   Single/never married 8 (12.9) 
   Married/living with partner 36 (58.1) 
   Separated/divorced 9 (14.5) 
   Widowed 9 (14.5) 
Employment, n (%)  
   Full-time  6 (9.5) 
   Part-time 7 (11.1) 
   Self-employed 2 (3.2) 
   Unemployed 4 (6.3) 
   Homemaker 4 (6.3) 
   Disabled/too ill to work 7 (11.1) 
   Retired 33 (52.4) 
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Participant clinical data was gathered from their online medical records, CDR. As can 
be seen in the table below, 76.2% of participants were diagnosed with stage III/IV 
disease, in keeping with expected stage distribution. As the initial study design was 
to recruit patients who would be having either tumour or germline testing, recruitment 
was initially open to all women with high-grade non-mucinous disease. After several 
months of recruitment when the focus shifted to only first-line tumour testing, Myriad 
Genetics also confirmed only tumours with high grade serous histology would be 
tested. Several participants with other histology types had already been recruited; 
tumour testing proceeded in some of these cases while some patients were instead 
referred for germline testing.   
The majority of participants (74.6%) were on active systemic treatment (either 
chemotherapy, clinical trial or bevacizumab) at the time of recruitment. Most 
participants (69.8%) were undergoing, or had completed, first line treatment. One 
participant had not undergone any systemic treatment for her ovarian cancer.  
Table 7.2 Disease stage at diagnosis 
Clinical characteristic Sample (n = 63) 
Disease stage, n (%)  
   Stage I 3 (4.8) 
   Stage II 7 (11.1) 
   Stage III 25 (39.7) 
   Stage IV 23 (36.5) 
   Unstaged 5 (7.9) 
Histology, n (%)  
   High grade serous 53 (84.1) 
   Carcinosarcoma 4 (6.3) 
   Clear cell 2 (3.2) 
   Endometrioid 3 (4.8)  
   Seromucinous 1 (1.6) 
Treatment line, n (%)  
   First line 44 (69.8) 
   Second line 16 (25.4) 
   Third line 2 (3.2) 
   No treatment 1 (1.6) 
Current treatment status, n (%)  
   Active 47 (74.6) 
   Surveillance 16 (25.4) 
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7.5.4 Results from study questionnaires  
As described earlier in this chapter, three questionnaires were completed by 
participants over the course of this study. For simplicity, the questionnaires will be 
abbreviated going forward, e.g. Questionnaire 1 (Q1) etc. A number of measures were 
repeated in each part of the study. Data for measures completed at each part of the 
study are presented together.  
There was a drop-off in terms of questionnaire completion over the course of this 
study. Sixty-three participants returned completed Q1 questionnaires, then 54 
completed questionnaires were received at Q2, and 33 at Q3. Only 29 participants 
completed all three questionnaires. Due to missing data on some of the measures, 
sample size (n) varied slightly. Of the 33 participants who completed and returned Q3, 
23 (69.7%) had no mutation identified, seven (21.2%) had a germline BRCA1/2 
mutation, one (3.0%) RAD51C mutation and two (6.1%) RAD51C VUS. 
It is important to note here that there were no participants with a somatic mutation 
amongst the completed questionnaires. Of the three participants who had somatic 
mutations (described in Chapter 6), two only learnt of their somatic mutation status 
after repeat tumour testing which was undertaken outside of this research, and after 
they had completed their last study questionnaire. The third participant who had a 
somatic mutation identified during study participation did not return Q3 despite several 
reminders. Therefore the results include only participants who carried germline 
mutations.   
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7.5.4.1 Distress 
Distress was measured using the self-reported HADS, where higher scores reflect 
greater levels of distress. This was measured at Q1, Q2 and Q3.  
 
Table 7.3 Descriptive statistics of HADS total scores at three timepoints  
 
 
A Friedman test was run to determine if there were differences in HADS total scores 
across the three questionnaires. Median HADS total scores varied decreased from 
Q1 (Mdn = 10.5) to Q2 (Mdn = 8.0) and then remained the same for Q3 (Mdn = 8.0); 
the differences were not statistically significant (p = .071).  
The Mann-Whitney U test was used to determine differences in HADS scores for the 
following pre-defined sub-groups: age at study recruitment, time from diagnosis, and 
treatment status.  The results are shown in the below.  
The median HADS score was significantly higher in participants younger than 70 
years of age than those 70 years or older at Q1 (p = .043) and Q3 (p = .021). There 
was no significant difference at Q2 (p = .510). At Q1, the median HADS score was 
significantly higher for participants diagnosed within the preceding 12 months 
compared to those more than 12 months from diagnosis (p = .035). There was no 
significant difference at Q2 (p = .854) or Q3 (p = .918).  There were no statistically 
significant differences for treatment status at Q1 (p = .439), Q2 (p = .067) or Q3 (p = 
.313).  
Mutation status data was available at Q3. There was no significant difference in 
median HADS total scores between participants with no genetic alteration, and those 
with a pathogenic mutation or VUS (p = .749). 
HADS  Q1 Q2 Q3 
n 63 53 31 
Median 10.5 8.0 8.0 
IQR 6.8-14.3 4.0-14.0 4.0-13.8 
Possible range 0-42 0-42 0-42 
Observed range 1-39 0-24 0-25 
Score ≥19, n (%) 10 (15.9) 3 (5.7) 3 (9.7) 
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Table 7.4 Distress scores across three study timepoints 
 
 
HADS   Q1 Q2 Q3 
Sub-groups n 
Median 
(IQR) 
U p-value n 
Median 
(IQR) 
U p-value n 
Median 
(IQR) 
U p-value 
Age 
<70 years 38 
11.5    
(8.0-18.0) 
316.0 .043 
33 
9.0     
(4.0-14.0) 
309.5 .510 
21 
11.0    
(7.5-16.5) 
51.0 .021 
≥70 years 25 
8.5       
(6.0-11.8) 
21 
7.0     
(4.0-12.5) 
11 
5.0     
(4.0-7.0) 
Time from 
diagnosis 
<12 months 28 
11.0    
(8.0-15.0) 
620.5 .035 
31 
8.0     
(5.0-12.0) 
346.0 .854 
16 
7.5      
(4.3-12.5) 
115.0 .918 
≥12 months 35 
9.0      
(4.0-14.0) 
23 
8.0     
(3.0-14.0) 
16 
8.5      
(3.3-17.0) 
Treatment 
status 
Active 
treatment 
47 
10.0     
(6.0-14.0) 
320.0 .439 
41 
8.0      
(4.0-12.5) 
204.5 .208 
17 
8.0     
(5.0-16.5) 
155.0 .313 
No 
treatment 
16 
11.5     
(7.3-20.3) 
13 
9.0     
(3.5-18.5) 
15 
7.0     
(4.0-11.0) 
Mutation 
status 
Mutation or 
VUS 
        10 
8.0     
(3.0-13.5) 
103.0 .749 
No genetic 
alteration 
        22 
8.0     
(4.8-14.3) 
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7.5.4.2 Health-related quality of life (HRQOL) 
HRQOL was measured using the NCCN FACT-G: Functional Assessment of Cancer 
Therapy - General (constitutes four core subscales; the FACT-G can be used with 
patients of any tumour type). It is one of the most widely used cancer-specific HRQOL 
questionnaires. The four subscales reflect physical, social, emotional and functional 
wellbeing, as well as a total HRQOL score. Higher scores represent better wellbeing 
and less symptom burden. HRQOL was measured at Q1, Q2 and Q3.  
Descriptive statistics are presented in Table 7.5 below. Overall participants appeared 
to have good HRQOL, with high median scores across the four domains. A Friedman 
test was run to determine if there were differences in FACT-G total scores across the 
three questionnaires. FACT-G total scores varied between Q1 (Mdn = 86.5), Q2 (Mdn 
= 84.0) and Q3 (Mdn = 93.0), but the differences were not statistically significant (p = 
.615).  
The Mann-Whitney test was used to determine differences in FACT-G scores for the 
following pre-defined subgroups: age at study recruitment, time from diagnosis, and 
treatment status. These results are shown in Table 7.6 below. Median FACT-G scores 
were significantly higher in participants younger than 70 years of age than those 70 
years or older at Q1 (p = .007) and Q3 (p = .005). There was no significant difference 
at Q2 (p = .475). At Q1, the median FACT-G score was significantly higher for 
participants diagnosed within the preceding 12 months compared to those more than 
12 months from diagnosis (p = .012). There was no significant difference at Q2 (p = 
.535) or Q3 (p = .717). There were no statistically significant differences for treatment 
status at Q1 (p = .522), Q2 (p = .420) or Q3 (p = .208). 
Mutation status data was available at Q3. There was no significant difference in 
FACT-G median scores between participants with no genetic alteration, and those 
with a pathogenic mutation or VUS (p = .672). 
 
 
150 
 
Table 7.5 Descriptive statistics for HRQOL scale FACT-G scores 
 
 
 
FACT-G Scores  
Q1 
(n=63) 
  
Q2 
(n=52) 
  
Q3 
(n=33) 
 
 
Median 
(IQR) 
Possible 
range 
Observed 
range 
Median  
(IQR) 
Possible 
range 
Observed 
range 
Median 
(IQR) 
Possible 
range 
Observed 
range 
Physical   
wellbeing 
24.0            
(20.0-26.0) 
0-28 0-28 
24.0           
(21.0-27.0) 
0-28 9-28 
25.5            
(21.0-27.0) 
0-28 0-28 
Social wellbeing 
25.0           
(21.0-27.0) 
0-28 12-28 
25.0            
(22.0-27.8) 
0-28 12-28 
26.0           
(20.0-28.0) 
0-28 13-28 
Emotional 
wellbeing 
19.0            
(16.0-22.0) 
0-24 3-24 
19.5           
(16.3-22.8) 
0-24 8-24 
20.0            
(17.0-22.0) 
0-24 6-24 
Functional 
wellbeing 
19.0             
(13.0-25.0) 
0-28 8-28 
20.0           
(14.3-24.0) 
0-28 4-28 
21.5           
(17.0-22.0) 
0-28 3-28 
FACT-G Total  
85.0           
(73.0-96.0) 
0-108 32-106 
87.0           
(73.5-98.3) 
0-108 42-107 
93.0             
(72.3-100.0) 
0-108 31-104 
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Table 7.6 HRQOL scale FACT-G scores across study timepoints by subgroups
FACT-G  Q1 Q2 Q3 
Sub-groups n Median (IQR) U 
p-
value 
n 
Median 
(IQR) 
U p-value n Median (IQR) U p-value 
Age 
<70 years 38 
80.5      
(66.3-90.0) 
667.0 .007 
32 
85.5     
(72.8-100.5) 
358.0 .475 
20 
85.0      
(65.3-95.0) 
147.0 .005 
≥70 years 25 
91.0      
(83.0-99.0) 
20 
90.5     
(73.5-95.0) 
10 
100.0     
(93.0-103.0) 
Time from 
diagnosis 
<12 months 28 
90.5      
(67.0-89.0) 
309.0 .012 
30 
87.0     
(76.5-99.3) 
363.5 .535 
15 
92.0      
(79.0-100.0) 
106.0 .717 
≥12 months 35 
80.0      
(81.5-98.8) 
22 
87.0     
(64.8-96.8) 
15 
94.0      
(70.0-100.0) 
Treatment 
status 
Active 
treatment 
47 
87.5      
(73.0-94.0) 
335.0 .522 
40 
87.0      
(77.5-99.0) 
261.5 .420 
16 
90.5      
(65.3-97.3) 
81.0 .208 
No 
treatment 
16 
83.0      
(75.0-98.3) 
11 
86.0     
(64.0-96.0) 
14 
95.5       
(82.8-100.8) 
Mutation 
status 
Mutation or 
VUS 
        21 
91.0      
(69.0-98.0) 
71.0 .672 
No genetic 
alteration 
        9 
95.0      
(74.5-100.0) 
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HRQOL was also measured more specifically for ovarian cancer. NCCN-FACT 
ovarian symptom index-18 (NFOSI-18) is an index of priority symptoms in advanced 
ovarian cancer. Higher scores represent better wellbeing and less symptom burden. 
Table 7.7 Descriptive statistics for N-FOSI scores across timepoints 
 
 
 
Similar to FACT-G scores, overall participants had high median NFOSI total scores, 
indicating better HRQOL. A Friedman test was run to determine if there were 
differences in NFOSI total scores between Q1, Q2 and Q3. There was some variation 
in median NFOSI total scores (see Table X), but the differences were not statistically 
significant (p = .638).  
The Mann-Whitney test was used to determine differences in NFOSI scores for the 
pre-defined subgroups: age at study recruitment, time from diagnosis, and treatment 
status (Table 7.8). There was no association between age and NFOSI scores, with 
no significant difference in total scores between younger and older participants at Q1 
(p = .093), Q2 (p = .573) or Q3 (p = .226). At Q1, the median NFOSI total score was 
significantly higher for participants diagnosed within the preceding 12 months 
compared to those more than 12 months from diagnosis, reflecting more symptom 
burden (p = .035). There was no significant difference at Q2 (p = .993) or Q3 (p = 
.294). There was no evidence that treatment status was associated with NFOSI 
scores at any timepoint (Q1, p = .424; Q2, p = .924; Q3, p=.085).
NFOSI Q1 Q2 Q3 
n 63 53 30 
Median 54.0 59.0 58.5 
IQR 48.0-62.0 51.0-65.5 51.0-64.0 
Possible range 0-42 0-42 0-42 
Observed range 11-72 27-72 17-69 
 153 
Table 7.8 NFOSI scores across study timepoints by subgroups
NFOSI  Q1 Q2 Q3 
Sub-groups n Median (IQR) U p-value n Median (IQR) U p-value n Median (IQR) U p-value 
Age 
<70 years 38 
54.0      
(46.3-60.3) 
594.0 .093 
32 
59.5      
(51.3-66.8) 
305.0 .573 
20 
55.0        
(46.0-65.8) 
115.5 .226 
≥70 years 25 
58.0      
(51.0-63.5) 
21 
58.0      
(50.5-64.5) 
10 
59.5        
(58.0-62.5) 
Time from 
diagnosis 
<12 
months 
28 
54.0      
(46.0-58.0) 
338.0 .035 
30 
60.0       
(52.8-64.3) 
345.0 .993 
15 
61.0        
(51.0-66.0) 
120.5 .294 
≥12 months 35 
59.0      
(53.0-64.8) 
23 
58.5       
(47.0-67.0) 
15 
58.0       
(46.0-62.0) 
Treatment 
status 
Active 
treatment 
47 
54.0      
(48.0-61.0) 
325.5 .424 
41 
56.0      
(52.0-64.3) 
241.5 .924 
16 
54.0       
(47.3-63.0) 
70.5 .085 
No 
treatment 
16 
57.0      
(46.8-61.0) 
12 
59.0      
(46.3-67.8) 
14 
61.5       
(57.3-66.0) 
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7.5.4.3 Genetic testing 
Testing knowledge 
Knowledge of genetic testing scale was measured at Q1 and Q2. Following the 
analysis plan, testing knowledge was grouped by ‘high’ (≥ 6 of 7 correct responses), 
‘sufficient’ (≥ 4 of 7) and ‘poor’ (< 4 of 7) by cut-offs defined from Peter’s 2005 paper 
[221].  
 
Table 7.9 Knowledge cut-off scores 
 
 
 
 
 
 
 
 
  
 
 
 
As can be seen in the table, at Q1 and Q2, approximately half of participants had poor 
testing knowledge, scoring less than half of the items correctly. At Q1 46.0% of 
participants showed sufficient testing knowledge, comparted to a smaller proportion 
of participants (35.8%) at Q2. At both timepoints only a small number of participants 
had testing knowledge scores which were ‘high’.   
The testing knowledge item with the most correct responses was the same for both 
Q1 and Q2; item ‘A woman who doesn’t have an altered BRCA gene can still get 
cancer’ having 81% (n = 51) and 83.3% (n = 45) of participants selecting ‘True’. The 
item with the most incorrect responses was also the same at both timepoints. This 
item was for the prevalence of BRCA1/2 mutations in the population ‘About 1 in 10 
women have an altered BRCA gene’; 81.5 % (n = 44) and 92.1% (n = 58) had an 
incorrect response, selecting ‘True’.  
Testing knowledge Q1 Q2 
n 63 53 
Mean 3.27 3.42 
SD 1.70 1.78 
Possible range 0-7 0-7 
Observed range 0-7 0-7 
Knowledge cut-offs n (%) n (%) 
High 3 (4.8) 7 (13.2) 
Sufficient  29 (46.0) 19 (35.8) 
Poor 31 (49.2) 27 (50.8) 
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A paired t-test was used to look at change in testing knowledge scores between Q1 
and Q2. There was no evidence of any statistically significant differences in scores 
between the two timepoints (t (52) = -.651, p = .518).  
Due to the small sample size the seven education categories were collapsed to create 
three educational groups: basic (still studying, no formal qualifications, other), 
secondary (O levels, ONC, BTEC) and further education (A levels or higher, degree 
or higher). One-way ANOVA was used to determine if there was an association 
between educational level and testing knowledge scores, these results are reported 
in Table 7.10. There was no evidence of an association at Q1 (F (2, 60) = 1.927, p = 
.154) or Q2 (F (2, 49) = 2.572, p = .087). 
 
Table 7.10  Knowledge by subgroups across study timepoints 
 
Testing 
knowledge 
 Q1 Q2 
 
 n 
Mean 
(SD) 
p-value n 
Mean 
(SD) 
p-value 
Education 
level 
Basic 21 3.14 
(1.32) 
 
.154 
18 2.67 
(1.33) 
 
.087 
Secondary  19 2.79 
(1.93) 
13 3.62 
(2.66) 
Further 23 3.78 
(1.73) 
22 3.90 
(1.90) 
Age  
<70 38 3.50 
(1.83) 
.186 
33 3.85 
(1.68) 
.021 
≥70 25 2.92 
(1.44) 
20 2.70 
(1.75) 
 
An independent-samples t-test was used to determine differences in testing 
knowledge scores between younger and older participants. At Q1 there was no 
significance difference in scores (p = .186), however at Q2, participants younger than 
70 years of age had significantly higher testing knowledge scores compared to those 
who were older than 70 years (p = .021).  
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Attitudes to genetic testing  
Participants attitudes to genetic testing were measured using a 12-item scale from 
Peters article with four benefit items, and 8 risk items (reverse scored). Higher scores 
indicated a more positive attitude. This scale was completed at Q1 and Q2. Table 
7.11 reports the descriptive statistics for this measure. 
A paired samples t-test was used to compare means scores between risks and 
benefits, with a higher mean score on risk items (negative attitudes) indicating 
participants were more likely to endorse the risks of genetic testing, compared to the 
benefits, and vice versa. There was no significant difference between mean risks and 
benefits scores for attitudes to genetic testing at either Q1 (t (61) = .995, p = .324) or 
Q2 (t (53) = -1.227, p = .225).  
 
Table 7.11 Descriptive statistics and attitude scores across study timepoints 
Attitudes to genetic testing Q1  Q2  
 n 62  53  
 Mean 31.34  33.31  
 SD 6.11  5.30  
 Possible range 0-52  0-52  
 Observed range 17-46  19-45  
   p-value  p-value 
Summative 
score (mean) 
Positive attitude 
items 
2.69 
.324 
2.70 
.225 
Negative attitude 
items 
2.58 2.84 
 
The independent-samples t-test was used to determine differences in attitudes scores 
in the three predefined groups of age, time from diagnosis and treatment status. There 
were no statistically significant differences as shown in the table below.    
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Table 7.12 Attitudes to genetic testing scores across study timepoints by subgroups
Attitudes to genetic testing  Q1 Q2 
  n Mean (95% CI) p-value n Mean (95% CI) p-value 
Age  <70 38 31.92 (29.94, 33.91) 
.350 
33 33.76 (31.99, 35.53) 
.922 
≥70 24 30.42 (27.78, 33.05) 20 33.90 (31.22, 36.59) 
Time from diagnosis <12 months 35 31.31 (29.49, 33.14) 
.973 
31 33.42 (31.22, 36.59) 
.530 
≥12 months 27 31.37 (28.55, 34.19) 23 34.35 (31.22, 36.59) 
Treatment status Active treatment 47 32.11 (30.32, 33.89) 
.078 
41 34.20 (32.61, 35.78) 
.412 
No treatment 15 28.93 (25.76, 32.10) 13 32.62(28.89, 36.34) 
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Motivations and concerns of genetic testing (MACGNET) 
This scale of items reflecting motivations and concerns of genetic testing was 
measured at a single timepoint at Q2, after participants had consented to tumour or 
germline testing. Median scores, IQR and ranges for each subscale are reported in 
the table below.  
Table 7.13 Descriptive statistics of MACGNET subscales  
 
 
 
A Friedman test was run to determine if there were differences in the distributions of 
MACGNET subscale scores. Pairwise comparisons were performed with a Bonferroni 
correction for multiple comparisons after this. Overall, MAGCNET scores were 
statistically significantly different between subscales (χ2 (2) = 113.159, p < .0005). 
Prevention and Medical Care subscale scores were significantly higher than other 
subscales, suggesting these items may have greater influence over motivations to 
have genetic testing. 
 
 
MACGNET Scores   Q2   
(n=54)  
No. of 
items 
Median IQR 
Possible 
range 
Observed 
range 
 Prevention and 
Medical Care (PMC) 
8 32.0 30.0- 36.0 8-40 26-40 
 Partner Influence 
(PI) 
3 12.0 11.0-13.3 3-15 7-15 
Subscales Future Planning 
(FP) 
4 10.0 9.0-12.0 4-20 3-15 
 Ability to Cope 
(ATC) 
5 13.0 11.0-14.0 5-25 8-25 
 Medical Influence 
(MI) 
3 12.0 10.0-13.0 3-15 7-15 
 Total MACGNET 23 79.0 77.3-84.5 23-115 58-92 
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Table 7.14 MACGNET scores by subgroups 
 
As the MACGNET total scores were normally distributed, an independent samples t-
test was used to examine the predefined dichotomous variables of age, time from 
diagnosis and treatment status. These results are shown in Table X.  
There were no significant differences in mean MACGNET scores for age (t (42) = 
.511, p = .612) or treatment status (t (16.265) = 1.199, p = .248).  There was a 
significant difference in mean MACGNET scores for time from diagnosis, with 
participants diagnosed more recently reporting higher scores compared to those more 
than 12 months from diagnosis (t (42) = 2.079, p = .044).  
 
Decisional conflict 
The DCS measure was completed at Q2, after participants had given consent for their 
tumour samples to be retrieved and sent for genetic testing. Participants were asked 
to reflect on their decision to have genetic testing. A score of 0 indicates no decisional 
conflict, increasing to 100 which is very high decisional conflict. Table X shows results 
for DCS subscale and total scores.  
Overall, participants appeared to have low levels of decision conflict, although there 
was a small number of participants (n = 3) who had total DCS scores of greater than 
50.  
 
 
 
MACGNET  Q2 
Sub-groups n Mean (CI) 
Mean 
difference 
p-value 
Age 
<70 years 31 79.42 (76.95-81.89) 
-1.12 .612 
≥70 years 13 80.54 (76.70-84.37) 
Time from 
diagnosis 
<12 months 16 81.25 (78.99-83.51) 
-4.13 .044 
≥12 months 28 77.13 (73.32-80.93) 
Treatment 
status 
Active treatment 33 80.45 (78.18-82.73) 
-2.88 .248 
No treatment 11 77.64 (73.03-82.24) 
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Table 7.15  Descriptive statistics for DCS subscales and total scores 
 
Similar to other measures, the Mann-Whitney U test was used to look at associations 
between DCS scores and pre-defined subgroups of age, time from diagnosis and 
treatment status. These results are shown in Table 7.16.  There was a statistically 
significant difference in DCS scores, with participants younger than 70 demonstrating 
lower scores (and therefore less decisional conflict) compared to participants more 
than 70 years of age (p = .027). There was no significant difference in DCS scores in 
terms of time from diagnosis (p = .027) or treatment status (p = .536). 
 
Table 7.16 DCS scores by subgroups 
 
 
DCS                       Q2   
(n=54)   Median IQR 
Possible 
range 
Observed 
range 
 Informed 25.0 25.0-44.0 0-100 0-75 
 Values 25.0 25.0-50.0 0-100 0-100 
Subscales Support 25.0 8.0-25.0 0-100 0-67 
 Uncertainty 25.0 0.0-27.0 0-100 0-100 
 Effective 
Decision 
25.0 0.0-25.0 0-100 0-75 
 Total DCS  25.0 18.3-33.0 0-100 0-81 
DCS  Q2 
Sub-groups n Median (IQR) U p-value 
Age 
<70 years 33 23.0 (13.5-27.0) 
470.5 .027 
≥70 years 21 28.0 (24.0-41.0) 
Time from 
diagnosis 
<12 months 23 25.0 (20.0-33.0) 
424.5 .233 
≥12 months 31 25.0 (9.0-33.0) 
Treatment 
status 
Active treatment 41 25.0 (17.5-30.5) 
236.0 .536 
No treatment 13 25.0 (15.5-37.5) 
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Decision Regret  
The DRS measure was completed at Q3, after participants had received their tumour 
and/or germline testing results. A score of 0 indicates no decision regret, increasing 
to 100 which is very high decision regret. The median DRS score was 0 (range 0-40, 
SD 11.76).  
The Mann-Whitney U test was used to determine if there was an association with DRS 
scores and the following sub-groups: mutation status, age, time from diagnosis and 
treatment status. These results are shown in Table 7.17 below.  
Mutation status was not associated with decision regret, with no significant difference 
in median DRS scores between participants with no genetic alteration, and those with 
a mutation or VUS (p = .749). There was also no significant difference in median DRS 
total scores for age (p = .921), time from diagnosis (p = .860) or treatment status (p = 
.845).  
 
Table 7.17 Descriptive statistics of DRS scores  
 
 
 
DRS  Q3 
 Median IQR Possible range Observed range 
n=33 0.0 0.0-10.0 0-100  0-40 
Sub-groups n Median (IQR) U p-value 
Mutation 
status 
Mutation or VUS 10 0.0 (0.0-12.5) 
91.0 .749 
No genetic alteration 23 0.0 (0.0-10.0) 
Age 
<70 years 21 0.0 (0.0-10.0) 
117.0 .921 
≥70 years 12 0.0 (0.0-18.8) 
Time from 
diagnosis 
<12 months 16 0.0 (0.0-17.5) 
124.0 .860 
≥12 months 17 0.0 (0.0-5.0) 
Treatment 
status 
Active treatment 17 0.0 (0.0-15.0) 
142.0 .845 
No treatment 16 0.0 (0.0-7.5) 
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Impact of genetic testing results 
The MICRA scale was designed to explore the impact of receiving genetic testing 
results. At the time of writing, 33 participants had received their tumour and/or 
germline testing results and completed the final study questionnaire (Q3). Four cases 
were excluded from analysis because of missing data, including one germline 
mutation carrier. Of this remaining group of 29 participants, 20 (69.0%) were mutation 
negative, seven (24.1%) carried a germline (BRCA1/2 or RAD51C) mutation, while 
two participants (7.0%) had a germline RAD51C VUS. The remaining participants had 
received no mutation identified results. Descriptive statistics of the MICRA scale, 
including the three subscales, are shown in Table 7.18. Overall the median total 
MICRA score was low.  
 
Table 7.18 Descriptive statistics for MICRA scores and subscales 
 
 
For participants with children, the majority (79.1%) sometimes or often wondered 
about the possibility of their child(ren) developing cancer. Nearly a third of participants 
(31.3%) felt that their genetic testing results often made it easier to cope with their 
cancer diagnosis, including two BRCA1/2 mutation carriers. More than half of 
participants (66.7%) sometimes or often worried about the risk of getting cancer again.  
Again, the Mann-Whitney U test was used to determine if there were differences in 
MICRA scores in the following subgroups: mutation status, age and time from 
diagnosis. These are reported in the table below. MICRA scores appeared to be 
sensitive to germline mutation status, with participants who had received mutation 
positive or VUS results having statistically significantly higher MICRA scores on 
MICRA    Q3  
(n=29) Median IQR 
Possible 
range 
Observed range 
Distress 0.0 0.0-4.0 0-35 0-30 
Uncertainty 4.5 1.5-8.8 0-35 0-19 
Positive experiences 1.0 0.0-8.0 0-20 0-13 
Total MICRA score 8.0 4.0-19.0 0-90 2-52 
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average compared to those who were mutation negative (p < .001).  There were no 
significant differences in MICRA scores for age (p = .871) or time from diagnosis (p = 
.813).  
 
Table 7.19 Subgroup analyses for MICRA 
 
  
Clinic evaluation 
The final part of Q3 was a series of questions asking participants to evaluate their 
experience of MTGT and recall their testing results, as well as a free text response 
option.  
Overall, participants agreed with having had sufficient time, information and support 
to make their decision about genetic testing. Similarly, almost all participants were 
satisfied with their experiences and planned to disclose results to family members. 
There was less agreement about the impact of testing results on treatment. Six of the 
nine participants (67%) who agreed that their genetic testing results had a significant 
impact on treatment, had received mutation positive results.  
 
 
  
MICRA  Q3  
Sub-groups n Median (IQR) U p-value 
Mutation 
status 
Mutation or VUS 9 25.0 (10.0-42.0) 
170.0 <.001 
No genetic alteration 20 5.0 (4.0-8.75) 
Age 
<70 years 21 5.0 (3.8-19.3) 
94.0 .871 
≥70 years 12 9.0 (4.0-20.0) 
Time from 
diagnosis 
<12 months 23 8.5 (4.0-24.5) 
99.5 .813 
≥12 months 31 5.0 (6.0-14.0) 
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Table 7.20 Clinic evaluation items. 
 
 
Of the 33 participants who returned Q3, eight (24.2%) participants did not respond 
when asked to recall their genetic testing results; three of these participants were 
germline mutation carriers. Twenty-three participants (69.7%) correctly recalled their 
result, while one participant did not know her result (3%, result was mutation 
negative). One participant (3%) incorrectly recalled her result as ‘Negative’, as she 
carries a RAD51C germline VUS.   
There were varying descriptions of genetic testing results. The majority of those with 
negative results recalled their result by simply stating ‘Negative’. Other descriptions 
of negative results included: ‘Do not have the BRCA gene’, ‘No mutant genes’, and 
‘Not genetic’. Two participants made specific references to tumour testing: ‘No 
pathogenic BRCA1 or BRCA2 mutation detected in tumour’, and ‘No genetic 
indication in tissue test’. Those who did report their mutation positive results either 
stated ‘Positive’ or reported their specific gene mutation i.e. ‘Positive BRCA2 
mutation, ‘BRCA1 Positive’.  
Twelve participants (36%) gave free text responses. Some comments were 
expressing gratitude for having had the opportunity to take part in this research 
project. One participant highlighted the benefits she perceived from taking part.  
Clinic Evaluation Strongly 
agree/agree 
Neither agree 
nor disagree 
Disagree/Stro
ngly disagree 
Item n (%) 
Did you have enough time to make 
the decision about genetic testing? 
30 (100.0) 0 (0.0) 0 (0.0) 
Did you have enough information to 
make the decision about genetic 
testing? 
30 (100.0) 0 (0.0) 0 (0.0) 
Did you have enough support about 
your genetic testing decision? 
29 (96.7) 1 (3.3) 0 (0.0) 
My genetic testing result had a 
significant impact on my medical 
treatment 
9 (30.0) 15 (50.0) 6 (20.0) 
I am satisfied with my experience of 
genetic testing 
29 (96.7) 1 (3.3) 0 (0.0) 
I plan to share my genetic test results 
with my family members 
30 (100.0) 0 (0.0) 0 (0.0) 
165 
 
I think there was a formulation in the first questionnaire 'Have you come 
to terms with your disease?'. I found this phrase helpful that I must come 
to terms with my illness. By now I feel I have accepted all that the illness 
causes to me. My participation in the research made me feel useful 
during my treatment. [MGT013, TT + GT, RAD51C+ve] 
Three participants described the relief from worry and anxiety after receiving negative 
results. 
I was happy to take part in this research. My concern was that there 
would be a genetic connection which might affect my granddaughters. I 
am delighted that this is not the case. [MGT020, TT, no mutation] 
I am relieved my mostly female family will have the peace of mind 
knowing that the mutant BRCA gene is not a part of their make-up. 
[MGT057, TT, no mutation] 
Even though I will continue to worry from time to time about the re-
occurrence of cancer, having the genetic test reduced my anxiety about 
myself and my family. [MGT035, GT, no mutation] 
Two mutation carriers highlighted the impact their results may have on future 
treatment. 
…my understanding is that when cancer recurs I will be able to have 
PARP inhibitors before further chemo. [MGT048, TT + GT, BRCA1+ve] 
Although I wouldn't say I was necessarily happy with the result, as I feel it 
may increase the likelihood of cancer returning, I do feel that following 
discussions with my consultant, that the results greatly increase my 
treatment and maintenance options, which can only be a good thing! 
[MGT059, TT + GT, BRCA1+ve] 
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7.6 Discussion 
7.6.1 Limitations 
The limitation section of a research paper is typically found after the Discussion 
section. However there were three limitations of this study that I felt were important to 
keep in mind as the results are discussed further.  
Firstly, as noted earlier in this chapter, unfortunately there were no participants with 
somatic mutations who completed the final study questionnaire (Q3). Therefore there 
was only data available for participants with germline mutations. Because of the small 
sample size, trying to make comparisons between mutation status and psychosocial 
outcomes using just three responses would have been prone to significant statistical 
bias. However, it is still disappointing that there is no quantitative data for this group.  
Secondly, because this study initially set out to recruit patients who would be offered 
either BRCA1/2 germline or tumour testing via MTGT, the wording of the 
questionnaires relates to ‘genetic testing’ in general. Furthermore a small number of 
items are only relevant to germline testing. As shown in Chapter 6, more than half of 
this sample went on to have follow-up germline testing after tumour testing. Although 
this data provides interesting insights into the experiences of ovarian cancer patients 
who have undergone MTGT, it is difficult to draw any conclusions about specific 
experiences related to tumour testing. For clarity, in the rest of this discussion I will 
use MTGT to illustrate that tumour and/or germline testing was undertaken. I will refer 
to tumour testing specifically where appropriate.  
Thirdly, this study only has a small sample size (particularly for Q3) and is likely to be 
underpowered which has implications for the statistical analysis. Limitations of small 
sample size include the increased possibility of false positive results by 
overestimating the size of an association. Similarly a lack of statistical significance 
may not reflect that there was no effect, but rather it failed to be detected (false 
negative result). Small sample sizes are also associated with lower levels of 
confidence and precision and a higher margin of error. Taken together, with such a 
small sample size the results are less conclusive and must be interpreted with caution.  
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7.6.2 Distress 
The experience of an illness such as cancer triggers a range of emotional responses 
such as shock, worry and sadness [240]. These emotions can persist along the cancer 
pathway from diagnosis, treatment, recurrence and survivorship. A large body of 
research has shown that symptoms of anxiety and depression are common, and 
frequently reported amongst cancer patients. In some patients, levels of mental or 
emotional distress meet the strict diagnostic criteria for psychological disorders such 
as major depression, generalised anxiety disorder and adjustment disorder [241]. 
There is a significant emotional burden associated with ovarian cancer due to a 
number of factors: it is a disease often diagnosed at an advanced stage with poor 
prognosis, low survival rates and a high risk of recurrence. Treatment typically 
involves significant invasive surgery and multiple courses of chemotherapy. As a 
result, psychological distress is not uncommon.  
Distress is defined by the National Comprehensive Cancer Network (NCCN) as a 
‘…multifactorial unpleasant emotional experience of a psychological (ie, cognitive, 
behavioural, emotional), social, and/or spiritual nature that may interfere with the 
ability to cope effectively with cancer, its physical symptoms, and its treatment. 
Distress extends along a continuum, ranging from common normal feelings of 
vulnerability, sadness, and fears to problems that can become disabling, such as 
depression, anxiety, panic, social isolation, and existential and spiritual crisis’ [242].  
As the NCCN definition demonstrates, distress is term that encompasses a whole 
range of emotional states and symptoms.  
Many of the psychological measures typically used within the psychosocial genetic 
testing literature are screening tools only and use cut-off points to indicate the 
likelihood of a clinical diagnosis. For this PhD, anxiety and depression does not refer 
to a clinically diagnosed disorder, but rather refers to the emotional symptoms that 
are experienced. 
One of the main criticism of the HADS measure is the lack of clearly defined cut-offs. 
Zigmond and Sniath recommend HADS total scores of ≥16 as a threshold for 
identifying suspicious cases [217]. However this is based on a general population 
sample and a number of other studies where HADS has been used within a sample 
of cancer patients has recommended that the threshold should be lower, in order not 
to miss potential cases [243-245]. For example, Singer recommend a cut-off of ≥6 for 
HADS total scores for clinical purposes [243]. A more recent meta-analysis of HADS 
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for a sample of cancer patients reported thresholds of 10 or 11 on HADS total score 
were best as a screening cut-off with sensitivity of 0.80 and specificity of 0.74 [244].  
Overall patients had mean total HADS scores of 11.46 at baseline, 8.76 after 
consenting to testing and 9.23 after receiving results; there was no statistically 
significant change in scores across the three timepoints. These results are 
comparable to what has been reported in the literature. For example, in a sample of 
100 ovarian cancer patients, the mean HADS total score was reported as 8.6 (SD 5.9) 
[246]. 
When examining some of the predefined sub-group analyses, there were a number 
of statistically significant differences. For age, younger participants (<70 years) had 
significantly higher HADS total scores compared to those who were older at both Q1 
and Q3, indicating they felt more distressed. There was no significant difference in 
HADS scores between younger and older participants at Q2. As highlighted at the 
beginning of this chapter, due to the small sample size all results should be interpreted 
with caution. Furthermore the age cut-off of 70 years to distinguish between ‘older’ 
and ‘younger’ participants is somewhat arbitrary, as there were too few participants 
falling into other categories (e.g. <60, or <50 years).  
Despite these limitations, the impact of age on distress is not unexpected and is 
consistent with previous literature. Younger cancer patients experiencing higher 
levels of distress compared to older patients has been reported in breast, endometrial  
and colorectal cancer [247, 248]. A number of factors are thought to contribute to the 
lower levels of distress in older cancer patients. Older patients display greater 
resilience which helps to mediate distress [249], and have better coping strategies 
[247]. Being diagnosed with a serious illness may be less unexpected in older 
individuals, who typically demonstrate less death anxiety [250]. Younger patients are 
more likely to face disruptions to daily life such as employment, household 
responsibilities and caregiving [247]. The physical and psychological morbidity 
associated with cancer treatment may also have a greater impact on younger patients 
[251].  
An additional statistically significant finding was in HADS scores at Q1 between 
participants diagnosed more recently (in the preceding 12 months) and participants 
who were more than 12 months post-diagnosis; those diagnosed more recently had 
higher HADS scores indicating more distress. This finding no longer reached 
significance at Q2 or Q3. Again due to the small sample size, these findings must be 
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interpreted with caution. However this finding is not unexpected given the initial 
trajectory of cancer diagnosis and treatment. More newly diagnosed patients may still 
be distressed from their recent diagnosis, starting and adjusting to a treatment regime, 
managing treatment side-effects, worrying about disease recurrence and feeling 
uncertain about prognosis and the future.  
As each part of the diagnostic and treatment trajectory is navigated, patients may feel 
less uncertain and more reassured about their future treatment and disease 
outcomes. In a sample of breast cancer patients there was a significant reduction in 
distress between baseline and 12 months post-diagnosis [252, 253]. A similar 
reduction in distress was seen during the first year of diagnosis for patients with a 
gynaecological malignancy; there was a significant decrease in anxiety and 
depression and an improvement in overall mood states over time [254]. Comparing 
baseline measurements at diagnosis, Chan et al reported a reduction in anxiety at 6 
months and 18 months post-treatment for gynaecological cancer patients, while 
depression remained stable [255].  
Treatment status had no impact on levels of distress, with no statistically significant 
differences between patients on active treatment and those on surveillance. Although 
it was anticipated that patients on active treatment may have higher levels of distress 
due to the intense and cyclic treatment with potential side effects of nausea and 
fatigue, other research has reported no changes in HADS scores between pre-
chemotherapy and end-of treatment [256]. A meta-analysis of psychological distress 
in ovarian cancer found that depression and anxiety varied along the treatment 
trajectory, with depression highest at pre-treatment before reducing during treatment 
and at end of treatment [257]. Anxiety, in contrast, was lowest at pre-treatment before 
rising and remaining stable during and after treatment. The authors speculate that this 
contrast may be due to the reduction in depression as patients adjust to their 
diagnosis, while increasing anxiety may be related initially to side-effects during 
treatment, and fear of cancer recurrence post-treatment.  
Participants in this study who were on treatment were either receiving chemotherapy, 
maintenance therapy (bevacizumab) or combination chemotherapy/immunotherapy 
as part of clinical trial participation. Anecdotally, although many participants were 
dealing with fatigue, hair loss and other side-effects, overall they appeared to manage 
treatment well. The disruptions caused by treatment may have had more of an impact 
on overall quality of life, rather than affecting psychological functioning.  
170 
 
At Q3 participants had received their results of tumour and/or germline testing. To 
look at the effect of mutation status on distress this sample was divided into two 
subgroups: participants with no genetic alteration, and participants with a genetic 
alteration (pathogenic germline mutation and VUS were both included). There was no 
significant difference in HADS scores between the groups.  
Studies which have also explored the psychological impact of BRCA1/2 mutation 
carrier status in breast and/or ovarian cancer patients have reported mixed findings. 
Two retrospective studies observed no significant differences between BRCA1/2 
carriers and non-carriers on anxiety, depression or cancer-related distress [110, 114]. 
Similarly, two prospective studies compared psychological outcomes pre- and post-
genetic counselling and testing in a large sample of breast cancer patients; no 
differences were observed between BRCA1/2 carrier status and distress, or between 
pre- and post-testing on anxiety and depression [112, 115]. A prospective study of 
patients newly diagnosed with breast and ovarian cancer found no differences in 
HADS anxiety or depression scores between mutation carriers and non-carriers [143]. 
In contrast, a retrospective study of carrier status and personal cancer history found 
patients with a BRCA1/2 mutation positive result were at significantly higher risk for 
global psychological distress compared to non-carriers [133]. Recent data from a 
program of systematic BRCA1/2 germline testing in East Anglia found that distress 
scores (as measured by the Depression Anxiety and Stress Scale, DASS-21) were 
significantly lower in response to genetic testing, compared to distress scores on  the 
same measure in response to their cancer diagnosis [74]. Mutation status did appear 
to have some impact on distress, with patients who had received mutation positive 
results reporting significantly higher cognitive avoidance scores on the Impact of 
Event Scale (IES) compared to those who had received no mutation results.  
7.6.3 HRQOL 
HRQOL is a multi-dimensional concept encompassing domains relating to disease 
status which can include physical, social, emotional, sexual, functional and cognitive 
outcomes. One of the key aspects of HRQOL is that it is self-reported and reflects the 
patients’ own perspectives, perceptions and experiences. HRQOL is becoming an 
increasingly important patient reported outcome measure for studies of new 
therapies, in particular clinical trials, where toxicities and side effects are balanced 
against clinical benefit and patient wellbeing. It is also used to inform clinical 
management and guide therapeutic decisions [258]; HRQOL has been shown to 
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correlate with disease status in ovarian cancer (e.g.) response, progression or 
survival [259] as well as overall and progression-free survival [260].  
As the FACT-G is a commonly used measure of HRQOL, it is possible to compare 
scores from this sample to data from the published literature. Mean FACT-G total 
scores within this sample were 81.56, 85.71 and 84.21 across Q1-Q3. This was 
similar to ambulatory gynaecological cancer patients with regionally advanced 
disease (FACT-G total scores, M 82.88) [254] and normative data from both a general 
population sample of American adults (M 80.1) and a sample patients with mixed 
cancer diagnosis (M 79.3) [261].  
Pearman et al demonstrated that FACT-G scores are sensitive to disease status; a 
large sample of cancer patients reported lower scores, reflecting poorer HRQOL, as 
performance status decreased, and as disease progressed from no evidence of 
disease to metastatic [261]. This is reflected in a sample of ovarian cancer patients 
with recurrent and progressive disease who reported much lower FACT-G scores (M 
66.9) [262]. In this study cohort, it does appear that participants were not only 
managing both the physical and psychosocial elements of their diagnosis and 
treatment well, but may have good performance status and stable disease. As noted 
earlier in this chapter, there may be some selection bias from the recruitment process 
towards patients with better physical and psychological functioning.   
There were statistically significant differences in HRQOL; at Q1 and Q3 younger 
participants reported poorer HRQOL compared to those who were older. A 
longitudinal study of ovarian cancer patients quality of life reported similar findings, 
with younger patients demonstrating poorer HRQOL [255]. The authors believe 
younger patients struggle more psychologically and socially with both the diagnosis 
and treatment of cancer [255]. This is not dissimilar with some of the factors related 
to younger age at cancer diagnosis and distress. In contrast, a study of Italian 
gynaecological cancer patients found older patients had lower HRQOL scores across 
all domains, indicating poorer quality of life [263].     
At Q1 only, participants who were more recently diagnosed within the last 12 months 
reported significantly poorer HRQOL than those more than 12 months post-diagnosis. 
As this result was significant at only one timepoint, due to the limitations of the sample 
size it may reflect a false positive result. However it may also reflect a genuine finding 
and therefore is also discussed further here. Participants who are more recently 
diagnosed may still be adjusting to the shock of diagnosis, including psychosocial 
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adjustments, affecting emotional and social domains of HRQOL. The impact of 
initiating treatment such as surgery and/or chemotherapy as well as managing 
treatment side-effects may in turn affect physical and functional wellbeing. This was 
also reflected in NFOSI scores at Q1, where participants who were more recently 
diagnosed reported higher disease- and treatment-related symptom burden. Although 
neither of these findings were statistically significant at Q2 and Q3, they do suggest 
there is a challenging physical and psychosocial period post-diagnosis which 
ameliorates over time. Other studies have shown improvements in HRQOL in the year 
after diagnosis. A study of patients with both early stage and advanced gynaecological 
cancer found HRQOL improved at 12 months post-diagnosis compared to baseline, 
regardless of differences in treatment and prognosis [254]. Similarly a sample of 
gynaecological cancer patients showed HRQOL improvements six months post-
treatment, suggesting patient HRQOL is impaired during, and for up to six months, 
after treatment is completed [255]. 
Receiving active treatment (chemotherapy or other systemic treatment) compared to 
surveillance was not related to HRQOL as measured by FACT-G or NFOSI-18 scores. 
Again this suggests that this sample of participants may be coping better with the 
physical, social and emotional aspects of treatment compared to other cancer patient 
cohorts. A literature review of some early QOL data in gynaecological cancer patients 
suggested that QOL can be affected by treatment [264]; QOL was lowest from the 
point of diagnosis until completion of treatment and when compared to treatment of 
other cancers, gynaecological patients had significantly worse QOL.  
There was no association between mutation status and HRQOL, with no statistically 
significant difference in FACT-G scores. A study comparing BRCA1/2 mutation 
carriers with a personal history of cancer (survivors), unaffected carriers (previvors) 
and non-carriers (controls) found that survivors had low HRQOL for both emotional 
and physical issues [265] which may reflect their experiences of cancer diagnosis 
and treatment.  
7.6.4 Genetic testing 
7.6.4.1 Knowledge  
Knowledge has been used as a measure of the ‘success’ of genetic counselling, 
where information has been imparted from the genetic counsellor to the counselee; a 
meta-analysis of genetic counselling outcomes has shown that knowledge of cancer 
genetics increases post-counselling [266].  
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Within the traditional genetic testing and counselling framework, individuals eligible 
for genetic testing would be provided with information regarding the disease, 
advantages and disadvantages of genetic testing, risks and limitations, possible 
outcomes and risk management options available. Patients would be supported in 
their decision, whether it be to have, or not have, genetic testing. Typically there is 
time available for patient’s to reach their decision, for deliberation or consultation with 
other family members or health professionals for advice.  
Information provision about genetic testing within a mainstreamed model of delivery, 
where testing is discussed alongside other medical issues within the patient’s 
oncology consultation, is a significant departure from the traditional genetic 
counselling model. Decisions regarding testing may need to be made quickly, in order 
to inform treatment decisions or participation in clinical trials. However, in the absence 
of genetic counselling, sufficient information still needs to be provided by oncologists 
for patients to make an informed decision about whether or not to have testing. 
Currently there is a paucity of data exploring how oncologists discuss BRCA1/2 
genetic testing with ovarian cancer patients and what information is imparted.  
Measures have been used as a way to assess knowledge of key concepts associated 
with BRCA1/2 genetic testing within the context of research studies. In this study 
genetic testing knowledge was measured using items adapted from some of the first 
research on knowledge and attitudes to genetic testing by Lerman et al [220], and 
later work from Peters et al [221]. As raised at the start of this chapter, the study 
questionnaires were intended to serve both modes of testing (germline and tumour) 
although are more reflective of items related to germline testing.   
In Lerman’s original study, participants were affected and unaffected individuals with 
a family history of HBOC. The BRCA knowledge measure was completed at baseline 
prior to an education session. On average participants answered 55% of items 
correctly at baseline [220]. In this study, participants answered slightly fewer items 
correctly, with 47% and 49% at Q1 and Q2, respectively.  
Another way to look at testing knowledge was to categorise participants as having 
high, sufficient and low knowledge with accompanying cut-off scores. Peters et al 
(2005) defined ‘high knowledge’ as responding correctly to at least six out of seven 
items. In a sample of breast cancer patients, a proportion of whom had already had 
germline BRCA1/2 testing or had considered testing, 46.2% of participants had high 
knowledge [221]. In the current study only 4.8% and 13.2% of participants at Q1 and 
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Q2 were categorised as having high knowledge. These differences may be due to 
socioeconomic variables; participants in Peters’ research were aged 50 years or 
younger and 66% had been educated to college degree or higher, while in this sample 
of participants had a mean age of 65 years at recruitment and only 12% had 
completed tertiary education. In this study, educational level appeared to be unrelated 
to testing knowledge. 
Although this did not reach significance at Q1, at Q2 younger participants had 
significantly higher knowledge scores compared to older participants. Other studies 
have also reported increasing genetic knowledge with younger age [267, 268]. This 
may be attributed to improved education in schools regarding genetic concepts and 
medical genetics as well as greater exposure to genetic concepts and terms through 
popular media. Perhaps the most pivotal recent event to bring breast and ovarian 
cancer genetics into the public spotlight is the ‘Angelina effect’. Actor and filmmaker 
Angelina Jolie Pitt disclosed her BRCA1 mutation carrier status in 2013. From the 
media attention and public interest that followed, referral rates to familial cancer clinics 
not only increased significantly but were sustained [269]. 
In Peters’ study women who had undergone BRCA1/2 testing had significantly higher 
knowledge than those who were untested [221]. The authors reported the largest 
differences on items related to: ovarian cancer risks, paternal transmission, and 
BRCA1/2 mutation prevalence [221]. This suggests these are specific knowledge 
items that may only be gained from a genetic counselling context, while other 
information relating to genetic testing may be part of existing knowledge or more 
easily attained from other sources such as popular media.  
When participants were first recruited to this study, they received a verbal explanation 
of tumour testing from their oncologist. If necessary I supplemented this information 
to explain the process of tumour testing and how it differs to the standard genetic 
(germline) testing typically available, and the potential outcomes of testing. When 
participants consented to testing they received written information in the form of the 
Myriad ‘Patient guide to tumour BRCA testing’ (please refer to the Appendix).  
In this study there was no change in knowledge scores between when participants 
were recruited to the study (Q1), and after consenting to testing and receiving the 
Myriad tumour testing information booklet (Q2). This suggests that the information 
booklet did little to add to participants’ testing knowledge. Participants may also not 
have sought further information from other sources such as the internet. However it 
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is important to consider the limitations of this knowledge measure, and whether it can 
be considered an accurate measure of information provision and understanding. For 
example, in order for the questionnaire to be used across participants who had either 
germline or tumour testing, none of the items were specific to tumour testing.  
7.6.4.2 Attitudes to genetic testing 
Attitudes to genetic testing have typically been measured by comparing positive 
(advantages, benefits) and negative outcomes (limitations, risks, disadvantages), with 
positive attitudes reflecting greater endorsement of potential testing benefits over 
risks.  
Positive attitudes to genetic testing have been anticipated to lead to increased 
intention and uptake of testing, however a number of studies have shown that testing 
attitudes do not necessarily correlate with uptake of testing. From 14 studies 
examining real breast cancer genetic testing decisions, the average uptake rate was 
59%, with a wide range from 25% to 96% across these studies [184]. Interest for 
testing for HNPCC has been shown to be high (up to 80%) in both general population 
and at-risk patient groups [270, 271]. However actual uptake rates are significantly 
lower, approximately 43% [272].   
The measure of attitudes to genetic testing used in this study was developed by 
Peters et al [221] and has been used in other research exploring testing attitudes in 
both cancer patients and the general population. As described above for use in this 
PhD study the wording in this measure was modified to reflect the MTGT context 
specifically, i.e. referring to ‘oncologist’, rather than ‘doctor’.  
Peters et al found the uptake of genetic testing in a sample of breast cancer patients 
was significantly associated with positive attitudes towards testing, with patients 
consistently endorsing the benefits of testing over potential risks [221]. A qualitative 
study exploring TFGT in a sample of ovarian cancer patients reported that the 
potential advantages of testing outweighed any disadvantages [142]. In contrast, this 
study found no statistically significant differences between risk and benefit item 
scores; participants did not endorse the benefits over the risks of testing, and vice 
versa, either before (Q1) or after (Q2) consenting to testing. This ‘ambivalence’ 
towards genetic testing may reflect poor genetics knowledge and/or a lack of 
understanding of the potential advantages and/or disadvantages of genetic testing. 
For example, a Finnish study found that individuals with lower levels of knowledge 
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had more difficulty in forming definitive responses to various genetic testing attitude 
statements [273].  
7.6.4.3 Motivations for testing 
Motivations for genetic testing have been explored since clinical testing became 
available in the 1990s for HBOC. This early data tended to study at-risk but unaffected 
individuals or members of the general population, with some studies presenting 
genetic testing as a hypothetical option only. Overall, in the literature motivations for 
testing have largely been related to contributing to research, concern about future 
health, and generating information for children and relatives [114, 274-277]. Less is 
known about the motivations for genetic testing in cancer patients, particularly in a 
‘real’ decision context.  
In this sample of ovarian cancer patients who had just consented to BRCA1/2 tumour 
(or germline) testing, items related to the ‘Prevention and Medical Care’ subscale 
were endorsed more than other subscales. The items in this subscale referred to 
personal medical decisions such as providing information for treatment decisions, 
monitoring for signs of cancer, getting appropriate medical care, with one item 
referring to clarifying cancer risks for children.  
Given the context in which testing is taking place, it is not surprising that perhaps the 
focus of genetic testing has shifted to the potential personal implications it may 
provide to cancer patients. In a qualitative study of women with advanced ovarian 
cancer, their main motivation for genetic testing was to increase treatment options 
[142]. In a small study of breast cancer patients offered rapid genetic testing and 
counselling shortly after diagnosis, the three most cited reasons for having testing 
were all related to medical decisions about their cancer [138]. Amongst Dutch 
counsellees who had been offered and undergone genetic testing for HBOC, a small 
subgroup of individuals who had ‘fast tracked’ genetic counselling and testing in order 
to inform treatment decisions were most motivated by interest in their own cancer risk, 
followed by risks for family [278]. This subgroup of counsellees were also significantly 
more interested in using genetic testing to identify the cause of their cancer, compared 
to the rest of the sample.   
As other genetic testing for somatic mutations in cancer does not provide inherited 
genetic information, motivations were associated with treatment and personal benefit 
rather than thoughts of unaffected relatives. In a qualitative study of advanced cancer 
patients examining their expectations of genomic sequencing of tumour tissue, 
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participants were motivated by the potential personal benefit offered by testing, in 
particular by a sense of hope that this testing was offering something novel [107]. In 
a survey of advanced cancer patients, 70% reported that the most important reason 
for choosing to have genomic sequencing of tumour tissues was to guide treatment 
decisions [109].  
7.6.4.4 Decision making  
Decisional conflict 
The decision to have MGT is not dissimilar from that of BRCA1/2 germline testing – 
individuals need to be provided with information regarding the test, possible 
outcomes, risks, advantages and disadvantages. However the context in which the 
decision is made for MGT is significantly different; the oncology setting potentially 
limits time available for decisions and the expertise of the health professional making 
the offer of genetic testing [279]. Currently there is little empirical data on the decision-
making experiences of women with ovarian cancer offered MGT. A recent study of 
unselected genetic testing in ovarian cancer patients included three questions about 
decision-making [74]:  
• I had access to enough information to make a decision about testing 
• It was difficult to decide whether to have the genetic test 
• I had enough time to think about whether to have the genetic test 
Participants had high mean scores indicating sufficient information and time to make 
a genetic testing decision. Interestingly, scores for perceived ease of decision-making 
showed the widest variation (SD 1.80) suggesting that some patients may have 
struggled with the decision whether or not to have testing.  
Decisional conflict is a psychological construct to reflect the level of ease (or difficulty) 
in making a specific decision. It refers to a state of uncertainty about choosing a 
course of action, particularly when the options may involve risk, loss or regret [280, 
281]. Decisional conflict arises when the decision is difficult, and if the decision 
outcomes entail significant disadvantages as well as advantages [281]. High 
decisional conflict has been shown to impact decision regret [225] and manifest as 
delayed decision-making [282]. Factors that influence decisional conflict include 
feeling uninformed, unclear about values, feeling unsupported or pressured to make 
a decision [282]. In a validation study of the DCS for HBOC genetic testing, probands 
who had already undergone genetic testing had significantly lower DCS scores 
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compared to their untested relatives [280]. This suggests that decisional conflict may 
have a detrimental impact on testing uptake. It may also reflect the ability of genetic 
counselling to mediate decisional conflict by the provision of information, clarification 
of values and psychosocial support.  
In this study, decisional conflict was measured in at the point at which participants 
consented to MTGT (Q2). Overall decisional conflict was low, with a median total 
score of 25.0, suggesting little difficulty with decision-making. Decisional conflict 
scores were also low (<25.0) across all subscales. However a small number of 
individuals (n = 3) did have total scores ≥ 50.0, indicating moderate to high levels of 
decisional conflict.  
A small number of studies have looked at decisional conflict for genetic testing in 
contexts outside of the traditional face-to-face model of genetic counselling. In a 
sample of breast cancer patients, participants were provided with the option of 
choosing face-to-face genetic counselling and testing, or ‘direct’ genetic testing where 
educational resources and a testing kit were provided directly. Individuals who chose 
face-to-face testing and counselling had significantly higher decisional conflict scores, 
indicating uncertainty about the decision to have genetic testing and reflecting the 
desire to have additional information or support [283]. This provides support to still 
have an option for face-to-face genetic counselling, rather than only a mainstreamed 
model of delivering testing. However there is also evidence to suggest that clear, 
written information may be as effective as genetic counselling. A study of TFGT in 
newly diagnosed breast cancer patients compared face-to-face genetic counselling 
and testing to receiving written information only. After controlling for baseline levels, 
Quinn et al found no statistically significant differences in decisional conflict scores 
between the two groups [284].   
In a sample of breast cancer patients, genetic testing decisional conflict was 
compared between patients who had already had definitive surgery (ADS) and those 
prior to surgery (BDS) [141]. There were no statistically significant differences in DCS 
totals scores before and after genetic counselling, and across both groups. Overall, 
DCS total and subscale scores were low and comparable to scores in this study 
cohort. On the Informed subscale, ADS patients had significantly higher scores 
(median 50.0) prior to genetic counselling indicating less clarity on the advantages 
and disadvantages of testing, although this decreased post-counselling (median 
25.0).  
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Decision regret 
Decision regret is defined as a negative emotion associated with thinking about a past 
choice [225]. It is distinct from disappointment, and typically involves comparison to 
other choices that could have been made or outcomes that may have been different 
[285, 286]. Post-decision regret is not uncommon in cancer patients and has typically 
been related to treatment decisions. For example, in localised prostate cancer 
decision regret was associated with treatment side effects such as sexual or bowel 
dysfunction [286, 287]. Decision regret has also been associated with the way in 
which the decision has been made. Patients reported more decision regret if they had 
been less involved in their treatment decisions than they wished [288] or perceived to 
have made an uninformed treatment decision [286].  
In this study the median total DRS score was 0.0, indicating overall participants 
experienced little regret over their decision to have genetic testing. However a small 
number of participants (n=4) had total DRS scores ≥25 suggesting that some decision 
regret was experienced. Decision regret was not associated with mutation status nor 
with any of the predetermined subgroups (age, time from diagnosis, treatment status).  
As MGT is still a relatively new way of delivering BRCA1/2 testing there is little 
literature around testing decisions, in particular decision regret. Quinn et al also 
measured decision regret related to TFGT 12 months post-testing. The authors 
reported no statistically significant differences in DRS scores between breast cancer 
patients who had face-to-face genetic testing and counselling and those who had 
received written educational materials only [284]. In this study it appeared that 
changing the context and mode in which genetic testing was delivered did not 
influence decision regret.  
In Brehaut’s development and validation of the DRS, the authors found that increased 
regret was related to poorer health outcomes as a result of the decision [225]. 
Depending on the timing of testing in the ovarian cancer treatment pathway, genetic 
testing may not immediately impact health outcomes, although the results of testing 
may influence treatment decisions which could affect health status in the future. As 
decision regret was measured shortly after participants received their testing results, 
there would have been no change to treatment prior to completing Q3. Interestingly, 
issues about decision regret emerged in the qualitative interviews which were 
conducted several months after Q3. Brehaut comments that the DRS is useful at a 
specific point in time, suggesting that decision regret may evolve over time [225]. 
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Currently it is unclear how long it takes for decision regret to be established [286] and 
this timeframe may to be specific to the particular disease or treatment context.       
Although data is still emerging it appears that in cohorts of cancer patients who are 
facing the decision of BRCA1/2 genetic testing, in general decisional conflict and 
decision regret for testing is low.  
7.6.4.5 Impact of receiving genetic testing results  
Chapter 3 in this thesis examined the psychological impact of genetic testing. In much 
of the literature this has largely been measured using psychometric assessment tools 
which may not be sensitive to the specific issues related to genetic testing [226]. The 
MICRA is a validated measure which was designed to measure the specific impact of 
receiving genetic testing results [226]. Increased MICRA scores indicate adverse 
psychological responses to genetic testing results. Currently there are no accepted 
‘cut-offs’ for this scale to define high genetic testing distress [110]; responses are 
typically provided on a continuum (i.e. ‘higher’ or ‘lower’ scores).  
In this cohort of participants, overall MICRA total and subscale scores were low. When 
looking more specifically at MICRA scores and mutation status, the measure was able 
to distinguish between participants who had received a mutation or VUS results and 
those with no genetic alteration; participants with a genetic alteration had significantly 
higher MICRA scores indicating more testing-related concerns compared to 
participants with no genetic alteration. Earlier in the chapter psychological distress, 
as measured by the HADS, was not associated with mutation status, which further 
suggests MICRA’s ability to differentiate specific testing related concerns.  
A study of ovarian cancer patients who had been referred for and undergone genetic 
counselling and testing were categorised into four groups: (1) mutation carriers, (2) 
patients with breast and ovarian cancer, (3) patients with a family history of breast 
and ovarian cancer and (4) patients with no family history [110]. Significantly higher 
mean scores on the MICRA were reported by mutation carriers, compared to the 
remaining three non-carrier groups. No significant differences were observed 
between groups on other generic distress measures (HADS and IES), again reflecting 
the ability of the MICRA to reflect specific testing concerns.     
The MICRA has also been used to demonstrate that testing-related concerns can 
persist. In a long-term follow up study of individuals who had undergone BRCA1/2 
genetic testing, women with a personal history of breast and/or ovarian cancer who 
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were BRCA1/2 mutation carriers reported significantly more genetic testing related 
distress, compared to women who had received uninformative results [124]. As 
mutation status was not related to cancer-specific distress as measured by the IES, 
the authors suggested that genetic testing specific distress and global psychological 
dysfunction is unrelated. In another long-term follow-up study, one year after receiving 
BRCA1/2 genetic testing results, across both affected and unaffected participants, 
those who had received mutation positive results reported increased testing related 
distress [125].  
It appears that the MICRA is a useful tool to identify individuals with genetic testing-
related distress. Given the long-term nature of the study published by Graves et al 
where participants were approximately five years post-testing [124], this does suggest 
the importance of longer term follow-up of patients and provision of psychosocial 
support specific to being a mutation carrier.  
7.6.5 Clinic evaluation 
This was the final part of the last questionnaire (Q3) and was designed to explore 
participants’ perceptions of their MTGT experience. It was encouraging to see that 
there was almost unanimous agreement with having had sufficient time, information 
and support to make the decision about MTGT. From a genetic counselling 
perspective, it was also reassuring to see there was intention to disseminate results 
from MTGT to relatives which is particularly important in the case of individuals 
identified as mutation carriers for predictive testing of unaffected at-risk individuals.  
It was not unexpected that only a small proportion of participants felt that their MTGT 
results had impacted their ovarian cancer treatment. As discussed previously in 
Chapter 6, there may be no immediate change to treatment following BRCA1/2 
germline or tumour testing because of the timing of testing in relation to their treatment 
pathway and eligibility for PARP-inhibitors (e.g. after three line of platinum-based 
chemotherapy).  
Up to 24% of participants did not respond to the recall of genetic testing results 
question; three non-respondents were mutation carriers. It is possible some 
participants could not recall their result and therefore did not provide a response. 
However as participants were specifically provided with a prompt to the recall question 
(‘If unsure, please write ‘don’t know’’), this is unlikely. For reasons of confidentiality, 
some participants may not have wanted to disclose their testing results. All 
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participants were also aware that I had knowledge of their testing results, and may 
therefore have felt that it was unnecessary to disclose them again. 
Of the participants who provided responses to the recall of genetic test results 
question (25 of 33, 67%), two participants (2 of 25, 8%) incorrectly recalled their 
results. One participant could not recall her result, giving a ‘Don’t know’ response 
(result was no mutation identified). One participant incorrectly recalled her result as 
‘Negative’, however her actual result was a germline RAD51C VUS.1 
Incorrect recall of results may suggest poor or lack of communication between 
oncologists and their patients. As we will see in the next chapter, disclosure of MTGT 
results could be improved. Regardless, incorrect recall of genetic testing results is not 
uncommon amongst individuals who have had BRCA1/2 testing. Previous research 
looking at mode of result delivery found that even after face-to-face genetic 
counselling, 2.9% of patients were unable to accurately recall their results [289]. The 
majority of those with incorrect result recall had received a germline VUS result.  
BRCA1/2 VUS results are complex to understand and interpret, and these results can 
be confusing to both patients and clinicians. A retrospective study of 24 patients who 
had previously received germline BRCA1/2 VUS results after genetic counselling and 
testing compared recall and interpretation [290]. When reporting factual recall seven 
participants (29%) incorrectly recalled their VUS result as a pathogenic mutation. 
Despite correctly recalling their result, a much larger proportion of participants (79%) 
subjectively interpreted their VUS as a pathogenic mutation.  It is important to note 
that the mean time between genetic test result disclosure and study participation was 
3.0 years, a much longer period of time between testing disclosure and recall 
compared to this study.   
7.7 (More) Limitations  
As mentioned earlier in the study, initial study plans were to compare experiences of 
patients offered mainstreamed BRCA1/2 germline or tumour testing and the language 
used in the study documents (including questionnaires) was designed to refer to 
‘genetic testing’ generically. However after recruitment began, I had to adapt to the 
clinical context and chose to focus this research purely on the tumour testing 
experience. It is difficult to comment on whether the language which referred to 
‘genetic testing’ acted as a primer to participants to reflect more on concepts related 
                                               
1 This result was later clarified with the patient by her oncologist, and the patient was referred to 
her local clinical genetics service for genetic counselling.  
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to germline testing rather than tumour testing. Furthermore given the number of 
participants in this sample who had second-line germline testing, it may not be 
possible to distinguish tumour testing from germline testing experiences. What these 
results contribute to is our growing understanding of the patient experience of 
mainstreaming in general.  
In this study there is likely to be a selection bias towards patients who were more 
physically and psychologically robust, partly driven by the recruitment strategy where 
oncologists were consulted initially as to which patients were suitable to approach for 
recruitment. There is an additional selection bias towards patients who were 
interested in genetic testing as participants also self-selected for this research.  
The Testing Knowledge measure used in this study includes items that mostly relate 
to germline rather than tumour testing. Therefore it does not reflect what information 
participants were actually provided with and is a poor measure of their knowledge. 
With hindsight a simple self-developed measure with tumour testing knowledge items 
would have provided much more insight.  
The small sample size of this study has been discussed earlier in relation to 
interpretation of results and also limits the generalisability of results.  
7.8 Summary 
This chapter presented quantitative data on the participant experience of MTGT. 
Participants in this study reported psychological distress scores that were similar to 
other samples of cancer patients; these scores remained stable over the MTGT 
pathway. Participants reported good HRQOL which remained unchanged over the 
course of the study and reflected their general demeanour and appearance during the 
study. It was interesting to note that participants had somewhat ambivalent attitudes 
to genetic testing, despite taking part in this study. Reflecting the context in which 
testing was provided, participants were primarily motivated by the perceived medical 
care and prevention aspects of testing. At the point of consenting to testing, 
participants’ scores did reflect some conflict about their decision. Encouragingly, there 
was no decision regret post-testing. There was no difference in distress or HRQOL 
scores by mutation status. Using a specific measure of impact of genetic testing 
showed that participants with a genetic alteration (mutation or VUS) had significantly 
more testing-related concerns compared to those without a genetic alteration.  
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Chapter 8 Exploring the patient experience of mainstreamed 
BRCA1/2 tumour testing in ovarian cancer: a qualitative 
approach  
 
8.1 Introduction 
This chapter moves away from the quantitative component of this study, which has 
used standardised measures and considered the patient group as a whole, to a 
qualitative perspective where the focus is on individual experiences. This component 
of this PhD study is an essential part of developing an understanding of how women 
with ovarian cancer experience MGT, in particular mainstreamed BRCA1/2 tumour 
testing.  
There is a small body of qualitative research on patient’s perspectives, experiences 
and impact of RGCT or TFGT in breast and ovarian cancer [142, 291-293]. Although 
there are shared features within these testing approaches and MGT, e.g. testing 
shortly after diagnosis and/or testing to guide treatment decisions, what is important 
to distinguish is the manner in which genetic testing and/or counselling is provided. 
Whilst different to the traditional model of genetic counselling and testing, TFGT may 
still involve information provision or consultation with a genetic counsellor or clinical 
geneticist. Similarly, while the testing may be undertaken within the specialty oncology 
centre or hospital, it may be organised by the clinical genetics service rather than the 
patients’ oncology team. MGT as it is defined in this study, from test offer to result 
delivery is provided by the oncology health professionals who are already involved in 
the patients’ care. BRCA1/2 tumour testing adds an additional layer of complexity to 
MGT, involving use of patient tumour tissue and potentially a two-step testing process.  
Genetic testing of tumour tissue has been an integral component of the Genomic 
England 100,000 Genome Project. There are a number of factors that indicate 
BRCA1/2 tumour testing could soon become part of standard clinical care for women 
with high grade serous ovarian cancer, including: (i) decreasing costs of testing, in 
the UK BRCA1/2 tumour testing costs are approximately £500-600, (ii) improved 
methods of DNA extraction from historic FFPE samples, (iii) a move to using fresh 
frozen tissue samples, providing better DNA quality for testing, and (iv) efforts to 
develop infrastructure to support testing between oncology, cellular pathology and 
molecular genetics. 
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If BRCA1/2 tumour testing will be provided within an MGT model that is oncology-led, 
qualitative research is an essential part of informing the development of these new 
clinical pathways and the health professionals involved.  
8.2 Aims 
The purpose of this qualitative component was to explore the patient experience of 
MTGT, both mainstreamed BRCA1/2 tumour and germline testing. This research 
aimed to expand our understanding of how women with ovarian cancer experience 
the process of MGT, in particular tumour testing, focusing on their understanding, 
expectations and experiences of making the decision to have MTGT, as well as the 
impact of receiving MTGT results.   
8.3 Methods 
8.3.1 Participants and selection 
In qualitative research, the sample should reflect the social world, culture or 
phenomena of interest [173]. Targeted, or purposive, sampling is used to recruit 
participants who represent certain aspects of the culture or phenomena. In this case, 
purposive sampling was used to ensure there was diversity in participants’ testing 
modes and testing outcomes, including: 
• Tumour testing no mutation identified, no further testing  
• Tumour testing MLPA fail, germline testing  
• Tumour testing mutation identified, germline testing confirms mutation 
• Tumour testing mutation identified, germline testing no mutation 
• Germline testing only. 
Participants were selected from the main cohort of ovarian cancer patients who had 
consented to take part in this PhD research on mainstreamed BRCA1/2 tumour 
testing (participants from the previous chapter). Patients who had completed MTGT 
and received their results were eligible to take part in a one-on-one interview with 
myself. Participants were invited consecutively as they returned to the gynaecology 
oncology outpatient clinics for their scheduled appointments.  
8.3.2 Development of the interview schedule 
The interview schedule was developed and pilot-tested with two participants from the 
previous study prior to being submitted for REC and HRA review. The wording of the 
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interview schedule was designed to be adapted to each participant depending on the 
mode and outcome of MTGT. The interview schedule was informed from both this 
PhD research and clinical experience to date recruiting and providing mainstreamed 
BRCA1/2 tumour testing (and at times, germline testing) to ovarian cancer patients, 
my previous research and clinical experience in psycho-oncology of genetic testing, 
as well as the published literature.  
To understand the participants’ experiences in context, it was important to include in 
the interview schedule questions about ovarian cancer diagnosis and treatment. This 
has been a significant, life altering event for participants and inevitably their 
perceptions and experiences of genetic testing will be shaped by their diagnosis. The 
interview scheduled explored specific areas of the genetic testing process that I had 
anticipated would provide insight and meaning into the patient experience. The 
interview aimed to cover several topics I felt would be particularly relevant, first looking 
at context in their experiences of diagnosis and treatment of ovarian cancer, 
perceptions and expectations of genetic testing, decision making process and 
outcomes from genetic testing.  
The interview schedule can be found in the Appendix.  
8.3.3 Recruitment 
All the participants invited for an interview were already enrolled in the MTGT study 
described in the previous chapter. In order to get a breadth of genetic testing 
experiences and outcomes, I firstly identified eligible participants based on their mode 
of genetic testing and testing results as outlined above. By this time, many of the 
participants had already been part of my research for at least three months. As I was 
familiar with all the participants and vice versa, it felt appropriate to take a more direct 
approach to recruitment. As each participant returned to the outpatient clinic, I 
approached her directly and asked if she would be interested in completing an 
interview as the final part of the study. Each participant was provided with an 
information sheet and given at least 24 hours to reach a decision whether or not they 
wished to take part in an interview. After this time, I followed up each invited 
participant by telephone. If she agreed to an interview, we decided on a date and time 
for the interview based on her preference.  
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8.4 Data collection 
Participants completed a one-on-one interview that typically lasted between 30 and 
60 minutes. Most commonly interviews were conducted by telephone while the 
participant was at home. Five interviews took place within the Macmillan Cancer 
Centre’s chemotherapy suite during the participant’s treatment.  
At the start of each interview, it was made clear to participants that they did not have 
to answer any questions that they did not wish to, and were free to stop the interview 
at any time. Participants were reminded that the interview would be recorded with 
their permission and transcribed verbatim, with the digital recording then being 
deleted. 
All information was treated anonymously. Transcribed interviews removed references 
made to named places or people.  
8.4.1 Transcription 
Transcription was undertaken by Devon Transcription, a professional transcribing 
service approved by UCL and one which we have previously used for other health 
research projects around ovarian cancer and genetic testing.  
Interviews were transcribed verbatim and returned securely in an anonymised Word 
document format, which were then exported in to NVivo (QSR International, 
Cambridge, MA), a qualitative data management software for coding and analysis. All 
transcripts were kept in password protected computer hard drives and in a password-
protected back-up drive (The UCL Data Safe Haven).  
8.5 Analysis  
8.5.1 Co-coding 
Two transcripts (10%) were be coded independently by my primary supervisor who 
has both experience in qualitative research and genetic testing. Any differences were 
discussed until agreement was reached. 
8.5.2 Thematic analysis  
The analysis method chosen for this data was thematic analysis, and was specifically 
guided by Braun and Clarke’s 2006 publication [294]. In general, thematic analysis is 
a method which identifies, analyses and reports patterns or themes within the data 
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[48]. Similar approaches to thematic analysis include interpretative phenomenological 
analysis (IPA) and grounded theory, as both methods involve looking for patterns in 
the data. However both methods are theoretically bounded; IPA follows a 
phenomenological epistemology exploring in great detail the lived experience of the 
phenomena of interest, while grounded theory aims to generate a theory from the 
phenomena ‘grounded’ in the data [294]. In contrast, Braun and Clarke argue that 
thematic analysis can be used within different theoretical frameworks. This was also 
an analysis approach that I had used previously and therefore was familiar with.  
8.5.3 Analysis choices 
Braun and Clarke highlight key analytic choices that should be made explicitly clear, 
preferably prior to any data is analysed. I felt the first four analysis choices 
described below were related, with one analysis choice influencing another. As I will 
elaborate further below, the study’s epistemology impacts whether themes are 
constructed on a semantic or latent level, if a rich description of the data set is 
produced rather than a more detailed account of a specific aspect, which is turn 
bound by the inductive vs deductive analytic approach taken.  
 
8.5.3.1 Research paradigm, ontology and epistemology  
In Chapter 4, I outlined different research paradigms and put forth the one I feel best 
reflects my own philosophical and research orientation. An interpretivist paradigm is 
informed by a relativist ontology and subjectivist epistemology, accepting that reality 
is interpretations by individuals. Each participant’s experience of MTGT is unique, 
reflecting their own subjective interpretation of events. Thus there will be multiple 
interpretations of the experience of testing, leading to multiple realities. Context is 
critical to an interpretivist paradigm, influencing experiences and meaning. What were 
previous separate disciplines, genetics and oncology, have become intertwined 
through mainstreaming. How these participants experience MTGT is in turn 
influenced by their experiences as a cancer patient. Finally, my own beliefs and 
outlook not only guide the research, but also how the research is interpreted. 
Throughout this chapter I acknowledge when my own biases and perceptions come 
in to play, and reflect on how this influences my interpretation of the data.  
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8.5.3.2 A rich description of the data set, or a detailed account of one particular 
aspect 
The main aim of this work was to explore how women with ovarian cancer experience 
mainstreamed BRCA1/2 tumour testing, which covers a breadth of topics from cancer 
diagnosis and treatment to the impact of receiving genetic testing results. To meet 
these aims I aimed to produce a rich description of the data set, reporting only the key 
themes, which inevitably loses some complexity, but is a useful method for 
investigating an area of research where little is known. Subsequent analyses of the 
same data set or a similar participant group could focus on more detailed accounts of 
a particular aspect, e.g. testing consent, which may lead to greater depth and more 
nuanced account of the patient experience. 
8.5.3.3 7.5.3.3 Semantic vs latent themes 
Another analytical choice is the ‘level’ at which themes are identified. Braun and 
Clarke refer to two options: (i) semantic level, where themes are identified within the 
‘…explicit or surface meanings of the data’ (p.84) and, (ii) latent level, which examines 
underlying ideas, patterns, and assumptions [294].   
Although semantic themes may appear to require a more superficial form of analysis 
when compared to latent themes, it should still involve interpretation where the 
researcher explores the significance of the patterns in the data, and considers their 
implications in the context of previous literature. This is the approach I took when 
identifying themes; I looked to not only describe, but also to understand and explain 
the patterns in the data. Reflecting the interpretivist research paradigm, it was 
important to draw on my own knowledge and experience of genetic testing and 
consider how this informed my interpretation of the data. In the Discussion section I 
continue looking for meaning and implications in the data whilst referring back to other 
published data in this area.  
8.5.3.4 Inductive vs theoretical thematic analysis  
An inductive analysis approach has no predetermined theory or framework, instead 
letting the data drive the identification of themes, in a way that is sometimes described 
as ‘bottom up’. Inductive analysis is seen to be particularly useful when little is known 
about the area under research, as it allows the themes to be driven by the data itself. 
Braun and Clarke describe inductive analysis as being ‘data-driven’ (p.83).  
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A deductive or theoretical approach, in comparison, follows a pre-existing framework 
driven by a particular theoretical focus. This is useful when there are specific research 
questions of interest, as it often leads to a detailed analysis of a specific aspect of the 
data, rather than description of the data overall [294].  
As little is known about the patient experience of mainstreamed BRCA1/2 tumour 
testing, an inductive approach gave more flexibility and allowed the themes to be a 
direct reflection of the data. Therefore in my analysis I coded freely rather than coding 
for a specific research question. However it is impossible to conduct any analysis 
without some theoretical or epistemological influence. In this case an interpretivist 
paradigm emphasises the role of the researcher; my existing knowledge and own 
experiences of genetic testing and counselling led me to search for certain elements 
in the data.  
8.5.3.5 When is a theme, a theme (Part 1)? 
The key component of thematic analysis is in its very name. A theme is defined as an 
idea that recurs in or pervades a piece of work. However, how the researcher decides 
on what data constitutes a theme is more nuanced. For example, a theme may be 
based on prevalence, that is how often the idea or concept is articulated by the 
interviewees. Alternatively, rather than the frequency in which a theme recurs within 
the dataset, a theme may also be related to how meaningful the idea or concept is to 
the phenomena of interest. Ultimately it is the researcher’s judgement to determine 
what a theme is, although consistency of judging ‘themeness’ is key within the 
analysis. Although Braun and Clarke advised that the decision on what constitutes a 
theme should be made prior to analysis, I took a more flexible approach and chose to 
first begin my analysis and then be guided by the data. 
8.5.4 Analysis process 
Braun and Clarke (2006) detail a step by-step guide to the six phases of their analysis 
process, which is also summarised in a table and reproduced below [294]. Their 
analysis process is recursive, allowing you to return to various phases during the 
analysis, rather than a rigid mode of analysis which is only linear in fashion.  
The authors highlight that it is important to reflect on when to delve into relevant 
literature, noting ‘…a more inductive approach would be enhanced by not engaging 
with literature in the early stages of analysis’ (p.86) [294]. At the beginning of my 
analysis process I decided not to formally explore the literature until Phase 5, when I 
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had developed and reviewed my themes. This was to allow me to take a more 
inductive analytic approach, but also given my previous research experience in this 
area I was already familiar with the psychosocial literature around genetic testing.   
Importantly Braun and Clarke emphasise that this is their guideline to analysis, and 
these are not fixed rules that must be followed in order to carry out a successful 
thematic analysis. This allowed me to follow the six phases of their analysis process 
while maintaining my own analytic style as well as drawing on my previous qualitative 
analysis experience to inform my overall analysis process; this is detailed in the last 
column of the table.  
 
Table 8.1 Description of thematic analysis process 
 
Phase 
Description of Braun & 
Clarke’s process 
Description of my process 
1 
Familiarising 
yourself with your 
data 
Transcribing data (if 
necessary), reading and re-
reading the data, noting down 
initial ideas 
Data was transcribed by a 
third party. I read each 
transcript several times while 
making brief notes on each 
interview guide areas (e.g. 
ovarian cancer diagnosis and 
treatment, attitudes to genetic 
testing, impact of results etc). 
2 
Generating initial 
codes 
Coding interesting features of 
the data in a systematic 
fashion across the entire data 
set, collating data relevant to 
each code 
Each transcript was coded 
systematically. Following 
Braun and Clarke’s advice to 
‘code for as many potential 
theme/patterns as possible’, 
coding generated more than 
800 codes across 18 
transcripts. I continued to 
make notes and record ideas 
for the results and discussion 
sections while coding. 
3 
Searching for 
themes 
Collating codes into potential 
themes, gathering all data 
relevant to each potential 
theme 
Codes were then reviewed, 
collapsing similar and/or 
repeating codes together to 
build rough themes. Initial 
ideas and notes were fleshed 
out and developed further as 
themes were built. I began to 
select extract examples, or 
‘quotes’, that were particularly 
striking. During this phase two 
distinct streams of themes 
emerged between those 
related to ovarian cancer, and 
themes related to genetic 
testing. 
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4 Reviewing themes 
Checking if the themes work 
in relation to the coded 
extracts (Level 1) and the 
entire data set (Level 2), 
generating a thematic ‘map’ 
of the analysis 
Checking and reviewing the 
themes generated key themes 
and their related and relevant 
sub-themes.     
5 
Defining and naming 
themes 
Ongoing analysis to refine the 
specifics of each theme, and 
the overall story the analysis 
tells, generating clear 
definitions and names for 
each theme 
Continuing refinement of each 
theme and subtheme. 
Developing an illustrated 
thematic map helped to 
visualise the two streams of 
data. 
6 Producing the report 
The final opportunity for 
analysis. Selection of vivid, 
compelling extract examples, 
final analysis of selected 
extracts, relating back of the 
analysis to the research 
question and literature, 
producing a scholarly report 
of the analysis. 
Relating the data to the 
literature and drawing together 
a cohesive account of the 
research question. In this last 
analysis phase, only the 
quotes which best 
represented the theme were 
included.  
 
 
In the table below is an extract from a participant interview showing my coding 
process.     
 
Table 8.2 Example of data extract and codes 
Data extract Codes 
I was okay about it, that the girls stood as much 
chance as anyone else then. They will be aware 
now because I have had it, so your 
grandmother’s got it, but I was okay with it not 
being genetic because then at least they would 
be more comfortable. So yes, I didn’t feel one 
way or the other about it. It was like making a 
decision between having to move quickly to tell 
medics that my family had this wonky gene, or 
to go oh, okay, we don’t have to panic yet then 
because my family doesn’t have the wonky 
gene.  
[MGT057, TT, no mutation] 
• Relatives’ risks same as general 
population 
• Female relatives aware about 
ovarian cancer 
• MGT result better for female 
relatives 
• Neutral feelings about MGT results 
• If gene mutation would need to tell 
HPs quickly 
• Wonky gene = gene mutation 
• MGT result no need to panic 
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8.5.4.1 When is a theme, a theme (Part 2)? 
I used the early phases of analysis, particularly coding and creating initial themes, to 
help shape and define what I would consider a theme. During the initial phases of 
data analysis, I was starting to see patterns in the data where codes were overlapping 
or clustering. I was also noticing two distinct but related streams of data – codes that 
related to ovarian cancer the disease, and codes relating to genetic testing. Codes 
were also naturally clustering around the interview topics of ovarian cancer diagnosis, 
experience of genetic testing and genetic testing outcomes. As I continued to collate 
my codes and search for themes, I defined a theme by both prevalence, how often 
the theme was occurring and recurring within the data set, and whether I felt that the 
theme represented an important finding.   
Once I was clear on what I would consider to be a theme, I continued on with phases 
3 and 4 of analysis where themes were further sought and reviewed. There were two 
key overarching themes around the experience of MTGT: (i) the specifics of MTGT, 
and (ii) the cognitive and emotional experiences. Relevant themes were reviewed 
again and denoted as sub-themes, which were then organised under their related key 
theme.     
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.1 Thematic map 
 
Ovarian cancer 
Genetic 
testing 
• Symptoms 
• Diagnostic 
odyssey 
• Ovarian cancer 
causation 
Experiencing MTGT 
• Perceptions 
• Expectations 
• Motivations 
• Decision making 
• Response to 
results 
MGTG specifics 
• Initial offer of 
MTGT 
• Initial response 
• Using tumour 
tissue 
• Germline vs 
tumour 
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As the thematic map illustrates, the ovarian cancer stream is depicted as a larger 
circle to reflect the greater influence the disease has had on the participants’ 
experiences, compared to genetic testing which is conceptualised as a smaller circle. 
These two streams, although distinct, are shown to overlap. This is to represent that 
to some extent these two events are intertwined; these participants were offered 
genetic testing as part of their clinical care for ovarian cancer.  
8.5.4.2 Data saturation 
Unlike quantitative research, there is no mathematical formula in qualitative research 
to determine a sufficient sample size of participants. Data saturation has been 
typically used to justify sample size, which refers to the point at which the emergence 
of new themes becomes rare and older themes repeat themselves [295]. There is no 
agreed method of how data saturation is established, and there is often little 
explanation or justification of how it was achieved. As Morse writes ‘Saturation is the 
most frequently touted guarantee of qualitative rigor offered by authors to reviewers 
and readers, yet it is the one we know least about’ (p.587) [296].  
Hennink et al have tried to address the poor definition of saturation, and develop 
parameters based on rigorous research to guide sample sizes for reaching saturation 
[297]. They begin by clarifying data saturation and making a distinction between code 
and meaning saturation. Code saturation refers to the point at which no additional 
issues are identified, and meaning saturation when the issues are fully understood. 
They undertook a study to determine what sample size would lead to code and 
meaning saturation. They found that most of the codes were developed in the initial 
interviews, and the number of new codes rapidly declined with successive interviews. 
The authors concluded that while it only took nine interviews to reach code saturation, 
between 16 to 24 interviews were needed to develop an in-depth understanding of 
the issues.  
Hennink et al use a rigorous and detailed process of determining when code and 
meaning is reached. Rather than follow this exact approach, I used their findings to 
guide both my sample size and to conclude when I reached data saturation. With this 
in mind I aimed to recruit up to 20 participants for an interview. Following Braun and 
Clarke’s analysis guide, I coded the transcribed interviews extensively. Unlike the 
findings of Hennink et al, I found that for each interview I was still generating a small 
but significant number of new codes. This was likely due to the breadth of interview 
topics coupled with the personal and individual experiences of cancer diagnosis and 
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genetic testing outcomes. As codes were collated to create themes, it became clear 
that for the purposes of this study many codes, by their prevalence and relevance to 
the research question, would not reach thematic level.  
As themes were generated, I used the iterative nature of my analysis to return to the 
codes and themes checking if any additional codes were arising, and if there were 
new or different meanings emerging for the themes. After 18 interviews I felt that for 
the themes presented in this thesis, I had reached both code and meaning saturation.  
As you will see below, there is some data included in the Results section that did not 
reach either code or meaning saturation, likely because these were both unique 
experiences of their specific MTGT outcomes. However I decided to include this data 
as it provides useful and informative insight into the patient experience, and will 
contribute to our overall understanding of MTGT implementation. 
8.6 Reflections on issues raised during interviews 
Depending on the topic area, qualitative in-depth interviews may cover sensitive 
topics. Participants may not have previously had the opportunity to voice their 
thoughts and feelings of their experiences. As a result, it is not uncommon for 
interviewees to become emotionally distressed during the course of the interview. 
This is a risk of qualitative research that is often outlined in the study protocol and 
made clear in both the research ethics process and when consenting participants.  
Participants spoke at length about their experiences of and journey to their diagnosis 
of advanced ovarian cancer. Despite some diagnoses having been many years ago, 
their recollections were clear and detailed; this was a memory that was still raw for 
many. Several interviewees became tearful when recalling the repeated delays and 
missed opportunities of their health care professionals. Whilst there was 
acknowledgement that a more rapid diagnosis was unlikely to have altered their 
prognosis, there was clearly frustration, anger and distress at what they perceived to 
be failures by the medical community.  
It can be particularly difficult to manage an interview where the participant becomes 
distressed when the interview is not in person, but conducted by telephone. There are 
no visual cues in body language to show empathy, or physical actions for example 
reaching out to touch their hand or arm, or a simple but practical gesture of providing 
tissues. I found that I drew on my genetic counselling training where distress is not 
ignored, but addressed. I did not respond immediately with words trying to comfort or 
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reassure the participant, instead I gave them time to be tearful or upset. Where 
appropriate I would acknowledge their distress, for example a simple statement ‘That 
must have been very upsetting. I’m here to listen’. When there was a quiet moment 
to gently ask if they would like to pause or stop the interview, participants invariably 
wanted to continue.  
Although I was embedded in the gynaecological oncology clinic for more than a year 
and had known some of these participants for many months, I was not familiar with 
the specifics of each participants’ journey to diagnosis. It was important, as a 
researcher, to hear these stories. It was a reminder that genetic testing is taking place 
within the context of ovarian cancer and any experiences of MTGT will be shaped by 
this.  
As discussed earlier in Chapter 6, there are times when the boundaries as a 
researcher became blurred. As you will read further on in this chapter, on some 
occasions participants directly asked me to explain or expand on their genetic testing 
results and the implications of those results. It was difficult having been trained as a 
genetic counsellor and therefore having the knowledge to answer their questions, to 
rebuff their queries. If the question was straightforward and the answer simple, then I 
felt it was appropriate to provide an answer, particularly for participants who would 
not have been referred to their local clinical genetics service (i.e. participants who had 
received no mutation results). In some cases the queries were more complex. For 
example Janet, who received a RAD51C VUS result, was particularly anxious and 
confused about what her result meant. During the interview I debated whether or not 
to explain in general what a germline VUS result meant in attempt to bring her some 
clarity. However I felt that my explanation was unlikely to bring her much reassurance. 
Janet’s sister had died from ovarian cancer several years earlier and her unexpected 
and uncertain result was only compounding her concern about a possible hereditary 
link. At the end of the interview Janet told me she was still waiting to be contacted by 
her local clinical genetics service. Although I felt it may be beyond by researcher role, 
I felt a genetic counselling appointment would bring relief and hopefully reduce 
ambiguity about her results. I contacted her oncologist to confirm that the referral had 
been made, and then provided Janet with a copy of the genetic testing report and 
referral, and the phone number of the relevant genetics service.  
I found myself navigating uncharted territory during the interviews with one participant 
[MGT059]. Her tumour testing results had identified a BRCA1/2 mutation and 
subsequent germline testing had also confirmed this. I assumed prior to the interview 
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that she had received her germline results as this report had been scanned into her 
medical records and a referral to her local clinical genetics service had been made. 
However during the interview she made reference to still waiting for the results of ‘the 
blood test’ which would be discussed in her upcoming genetic counselling 
appointment. Her narrative about tumour testing indicated that she believed she 
carried an inherited mutation, despite not yet having received her germline results. I 
was unsure of how to proceed; should I clarify that her tumour testing results were not 
actually indicative of the nature of the mutation until her germline testing results were 
disclosed, therefore as it stood whether the mutation is inherited or not was unknown? 
Or should I disclose her germline results to clarify that it is indeed an inherited 
mutation based on these results, rather than the tumour testing results? In this 
ethically important moment with little time to consider how to manage the remainder 
of the interview, I decided that the most ethical approach would be to continue the 
interview following her beliefs and her narrative. I felt it was beyond my role as a 
researcher to disclose her germline results. Rather than correct her misinterpretation 
of her tumour testing results, what she believes and understands her results to be, 
whether correct or not, is an important part of this research. I was also reassured to 
some degree that she had an upcoming clinical genetics appointment where she 
would have both the time and expertise from the genetic counsellor to discuss and 
clarify any misconceptions.  
8.7 Results 
8.7.1 Participants 
As discussed earlier in this chapter, the aim was to complete interviews with 
participants across different MTGT modes and with different outcomes. As shown in 
the table below, of the 18 participants who were interviewed, half (n = 9) had first line 
tumour testing, received no mutation identified results and required no further testing. 
Three participants who had first line tumour testing where MLPA failed and had follow-
up germline testing completed an interview, including one patient who then received 
a RAD51C mutation result and another a RAD51C VUS. Four patients where a 
mutation was identified on tumour testing and then confirmed on germline testing were 
included in this sample. As described in Chapter 6 on the clinical outcomes of tumour 
testing, only three participants were found to carry BRCA1/2 somatic mutations; one 
completed an interview. One participant who had first line germline testing and was 
found to carry a BRCA1/2 mutation also completed an interview.   
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Table 8.3 Genetic testing mode and outcome of interview participants 
 
*This participant was later found to carry a somatic BRCA1/2 mutation as identified on repeat 
tumour testing by Foundation Medicine 
  
Participant 
Initial MTGT 
mode 
First MTGT 
result 
Additional MTGT 
Final MTGT 
result 
MGT006 Tumour  No mutation No N/A 
MGT013 Tumour 
No mutation, 
MLPA fail  
Germline testing –
extended  panel 
gRAD51C 
mutation 
MGT020 Tumour  No mutation No N/A 
MGT021 Tumour  No mutation No N/A 
MGT022 Tumour  No mutation No N/A 
MGT029 Tumour BRCA mutation 
Germline testing – 
specified mutation  
gBRCA 
mutation 
MGT031 Tumour 
No mutation, 
MLPA fail 
Germline testing –
extended  panel 
gRAD51C 
VUS 
MGT032 Germline BRCA mutation No N/A 
MGT033 Tumour  No mutation No N/A 
MGT019 Tumour No mutation No N/A 
MGT039 Tumour  No mutation No N/A 
MGT042 Tumour BRCA mutation 
Germline testing – 
specified mutation 
gBRCA 
mutation 
MGT048 Tumour BRCA mutation 
Germline testing – 
specified mutation 
gBRCA 
mutation 
MGT053 Tumour  No mutation No N/A 
MGT057 Tumour  No mutation No N/A 
MGT059 Tumour BRCA mutation 
Germline testing – 
specified mutation 
gBRCA 
mutation 
MGT062 Tumour 
No mutation, 
MLPA fail 
Germline testing –
extended  panel 
No mutation 
MGT056 Tumour Inconclusive 
Germline testing – 
extended panel 
No mutation* 
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Three participants who were approached and invited to do an interview declined due 
to feeling too unwell. This included another patient with a somatic BRCA1/2 mutation, 
and a younger patient who was a germline BRCA1/2 mutation carrier. Two of these 
participants had recently relapsed, while another had progressive disease while on 
clinical trial treatment.   
8.7.2 Themes  
Each interview began with asking participants to recall how they had been diagnosed 
with ovarian cancer, and then to talk about their experiences since their diagnosis. 
Questions relating to genetic testing often flowed naturally from their stories of 
diagnostic journey and treatment.  
Resulting themes fell into two streams: experiences around ovarian cancer, and 
experiences around genetic testing. 
8.7.2.1 Ovarian cancer experience 
The signs and symptoms 
All participants began, unprompted, with their own recall and identification of their 
symptoms that eventually led to medical investigations and ultimately diagnosis of 
ovarian cancer. Across all the interviews, symptoms fell into several categories: 
digestive, gynaecological, urinary and systemic (fatigue, weight gain or loss, infection, 
pain). The majority of participants described experiencing at least one symptom, 
although multiple symptoms (either concurrent, or progressive) were also commonly 
reported. Symptoms were important to participants, as these were indications where 
they recognised something was not right.   
The most commonly reported digestive symptom was bloating, which was initially 
intermittent and attributed to menopause, weight gain or IBS, before becoming 
persistent and increasingly uncomfortable. Systemic symptoms such as weight gain 
and weight loss were also associated with bloating. Some participants struggled with 
ongoing fatigue and persistent infections.  
All the while, my stomach was getting more and more bloated. I gradually 
found that I was having trouble fitting into clothes. [MGT059, TT + GT, 
BRCA+ve] 
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And I was going on holiday, I had another couple of attacks in between, 
they were so far apart and I just thought it must have been IBS or 
something like that. [MGT020, TT, no mutation] 
Gynaecological symptoms were typically bleeding. Participants found this to be a 
particularly distressing symptom; all the participants who completed an interview were 
post-menopausal either due to age or as a result of their ovarian cancer debulking 
surgery. This symptom was often the catalyst for participants to seek medical attention 
if they had not already. Urinary symptoms were described as haematuria and also 
prompted participants to visit their GP.  
Luckily, my eldest daughter had called in to see me, and I was crying. I 
said, ‘I’m bleeding, I can’t have periods at my age’. [MGT021, TT, no 
mutation] 
So, he did a urine sample, and he said, ‘Oh, yes, you’ve got blood in your 
urine. You’ve probably got an infection. I’ll send the test to hospital, and it 
will be back within a week. You can phone.’ I phoned, and they just said, 
‘Oh, no, it’s not an infection, don’t worry’. [MGT021, TT, no mutation] 
Only three participants described their experience prior to diagnosis as asymptomatic. 
However two participants experienced an acute period of digestive symptoms 
(vomiting) which led to A&E admission, while the sudden onset of PV bleeding for 
another participant did lead to medical investigations.  
I didn’t have any clue at the original, I didn’t have bloating and things that 
you're supposed to have, or going to the loo more often. [MGT032, GT, 
BRCA+ve] 
Well I suppose I developed some post-menopausal bleeding which was 
at the beginning of last year but prior to that I’d had a little bit of 
constipation but not enough to go to the doctor, then when I got the 
bleeding, that was the reason I went. Then I was told it wasn’t that typical 
for ovarian cancer, so in a way I suppose it was fortunate I did, because I 
felt fine, I wasn’t ill at all. [MGT048, TT + GT, BRCA+ve] 
The diagnostic odyssey 
For the vast majority of patients, the process of diagnosis is perhaps best described 
as an ‘odyssey’. Many spoke at length about their experience of the journey from 
symptom manifestation to eventual diagnosis of ovarian cancer. For most of the 
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participants, the diagnostic odyssey began with repeated visits to their GP, often over 
several months. 
So, after Christmas, I went back to the GP, maybe three times over the 
next eight weeks, something like that. I saw different people each time… 
For months of going to the GP, he was the first person to flag it up. 
[MGT059, TT + GT, BRCA+ve] 
Yes. I didn’t feel well, my stomach was so bad, it was so bloated and I 
went to the GP for a blood test and they didn’t discover anything, nothing. 
So I changed my diet, that didn’t do anything to me either. So I went back 
to the GP and she took another blood test and it wasn’t right… So I went 
back, and the GPs, they don’t want to know, and they just say ‘No, go to 
A&E.’ [MGT039, TT, no mutation] 
Delays were also encountered once a referral was actioned by the participants’ GP. 
The process of diagnosis was sometimes protracted, with multiple investigations 
involving different medical specialties.  
I went through so many departments, I went through one department, 
then another, then another, then eventually ended up moving to 
oncology. [MGT006, TT, no mutation]. 
I: So once you went to the GP, what happened then? 
R: I was sent for scan. 
I: Straight away? 
R: On a waiting list and after that, from one hospital to another 
           hospital and I ended up in the best hospital. 
I: And how long do you think that process took, once you went to the 
           GP? 
R: Half a year.  
[I = interviewer, R = respondent; MGT013, TT + GT, RAD51C+ve] 
 
Once the diagnosis was confirmed, a number of participants reflected on their shock 
at learning they had ovarian cancer.  
I got the impression the doctor didn’t quite know how to tell me, when I 
look back, he seemed to be twitching a lot and couldn’t sit still, and didn’t 
know how to say it, and eventually spilled the beans, and I was absolutely 
shocked. I just never thought it was cancer, completely shocked. 
[MGT053, TT, no mutation] 
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Well I don’t know. I never suspected I had ovarian cancer. I was losing 
weight. That was it, I was losing a lot of weight and I just… That’s right, I 
was sent to the [Hospital 1] and never in a million years did I think it was 
cancer. It was the biggest shock of my life when they told me that, 
absolutely shocked. [MGT042, TT + GT, no mutation] 
For some participants, there was a sense of self-blame about their delayed diagnosis; 
they felt they should have pushed their GP more or insisted on expedited 
investigations or referrals. Lack of recognition of symptoms was often blamed on 
menopause or IBS. Others spoke about the inherent sense that something was 
wrong, and the frustration to convince health professionals  
I’d never ever carried a belly like this in my life. I had been every size 
under the sun, so I knew what my body is capable of. But of course most 
of it got put down to menopause. The doctor says something, you're not 
medically trained, you tend to believe it. But I am quite intuitive and I've 
had this body for 60-odd years now. I know what it does, and no one 
would listen. [MGT057, TT, no mutation] 
Okay, I’ve got a virus, there may be stomach problems, bloating, et 
cetera, because of antibiotics, maybe it could be, but there was a general 
feeling that something’s not quite right. [MGT059, TT + GT, BRCA+ve] 
 
Ovarian cancer causation 
The aetiology of ovarian cancer is complex and still poorly understood; only a small 
proportion of cases can be attributed to inherited mutations which predispose 
individuals to developing the disease. Part of the interview focused on participants’ 
own perceptions of why they had developed ovarian cancer, to explore if there was 
any attribution to family history or an inherited component. Some participants had 
never considered possible causality of their ovarian cancer diagnosis.  
I wouldn’t even know. I hadn’t thought about that. I accepted the fact that 
I’d got it [ovarian cancer] and wanted to deal with it really. [MGT029, TT + 
GT, BRCA+ve] 
Well I suppose I don’t really know. There are various things and I don’t 
really know why, it’s just unfortunately one of those things. [MGT033, TT, 
no mutation] 
I don’t think I've actually really thought about the cause, you just think 
well, cancer hits and that’s it. [MGT020, TT, no mutation] 
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A small number of participants felt ovarian cancer may have been linked to specific 
event in their life, such as exposure to x-ray in the pelvis, longstanding gynaecological 
problems, shock or stress. Others described cancer as occurring by chance. Five 
participants who received a germline mutation positive result during participation in 
this study were interviewed. Only one specifically commented on the link between 
family history, genetics and ovarian cancer.  
My attitude towards cancer I suppose when I hear about it is ouch, when 
people tell me that they developed cancer, I just feel very, very sorry. It’s 
almost like a game of chance these days. Are you going to get cancer? 
[MGT006, TT, no mutation] 
Just luck. It’s a draw, some of us get it and some of us don’t… So I didn’t 
think anything about anything else that could be causing it. [MGT032, GT, 
BRCA+ve] 
Well, certainly having had the genetic testing now and having five in a 
family of six I think there must be a genetic link somewhere. [MGT048, 
TT + GT, BRCA+ve] 
8.7.2.2 The specifics of MTGT  
Initial offer of MTGT 
Participants were asked about the first time they could recall genetic testing was 
raised. One participant had genetic testing raised by her GP, because of a family 
history of ovarian cancer, although this was not followed up any further. A few 
participants had already taken the initiative to discuss genetic testing with their 
oncologist, although there was no further follow-up in these cases either. Instead for 
most participants, MTGT was first discussed during one of their oncology 
consultations and recruitment into this PhD study was typically a catalyst for that 
conversation. A brief explanation of genetic testing was provided by oncologists.  
Dr [name] when I saw her. I think it was when I came to have the first 
session of chemotherapy. I think it was then, and that was when she 
mentioned it to me… that it could be to see whether there might be a 
future drug available and see whether I would be eligible... Briefly she 
told me what it was, and I just thought well if it could help the future… It 
wasn’t going to do me any harm, having it done, so I said yes, I’d go 
along with it. That’s when she referred me to you. [MGT033, TT, no 
mutation] 
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Prior to that, I remember speaking with Dr [name] quite a long while ago, 
even before the end of the initial treatment, about the genetic testing 
being something that would be done in the future, but it was a case of, 
there isn’t a rush for it now, looking at the age of the children as well. It 
would be after the initial treatment is all finished. But it certainly was 
mentioned, and I think we’d also asked about it, having a daughter as 
well as a son. [MGT059, TT + GT, BRCA+ve].  
Initial response to GT 
Overall, participants described a positive response when genetic testing was first 
raised. Participants were also quick to establish a link between genetic testing and 
risk to family members, with their first thoughts turning to female relatives. For a few 
participants, the offer of genetic testing was unexpected; they had not previously 
anticipated ovarian cancer could be inherited.  
My first thoughts were actually oh my god, I've got two granddaughters. I 
went home and thought about that, oh I've got two granddaughters… I 
was immediately thinking of family. I've got to do this because I want to 
know if there is a chance so I can warn them that things could happen. 
[MGT020, TT, no mutation] 
My initial thought, to be honest, was, yes, I want to get it done, I’d like to 
help with the research. I realised how important it is for the future, for my 
children, for other peoples’ children, and for treatments, for other people’s 
treatments. So, I was always inclined, yes… [MGT059, TT + GT, 
BRCA+ve] 
Well, I was a little bit shocked that that’s what it could be. [MGT029, TT + 
GT, BRCA+ve] 
Using tumour tissue for genetic testing 
Participants had no concerns about the process of tumour testing, largely due to its 
non-invasive nature of using tissue which had already been removed during previous 
biopsy or debulking surgery. Using tumour tissue for genetic testing was seen as an 
action that was completely separate to them. Participants had a sense that if the 
tumour tissue could be used to benefit them in some way, then this was a positive 
course of action.   
But as far as your tumour testing, that’s your job now. This is something 
that you’ve found that needs investigating. I don’t even see why I was 
asked quite honestly… It’s something you took out to stop me from dying, 
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so really I was glad to be rid of it… I would have thrown it away or burnt it 
[laughs]. If you guys need it still then knock yourselves out. [MGT057, TT, 
no mutation] 
So, maybe, because feeling that it’s a tumour that I’ve had, it’s been and 
done. It’s done the awful work already, so whatever you find out about it 
afterwards, it’s a bit, helping with moving on for the future. [MGT059, TT 
+ GT, BRCA+ve] 
There was no physical process being done on me to genetically test me. 
They were testing the tumour that had already been taken out. I could 
see no reason to stress about that. It didn’t make any difference where it 
was. That process was apart from me physically so it was easy. It’s 
simple. [MGT020, TT, no mutation] 
Tumour vs germline testing 
Tumour testing is one mode of genetic testing to identify BRCA1/2 mutations that may 
or may not be hereditary. Throughout the interviews participants mainly used the term 
‘genetic testing’ unless specific questions or references were made to using tumour 
tissue or tumour testing. Some participants demonstrated a good recall and 
understanding of the logistical processes of tumour testing, e.g. retrieval of stored 
tumour samples, transport to Germany for genetic testing, and return of testing 
results. They were also able to distinguish the different processes between germline 
and tumour testing, i.e. blood vs tumour samples. However very few participants had 
a good understanding that mutations identified on tumour testing could be non-
inherited; only one participant was able to describe somatic mutations unprompted. 
I understood that you were going to test my tumour and that there was a 
chance that my tumour might have the BRCA gene, even if I didn’t. So I 
thought that was a good thing… I did explain to her [sister] if there was 
something it won't prove because it might be just in the tumour, but then 
either I could organise a blood test or she could organise. [MGT022, TT, 
no mutation] 
Obviously I’d already been asked about the tumour tissue, so I presumed 
that they would analyse that and then inevitably some sort of blood test 
would follow because blood seems to be integral to all this. [MGT048, TT 
+ GT, BRCA+ve] 
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Well I’m surprised that it is, I just assumed I just was having the normal 
tests and it seemed appropriate to have had the tumour analysed first 
and then having a blood test. But I suppose… Are you saying with the 
blood test alone you can tell whether you have an inherited mutation? 
[MGT048, TT + GT, BRCA+ve] 
From participants’ recall of genetic testing discussions with their oncologists, the 
language used reflects concepts related to germline testing such as risk for family.  
It was mentioned quite early on that it was something that one could take 
part in, and it was Dr [name] and she said some people choose not to, 
they don’t want to know and they don’t want their families to know, they 
don’t want any onus on them. [MGT006, TT, no mutation] 
’She said the same, like I said, ‘We want to find out if it has something to 
do with your parents or grandparents, so it could affect your children as 
well’ – along that way. She explained it to me, I agreed with her. 
[MGT039, TT, no mutation] 
During the course of the interview it emerged that two participants had forgotten they 
had tumour testing; they both incorrectly recalled giving blood for genetic testing 
rather than using tumour samples.   
So now this is really embarrassing, this is what I mean when I say I forget 
things. Did I have my tumour tested then? Did I have a tumour test? 
[MGT053, TT, no mutation] 
8.7.2.3 Experiencing MTGT  
Perceptions, expectations and motivations 
Perceptions related to the way participants regarded, understood and/or interpreted 
genetic testing. There was a perception that genetic testing was a positive action, with 
participants describing it as ‘a good thing’ to do. Most participants felt that genetic 
testing was primarily to benefit others, either family members or other ovarian cancer 
patients.  
Well, I knew vaguely what it would involve and I just thought well, if they 
can improve how treatment is done, whether it’s just for the person who’s 
having the testing or for other people, then I just feel it’s a good thing to 
happen. [MGT033, TT, no mutation] 
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I didn’t have any hopes for myself, I could see that it would benefit my 
family, having a daughter and grandchildren, granddaughters. I didn’t 
think it would benefit me, I just thought it was a good thing to do, that it 
would benefit somebody. Not me. I never thought it would benefit me. 
[MGT032, GT, BRCA+ve] 
There was an expectation for some participants that genetic testing would provide an 
answer to why they had developed ovarian cancer.  
My only expectation was it would come back with an answer, what would 
the answer mean and that I wasn’t sure of. So whether I had the genes or 
whether I hadn’t the genes. [MGT062, TT + GT, no mutation] 
I did actually think it would tell me one way or the other whether it was 
hereditary and I think most possibly because one of my daughters-in-law 
was particularly anxious about it, so I thought I need to know so that I can 
pass on the information. [MGT056, TT + GT + TT, sBRCA+ve] 
For almost every participant, their primary motivation to have genetic testing was for 
family. Genetic testing was perceived as being able to provide information for family 
members that could be of value. Only one participants expressed the possible 
personal benefit of tumour (or germline) testing, in terms of potentially accessing more 
treatment options.   
I suppose, there’s two things really. Moving forward for family, I think, it’s 
important that I should do it for them, even if we can be scared of the 
results [laughing]. Knowledge is power. It’s empowering. That probably 
sums up why. [MGT059, TT + GT, BRCA+ve] 
Well, because they said it could be passed on to the family. My son as 
well, and he’s got three daughters. So mainly it was for them. I didn’t 
know what it would mean for me personally. It’s more they’ve got their 
lives to look forward to. [MGT031, TT + GT, RAD51C VUS].    
If I was positive, it would open up more treatments for me, even though I 
didn’t think I would be positive. [MGT022, TT, no mutation] 
Curiosity was another motivation for testing; participants were curious about what 
genetic testing might reveal and how it might inform their own understanding of 
ovarian cancer. Participants were interested in the possible outcomes of genetic 
testing, they ‘wanted to know’ what their results might be, whilst acknowledging it may 
be of little use.      
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There was that curiosity, okay, there is this genetic thing, how it all fits in 
with the illness, what does that mean, why this one person who has the 
genetic mutation would get cancer? Presumably not everybody who has 
the genetic mutation will get cancer. I think I looked at it more from the 
curiosity point of view. [MGT059, TT + GT, BRCA+ve].  
I just thought it was quite interesting. I also think I was quite interested to 
see that people might find out more about the illness, it might help other 
people, might help me anyway just out of curiosity. [MGT006, TT, no 
mutation] 
I thought it would be interesting to know what the results were. There 
wasn’t much I could do about it. But I would like to know. [MGT062, TT + 
GT, no mutation] 
Decision-making for MTGT 
Of the participants interviewed, they unanimously felt it was ‘easy’ to make the 
decision to have MTGT. Many described making their decision immediately, as soon 
as testing was offered by their oncologist.   
Well, I’d already made up my mind I was doing it. I discussed it with my 
daughter and my husband – I don’t know if discuss is the right word, I just 
said I'm going to do it. [MGT032, GT, BRCA+ve] 
To me, as I said to you, there wasn’t any question about not doing it. 
There wasn’t any question about not doing it, just the sheer fact that it 
was available and this sort of thing is important was enough. [MGT020, 
TT, no mutation] 
Some participants involved their family members in the decision-making process by 
discussing it with them prior to consenting to testing. For a few participants, it was a 
deliberate choice not to involve family members in the discussion and decisions 
around genetic testing, primarily to alleviate any worry or anxiety this may have 
caused.  
They were all very anxious about my health status and I didn’t want to 
add anything else to their anxiety really until I knew the results because 
what I had learnt was that it could be, if there was the BRCA genes, if I 
had them, it could be passed from mother to daughters and to sons who 
could then pass it on to their own offspring and I didn’t want to cause 
them that anxiety until I knew the answer. That’s definitely why I didn’t 
include them in my decision making. [MGT062, TT + GT, no mutation] 
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As part of the interview schedule, participants were asked if they felt they had 
sufficient information and discussion with their oncologist to make the decision about 
genetic testing. Overall participants felt as if they had enough information and 
opportunity for discussion with their oncologists. Participants didn’t seem to seek 
additional information from other resources. There was a sense that because of their 
illness and treatment, participants already had enough on their mind.    
I don’t think I needed too much discussion about it. Dr [name] explained it 
to me, what could happen etcetera, and I just thought well, this is in 
important. So therefore you don’t have to go on for much longer, I don’t 
want every detail. [MGT020, TT, no mutation] 
No, I wouldn’t have liked any more information. If I’d have wanted 
information I’d have gone onto Google. [MGT042, TT + GT, BRCA+ve] 
Results of MTGT 
No mutation: What a relief 
The most common reaction to receiving tumour testing results was a sense of relief. 
For participants who received negative (no mutation identified) results, relief was 
associated with their perceived hereditary cancer risk to children and family members. 
Participants were also ‘pleased’ and ‘grateful’ that their results were negative. For 
most participants, once they received their mutation negative results there was little 
time spent ruminating on the outcomes.  
Yes, I felt quite relieved that I didn’t have a disease I’m passing on. 
[MGT021, TT, no mutation].  
I felt quite proud of myself [laughs], there you are then sort of thing. And 
yes, the funny feeling of relief I suppose. And I remember being quite 
pleased to say to the boys ‘By the way there's no problem, you haven't 
got to go and all be tested, it’s not a mutation.’  [MGT006, TT, no 
mutation] 
Well, the thing is when you're reading these stories about people in the 
family and all this, one daughter and another and another, grandmother, 
granddaughter, and they all have to be treated, if it’s breast cancer or 
ovarian cancer, they get operated straight away, everything has to be 
removed, so you're quite happy that your girls don’t have to go through 
that. They're only young. So that’s a positive thing. [MGT039, TT, no 
mutation] 
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A few participants recalled mixed feelings about their result, reflecting some 
ambivalence to the outcome because of the perceived lack of personal utility or 
benefit. One participant who was mutation negative, was relieved that there were no 
implications for her children, but had also been hoping that the results from genetic 
testing would expand her treatment options.  
As I said, in one way I thought good, I'm glad, it’s nothing to do with that, 
so no problems there. And on the other hand because as I said I could 
have done something differently in treatment. But there you are. 
[MGT039, TT, no mutation] 
Mutation carriers: The positives of being mutation positive 
During the course of the study, five of the participants interviewed learned they carried 
a germline mutation. Some of the participants had anticipated that their genetic testing 
results would reveal they carried a mutation, with two referring to a family history of 
cancer.  
I was expecting it to be positive because of my daughter. My husband 
wasn’t, ‘Oh, don’t be stupid’ [laughter]. But I did think it would come back, 
so when it did come back positive I wasn’t surprised. [MGT032, TT + GT, 
BRCA+ve] 
Well I was fairly confident that I would be positive. I would have a 
mutation given the history, so… I expected it. I wasn’t the slightest bit… I 
wasn’t surprised. [MGT048, TT + GT, BRCA+ve] 
Overall, participants felt that learning they carried a genetic mutation was in fact a 
positive outcome. There were perceived positive benefits in terms of their perceptions 
of the disease and understanding why they had developed ovarian cancer. For some 
participants, their results helped to alleviate feelings of guilt and self-blame. Perhaps 
the most striking impact of receiving a mutation positive result was for one participant 
who had blamed herself for developing ovarian cancer, and described her result as 
‘…makes me feel more normal’ [MGT013, TT + GT, RAD51C+ve].  
In some ways, getting re-diagnosed with the cancer and having the 
treatment, and then with the genetic thing, that there is the genetic link, 
maybe it’s almost helped me come to terms with it a little, that this is 
going to be an ongoing condition that I will need to live with... and I 
almost feel that it’s more manageable, mentally, moving forward, and it 
will make me stronger about dealing with it, rather than not. That might 
sound strange, but yes. [MGT059, TT + GT, BRCA+ve] 
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I think I felt quite happy about it, to be honest, because it was an answer 
to what I’d got and basically how I’d got it and it was an explanation, I 
suppose. [MGT029, BRCA+ve] 
Yeah, because I blamed myself all the time, why did I inflict this illness on 
myself?... I was asked for another blood test which brought the 
conclusive results, and I understood that it wasn’t my fault. This is the 
good influence of the research on me actually. I enjoy life more now. 
[MGT013, TT + GT, RAD51C+ve] 
When reflecting on what they felt were the positive and negative aspects of being a 
mutation carrier, participants largely felt there were no drawbacks. For most 
participants, the positive aspects of being a mutation carrier were actually related to 
their children, and how this genetic information would be of potential benefit to them. 
Only one participant explicitly spoke about a direct personal benefit in being able to 
access PARP-inhibitors. 
There are no positives, I don’t feel, for me. But I do think it’s fantastic for 
my daughter and all my granddaughters that I know they won't go 
through this. Well, they might do but they have a choice. They can 
choose to go down the path of being tested and making their own 
choices. [MGT032, GT, BRCA+ve] 
I mean, the interesting thing was I thought all along it was purely the next 
generation who would sort of benefit or otherwise or they are the ones 
who need to take it forward, but it was interesting to know that from my 
point of view, I would be more responsive to the PARP-inhibitors should 
the need arise. [MGT048, TT + GT, BRCA+ve] 
The only positive that I think is for the family because they’ve had the 
test, they can now be dealt with if they have actually got it… So if I 
haven’t have had the test then none of these would have found out or 
known whether they’d got it or not. [MGT029, TT + GT, BRCA+ve] 
Results disclosure  
Participants were asked if they could recall receiving their MTGT results, in particular 
how they were delivered and what explanation was provided. Overall participants felt 
satisfied with how the results were communicated although some, both those who 
had received no mutation or mutation positive results, struggled to comprehend the 
meaning of the results.    
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The person that I saw just said there's nothing there and handed me the 
sheet of paper [tumour testing report]. I think if I’d been worried or if it 
was positive I think that might have been a bit startling. I was a bit startled 
actually anyway, but I wasn’t worried. [MGT022, TT, no mutation] 
Yes. I don’t have the BRCA genes…To be absolutely honest, I didn’t 
really know what it meant in a way, I really didn’t. [MGT062, TT + GT, no 
mutation] 
So I don’t know what the results mean for me. You tell me what they 
mean for me. [MGT042, TT + GT, BRCA+ve] 
Two unique cases 
There were particular aspects of two cases which due to their specific MGTG 
outcomes, germline RAD51C VUS and somatic BRCA1/2 mutation, did not reach 
inclusion within the thematic analysis and presentation of data. However their stories 
provide important insight into the genetic, tumour and germline, testing experiences 
of ovarian cancer patients which can help inform our understanding of these 
experiences and which may not be unique in other settings.  
The unknowns of carrying a variant of unknown significance 
One participant, Janet2, [MGT031, TT + GT, RAD51C VUS] interviewed was found to 
carry a germline RAD51C VUS. First-line tumour testing did not identify any genetic 
alterations. However as the MLPA portion of testing failed, she had follow-up germline 
testing which reported a RAD51C VUS. She was the first patient in this cohort to be 
found to carry a VUS in this gene. Not only was Janet uncertain about what her result 
meant, so too was her oncologist.  
I had the initial letter. It told me that I wasn’t carrying it and everything like 
that. So I was thrilled. I told them all that was fine, they haven't got to 
worry. Then I don't know at what point I saw [oncologist] and she said, 
‘There’s this tiny bit of the bottom about something that’s totally 
unknown.’ She said, ‘We know nothing about it. It’s totally new,’ and 
they’re starting to look into it, and they’ve found this little bit of whatever 
this is, so I don't really understand it, to be honest.  
A referral had been made to the patient’s local clinical genetics service, however at 
the time of the interview this was delayed and no appointment was forthcoming. As 
                                               
2 Pseudonyms used 
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the participant describes in her own words below, her initial relief of not carrying a 
mutation then turns to worry and confusion. Reassurance from her oncologist 
provides little comfort, and she reveals her concerns about what this new, unknown 
finding might mean for her and her family. Until this patient was able to attend a clinical 
genetics service for genetic counselling, she was left feeling uncertain and anxious 
about her results.  
Over that bit now, yes, I do, because she [oncologist] said, ‘It won’t affect 
you and it won’t change your treatment.’ But obviously, you want to know 
everything's okay. As I say, it’s only when letters come through and 
things are in black and white, which obviously I’ve got a folder full of 
them; that is when you feel concerned. I read it and feel quite sick, but I 
think thank god I am where I am and I just keep telling myself that I’m 
going to be alright.  
When a positive tumour test result isn’t that positive 
In this cohort of ovarian cancer patients, one participant, Leanne [MGT056, TT + GT 
+ TT, sBRCA+ve], was eventually found to carry a BRCA1 somatic mutation after 
additional tumour testing (this is discussed further in Chapter 6). Leanne shared a 
similar narrative when reflecting on her experience of ovarian cancer diagnosis and 
treatment, motivations for genetic testing and decision-making. Despite the repeated 
tumour testing being undertaken specifically to determine trial eligibility, she was 
explicit in her lack of motivation to have testing for this purpose and still refers to 
testing to inform family members.   
I think I was more concerned about the possibility of it being hereditary 
and I thought if I could at least know one way or the other. I didn’t really 
know about gene mutations or anything like that at the time, it was just 
can I… I thought is it like breast cancer where sometimes it’s in the family 
and it’s hereditary and I need to think about my children and my 
grandchildren and I suppose selfishly it was for those reasons as well, it 
was possibly a bit more knowledge for me. [MGT056, TT + GT + TT, 
sBRCA+ve] 
To try and have possibly more information about whether it was 
hereditary or not. I know that’s a selfish reason but that was the main 
reason for me. It wasn’t so much that it would do me any good but I didn’t 
expect anybody to say, “Hey, look, you’ll be perfect for this trial, you’ve 
got all the right criteria, blah-blah-blah,” it was really just to say, “Yes, 
your family, they need to be screened, they need to go for regular check-
ups,” or, “No, it’s okay,” sort of thing.  
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Similar to other participants’ experiences, Leanne spoke at her relief that her genetic 
testing results meant there was no hereditary implications for her children. Despite 
her lack of expectations, she also recalled being pleased that her results had meant 
she was able to take part in the clinical trial.   
So I suppose at the time, I was talking to the registrar before we started 
and he was explaining it, he said, “Well if you do the trial, you sort of get 
two shots, but if you decide just to go for chemo and then we find the 
chemo isn’t working you can’t then say, ‘Oh well, can you put me on the 
clinical trial?’ because the window will have gone by then”. So yes. So 
when I knew that I did fit the criteria, I suppose I was glad, I had an extra 
chance at it.  
However, any hopes of the benefits taking part in the trial might bring were not met. 
Leanne struggled with the side effects of treatment and on reflection, wished she had 
not taken part. However she still spoke of her appreciation that she was able to take 
part in the trial thanks to having had tumour testing. 
Anyway, so the trial was a waste of time. For me, it was a waste of time. 
Whether it helps anybody else, I have no idea, but I had to have a 
transfusion because I just felt so low and my blood count was low. I just 
felt rubbish the whole time. I don’t think there was a day when I didn’t feel 
rubbish.  
I wish it was different and I really would have to think if another 
opportunity came up, say… If I was here in a year’s time and something 
else came up, I’d think very seriously about my quality of life before I 
made… I would then think carefully when I made my decision knowing 
what I’d been through this time. But I don’t think… I’d still say I was 
relieved when I got the result that yes, I did fit the criteria and that 
wouldn’t have happened if the tumours hadn’t been tested, would they, 
really?  
 
215 
 
8.8 Discussion  
Targeted therapies are transforming oncology care where treatment can be 
increasingly individualised. BRCA1/2 tumour testing is one of many approaches to 
using genetic information to inform treatment decisions. For example Oncotype Dx 
has been recommended by NICE guidance to inform adjuvant chemotherapy 
decisions in early breast cancer, where gene expression is measured by extracting 
RNA from FFPE tumour blocks [298]. However there is an important distinction 
between BRCA1/2 tumour testing and other forms of gene profiling that are used in 
the oncology setting, in that the outcome of BRCA1/2 tumour testing has the potential 
to provide information about inherited genetic alterations.     
In this cohort of participants who were interviewed, only one was found to have a 
BRCA1/2 somatic mutation, while five other participants carried a germline mutation. 
Given the vast majority of participants have a germline mutation and there is a paucity 
of literature around the patient experience of BRCA1/2 tumour testing specifically, this 
qualitative data will be considered mostly in the context of germline testing literature 
and will include somatic testing literature where possible.  
Context has been an important part of this research. In Chapter 4 the context for this 
case study was defined as genetic testing in ovarian cancer, with the case 
(mainstreamed tumour testing) and the embedded subunits then bound within this 
context. The service evaluation in Chapter 5 and my experiences organising BRCA1/2 
tumour testing in Chapter 6 were an invaluable part of developing my understanding 
of the overall context, in particular how genetic testing intersects with the oncology 
setting.  
Over the months I spent in the clinic and with my participants, I was familiar with their 
cancer pathway and current treatment regimes. However I was much less familiar 
with their routes to diagnosis, and what their experiences of ovarian cancer had been 
prior to enrolling in this research. I wanted to try and understand the patient’s own 
context in which MTGT would be taking place. Thus the introductory part of the 
interviews asked participants to tell their story of how they came to be diagnosed with 
ovarian cancer, and their experiences of treatment thereafter.  
Whether it had been months or years from diagnosis, participants had very clear 
recollection of the events that led up to their diagnosis, even recalling exact dates and 
small details such as the weather on that day. The vast majority of participants had 
experienced diagnostic delay. This protracted route to diagnosis had had a significant 
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detrimental and long lasting impact. The diagnostic delay in ovarian cancer is well 
known and has been reported extensively [299]. Other qualitative studies of women’s 
prediagnostic experiences of ovarian cancer have also reported their distress when 
concerns about their symptoms were dismissed by health professionals [300]. Part of 
the challenge of a timely diagnosis are the non-specific symptoms of ovarian cancer 
[299]. As one participant commented in her interview, ‘I read ovarian is very silent, 
isn't it, a silent cancer. Is it still like that?’ [MGT039, TT, no mutation]. As participants 
recounted their symptoms, they were related to gastrointestinal, gynaecological and 
general systemic symptoms, none individually being particularly indicative of ovarian 
cancer. Participants acknowledged that it was unlikely a more timely diagnosis would 
have had a significant impact on their prognosis, but they were frustrated that the 
signs that ‘something wasn’t right’ were missed or ignored. The conviction that 
something was physically amiss within themselves, recognising their own embodied 
knowledge, has also been reported by other ovarian cancer patients [300, 301]. What 
their diagnostic experiences seemed to drive was a desire to prevent ovarian cancer 
happening not only for their own female relatives, but for other women in general. 
Scattered throughout the interviews were references to the need for a screening 
programme, in particular using CA125, to either prevent or detect ovarian cancer at 
an earlier stage. This may also have influenced their desire to have MTGT, seeing 
this as an opportunity to inform their family members of any potential cancer risks.  
The experience of diagnosis was clearly a significant experience in these women’s 
lives, triggering their cancer treatment pathway that would continue for many months 
and years. What became clear as the interviews progressed and the focus shifted 
from ovarian cancer to MTGT, was that genetic testing paled in comparison. As one 
participant put it succinctly, ‘The worst thing had already happened: I’d got it’ 
[MGT057, TT, no mutation]. The rich detail from their interviews emerged when 
participants were talking about their cancer diagnosis or treatment while their 
accounts of MTGT were fairly brief. Shipman et al reported similar findings after 
interviewing breast and ovarian cancer patients who had undergone TFGT, including 
some who had been tested via a mainstreamed model [292]. Women’s accounts of 
their diagnosis and treatment were long and detailed, while their accounts of genetic 
testing were minimal with the authors concluding that genetic testing was not a 
concern in the context of ovarian cancer. For the majority of participants, genetic 
testing was just a brief interlude with little impact on their long and life changing 
journey of ovarian cancer.  
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Providing genetic testing during the ovarian cancer pathway also influenced how 
much participants were able to engage with it. Woven through the interviews was their 
narrative of managing the cycles of treatment and relapse. Focusing on cancer was 
the priority and at an already overwhelming time, MTGT could not be given the same 
attention. One participant encapsulated this, ‘While you’re dealing with everything that 
was going on, it didn’t give a chance to put a lot of thought to it. I just got on with it’ 
[MGT031, TT + GT, RAD31 VUS]. A focus group study of breast cancer patients who 
had genetic testing shortly after their diagnosis described the diagnosis of cancer itself 
as ‘a great burden’ (p.184) [302]. The tumultuous experiences of being diagnosed 
impacted their ability to fully absorb information and all that was happening around 
them. They were often preoccupied with thoughts and decisions related to their breast 
cancer diagnosis and treatment, making it difficult to focuson other issues like genetic 
testing. Liang et al reported similar findings in a cohort of advanced lung or melanoma 
cancer patients who had undergone somatic testing. Patients attributed their struggle 
with retention of information to cancer-related psychological distress [106]. In all these 
cases, the cancer context in which genetic testing was taking place was an 
impediment to engaging fully with the testing process. 
Unlike other gynaecological cancers such as cervical cancer cases where the majority 
of cases can be attributed to the HPV virus, the aetiology of ovarian cancer is still 
relatively unknown. Only a small proportion of ovarian cancer cases, around 15%, can 
be attributed to inherited germline mutations [12, 75, 303, 304]. I was interested in 
exploring if participants perceived there to be a specific or underlying cause of their 
ovarian cancer, in particular if there was any attribution to genetic causes.  
Many of the women interviewed had not previously considered what may have been 
the cause of their ovarian cancer. For some participants they did not speculate on 
possible causes, instead responding that they just did not know why cancer had 
developed. Despite being a participant in a study about genetic testing, there was little 
mention of any genetic or inherited cause to their cancer. Instead there was a sense 
that cancer was just ‘one of those things’, and their focus was on dealing with the 
diagnosis rather than trying to make sense of what had caused it. Other participants 
described their ovarian cancer as being down to chance or luck, implying the 
frequency of cancer as well as having little or no control over the development of 
cancer. In a qualitative study of Australian women’s perspectives of gynaecological 
cancer causation shortly after diagnosis, women predominantly did not know why 
cancer had developed [305]. Similar to participants in this study, Manderson et al 
described women’s beliefs about cause of gynaecological cancer as ‘non-predictable’, 
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likening it to the game of chance, roulette. For other women with a personal history of 
breast or ovarian cancer, they believed their diagnosis and the cancers within the 
family had an underlying genetic predisposition and genetic testing was a way to 
confirm their suspicions [127]. This may also reflect the impact of moving from the 
previous criteria required for BRCA1/2 testing to the unselected approach now used. 
Previously family history was one of the main criteria of eligibility for testing, which 
was reflected in Hallowell’s paper where participants had a total of 119 relatives who 
had been affected with cancer [127]. In contrast, family history is no longer used as a 
and patients who are offered testing may be the only person in the family to have a 
cancer diagnosis.    
This sample of participants included five women who had been identified as carrying 
germline mutations during the course of the study, however only one participant 
initially made the link between their family history and genetic testing result as having 
led to ovarian cancer. Even amongst a sample of women at high risk for ovarian 
cancer due to their family history or BRCA1/2 mutation status, participants described 
having little knowledge that ovarian cancer was also linked to BRCA1/2 mutations 
[306]. In a survey of Canadian ovarian cancer patients, more than a third (36.5%) of 
participants cited genes as being causative [307]. However the ‘genes’ were not 
specified as the high penetrance genes BRCA1 and BRCA2, more likely reflecting a 
general understanding of the role genetics plays in many diseases.     
Most participants could recall when genetic testing was first raised by their oncologist. 
For one participant, her oncologist had already mentioned genetic testing at some 
point during their routine oncology outpatient appointment although testing was not 
undertaken. A small number of participants actually asked about the possibility of 
genetic testing themselves but again there was no further action. This reflected some 
of the observations from the service evaluation in Chapter 5; after MGT was 
implemented and BRCA1/2 germline testing was available for the majority of patients, 
genetic testing was offered at any point in the patient’s clinical pathway. There was 
no systematic approach to MGT, with some oncologists choosing to offer testing 
shortly after diagnosis, while others preferred to wait for patients to settle into their 
treatment regime. As one participant recalled of discussing genetic testing with her 
oncologist prior to this study, ‘…It [genetic testing] would be after the initial treatment 
is all finished’. From a treatment decision point of view, based on the current criteria 
for olaparib results from testing would have little bearing until the patient had 
completed at least two lines of platinum-based chemotherapy. Therefore there is no 
clinical impetus for patients to have genetic testing during first line treatment, although 
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there may be benefit for unaffected family members. The timing of testing seems to 
be led by clinician preference, rather than an established timepoint or systematic 
approach.  
For the remaining participants, genetic testing had not already been raised in their 
previous oncology consultations and the introduction of my PhD project was the first 
mention of testing. When participants recalled how MTGT was first offered, it was 
typically in the context of providing more treatment options or to identify if there was 
an inherited component. Participants made an instant connection between MTGT and 
potential familial implications, already highlighting that concern for family members 
was likely to be a primary motivation. Participants also described having an altruistic 
response, instinctively ‘wanting to help’ not only themselves and their families, but 
also others. There was a perception that they would be able to do so via MTGT and 
this research.  
When recounting their initial response to MTGT, women often described making their 
minds up instantaneously that this was something they wanted to do. Despite at the 
time knowing little about what it involved, or the potential outcomes and implications, 
its perceived ability to be of benefit to female relatives seemed to be sufficient reason 
to agree to testing. In a recent study, TFGT was also received very positively by breast 
and ovarian cancer patients [308]. In this cohort there was a sense of familiarity with 
testing, either because it was something they had tried to pursue earlier or from 
general media highlighting celebrity testing experiences.    
As tumour testing is still a new way of providing genetic testing to women with ovarian 
cancer, I was interested in how participants felt about their tumour tissue being used 
in this way. Participants had no concerns; as the tumour tissue had already been 
removed, how it was used after this point was of little relevance to them. Perhaps 
because of the non-invasive nature of tumour testing which did not involve providing 
a blood sample, it was seen as an external and separate process.  
What began to emerge from the interviews as we discussed the process of tumour 
testing, was participants’ struggle to distinguish between tumour and germline testing. 
In general participants had a good understanding of the logistics of tumour testing and 
how it involved using tumour tissue to look for genetic mutations. They could also 
recall that a blood test for further genetic testing may be required. However only one 
participant was able to specify that a mutation found on tumour testing could be 
somatic, and the purpose of germline testing via a blood test was to confirm the 
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inherited nature of the mutation. Two participants could not initially recall having 
tumour testing, and referred only to giving a blood sample for genetic testing.  
Reflecting on some of the factors that may have contributed to this poor understanding 
of the nature of tumour testing, perhaps the explanations of tumour and germline 
testing that I and/or their oncologist provided were insufficient. The language we use 
to talk about genetic testing can be confusing. In this thesis alone I have used four 
terms relating to genetic testing (MGT, MTGT, germline testing, tumour testing) 
interchangeably depending on the specific type of testing. The term somatic mutation 
is specific to clinical genetics and oncology and would be very rarely found outside of 
these settings. The idea that genetic mutations, which until now have been associated 
with being hereditary, can be acquired and non-inherited is also novel. Furthermore I 
question whether it is possible to discuss tumour testing without germline testing, as 
a mutation identified on tumour testing requires germline testing to confirm whether it 
is somatic or inherited; in the main cohort of participants, more than half the sample 
went on to have follow-up germline testing. Thus this is both a new vocabulary and a 
new concept for participants to grasp. Compared to a typical genetic counselling 
session, in the MTGT context discussions about tumour testing took place in a much 
shorter timeframe and were often in addition to other clinical information about the 
participant’s treatment or disease.  
Because my research initially intended to capture participants offered either germline 
or tumour testing, the study documentation and questionnaires referred to ‘genetic 
testing’ as a way of encompassing both modes of testing. ‘Genetic testing’, when 
referring to germline testing, is much more familiar terminology that has become 
increasingly part of public discourse [108]. Any genetic testing previously discussed 
with their oncologist would most likely have referred to germline testing. References 
to their oncologists’ description of MTGT revealed that their language often reflected 
inherited attributes. 
Yes, I think Dr [name], we had a chat and she mentioned it. It was before 
we met… It’s a bit of a blur. She gave me the paperwork for it and I read 
through it and she just said ‘Are you alright with that?’ And I said ‘Yes, 
that’s okay.’ She said the same, like I said, ‘We want to find out if it has 
something to do with your parents or grandparents, so it could affect your 
children as well’ – along that way. She explained it to me, I agreed with 
her. [MGT039, TT, no mutation] 
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Furthermore participants in this study had already anchored notions of inheritance to 
the term genetic testing. As one participants comments clearly describe the traditional 
model of genetic testing and counselling: 
What I knew about it was that I thought it was a blood test or saliva test 
and it was very hard to get it and it took a long time to get the results and 
you had to see a counsellor which I didn’t quite see the point of. 
[MGT022, TT, no mutation] 
Terms that other research papers have used to distinguish germline testing from 
tumour testing include: ‘Screening for somatic mutations in tumour’, ‘tumour profiling’, 
‘genomic testing in cancer’ and ‘molecular testing’. This demonstrates the variability 
and inconsistency of language used to describe the same type of testing – genetic 
testing of tumour tissue to look for somatic mutations. With more personalised 
medicine options for cancer patients being encompassed into oncology, it is unlikely 
that the confusion between germline and tumour testing experienced by participants 
in this study will be unique.   
Using the example of biomarker research for stratification in colon cancer which 
involved genetic testing to guide chemotherapy decisions, Perry et al described the 
concept of ‘genetic misconception’ whereby patients incorrectly assumed a hereditary 
component to testing [309]. Although this biomarker research did not involve germline 
testing, the physician’s references to words typically associated with genetic testing 
for inherited mutations such as ‘family’, led patients to make incorrect associations 
with the term ‘genetic’. The most striking example of genetic misconception in the 
interviews was the participant (MGT059) who discussed her tumour testing results 
(mutation identified) as if they were germline results, even though she had yet to 
receive these. 
A qualitative study of attitudes towards personalised medicine and genetic testing also 
found misattribution of genetic testing; when cancer patients were asked to report the 
advantages and concerns related to somatic testing, they also listed those which are 
associated with germline testing [108]. The authors believe participants may have 
drawn on their existing understanding of germline testing, extrapolating these 
meanings to any type of testing that falls under the umbrella term of ‘genetic testing’. 
Similarly in a sample of lung and melanoma patients with advanced cancer who were 
interviewed about their attitudes to somatic testing, a small number of patients 
indicated concerns related to heritability and incidental findings despite neither being 
relevant to the type of testing that was undertaken [106].  
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A recent study of physician and patient communication about molecular testing in 
cancer found that patients’ top three preferred topics were benefits of testing (88%), 
how testing is used for treatment (88%) and implications for family (71%) [310]. 
Although there was significant overlap between physician and patient rated topics, 
familial implications was not listed as a topic by physicians. These findings highlight 
the importance of accurate communication about the differences between testing for 
germline and somatic mutations.  
Perry makes the important distinction that ‘…genetics in this case does not 
necessarily entail heredity’ (p.6) [309]. Genetic misconception is a significant 
misunderstanding in tumour testing and may have led to undue concerns about 
testing.  However communicating this clearly to patients may present a challenge in 
an already busy and information laden oncology appointment. Gray suggests that 
visual aids and oversimplification of concepts may be necessary to improve patient 
understanding [108]. Different terminology may also be needed to clearly distinguish 
germline from tumour testing.  
In an earlier chapter in this thesis, I proposed support for implementing tumour testing 
as a first-line genetic test with follow-up germline testing only when necessary. The 
rationale being that in this approach tumour testing could potentially alleviate concern 
and anxiety around the familial implications typically associated with genetic testing 
because the results would not initially reveal if a mutation was acquired or inherited; 
patients could then choose if and when they wanted to have follow-up germline 
testing. However the findings from this study suggest that the majority of participants 
responded to tumour testing as though it was germline testing, negating any potential 
protective factors of a two-step testing approach.  
To some degree, tumour testing is an abstract activity for patients. As the tissue 
required for testing has already been removed, sometimes months or even years 
earlier, all that is required is providing written consent. The intangible nature of tumour 
testing may help to explain how two participants could initially not recall having tumour 
testing. Both made (incorrect) references to giving a blood sample, despite neither 
having been required to have follow-up germline testing. This may also reflect their 
existing perceptions of genetic testing, demonstrating prior knowledge that testing 
typically involves a blood test.  
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Participants voiced few concerns about genetic testing, perceiving testing to be a 
positive action. Although two participants mentioned the impact on treatment, the 
perceived benefits from genetic testing were largely felt as being for relatives rather 
than testing conferring any personal advantage. This was also reflected in 
participants’ motivations for testing, with nearly every participant describing their 
primary reason as providing information to family members. This is an often cited 
motivation in the genetic testing literature, where testing is undertaken as an altruistic 
activity to benefit others rather than themselves [127].  
Participants expectations for genetic testing was that it would provide answers, 
although as one participant put it, ‘…what would the answer mean I wasn’t sure of’’ 
[MGT062, TT + GT, no mutation]. Other participants expected the results of testing to 
explain why they developed ovarian cancer, or if their cancer had an inherited basis. 
The perceptions and motivations participants described continued to reflect the 
genetic misconception of tumour testing, with concern for family clearly alluding to the 
hereditary implications of germline testing.  
Despite the intention of MTGT to inform and potentially expand treatment options, this 
lack of perceived personal benefit may reflect poor communication about the potential 
treatment impact from myself and/or their oncologist. Conversely participants’ 
perceptions of the familial nature of genetic testing and potential for cancer prevention 
may have been of more value, and therefore greater emphasis was placed on this. 
Despite well recognised and actionable clinical implications of BRCA1/2 germline and 
tumour testing, a recent qualitative study of breast and ovarian cancer patients who 
had undergone TFGT reported very similar findings [308]. Wright et al found that 
ovarian cancer patients’ single motivation for testing was to prevent future cancers 
both for oneself and for relatives, rather than using testing for any potential personal 
or treatment benefit. In contrast, Meiser et al found that ovarian cancer patients who 
had already undergone or were reflecting on a hypothetical decision about TFGT most 
commonly cited motivations for testing to increase treatment options, followed by a 
desire to help family members [142]. The participants in Meiser’s paper who had 
TFGT had done so specifically to determine eligibility for a PARP-inhibitor clinical trial, 
which is likely to have brought the focus of testing on to treatment. For the women in 
both my own and Wright’s research, the point at which testing was offered was not to 
inform treatment decisions immediately, and therefore the focus may have remained 
more with familial implications.  
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At the time the interviews were undertaken, there had been no change to treatment 
based on MTGT results for the vast majority of participants. Thus there had been no 
direct, or tangible, impact of testing. The only change to treatment had been for one 
participant who became eligible for a clinical trial because of a somatic BRCA1/2 
mutation that was identified on repeat tumour testing. Although tumour testing had 
given her the opportunity to take part in this trial, she suffered with severe side effects 
from the trial drug and eventually treatment was stopped. Our perception as 
researchers and/or health professionals is that by expanding the treatment options 
available for ovarian cancer patients via genetic testing, this is advantageous. What 
this participant’s experience demonstrated is although genetic testing provided her 
with a new option for treatment, ultimately she felt her time on the clinical trial was 
detrimental to her health and expressed regret for having been part of it.  
Of the participants interviewed, none of them disclosed any difficulties with decision-
making. In fact, many described making an instant decision to have testing as soon 
as it was offered with one participant commenting, ‘I didn’t have any hesitation at all’ 
[MGT062, TT + GT, no mutation]. In Meiser’s study, ovarian cancer patients who had 
already undergone TFGT reported similar decision-making behaviour, needing little 
or no time to make their decision as ‘…there was no real decision to make’ (p.155) 
[142]. Other research on RGCT for breast cancer patients found negotiating the 
decision process more challenging [302]. In Augestad’s study, some women struggled 
with their decision, fearing the outcome of testing and the potential impact a mutation 
positive result could have on their children. However the ability of genetic testing to 
potentially prevent cancer for their children was also a priority; some women 
anticipated that the decision to have genetic testing would have been more difficult 
without this element.  
Certainly in this study, there was a selection bias of participants who were interested 
in and wanted to have genetic testing so it is not surprising that participants 
experienced decision-making to be straightforward. To some degree this certainty in 
decision-making was reflected in the quantitative component of Chapter 7. From the 
survey data, total scores on the Decisional Conflict Scale were low overall (median 
25.0), but did indicate there was perhaps greater struggle with the decision than 
participants recalled.   
There was quite a dichotomous response in terms of whether family members were 
involved in the decision-making process. For participants who made their decision 
independently, there was a protective element of not wanting to cause additional 
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concern for family members, especially children. Meiser et al also reported a similar 
pattern of decision-making, with only half of the women who had already undergone 
TFGT involving other family members (apart from their partner) in their decision [142].  
MTGT in this study took place following a mainstreamed model. As mentioned earlier, 
how much and how well oncologists impart information about tumour or germline 
testing is largely unknown. Although from a genetic counselling perspective (and my 
own bias) it may seem like there was insufficient time and information provided during 
the oncology consultation, perhaps what is more important is how patients perceived 
this interaction. Encouragingly, all participants who were interviewed felt that they had 
sufficient information and discussion with their oncologist to make the decision about 
genetic testing. In particular, participants did not want to be overloaded with 
information at what was already an overwhelming time. Reflecting this, participants 
did not seek additional information outside what was their own knowledge or provided 
by myself, their oncologist or the study documents. One participant noted how she 
relied on her existing knowledge about MGT to inform her current understanding of 
MGT:  
The other things, I suppose now that I'm thinking about it, now that you're 
asking me, I guess since I have got ovarian cancer I could perhaps have 
found out a lot more about the BRCA testing than what I did, which was 
nothing other than what I thought I already knew. [MGT022, TT, no 
mutation] 
This preference for brevity of information is shared by other ovarian cancer patients 
who have undergone or are offered genetic testing. A qualitative study of ovarian 
cancer patients regarding TFGT found that most women wanted to receive brief 
information verbally, with a slight preference to receive this from their medical 
oncologist [291]. Although women wanted to know about the familial implications of 
TFGT, they did not want detailed information unless they were identified as carrying 
a pathogenic mutation. Some women reported only needing information on treatment 
implications in order to make their testing decision. Advanced lung and melanoma 
cancer patients who had somatic testing to guide treatment wanted to receive verbal 
information preferably from their treating oncologist, with written information as a 
supplement [106]. Patients preferred less detail about genomic information, with a 
focus on practical and treatment-related issues.  
It is difficult to comment on how oncologists discussed and provided information about 
MGT, and in particular tumour testing, to their patients without having been privy to 
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these conversations. Although patients’ perceptions of having received enough 
information are encouraging, there are noticeable gaps in their understanding that 
indicate that communication could be improved. What was most striking is the lack of 
information participants received after their MGT results were disclosed. Recent 
research by Hallowell et al reported that oncologists felt confident discussing genetic 
testing with their breast cancer patients and they had sufficient experience and 
expertise to do so [311]. However other research on patients’ views of TFGT noted 
that in reality ‘…there is little discussion of familial implications, or treatment 
implications associated with a PV3 or VUS’ (p. 463), although patients were provided 
with written information [308]. Other research has reported that non-genetic health 
professionals may be ill-prepared to discuss and provide genetic testing to their 
patients [312]. As noted in one paper, ‘…non-geneticists’ unfamiliarity with specific 
requirements of genetic counselling may impair the quality of care for clients’ (p.231) 
[313]. In a scoping review of communication about genetic testing with breast and 
ovarian cancer patients Jacobs et al acknowledge that there are differences between 
oncology and genetics health professionals that could impact the information that is 
communicated to patients [314].  
A key distinction Middleton et al makes between the two specialties is the focus on 
the family by clinical genetics, while in oncology it is the individual [315]. Thus context 
may influence not only how information is delivered, but what content is disseminated. 
Although oncologists may lack specialised genetics knowledge, it is likely they share 
the goals, use similar language and communication style as clinical geneticists and 
genetic counsellors. Smets et al compared genetic counselling with non-genetic 
health care interactions and found both disciplines take a patient-centred approach, 
strive for shared decision-making and endorse an equal relationship between health 
professional and patient [313]. However, both face challenges to effectively address 
the patient’s agenda and enhancing patient understanding.   
Eleven participants who were interviewed had received results where no mutation 
was identified. Ten of these participants had tumour testing only, while one participant 
had also had follow-up germline testing because the MLPA portion of her tumour test 
had failed. Genetic misconceptions persisted throughout accounts of receiving 
results; most participants described feeling relieved at their results, as this had 
alleviated their concerns about potentially passing on a genetic mutation to their 
children. In a recent study of TFGT and mainstreamed testing, a sense of relief was 
                                               
3 PV = pathogenic variant  
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also described by breast and ovarian cancer patients, with negative testing results 
also providing reassurance to family members [292]. In contrast, in the context of 
tumour testing for somatic mutations ‘not having the gene’ is more likely to be 
experienced as disappointment because of the loss of hope associated with not being 
able to access new or different treatment options [316]. 
Receiving a no mutation identified result appeared to have little impact, possibly 
because there were no implications for family or change to clinical care. Therefore it 
was often promptly forgotten, as one participant said, ‘I've forgotten all about it, it’s 
done now, ticked off’ [MGT022, TT, no mutation]. However, because of the potential 
of genetic testing to expand the treatment options available, a few participants felt 
somewhat conflicted about their results. They were pleased that their MTGT results 
meant there were no implications to children and other family members, but there was 
also a sense of disappointment that that they would be unable to access PARP-
inhibitors.  
There have only been snippets of direct references to expanded treatment options 
attributed to MTGT throughout the interview, but this finding demonstrates there is 
some recognition that a different testing outcome could have led to different 
treatments. Rather than participants not realising the potential impact of MTGT on 
treatment options, perhaps their focus is more oriented towards what they perceive to 
be of more tangible importance, that is the prevention of cancer in their family.  
Some of the literature around BRCA1/2 genetic testing has reported on the adverse 
psychosocial impact of receiving mutation positive results, in particular increased 
anxiety and cancer worry [110, 123, 133]. Even in the previous chapter I found that 
participants who were identified as mutation carriers had significantly more genetic 
testing-specific concerns.  
Of the participants who were interviewed, four were found to carry a germline 
BRCA1/2 mutation while one participant was a RAD51C mutation carrier. At the time 
of interview participants appeared to be adjusting well to their results. Two described 
their results as being ‘expected’ because of a family history of cancer. None of the 
participants felt that their results came as a shock or a surprise, suggesting that they 
had prepared themselves to some degree that testing might identify a mutation.  
It was interesting to find during the interviews that overall, participants perceived their 
mutation positive result to be a positive outcome, primarily by providing some 
explanation as to why they had develop ovarian cancer. It also alleviated self-blame, 
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highlighting to participants that this was something unavoidable. For one participant 
receiving her result of a RAD51C mutation had an almost transformative effect. She 
had blamed her diagnosis of ovarian cancer on herself, attributing it to her stressful 
lifestyle and poor diet. Learning that there was a genetic basis to her disease was a 
relief because she no longer felt guilt, but it also gave her a renewed sense of 
optimism.  
The positive outcome of testing was less related to the impact on treatment, in fact 
the majority of participants could not perceive any direct benefit to themselves. As 
noted earlier in this chapter, only one participant had had a change to treatment based 
on her results (see vignette: Leanne). The clinical utility of carrying a mutation may 
become more evident for participants at a later date if they become eligible to access 
a PARP-inhibitor. The main advantage of mutation positive results was that it provided 
useful information for family members, with some relatives already choosing to have 
predictive testing to determine their own cancer risks.  
In general, participants did not perceive there to be any disadvantages of their 
mutation positive results. One participant briefly mentioned the guilt she felt at having 
passed on the mutation to her daughter: 
I feel guilty that I’ve got it. Because my daughter’s got it, I do feel a bit 
guilty about it, but I don't think there’s anything else. [MGT029, TT + GT, 
BRCA+ve] 
From these interviews it appeared that overall participants were coping well with their 
results. There was no sense of heightened anxiety or distress as a result of learning 
they carried a mutation and no other concerns were reported.  
In Shipman’s research, these results also provided an explanation for cancer but also 
created uncertainty about risk management for themselves and relatives [292]. 
Similar concerns were not raised by participants in this study, primarily because 
participants were uninformed about what their results meant and the possible 
implications.  
As we discussed MTGT results disclosure in the interviews it emerged that while for 
some participants communication had been sufficient, others were left feeling 
confused and unsure. From my own experiences in the clinic, the oncologists were 
usually unconcerned about results where no mutation had been identified and had a 
tendency to forget to disclose these results to patients. Participants’ own recollection 
of results disclosure included little opportunity to ask questions or clarify any 
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implications of the results. While participants were reassured by the result itself, they 
still would have preferred more opportunity for discussion. There also appeared to be 
poor communication when results had identified a germline mutation, with one 
participant asking me to clarify the implications of her results during our interview.  
Currently it is unclear whether oncologists did not have the information to provide to 
patients, or if they assumed that, in the case of mutation carriers, this would be 
discussed during their genetic counselling appointment. However as we have seen 
from the service evaluation in Chapter 5, there can be delays in referring patients to 
clinical genetics services which in turn have a long waitlist for appointments. In the 
meantime patients are left without sufficient knowledge. Interestingly none of the 
patients reported using other resources to try and understand their results, nor did 
they question their oncologist further.   
It was just a little bit odd, the way I was told the result, and I think if you’d 
been able to tell me the result it would have been more beneficial 
actually. [MGT022, TT, no mutation] 
Augestad et al proposed that cancer patients who have genetic testing outside the 
traditional face-to-face genetic counselling model may not have sufficient information 
or understanding prior to testing, which may increase vulnerability to stress [302]. 
Furthermore the authors comment that there are ethical challenges where testing is 
accepted without an awareness of the potential consequences. Although participants 
in this PhD research appeared to be poorly informed about the possible outcomes of 
testing and possible implications, for the majority of participants this did not seem to 
have a detrimental impact on their wellbeing. The fact that patients did not seek further 
explanation for their MTGT results suggests that in the context of managing ovarian 
cancer this was of less significance. However, Janet’s RAD51C VUS result and the 
uncertainty about its meaning did lead to anxiety which was not allayed until her 
genetic counselling appointment several months later.  
I agree with Augestad that a lack of clarity about what patients are consenting to and 
the possible outcomes is concerning. Despite the overall positive response to genetic 
testing and little psychosocial impact, as with any medical decision patients need to 
have information about the process, advantages and disadvantages and potential 
outcomes. The context in which MTGT took place was a ‘pro-testing’ environment 
where oncologists perceive there to be a real benefit from testing but patients need 
balanced information in order to make an informed decision, particularly as the opinion 
of their health professional has shown to impact testing choices [317].    
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I decided to include some of the experiences of the participants which were not shared 
across the group, so called ‘negative cases’, to highlight the diversity of MTGT 
experiences. These divergent cases emerged because of the specific genetic testing 
results that these participants received. One participant, Janet, had received a 
germline RAD51C VUS result while Leanne was the only participant with a somatic 
BRCA1/2 mutation who was interviewed. 
Both of these participants would have benefited from genetic counselling shortly after 
receiving their (final) testing results. In Janet’s case, VUS results are difficult to 
interpret even within the specialised genetics community; studies have shown 
oncologists struggle to interpret and communicate these results correctly and take 
appropriate action [318]. Compounding this situation was Janet’s sister had also been 
diagnosed with ovarian cancer and died from the disease several years earlier.  
I was only aware that Leanne had had repeat somatic testing when this was brought 
to my attention by her oncologist. I then happened to bump into Leanne the following 
week on her way to the Macmillan Cancer Centre and she agreed to meet me in the 
chemotherapy suite so I could find out a bit more about what had happened and invite 
her to take part in an interview. Leanne still had a poor understanding of what her 
somatic mutation meant and had only been told these results verbally. In the end I 
printed off all three genetic testing reports for her to read and briefly clarified that her 
final testing result showed an acquired, non-inherited mutation. In contrast to Janet, 
Leanne was relatively unconcerned about her genetic testing results, rather it was her 
experiences on the clinical trial that had had a significant impact.  
8.9 Limitations 
One limitation has already been raised earlier in the chapter in relation to the language 
I used to refer to genetic testing during the interviews and over the course of the study 
which may have contributed to participants’ genetic misconception.   
The retrospective nature of the interviews means that for some participants many 
months had passed since they had received their MTGT results which can affect recall 
as well as introduce bias. As some participants said themselves, MTGT was often 
forgotten about. By the time the interviews were undertaken I had known some of 
these participants for nearly one year. Although familiarity can be advantageous in 
interviews as the participant feels more comfortable and already has trust in the 
researcher, shared knowledge and experiences between myself and the participant 
may have resulted in less detail shared and less detail sought.   
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Although the participant interviews have revealed novel and interesting insights into 
the patient experience of MTGT there is a distinct lack of awareness of what and how 
oncologists discuss testing. Interviews or observations of clinical encounters between 
oncologists and their patients are needed to fill this gap in our knowledge.  
8.10 Summary 
Including participants’ experiences of ovarian cancer prior to MTGT was to 
understand the context in which BRCA1/2 testing was taking place for them. For many 
participants their experience of the diagnostic odyssey had been traumatic and the 
effects had lingered. The ovarian cancer trajectory of treatment, remission and 
eventual relapse was their primary concern; genetic testing was a brief interlude into 
this context.  
MTGT seemed to exacerbate existing concerns for family members, reflected in their 
motivations for testing, but was also perceived as a means of cancer prevention for 
unaffected relatives. Participants recounted their decision-making process for testing 
as easy and straightforward, and felt they had had sufficient information and 
discussion with their oncologist to reach their decision. However participants’ recall 
and discourse about tumour testing reflected genetic misconceptions, attributing 
features of germline testing and outcomes. Disclosure and discussion of testing 
results could also be improved.    
Although the intention of providing MTGT is to inform treatment options, this benefit 
of testing did not appear to be a priority and more value was placed on the perceived 
benefits of testing for unaffected family members. Participants who received no 
mutation results expressed relief because this alleviated concern about family 
members. Where a (germline) mutation had been identified, participants felt this was 
a positive outcome as it provided important information to unaffected relatives and 
assigned a cause to their ovarian cancer.   
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Chapter 9 Discussion and future plans  
 
9.1 Introduction 
We are witnessing rapid changes in the way genetic testing and genetic counselling 
is being delivered to cancer patients. Genetic testing is being used to inform surgical 
and chemotherapy decisions for breast cancer patients and to expand treatment 
options in ovarian cancer. Genetic testing is no longer only associated with testing for 
inherited predisposition genes, as we move to an era where acquired mutations can 
also play an important role in patient management. Genetic testing has also moved 
from the specialised domain of clinical genetics to become incorporated into 
mainstreamed medicine, facilitating the testing of more patients. Crucially, taking an 
oncology-led, mainstreamed approach to testing, removes the role of the genetic 
counsellor who has historically been responsible for information provision and 
psychosocial support.  
With targeted treatments such as olaparib now available for BRCA-mutated ovarian 
cancer there is an impetus to identify more patients who carry somatic or germline 
mutations. MTGT offers a way to provide more testing to eligible patients while 
reducing the burden on clinical genetics services. Using a case study approach, this 
thesis aimed to explore the introduction of mainstreamed BRCA1/2 tumour testing in 
ovarian cancer with a focus on the patient experience and clinical outcomes.  
To set the context of testing, Chapter 5 used a service evaluation to describe the 
current state of MGT in ovarian cancer at UCLH. Chapter 6 detailed the experience 
of implementing and providing BRCA1/2 tumour testing as well as reporting the 
clinical outcomes of testing. Chapter 7 and 8 used quantitative and qualitative 
methods, respectively, to explore the patient experience of MTGT. The key findings 
of each research question are addressed in the table below. This final chapter of the 
thesis draws together the key findings from each chapter to address the research 
questions posed in Chapter 4, for a holistic description of mainstreamed BRCA1/2 
tumour testing.  
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Table 9.1. Summary of key findings in relation to research questions  
 
Research question  Methodology Results Key findings  
How is MGT currently 
used in ovarian 
cancer? 
Service 
evaluation 
• No systematic method of recording offers and 
declines of MGT 
• Prevalence of germline BRCA1/2 mutations  
14.8%  
• Four BRCA1/2 carriers would not have met 
previous testing guidelines 
• 78.0% of patients with VUS not referred to clinical 
genetics 
• 33.0% of BRCA1/2 carriers accessed PARP-
inhibitors after receiving MGT results  
• The prevalence of germline BRCA1/2 
mutations is similar to published data 
• Depending on timing of testing in cancer 
pathway, MGT may not have an immediate 
impact on patient management  
• Non-referral to clinical genetics for patients with 
a VUS suggests oncologists are uncertain of 
clinical relevance  
•  
What are the clinical 
outcomes of BRCA1/2 
tumour testing?  
Provision of 
tumour testing, 
review of medical 
records 
• Average turnaround time from consent to results 
reported 55 days; 42 days for retrieval and review 
of tumour blocks 
• 7 germline mutations identified; 6 BRCA1/2 
mutations, 1 RAD51C mutation 
• 1 somatic mutation identified during MTGT; 2 
more identified on repeat tumour testing  
• 52.6% of sample required follow-up germline 
testing 
• 58.3% of germline/somatic mutation carriers 
accessed PARP-inhibitor post-MTGT 
• Challenges to developing an efficient tumour 
testing pathway related to delays in retrieval 
and review of archived tumour tissue 
• An ‘inconclusive’ result reported by Myriad was 
reclassified as pathogenic by a different genetic 
testing company reflecting the implications of 
different classification systems 
• The majority of patients had testing during first 
line treatment where MTGT may have less 
impact on clinical management  
• Given the number of patients who required 
follow-up germline testing, tumour and germline 
testing should be provided simultaneously 
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How do patients 
experience 
mainstreamed 
BRCA1/2 tumour 
testing? 
Quantitative 
survey, three 
timepoints 
• Distress and health related quality of life scores 
comparable to data of other cancer populations 
and general public  
• No significant change in distress or quality of life 
scores across timepoints 
• Most endorsed motivations for testing subscale 
related to prevention and medical care 
• At time of consent decisional conflict scores were 
low; post-MTGT decision regret scores were zero  
• Mutation carriers reported significantly more 
testing-related concerns than non-carriers 
• 8% incorrect recall of MTGT results 
• Participants appeared to have ambivalent 
attitudes towards genetic testing 
• Overall this group of participants had good 
physical and psychological functioning which 
may reflect a selection bias 
• Although decisional conflict scores were low 
overall, the range of scores indicated some 
participants had substantial uncertainty over 
their decision  
• Participants reported having had sufficient time, 
information and support to make decision about 
MTGT 
Qualitative 
interviews, post-
MGT  
• Experience of diagnosis traumatic 
• Genetics not believed to be cause of ovarian 
cancer 
• No concern about using tumour tissue for MTGT 
• Good recall of logistics and process of tumour 
testing, poor understanding of somatic vs 
germline mutations 
• Participants did not perceive much personal 
benefits from testing, rather for family members  
• Motivations for testing related to concern for 
family members 
• Poor understanding of MTGT results and 
implications  
• In the context of facing ovarian cancer, MTGT 
is a brief, transient experience 
• Participants felt the decision for MTGT was 
easy to make   
• Genetic misconceptions of tumour testing were 
common and impacted participants 
understanding and perceptions of MTGT 
• A lack of explanation about what their MTGT 
results meant participants were confused and 
uncertain about implications 
• Receiving no mutation results was associated 
with a sense of relief related to concerns for 
family; receiving mutation positive results 
provided explanation for why cancer had 
developed and alleviated self-blame  
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9.1.1 Research question 1: How is BRCA1/2 germline testing in ovarian cancer 
currently used in the gynaecological oncology department?  
There has been increasing recognition of the need to move towards a systematic or 
universal testing approach for women with ovarian cancer as using previous criteria 
such as family history and relying on referral from oncology to clinical genetics was 
no longer sufficient to identify all BRCA1/2 mutation carriers [12, 63, 75]. With olaparib 
now licensed for use within the UK and other PARP-inhibitors available via clinical 
trials or managed access programs, there is a potential therapeutic benefit to 
identifying ovarian cancer patients with a BRCA1/2 germline or somatic mutation. 
Across the UK, systematic genetic testing programs were implemented in Scotland in 
2012, at the Royal Marsden and across East Anglia in 2013 [73-75]. The 
gynaecological oncology department at UCLH soon followed, introducing BRCA1/2 
germline testing as a clinical service using an oncology-led model of MGT in 2015. 
Eligible patients would have a diagnosis of high grade non-mucinous ovarian cancer, 
unselected for age or family history. Over the first 12 months of MGT, 122 ovarian 
cancer patients underwent BRCA1/2 germline testing. The prevalence of BRCA1/2 
mutations was found to be 14.8% (18/122), similar to other reported prevalence rates 
both in the UK and internationally [12, 73, 75, 304].  
There had been a small impact on patient management with six of the 18 mutation 
carriers (33%) having been able to access a PARP-inhibitor treatment (typically 
olaparib) or clinical trial as a result of MGT. As the current eligibility criteria for olaparib 
requires patients to have completed a minimum of three lines of platinum-based 
chemotherapy, more patients are likely to become eligible for olaparib over time as 
they continue on their cancer pathway. 
Reviewing the referral patterns of patients who received germline mutation or VUS 
results from MGT revealed only 22% (2/9) patients had been referred to their local 
clinical genetics service. This may reflect some uncertainty about the clinical utility of 
VUS results in ovarian cancer and a lack of understanding of the potential for these 
results to be reclassified as benign or pathogenic. Once this pattern was recognised, 
recommendations from the local clinical genetics service were introduced to ensure 
referral of appropriate patients.  
By taking a mainstreamed approach, unrestricted by family history or age criteria, 
more ovarian cancer patients were able to access BRCA1/2 germline testing. After 
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family history was reviewed, four BRCA1/2 carriers would not have met previous 
testing guidelines and therefore been missed, demonstrating the importance of taking 
a more unselected approach to testing. The lack of a systematic record of MGT offers 
and those accepted or declined makes it difficult to ascertain the uptake rate of testing, 
or whether all eligible patients had been reached. Moving forward, the introduction of 
more rigorous record-keeping would help to ensure that eligible patients are offered 
MGT. Developing an in-house database may be a useful means of consistently 
recording MGT results which could be easily accessed by the oncology team.   
A service evaluation of the second year of MGT would reveal whether similar numbers 
of patients were tested. BRCA1/2 mutation prevalence rates could be compared 
between the first and second years of MGT, particularly as the first year prevalence 
is likely to be slightly inflated due to the retrospective nature in which testing was 
offered. A second service evaluation could also explore further the variation in number 
of tests ordered across clinicians by comparing clinic case load and patient 
characteristics.   
9.1.2 Research question 2: What are the clinical outcomes of mainstreamed 
BRCA1/2 tumour testing? 
With more data gathering about the prevalence of BRCA1/2 somatic mutations in 
ovarian cancer and the feasibility of using archived tumour tissue for testing, it is 
becoming increasing likely that tumour testing will be offered alongside germline 
testing. Understanding the processes involved in implementing a new genetic testing 
service following a mainstreamed model will provide useful insight for other centres 
which are looking to introduce a similar testing strategy.  
Despite specialist services and clinical expertise already existing at UCLH, such as 
the cellular pathology department and consultant pathologists, it was challenging to 
implement an efficient, streamlined tumour testing pathway. Retrieval of archived 
pathology material, reviewing and selecting relevant tumour blocks, cutting of new 
H&E slides all involved delays. For a busy and overstretched pathology service, 
tumour testing undertaken for research purposes was a low priority, despite the 
potential impact on patient management. If mainstreamed BRCA1/2 tumour testing is 
incorporated into the clinical service, sustainable processes would need to be in place 
to ensure that testing could be expedited.   
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A key learning point was that the physical amount of archival tumour tissue available 
can have an important impact on testing feasibility. Firstly, for some patients there 
was only a single tumour block from an omental biopsy, typically with only a small 
amount of tissue. The reluctance of clinicians to use the limited tumour tissue 
available was related to ensuring there would be tissue available for determining 
suitability for clinical trial participation, i.e. for additional tumour testing. Anecdotally, 
several participants expressed reluctance to undergo repeat biopsy if more tissue 
would be needed for testing, suggesting that there may be challenges to obtaining 
additional tumour tissue if required. Even patients with multiple tumour blocks may 
have insufficient tumour tissue for testing, particularly if the samples are from IDS 
where chemotherapy response may affect the quality of tissue and/or DNA. Thus the 
quantity and quality of tumour tissue may determine eligibility for BRCA1/2 tumour 
testing. Knowledge of the quantity of tumour tissue prior to consenting patients to 
testing could help to expedite the process.   
Outcomes from this cohort identified one germline RAD51C mutation (prevalence 
1.8%), seven germline BRCA1/2 mutations (prevalence 12.3%) and three somatic 
BRCA1/2 mutations (5.3%). Two of the three confirmed somatic mutations in this 
cohort were identified on repeat testing at a later date by a different genetic testing 
laboratory; one somatic mutation was identified in a patient where tumour testing had 
failed, and the other where Myriad had reported the result as inconclusive. Aside from 
the possible impact of IHT, tumour testing may not identify all somatic mutations in a 
patient cohort due to the use of different testing platforms and classification systems. 
Implementing a standardised tumour testing program across the UK would be a 
significant endeavour, particularly as there still remains variation in practice and 
access for germline testing [75].    
There was a small impact on patient management as a result of genetic testing; of the 
participants who were found to carry a germline or somatic mutation, 58.3% had been 
able to access a PARP-inhibitor after receiving results. As testing was mostly 
undertaken during first or second line treatment, it is likely more participants will 
become eligible for olaparib over time.  
In this PhD research tumour testing was provided as a first line genetic test, with 
follow-up germline testing when necessary. Capoluongo also recommended this 
strategy, suggesting that first-line tumour testing would lead to more focused germline 
testing [76]. However the perceived advantages of first-line tumour testing, such as 
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reducing the number of patients requiring germline testing and protective 
psychosocial impact (discussed further below), did not come to fruition. More than 
half of participants (30/57, 52.6%) went on to have second line germline testing, 19 
due to testing issues alone. The two stage testing format also extended the testing 
timeframe; from initial consent to tumour testing to receiving final germline testing 
results took more than five months in some cases.  
The experience of providing BRCA1/2 tumour testing and the outcomes of testing 
suggest that taking a concurrent approach to germline and tumour testing is likely to 
be a more time efficient means of delivering results. Logistics surrounding the process 
of tumour testing still need to be improved in order to deliver testing on a larger scale.  
9.1.3 Research question 3: How do patients experience mainstreamed BRCA1/2 
tumour testing? 
This is some of the first research to explore the patient experience of MTGT, and in 
particular BRCA1/2 tumour testing. The quantitative component focused on three key 
timepoints of the MTGT pathway: attitudes and knowledge prior to testing, decision 
making when consenting to testing, and the impact of testing after receiving results. 
The patient experience covered more general topics such as distress and health 
related quality of life as well as measures specific to genetic testing. Participants were 
interviewed for the qualitative component after they had received their MTGT results, 
reflecting back over their testing experiences. To address the third research question, 
this discussion draws together the quantitative and qualitative data. 
Context has been an important part of this research. For ovarian cancer patients who 
are offered MTGT, testing takes place physically within the oncology setting but also 
within their own experiences of diagnosis and treatment. As participants shared their 
narrative, it was evident that MTGT was a brief and relatively insignificant part of the 
long and challenging journey of being an ovarian cancer patient. Participants spoke 
in great detail about their diagnostic odyssey, recalling dates and names even if the 
events had passed years earlier. Overall MTGT seemed of little concern in the context 
of ovarian cancer.  
Over the course of participating, many participants transitioned through treatment, 
follow-up and eventual relapse. Despite negotiating the cancer pathway, participants 
were of good humour and spirit and generally well. This was reflected in the 
quantitative data, where health related quality of life scores were comparable to other 
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published data in a gynaecological cancer patient cohort but also the general 
population. General distress scores were also comparable to other published data of 
cancer patient cohorts. Neither distress nor quality of life scores changed significantly 
over the three key timepoints on the MTGT pathway. As noted earlier in this thesis, 
the good physical and psychological function of participants may reflect some 
selection bias.  
An important finding that emerged from the participant interviews, was the notion of 
genetic misconception, where patients incorrectly assumed a hereditary component 
to testing. Despite correctly recalling the process of tumour testing and what was 
involved, as well as being provided with verbal and written information about tumour 
testing throughout the study, participants’ discourse about genetic testing reflected 
concepts associated with germline testing. For example when describing their 
expectations of tumour testing, participants often cited their desire to provide 
information to family members, in particular female relatives. For participants, the 
word ‘genetics’ is synonymous with the attributes related to germline testing only, as 
notions of familiarity and inheritance were anchored to this term. It is challenging to 
unpick this finding – to some extent the limitations of this research where study 
documentation referred to ‘genetic testing’, rather than ‘tumour testing’ are likely to 
have influenced participants’ perceptions and understanding of the nature of genetic 
testing that was taking place. Furthermore more than half the sample of participants 
had in fact undergone germline testing as a follow-up after tumour testing, when 
notions of inheritance are correct and valid. Similar findings of misattribution of 
germline testing features to somatic testing have been reported [108, 309], indicating 
this is an important area for further research.  
Genetic misconceptions were also reflected in motivations for testing, with ‘family’ 
named as the primary reason for deciding to have testing. Although it did not emerge 
as the main driver for testing, throughout the interviews were references to potential 
treatment benefits based on testing outcomes. This was also reflected in the 
quantitative data, with the most endorsed subscale relating to prevention and medical 
care items, suggesting that participants were interested in how testing could benefit 
them directly. Free text responses from two mutation carriers also made reference to 
increased treatment options as a result of MGT. More clarity about the purpose of 
MTGT and how the outcomes have the potential to impact treatment is needed for 
ovarian cancer patients.  
  240 
From the quantitative data, participants appeared to have somewhat ambivalent 
attitudes to MTGT which may reflect poor understanding about the relative 
advantages and disadvantages of testing. To some degree this was also reflected in 
the interviews as participants did not perceive there to be any personal benefit from 
testing, but also did not mention any concerns from the testing process or outcomes. 
This identifies an area in the MTGT process which requires better information and 
communication so that participants are informed of all the risks and benefits prior to 
making their testing decision.  
Decision-making for MTGT appeared to be a straightforward process. Participants 
described it as an easy decision, and one which was made with little hesitation. 
Participants felt they had received enough information and opportunity for discussion 
to make their decision, perceiving that more information would have been 
overwhelming. Perceived ease of decision making was also reflected in the 
quantitative data, which was collected at the point at which participants consented to 
MGT. Overall it showed that decisional conflict was low with a median total score of 
25.0 (max 100). However the range of scores indicated that for some participants 
there was greater personal uncertainty about their choice which was not reflected in 
the interviews. Decision regret was measured at the final point of the MGT pathway 
after participants received their results. Participants reported little decision regret, with 
a median total score of 0. One participant with a somatic mutation was interviewed; 
the decision regret she expressed was related to taking part in the clinical trial, rather 
than regret about having had MTGT.    
For participants who learnt that they did not carry a mutation (somatic or germline), 
these results provided a sense of relief from the concern about the hereditary 
implications for children. As there was no impact on treatment or family MTGT was 
often forgotten, to the extent that two participants were initially unable to recall having 
had tumour testing. Participants who learned they carried a germline mutation felt that 
this was in fact a positive outcome, providing an explanation as to why they had 
developed cancer as well as providing vital information for relatives. Despite 
participants voicing few disadvantages about their mutation positive results, in the 
quantitative component measuring the impact of MGT using a validated scale found 
that participants with a mutation had significantly more testing related concerns 
compared to those without a genetic alteration. It is important to ensure these 
individuals have relevant support which may be best provided within the clinical 
genetics specialty, rather than oncology.  
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For some participants, their experiences with MTGT results disclosure had been 
unsatisfactory with little explanation provided. This is of particular concern for 
participants with a germline mutation or VUS result. Oncologists may be relying on 
the clinical genetics service to clarify the implications of testing. Due to long waiting 
lists there is often a delay between when the referral is made and the actual genetic 
counselling appointment, during which time they may be left in a state of uncertainty 
or have misperceptions about their results.  
Limitations in interpreting findings from the quantitative component due to the small 
sample size and the impact of language and wording of study documents must all be 
taken into consideration. However these findings suggest that MTGT does not have 
a significant psychosocial impact on patients. Patients and oncologists appear to have 
different agendas; oncologists are driven by the opportunity of expanding treatment 
options while participants’ priorities remain with preventing cancer in their families. A 
key area for future research is how to improve communication and patient 
comprehension of tumour testing and somatic mutations, particularly in the context of 
BRCA1/2 genes which are already associated with germline testing. Addressing 
genetic misconceptions will be a priority as Blanchette notes, ‘The distinction between 
somatic and germline mutations is fundamental’ (p.3070) [109].  
9.2 The future of genetic testing and counselling and PARP-inhibitors.  
An article published in 1997 highlights how much has changed over the last two 
decades in the provision of BRCA1/2 genetic counselling and testing [319]. 
Determining eligibility involved collecting, confirming and interpreting family history, 
considering ethnic background, deciding who to test and managing counselling issues 
that emerge from this information gathering process. Pre-test genetic counselling 
would discuss various topics including risks of having a mutation and possible results, 
cancer risks, benefits and risks of testing, logistics of testing and addressing any 
counselling issues that may have emerged during the appointment. These initial pre-
genetic counselling session took an average of two hours. In the results disclosure 
appointment, the genetic counsellor would disclose the result while preparing for any 
psychological reactions, review any implications of the results as well as coordinate 
any follow-up appointments or services such as breast screening.  
In order to meet the growing demand of genetic testing in ovarian cancer, this model 
of testing delivery is no longer feasible. Testing is increasingly being provided by other 
health professionals or without the traditional face-to-face format of genetic 
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counselling. There are some concerns with moving away from the expertise of clinical 
genetics. For example a survey of non-genetic specialist clinicians in the US who 
provide BRCA1/2 testing reported that while 57% spent up to 30 minutes counselling 
patients prior to testing and 61% discussed implications for family members, less than 
half discussed the psychological impact of testing and only 27% took a three 
generation pedigree [320]. The authors believed that inability to adhere to the current 
guidelines based practice could lead to harm for patients and their relatives due to 
incorrect test requests, misinterpretation of results and negative emotional impact. 
However other research has shown that testing without counselling can provide 
sufficient information [73, 284], does not cause undue psychological distress [144], 
and in fact patients may prefer this approach [283]. 
In taking an oncology-led mainstreamed approach to delivering tumour or germline 
testing, I believe the intention is not to attempt to replicate what is provided within a 
genetic counselling consultation. Instead it is about defining what information is crucial 
to making an informed choice in relation to testing and how this information can be 
delivered effectively to patients. Of importance will be the ability to identify patients 
who would either prefer or benefit from a referral to clinical genetics which has the 
advantage of more time and greater genetics-specific expertise.  
There are also important changes coming to the provision of genetic testing within the 
UK which will impact what testing is available for ovarian cancer patients and how it 
is delivered. The NHS Genomic Medicine Service was established as part of NHS 
England’s five year view to provide equitable access to genomic testing and 
technology, through a national genomic laboratory network and National Genomic 
Test Directory. The role of the Test Directory will be to ‘…specify which genomic tests 
are commissioned by the NHS in England, the technology by which they are available, 
and the patients who will be eligible to access to a test’ (p.3) [321]. In the latest draft 
Test Directory for cancer published in July 2018, BRCA1/2 genetic testing in ovarian 
cancer will be commissioned for confirmed cases of high grades serous disease. 
Importantly, both somatic and germline testing will be available for patients. At this 
stage it is unclear what delivery model will be used in order to support this testing. 
More centres may be adopting a similar mainstreamed model of testing for cancer 
patients while testing for unaffected relatives remains in the domain of clinical 
genetics services. However there is an argument that the rapid advances in both 
genetic testing and targeted therapies have vastly overtaken accompanying 
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psychosocial research [316], and more evidence is needed on the potential outcomes 
and impact of testing before it becomes standard of care.  
The findings from this thesis suggest that although using a mainstreamed oncology-
led model of BRCA1/2 tumour and germline testing is feasible and appeared to have 
little detrimental impact on patients, it is a process that could be improved. An 
alternative to the oncology-led model would be to embed a genetic counsellor within 
the gynaecological oncology team. In this role the counsellor would attend weekly 
multi-disciplinary and pre-clinical team meetings to identify patients eligible for genetic 
testing (which may extend beyond BRCA1/2, for example endometrial cancer patients 
where genetic testing for HNPCC may be indicated). During the outpatient clinic, the 
counsellor would be available to discuss testing with patients, take informed consent 
and organise tumour and/or germline testing. Importantly the genetic counsellor is 
available to provide support in the oncology setting as needed, without lengthy delays 
for an appointment externally at the local clinical genetics service. 
This approach was implemented at a central, tertiary hospital in Melbourne, Australia, 
where a genetic counsellor was embedded within the gynaecology oncology team 
[322]. Pre-test counselling was provided by a genetic counsellor during the patient’s 
chemotherapy treatment or immediately after an oncology appointment. Results 
delivery and post-test counselling were provided in person or by telephone. This 
model of service delivery was undertaken using previous testing guidelines rather 
than an unselected testing approach therefore there was a much smaller number of 
patients (n=64) tested over a two year period.  
Some adaptations may be necessary to meet the demand of unselected testing – for 
example patients could be offered the choice whether to have testing with genetic 
counselling, or directly via their oncologist. A study of breast cancer patients who 
could choose between in person genetic counselling and testing (DNA-intake) or 
receiving a testing kit at home (DNA-direct), found that 59% of patients preferred the 
‘direct’ method of testing [283]. Patients who opted for DNA-intake had more 
decisional conflict and higher heredity-specific distress. In a sample of advanced 
cancer patients who were offered genomic testing in cancer found 34% of wanted 
formal genetic counselling before consenting to testing [109]. These findings suggest 
that patients who feel they need further support when facing a genetic testing decision 
may self-select for the approach that offers the potential for more psychosocial care.   
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The advent of PARP-inhibitors and data reporting increased efficacy in BRCA-
mutated ovarian cancer has been the impetus for ensuring more patients have access 
to genetic testing [14]. At the time of writing, in the UK olaparib is licensed for use in 
ovarian cancer for women with a germline or somatic BRCA1/2 mutation after a 
minimum of three lines of platinum-based chemotherapy [191]. A request for 
extension to olaparib authorisation by the EMA means it may be licensed for use in 
the EU regardless of BRCA1/2 mutation status [97, 98]. Although this has yet to 
impact UK authorisation and licensing, it is important to consider the potential 
implications this may have for genetic testing. BRCA1/2 germline testing still provides 
important cancer risk information for unaffected relatives, regardless of whether it 
informs a patient’s treatment options or not. But will tumour testing still be relevant if 
it is not required for determining PARP-inhibitor eligibility?  
PARP-inhibitors are an area of rapid development, and olaparib is likely to be the first 
of many other targeted treatments to become part of standard clinical care for ovarian 
cancer patients. Genetic testing beyond BRCA1 and BRCA2 genes is also on the 
horizon, with three additional ovarian cancer susceptibility genes, BRIP1, RAD51C 
and RAD51D, already part of germline testing at UCLH. Although germline and 
somatic BRCA1/2 mutations are the most well-known mechanisms of HRD, up to 50% 
of high grade serous ovarian cancer cases will demonstrate HRD [323]. Ovarian 
cancers with germline or somatic mutations in other genes involved in the HR pathway 
have a similar phenotype to BRCA1/2 mutations, known as BRCAness [104]. 
Therapeutic approaches can now target HRD, broadening the potential use of PARP-
inhibitors beyond ovarian cancer patients with a BRCA1/2 mutation.  
With more targeted therapies comes the need to identify more patients who may be 
eligible for these novel treatments. As illustrated by the qualitative data, patients do 
not necessarily share the same agenda with oncologists in using genetic testing 
outcomes to expand treatment options. The potential clinical benefits of genetic 
testing for targeted therapies needs to be balanced against the potential psychosocial 
impact for patients. As Macfarland argues:   
…it is incumbent upon the oncology community to examine psychological 
and social implications of targeted therapy in order to provide an 
approach to patient-centered care with an eye toward improving quality. 
[316] 
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9.3 Conclusion 
To the best of my knowledge, this thesis presents some of the first research to 
examine the patient experience of mainstreamed BRCA1/2 tumour testing. In this 
study BRCA1/2 tumour testing in ovarian cancer was a feasible but time consuming 
process. Overall testing did not lead to poor psychosocial outcomes in patients and 
was perceived to be a positive experience. Providing tumour and germline testing 
concurrently is likely to be a more time efficient and streamlined process. Given the 
challenges associated with distinguishing somatic and germline mutations, a 
concurrent approach which consents patients to both testing methods may help to 
reduce genetic misconceptions. Other deficits in patient knowledge suggest the need 
for improved communication and information provision from oncologists. There may 
be scope for a genetic counselling role in a mainstreamed approach to delivering 
tumour testing.     
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PRISMA flow diagram for literature review 
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Appendix II 
Data extraction tables of literature review 
Table 1 Psychological impact of genetic counselling and/or testing in women with a personal history of cancer (affected): Qualitative studies 
Study, 
country 
Study design Sample Genetic 
testing 
Outcome 
measures 
Measurement 
timepoint(s) 
Findings 
Claes  
(2004), 
Belgium 
 
Retrospective  
Mixed 
methods  
62 affected 
24 BRCA+ve 
7 BRCA-ve 
36 inconclusive 
BRCA1/2 Evaluation of 
impact of genetic 
test results 
(interview, STAI, 
IES) 
Median time 
between interview 
and GT results 
disclosure 17 
months 
BRCA carriers: 5 upset (increased 
risk developing second cancer), 5 
afraid/ concerned (risk to offspring), 
8 acquiescent (expected) 
6 affected non-carriers: relief 
Hallowell  
(2002), UK 
 
Retrospective 
Semi-
structured 
interviews 
30 affected  
10 BRCA+ve 
12 inconclusive 
 8 awaiting 
results 
BRCA1/2 Experiences 
diagnostic testing 
1-9 years since 
blood draw for GT 
Majority reported no emotional 
difficulties during testing and while 
waiting for results 
‘Non-event’ when compared to 
cancer experiences 
Receiving BRCA+ve results: costs 
and benefits, anxiety about self 
(future cancer), anxiety about 
relatives, disclosure of information 
Receiving inconclusive results: relief, 
disappointment, acceptance, anger, 
disbelief  
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Hallowell  
(2004), UK 
 
Retrospective 
Semi-
structured 
interviews 
30 affected  
10 BRCA+ve 
12 inconclusive 
8 awaiting 
results 
HBOC Experiences 
genetic testing, 
accommodating 
risk 
GT results 
disclosure 
between 2 
months and 4 
years ago 
Majority took fatalistic approach for 
future cancer risks 
In small group GT led to negative 
impact of perceived future (fear and 
uncertainty) 
Overall GT not experienced as 
anxiety provoking or disturbing 
identity 
GT insignificant in the context of 
cancer experiences 
Kenen  
(2006), UK 
 
Retrospective  
Focus group 
13 affected  
All BRCA+ve 
HBOC Feelings and 
experiences of 
young affected 
BRCA carriers 
GT between 2 
months-10 years 
post-cancer 
diagnosis 
Several women felt re-traumatised 
after BRCA+ve results 
Effects of cancer worse than GT 
Implications of testing more long-
lasting 
Anxiety communicating ‘bad news’ 
results within family 
Some experience of relief (from guilt) 
and empowerment 
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Table 2. Psychological impact of genetic counselling and/or testing in women with a personal history of cancer (affected): Quantitative studies 
Study, 
country 
Study design Sample 
Genetic 
testing 
Outcome measures 
Measurement 
timepoint(s) 
Findings 
Bjornslett 
(2015), 
Norway 
 
 
 
 
Retrospective  354 ovarian 
cancer patients  
32 BRCA+ve 
Remaining non-
carriers 
BRCA1/2 Psychological distress 
(IES, HADS); genetic 
testing-related distress 
(MICRA) 
Mean time 
between 
questionnaires 
and GT results 
disclosure 31 
months 
14.4% of women had high MICRA score  
Carriers had significantly higher mean 
scores on MICRA compared to non-
carriers 
No significant differences between 
groups on HADS or IES 
Bonadona   
(2002), 
France 
 
Prospective 
Mixed methods 
 
23 breast, 
ovarian, 
colorectal or other 
cancer patients 
All mutation 
carriers 
BRCA1/2 
and MMR 
genes 
Personal feelings and 
reactions before and 
after disclosure of 
positive genetic test 
results; general distress 
(HADS) 
1 month post-GT 
results disclosure 
52% no major emotional changes 
35% distressed responses  
52% felt reassured 
91% reported no surprise at receiving 
mutation positive results 
Mean HADS score of 12 (range 2-20) 
 
Bredart 
(2013), 
France 
 
 
 
 
 
Prospective 
 
243 breast cancer 
patients 
11% BRCA+ve 
74% Inconclusive 
15% VUS 
BRCA1/2 General distress 
(HADS); cancer-related 
distress (IES) 
Baseline (at GC 
and blood draw) 
and 1 month post-
GT results 
disclosure 
Mean scores on HADS low to moderate 
24% and 31% of sample had clinically 
significant anxiety scores at genetic 
counselling and post-testing 
Pre-test anxiety predicted by being on 
treatment compared to remission  
No association between BRCA result and 
distress 
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Claes  
(2004), 
Belgium 
 
Retrospective 
Mixed methods 
Semi-structure 
interviews and 
questionnaires 
 
62 breast and/or 
ovarian cancer 
patients 
19 BRCA+ve 
7 BRCA-ve 
36 inconclusive 
BRCA1/2 Distress (STAI, IES) 
 
Median time 
between interview 
and GT results 
disclosure 17 
months 
No significant differences between 
carriers, non-carriers and inconclusive 
groups 
Scores on STAI comparable to 
population norms 
High levels of anxiety and/or depression 
found in 23% and 30% of patients 
 
Hughes 
Halbert 
(2004), 
Canada 
 
 
Retrospective 
 
130 breast and/or 
ovarian cancer 
patients   
25% BRCA+ve 
40% BRCA-ve 
35% AJ panel-ve 
BRCA1/2 Trait anxiety (STAI); 
perceptions of stress 
(newly developed 
measure) 
1 month post-GT 
results disclosure 
Long-term survivors reported greater 
perceptions of stress 
Current cancer treatment not significantly 
associated with perceptions of stress, 
interpersonal factors, individual 
differences  
BRCA+ve reported significantly more 
perceived stress related to GT concerns 
 
Wood  
(2000), 
USA 
Prospective  35 breast and/or 
ovarian cancer 
patients  
10 BRCA+tve 
1 BRCA-ve 
3 VUS 
 
BRCA1 Distress (IES); anxiety 
and depression 
(Hopkins Symptom 
Checklist-25);  
Baseline (pre-GC), 
post-GC and 
blood draw, and 1 
month post-GT 
results disclosure 
Significant decrease in anxiety between 
pre to post-test results – no differences 
between BRCA+ve or –ve 
BRCA+ve did not experience decrease in 
genetic testing specific distress 
Significant difference between women 
diagnosed <1 and those >1 year on 
cancer-related and genetic testing 
distress (but both decrease after GC/GT) 
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Qiu (2016) 
 
Retrospective  
 
 
 
67 breast cancer 
patients 
BRCA1/2 FACT-B (Chinese 
version); Irritability, 
Depression 
and Anxiety scale (IDA); 
qualitative interview 
10–13 months 
post-GT results 
disclosure 
No significant difference in the QOL or 
IDA scores between mx carriers and non-
carriers 
  253 
Table 3 Psychological impact of genetic counselling and/or testing comparing women with and without personal history of cancer (affected vs unaffected) 
Study, 
country 
Study 
design 
Sample Genetic 
testing 
Outcome 
measures 
Measurement 
timepoint(s) 
Findings 
Dagan 
(2004), Israel 
 
Retrospective  138 breast cancer 
138 unaffected 
15% affected 
BRCA+ve 
34% affected 
BRCA-ve 
13% unaffected 
BRCA+ve 
38% unaffected 
BRCA-ve 
 
BRCA1/2 
(AJ 
founder 
mutations 
only) 
Mutation carrier vs 
affected status; 
distress (BSI) 
3 months post-
GT results 
disclosure 
Mutation carrier and breast cancer history 
significantly affect psychological distress 
Having breast cancer and BRCA carrier status 
increases risk for psychological distress  
BRCA carriers without breast cancer reported 
highest levels of distress 
 
Bosch  
(2012), Spain 
 
Prospective  364 participants  
(57% affected) 
BRCA1/2 Psychological 
distress (HADS) 
3 months and 1 
year post-GT 
results 
disclosure 
Overall low distress 16% prior to and 14% 
post-testing scored above 10 on HADS 
Having a prior cancer diagnosis associated 
with clinically significant anxiety score on 
HADS at 3 and 12 months post-test results 
Genetic test result not associated with HADS 
scores  
 
Croyle 
(1997), USA 
 
Prospective  60 women  
(10 affected) 
25 BRCA+ve 
35 BRCA non-
carriers 
BRCA1 Psychological 
distress (STAI); 
test-related 
distress (IES) 
Baseline and 1-
2 weeks post-
GT results 
disclosure 
Post-testing, non-affected carriers showed 
greatest distress on IES 
Overall BRCA carriers showed more test-
related distress (IES) and general distress 
(STAI) post-testing than non-carriers 
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Ertmanski 
(2009), 
Poland 
 
Prospective  
 
111 BRCA+ve  
(50% affected) 
BRCA1 (3 
Polish 
founder 
mutations) 
Anxiety (STAI); 
distress (IES) 
Baseline, 1 
month and 1 
year post-GT 
results 
disclosure 
Anxiety stable between pre- and post-testing 
across both groups, decreases for affected at 
12 months  
Overall, anxiety does not increase amongst 
BRCA carriers 
No differences in anxiety between affected and 
unaffected women 
Affected women had significantly higher levels 
of cancer-related distress at 1 month compared 
to unaffected (attributed to personal cancer 
history)  
 
Graves 
(2012), USA 
 
Prospective 
 
464 participants  
76% affected 
31% BRCA+ve 
56.1% 
inconclusive 
12.9% BRCA –ve 
 
BRCA1/2 Distress (IES, 
STAI, MICRA) 
Median 5 years 
post-GT results 
disclosure 
Affected BRCA+ve significantly higher levels of 
GT distress compared to affected receiving 
inconclusive results  
Same results found for unaffected group 
Affected BRCA+ve reported significantly more 
uncertainty compared to receiving inconclusive 
results 
 
Hughes 
Halbert 
(2011), USA 
Retrospective 
  
167 participants 
 (60% affected) 
40% BRCA+ve 
60% BRCA non-
carriers 
 
BRCA1/2 Genetic testing 
specific concerns 
(MICRA) 
Mean 7.2 years 
post-GT results 
disclosure 
Non-significant association between distress 
and cancer history (unaffected more likely to 
experience distress) 
Mutation carriers were most likely to 
experience distress than non-carriers 
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Lumish 
(2017), USA 
 
Retrospective 232 participants 
(224 women) 
Affected+ve: 11 
Affected+VUS:14  
Affected-ve:104 
Unaffected+ve:14  
Unaffected+ VUS: 
20  
Unaffected-ve: 69  
BRCA1/2; 
Multisite 
panels: 
Small (5–6 
genes); 
medium 
(17–18 
genes); 
Large (25+ 
genes) 
Impact of Event 
Scale (IES); 
Multidimensional 
Impact of Cancer 
Risk Assessment 
(MICRA);  
Satisfaction with 
Decision 
Instrument (SWD);  
12 months 
following genetic 
testing. 
MICRA total scores greater in the 
Unaffected/mutation+ve group than in either of 
the mutation -ve groups or in the affected+VUS 
group 
No difference between groups for the MICRA 
uncertainty subscale 
Median IES total, avoidance, intrusion, and 
hyperarousal scores significantly higher in 
Unaffected/mutation+ve group than in any 
other groups 
 
Mella  
(2017), Italy 
 
Retrospective 91 women 
(88% affected) 
13% BRCA+ve 
87% BRCA-ve 
BRCA1/2 Anxiety and 
depression 
(HADS); Profile of 
Mood States 
(POMS) 
1 month post-
GT results 
disclosure 
HADS and POMS: No association emerged 
between being a carrier/non-carrier 
No difference in negative emotions or mood 
states between women who received mutation 
positive results and those with no mutation 
identified  
 
Reichelt 
(2004), 
Norway 
 
Prospective  244 unaffected (80 
BRCA+ve) 
43 affected   (39 
BRCA+ve) 
BRCA1 
(founder 
mutations) 
Anxiety and 
depression 
(HADS), distress 
(GHQ-28), 
hopelessness 
(BHS), cancer 
distress (IES) 
Baseline (pre-
testing), at and 6 
weeks post-GT 
results 
disclosure  
No differences between affected and 
unaffected from baseline to follow-up 
GT and affected status not associated with 
increased levels of distress in short-term 
Type of GT result did not influence distress 
Affected women had higher levels of cancer-
related distress 
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Reichelt 
(2008), 
Norway 
 
Prospective  
 
214 women  
(15% affected) 
83 BRCA+ve 
131 BRCA-ve 
BRCA1 
(founder 
mutations) 
Distress (HADS, 
IES) 
Baseline (pre-
testing) and 18 
months post-GT 
results 
disclosure 
 
Affected/unaffected status or BRCA carrier 
status did not predict distress 18 months-post 
testing 
Schwartz 
(2002), USA 
 
Prospective  279 women  
(186 affected) 
78 BRCA+ve  
58 BRCA-ve 
143 inconclusive 
BRCA1/2 Distress (IES, 
HSCL-25) 
6 months post-
GT results 
No adverse psychological outcomes for 
affected or unaffected women 
No differences between BRCA+ve and non-
carriers  
 
 
Tercyak 
(2001), USA 
 
Prospective  107 women  
38 affected, all 
BRCA+ve 
69 unaffected, 31 
BRCA+ve) 
BRCA1/2 State Anxiety 
(STAI) 
Baseline (prior 
to education 
session), at pre-
test education 
session, and 
post-GT results 
disclosure 
At pre-disclosure, unaffected women were 
more anxious 
At post-disclosure, BRCA+ve carriers were 
more anxious compared to non-carriers  
 
 
 
Van Dijk 
(2006), 
Netherlands 
 
Prospective  238 women 
42 BRCA+ve (48% 
affected) 
43 BRCA-ve (5% 
affected) 
153 inconclusive 
(54% affected) 
 
BRCA1/2 Breast-cancer 
worry; breast-
cancer distress 
(IES) 
Pre-test, post-
testing and 6 
months post-GT 
results 
disclosure 
Affected women with inconclusive results had 
significantly higher levels of breast cancer 
worry and distress compared to unaffected 
women 
No differences observed between affected and 
unaffected BRCA carriers at any timepoints 
Worry and distress levels in affected BRCA 
carriers comparable to affected women with 
inconclusive results   
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Van 
Roosmalen, 
(2004), 
Netherlands  
 
Prospective 
 
368 women 
baseline, at follow-
up 89 BRCA+ (23 
affected, 66 
unaffected) 
 
BRCA1/2 Depression (CES-
D); anxiety (STAI); 
cancer-related 
distress (IES) 
Baseline (post-
blood draw), 2 
weeks post-GT 
results 
disclosure 
Women with BRCA+ve results only included  
Affected women had significantly higher 
baseline scores on depression and cancer-
related distress 
No differences between affected and 
unaffected women across time on anxiety, 
depression and distress (all increased) 
At follow up affected women BRCA+ve 
diagnosed <1 year had higher anxiety and 
cancer-related distress 
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Table 4 Psychological impact of genetic counselling and/or testing at diagnosis 
Study, 
country 
Study design Sample 
Genetic 
testing 
Outcome 
measures 
Measurement 
timepoint(s) 
Findings 
Baars  
(2014), 
Netherlands 
Retrospective Breast cancer 
patients 
112 offered 
GC/GT during 
radiotherapy  
(3 no testing, 
11 BRCA+ve, 
7 VUS, 91 
inconclusive) 
127 usual care  
BRCA1/2 Distress (HADS), 
cancer distress 
(IES), cancer 
worries (CWS) 
Mean 10 years 
post-GT results 
disclosure 
Follow-up study to Schlich-Bakker (2008) 
Low levels of distress 
No significant differences between groups 
Cancer worries not predicted by GT results 
Overall no long term impact of GC/GT during 
breast cancer treatment  
Some patients from both groups experience 
high levels of depression and distress in long 
term  
Christie 
(2012), USA 
 
 
Prospective  
 
Breast cancer 
patients  
87 post-
surgery 
16 pre-surgery 
BRCA1/2 Cancer related 
distress (IES), 
decisional conflict 
(DCS) 
Before GC 
session, and 
2–3 weeks 
after pre-test 
GC  
GT results not available 
Significant decrease in cancer-related distress 
from pre- to post-GC for before definitive 
surgery group 
Non-significant trend for after definitive surgery 
group 
Hoberg-Vetti, 
(2016), 
Norway 
 
Prospective 215 breast or 
ovarian cancer 
patients 
26 BRCA+ve 
BRCA1/2 Distress (HADS) Baseline (GT 
offer), 1 week 
and 6 months 
post-GT results 
disclosure 
HADS scores significantly decreased from 
baseline to 6 months post-GT results 
disclosure 
No significant difference in distress scores 
between mutation carriers and non-carriers 
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Meiser (2012), 
Australia 
 
Retrospective 
(Qualitative) 
Ovarian 
cancer 
patients 
12 offered 
TFGT 
10 control  
BRCA1/2 Experiences and 
attitudes for TFGT  
Not specified Women receiving BRCA+ve result reactions of 
sadness (implications for relatives) and relief 
(more treatment options, cause of cancer 
explained) 
Inconclusive results is relief (no implications for 
relatives) and no disappointment for ineligibility 
for targeted treatments 
Meiser, 
Australia 
(2018) 
 
Prospective 128 breast 
cancer 
patients 
Strong FH 
n=74, no FH 
n=54 
18 BRCA mx 
(50% strong 
FH) 
 
BRCA1/2 Anxiety and 
depression: 
(HADS); Impact of 
Events Scale (IES) 
(breast cancer 
specific worry);  
test-related distress 
and positive 
experiences, 
Decisions Regret 
Scale (DRS) GT 
choice 
Baseline, 1 
week post-GC 
or educational 
materials, 2 
weeks post-GT 
results, 6 
months post-
recruitment 
DRS: When averaged across mx status, FH– 
women reported significantly greater decision 
regret regarding undergoing TFGT than FH+ 
women. For mx carriers, FH− women reported 
significantly higher regret scores than FH+ 
women (no difference in non-carriers) 
Test-related distress: Significantly higher in mx 
carriers compared to non-carriers when 
averaged across family history and time. In mx 
carriers, FH− women reported significantly 
higher test-related distress scores than FH+ 
women (no difference in non-carriers)  
Plaskocinska 
(2017), UK 
 
Prospective 232 ovarian 
cancer 
patients 
18 BRCA+ve 
BRCA1/2 Depression Anxiety 
and Stress Scale 
(DASS-21); Impact 
of Event Scale 
(IES) 
Post-results 
disclosure 
(exact 
timepoint not 
stated) 
Measures completed twice: once anchoring to 
OC diagnosis, and once to GT 
IES and DASS scores significantly lower on 
measures for GT compared to OC  
Younger OC patients significantly higher 
intrusion and stress scores 
BRCA mutation carriers had highest cognitive 
avoidance scores 
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Schlich-Bakker 
(2008), 
Netherlands 
 
Prospective  402 breast 
cancer 
patients: 
58 GT 
118 no referral 
44 decline 
182 control 
 
BRCA1/2 Distress (HADS, 
IES) 
Multiple 
timepoints 
GT results not reported 
No adverse effect from active approach for 
GC/GT during primary treatment for breast 
cancer 
No change over time up to 43 weeks post-
approach for GC 
Increase in distress in subgroup of affected 
women: high baseline levels distress, not 
referred for GC, decliners 
Wevers (2012), 
Netherlands 
 
Retrospective 26 breast 
cancer 
patients  
10 BRCA+ve 
BRCA1/2 Psychological 
impact (self-
developed scale); 
cancer-related 
distress (adapted 
Cancer Worry 
Scale, IES) 
Mean 29.2 
months 
between GT 
and 
questionnaire 
completion 
54% reported RGCT caused additional distress 
above cancer diagnosis, 19% reported RGCT 
reduced distress, 27% reported no effect  
23% of women had clinically relevant scores 
on IES; BRCA carriers significantly higher total 
IES scores compared to non-carriers 
Wevers 
(2016), 
Netherlands 
 
Prospective  Breast cancer 
patients 
178 offered 
RGCT 
87 control 
(usual care) 
 
BRCA1/2 Cancer-related 
distress (IES); 
psychological 
distress (HADS); 
cancer worries 
(CWS) 
Baseline, 6 and 
12 months 
follow-up 
Focus not on GT results 
No significant differences at short-term or long-
term follow up for cancer worries, cancer-
related distress, anxiety, depression between 
RCGT group and control  
Overall women had substantial distress at 
baseline which decreased over time (see 
supplementary data) 
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Appendix IV 
Description of the setting 
The gynaecological oncology outpatient clinic is on the first floor of the Macmillan 
Cancer Centre, on one end of the large open atrium. Rows of seats face the reception 
desk, with the consulting rooms hidden along corridors. There are wall mounted 
stands for TVs which sit empty. A tall rack holds a few old magazines.  
The clinic appointments start at 8.30 in the morning, but from 8.00 there will already 
be a few patients sitting in the waiting room even before the reception or clinical staff 
arrive to begin their shift. The waiting room is always too warm, even in the middle of 
winter. A large Dyson fan pushes warm air around the room. By 9.00 the waiting room 
will already be filling up with patients waiting for their appointments. The clinic still 
feels calm and quiet. Many of the patients have been coming to this clinic for years, 
and greet the reception team with a genuine warmth and friendliness.  
At some point during the clinic, the waiting room will be completely full of patients and 
their family members. Some patients choose to stand, leaning against the wall under 
the empty TV stands. Others pace at the back of the waiting room. Inevitably the clinic 
will run late, sometimes up to two or three hours behind schedule. Some patients are 
unflappable, and wait patiently with a book or a newspaper. Others are restless with 
anxiety and boredom, going back and forth to the reception desk desperate to know 
when they will be seen by the doctor. The nurses and health care assistants run 
between the waiting room and clinic room, weighing and measuring patients before 
their appointments. The clinical trials staff duck in and out of their room, trying to spot 
their trial participants in the crowd of patients. Now the clinic feels chaotic, and a sense 
of frustration fills the air as patience (from everyone) begins to run thin.  
Most patients look physically quite well, and despite the uncomfortable setting, able 
to navigate their blood tests and clinic appointments before heading home or on to 
the chemotherapy suite. At least one patient will be visibly very unwell, pale faced and 
breathing shallowly. There is such a lack of space for clinic rooms there is often 
nowhere else to go, and these patients remain seated in the waiting room, waiting 
their turn to be seen.  
Once I was introduced to a patient who was interested in taking part, we often 
continued our discussion about my research on the chemotherapy suite. This is a 
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much larger space than the outpatient clinic, an expansive room with rows of beds on 
one side and large recliner chairs on the other. In the middle of the room are more 
chairs and a large, communal table with puzzles, magazines and craft activities. 
Patients with all different cancer diagnoses have their treatments here. It is much 
quieter, and cooler up here; intermittently a patient’s name is called out across the 
room. Most chairs are occupied. Some patients are still waiting to start their treatment, 
cannulas already in place. Other patients have already started their chemotherapy 
infusions, IV drip stands holding bags of clear solutions. Many treatments span 
several hours and patients settle in to pass the time. Some come armed with reading 
material, kindles and iPads, while other patients sleepy from the ‘pre-meds’ (strong 
antihistamines), doze off.  
  
  269 
Appendix V 
Myriad Tumour BRACAnalysis CDx® technical specifications 
  
  270 
 
  
  271 
Appendix VI 
Myriad Tumour BRACAnalysis CDx information leaflet 
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INSTITUTE FOR WOMEN’S HEALTH 
 
 
 
 
 
 
Attitudes to genetic testing  
Questionnaire Booklet 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Participant ID number:        Date:              
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Thank you for taking the time to complete this questionnaire.  There are no right or 
wrong answers to these questions. The best responses to the questions are those 
that describe your situation.  
Please carefully read the instructions at the beginning of each section. The 
questions can be answered by placing a tick clearly in the box that is closest to your 
views. Do not worry if you make a mistake or want to change your answer; simply 
cross out your previous answer and put a tick in the correct box. 
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Date of birth: __ __ / __ __ / __ __ __ (DD/MM/YYYY) 
 
Which of these best describes your ethnic group?  
White Mixed Asian or Asian 
British 
Black or Black 
British 
Chinese/other 
 White British 
 White Irish 
 Any other 
white 
background 
 White and 
Black Caribbean 
 White and 
Black African 
 White and 
Asian 
 Any other 
Mixed 
background 
 Indian 
 Pakistani 
 Bangladeshi 
 Any other 
Asian 
background 
 Black 
Caribbean 
 Black African 
 Any other 
Black 
background 
 Chinese 
 Other 
Please tick the box which best describes your living arrangements:  
 Own outright  Own 
mortgage 
 Rent from 
Local Authority / 
Housing 
Association 
 Rent privately  Other 
What is your marital status?  
Single/never 
married 
 
Married/living 
with partner 
 
Separated             
 
Divorced 
 
Widowed 
 
Civil 
partnership 
 
What is the highest level of education qualification you have obtained?  
 Degree or higher 
degree 
 O Level or GSCE 
equivalent 
 No formal 
qualifications 
 Other 
 A-levels or higher  ONC/BTEC  Still studying  
What is your current employment status? 
 Employed full-time           Unemployed  Full-time homemaker        Still studying 
 Employed part-time         Self-
employed 
 Disabled/ too ill to work     Retired             
Do you have children? 
 Yes                 No                         If yes, how many children do you have? 
_____________________ 
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Please read each item and tick the box that comes closest to how you have been feeling 
in the past week. Don’t take too long over your replies – your immediate reaction to each 
item will be more accurate than a long thought out response. 
 
I feel tense or ‘wound up’: 
   
I feel as if I am slowed down: 
 
Most of the time    Nearly all of the time  
A lot of the time  Very often  
Time to time, occasionally  Sometimes  
Not at all  Not at all  
   
I still enjoy the things I used to 
enjoy: 
 I get a sort of frightened feeling 
like ‘butterflies in the stomach’: 
 
Definitely as much  Not at all  
Not quite so much  Occasionally  
Only a little  Quite often  
Not at all  Very often  
    
I get a sort of frightened feeling like 
something awful is about to happen: 
I have lost interest in my 
appearance: 
 
Very definitely and quite badly  Definitely  
Yes, but not too badly 
 I don’t take as much care as I 
should 
 
A little, but it doesn’t worry me  I may not take quite as much care  
Not at all  I take just as much care as ever  
    
I can laugh and see the funny 
side of things: 
 I fell restless as if I have to be on 
the move: 
 
As much as I always could  Very much indeed  
Not quite so much now  Quite a lot  
Definitely not so much now  Not very much  
Not at all  Not at all  
    
Worrying thoughts go through 
my mind: 
 I look forward with enjoyment to 
things: 
A great deal of the time  As much as I ever did  
A lot of the time  Rather less than I used to  
From time to time but not too often  Definitely less than I used to  
Only occasionally  Hardly at all  
    
I feel cheerful:  I get sudden feelings of panic:  
Not at all  Very often indeed  
Not often  Quite often  
Sometimes  Not very often  
Most of the time  Not at all  
    
I can sit at ease and feel relaxed:  I can enjoy a good book or radio 
or TV programme:  
 
Definitely  Often  
Usually  Sometimes  
Not often  Not often  
Not at all  Very seldom  
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Below is a list of statements that other people with your illness have said are important.  
Please circle or mark one number per line to indicate your response as it applies to the 
past 7 days. 
 
Not a 
lot 
A little 
Some 
what 
Quite a 
bit 
Very 
much 
I have a lack of energy      
I have pain       
I feel ill      
I have cramps in my stomach area      
I feel fatigued      
I am bothered by constipation      
I have swelling in my stomach area      
I have control of my bowels      
I am sleeping well      
I worry that my condition will get 
worse 
     
I have nausea      
I am bothered by hair loss       
I am bothered by side effects of 
treatment  
     
I have been vomiting      
I am bothered by skin problems      
I am able to get around by myself      
I am able to enjoy life      
I am content with the quality of my life 
right now 
     
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Genes are made up of DNA. Each with a specific function that helps our bodies grow and 
function normally. BRCA genetic testing is a blood test that uses DNA analysis to look for 
changes (mutations) in two different genes. These genes are called BRCA1 and BRCA2. 
People who have changes in these genes have an increased risk of cancer; in particular 
ovarian and breast cancer. Genetic testing usually takes place at a separate genetics 
clinic appointment with a genetics specialist. The statements below are about your 
attitudes towards BRCA genetic testing.     
 
Strongly 
agree 
Agree 
Neither 
Agree or 
Disagree 
Disagree 
Strongly 
disagree 
Genetic test results would help 
my oncologist manage my 
health care 
     
Having a BRCA mutation would 
encourage me to live a healthier 
lifestyle 
     
Having BRCA test results would 
help me prioritize my life 
     
Genetic test results would give 
me greater control over my 
health 
     
Being found to have a BRCA 
mutation could lead to problems 
with my health insurance 
     
Being found to have a BRCA 
mutation could lead to problems 
with my life insurance 
     
I am concerned about a false 
positive BRCA result 
     
I think my oncologist is 
unprepared to counsel me about 
undergoing BRCA testing 
     
I am concerned that if I have 
BRCA testing done my 
oncologist won’t know what to 
do with the information 
     
BRCA mutation could lead to 
problems with my job 
     
I am afraid of the genetic testing 
procedure 
     
I don’t want to know my BRCA 
test results 
     
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The following statements are about BRCA genetic testing. Please choose the best 
response for you: ‘True’ or ‘False’ or ‘Don’t know’  
 True False 
Don’t 
know 
A father can pass down an altered BRCA gene 
to his daughters 
   
A woman who doesn’t have an altered BRCA 
gene can still get cancer   
   
The BRCA gene causes about one half of all 
breast cancers  
   
There are many different genes that cause 
cancer  
   
About 1 in 10 women have an altered BRCA 
gene  
   
All women who have an altered BRCA gene 
will get cancer  
   
A woman who has a sister with an altered 
BRCA gene has a 50% chance of having an 
altered gene herself  
   
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Please think about whether or not you would have BRCA genetic testing if it was offered 
to you.   
 Definitely Probably Unsure 
Probably 
not 
Definitely 
not 
If you were offered BRCA 
genetic testing, would you 
choose to have this test? 
     
If BRCA genetic testing 
could be offered in the 
oncology clinic by your 
cancer clinician, would this 
change your decision?  
     
If you were offered a 
separate appointment with a 
genetics clinician to discuss 
genetic testing, would this 
change your decision? 
     
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You have reached the end of this questionnaire booklet. 
Thank you very much for completing this questionnaire! 
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INSTITUTE FOR WOMEN’S HEALTH 
 
 
 
 
 
 
Decision-making for mainstreamed genetic 
testing 
 
Questionnaire Booklet  
 
 
 
 
 
 
 
 
 
 
 
 
Participant ID number:        Date:  
 
            
 
 
290 
 
 
 
 
 
 
 
 
 
 
 
Thank you for taking the time to complete this questionnaire.  There are no right or 
wrong answers to these questions. The best responses to the questions are those 
that describe your situation.  
Please carefully read the instructions at the beginning of each section. The 
questions can be answered by placing a tick clearly in the box that is closest to your 
views. Do not worry if you make a mistake or want to change your answer; simply 
cross out your previous answer and put a tick in the correct box. 
  
 
 
291 
 
Please read each item and tick the box that comes closest to how you have been feeling 
in the past week. Don’t take too long over your replies – your immediate reaction to each 
item will be more accurate than a long thought out response. 
 
I feel tense or ‘wound up’: 
   
I feel as if I am slowed down: 
 
Most of the time    Nearly all of the time  
A lot of the time  Very often  
Time to time, occasionally  Sometimes  
Not at all  Not at all  
   
I still enjoy the things I used to 
enjoy: 
 I get a sort of frightened feeling 
like ‘butterflies in the stomach’: 
 
Definitely as much  Not at all  
Not quite so much  Occasionally  
Only a little  Quite often  
Not at all  Very often  
    
I get a sort of frightened feeling like 
something awful is about to happen: 
I have lost interest in my 
appearance: 
 
Very definitely and quite badly  Definitely  
Yes, but not too badly  I don’t take as much care as I 
should 
 
A little, but it doesn’t worry me  I may not take quite as much care  
Not at all  I take just as much care as ever  
    
I can laugh and see the funny 
side of things: 
 I fell restless as if I have to be on 
the move: 
 
As much as I always could  Very much indeed  
Not quite so much now  Quite a lot  
Definitely not so much now  Not very much  
Not at all  Not at all  
    
Worrying thoughts go through 
my mind: 
 I look forward with enjoyment to 
things: 
A great deal of the time  As much as I ever did  
A lot of the time  Rather less than I used to  
From time to time but not too often  Definitely less than I used to  
Only occasionally  Hardly at all  
    
I feel cheerful:  I get sudden feelings of panic:  
Not at all  Very often indeed  
Not often  Quite often  
Sometimes  Not very often  
Most of the time  Not at all  
    
I can sit at ease and feel relaxed:  I can enjoy a good book or radio 
or TV programme:  
 
Definitely  Often  
Usually  Sometimes  
Not often  Not often  
Not at all  Very seldom  
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Below is a list of statements that other people with your illness have said are important.  
Please circle or mark one number per line to indicate your response as it applies to the 
past 7 days. 
 
Not a 
lot 
A little 
Some 
what 
Quite a 
bit 
Very 
much 
I have a lack of energy      
I have pain       
I feel ill      
I have cramps in my stomach area      
I feel fatigued      
I am bothered by constipation      
I have swelling in my stomach area      
I have control of my bowels      
I am sleeping well      
I worry that my condition will get 
worse 
     
I have nausea      
I am bothered by hair loss       
I am bothered by side effects of 
treatment  
     
I have been vomiting      
I am bothered by skin problems      
I am able to get around by myself      
I am able to enjoy life      
I am content with the quality of my life 
right now 
     
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Genes are made up of DNA. Each with a specific function that helps our bodies grow and 
function normally. BRCA genetic testing is a blood test that uses DNA analysis to look for 
changes (mutations) in two different genes. These genes are called BRCA1 and BRCA2. 
People who have changes in these genes have an increased risk of cancer; in particular 
ovarian and breast cancer. Genetic testing usually takes place at a separate genetics 
clinic appointment with a genetics specialist. The statements below are about your 
attitudes towards BRCA genetic testing.     
 
Strongly 
agree 
Agree 
Neither 
Agree or 
Disagree 
Disagree 
Strongly 
disagree 
Genetic test results would help 
my oncologist manage my 
health care 
     
Having a BRCA mutation would 
encourage me to live a 
healthier lifestyle 
     
Having BRCA test results 
would help me prioritize my life 
     
Genetic test results would give 
me greater control over my 
health 
     
Being found to have a BRCA 
mutation could lead to 
problems with my health 
insurance 
     
Being found to have a BRCA 
mutation could lead to 
problems with my life insurance 
     
I am concerned about a false 
positive BRCA result 
     
I think my oncologist is 
unprepared to counsel me 
about undergoing BRCA testing 
     
I am concerned that if I have 
BRCA testing done my 
oncologist won’t know what to 
do with the information 
     
BRCA mutation could lead to 
problems with my job 
     
I am afraid of the genetic 
testing procedure 
     
I don’t want to know my BRCA 
test results 
     
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The following statements are about BRCA genetic testing. Please choose the best 
response for you: ‘True’ or ‘False’ or ‘Don’t know’  
 True False Don’t know 
A father can pass down an altered BRCA gene 
to his daughters 
   
A woman who doesn’t have an altered BRCA 
gene can still get cancer   
   
The BRCA gene causes about one half of all 
breast cancers  
   
There are many different genes that cause 
cancer  
   
About 1 in 10 women have an altered BRCA 
gene  
   
All women who have an altered BRCA gene 
will get cancer  
   
A woman who has a sister with an altered 
BRCA gene has a 50% chance of having an 
altered gene herself  
   
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Making the decision to have genetic testing. Please indicate how much you agree or 
disagree with each statement by ticking the box that best indicates your level of 
agreement.   
 
Strongly 
agree 
Agree 
Neither 
Agree or 
Disagree 
Disagree 
Strongly 
disagree 
Learning my results will 
allow me to plan better for 
the future 
     
I want to know my results so 
I can get appropriate 
medical care  
     
If I have an altered cancer 
gene, I want to know 
     
I want to learn my results, 
so I will know my 
child(ren)’s chances of 
getting cancer 
     
Learning my results will help 
my doctor and me make a 
plan for monitoring for signs 
of cancer 
     
Learning my results will help 
my doctor and me make 
decision about treatment 
     
Learning my results will help 
me live longer 
     
If I do not have an altered 
cancer gene, I want to know 
     
It is important for my partner 
that I am tested 
     
My partner does not want to 
know if I have an altered 
cancer gene 
     
My partner will be upset if I 
have genetic testing 
     
Having genetic testing is the 
responsible thing to do 
     
Knowing that I do have an 
altered cancer gene will 
help me live my life to the 
fullest 
     
Questions continue on the next page 
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Continued from previous page 
Making the decision to have genetic testing. Please indicate how much you agree or 
disagree with each statement by ticking the box that best indicates your level of 
agreement.   
 
Strongly 
agree 
Agree 
Neither 
Agree or 
Disagree 
Disagree 
Strongly 
disagree 
Learning my results will help 
my child(ren) make 
decisions about marriage 
and family 
     
Knowing that I do not have 
an altered cancer 
susceptibility gene will help 
me live my life to the fullest 
     
I do not know how I would 
cope with knowing that I 
have an altered cancer 
gene 
     
Learning my results will be 
upsetting to me 
     
Knowing my results will 
change how I feel about 
myself 
     
I will be fine emotionally 
regardless of what my 
results are 
     
It seems wrong to have this 
type of testing. Time will tell 
if I have an altered gene 
     
My doctor advised me to 
have genetic testing 
     
I want to help research on 
ovarian cancer and genetic 
testing 
     
Genetic testing might 
explain why I have cancer 
     
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Making the decision to have genetic testing. Please indicate how much you agree or 
disagree with each statement by ticking the box that best indicates your level of 
agreement.   
 
Strongly 
agree 
Agree 
Neither 
Agree or 
Disagree 
Disagree 
Strongly 
disagree 
I know which options are 
available for me 
     
I know the benefits of each 
option  
     
I know the risks and side 
effects of each option 
     
I am clear about which benefits 
matter most to me 
     
I am clear about which risks 
and side effects matter most 
     
I am clear about which is more 
important to me (the benefits 
or the risks and side effects) 
     
I have enough support from 
others to make a choice 
     
I am choosing without pressure 
from others 
     
I have enough advice to make 
a choice 
     
I am clear about the best 
choice for me 
     
I feel sure about what to 
choose 
     
This decision is easy for me to 
make 
     
I feel I have made an informed 
choice 
     
My decision shows what is 
important to me  
     
I expect to stick with my decision      
I am satisfied with my decision      
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You have reached the end of this questionnaire booklet. 
Thank you very much for completing this questionnaire! 
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Thank you for taking the time to complete this questionnaire. There are no right or 
wrong answers to these questions. The best responses to the questions are those 
that describe your situation.  
Please carefully read the instructions at the beginning of each section. The 
questions can be answered by placing a tick clearly in the box that is closest to your 
views. Do not worry if you make a mistake or want to change your answer; simply 
cross out your previous answer and put a tick in the correct box. 
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Please read each item and tick the box that comes closest to how you have been feeling 
in the past week. Don’t take too long over your replies – your immediate reaction to each 
item will be more accurate than a long thought out response. 
 
I feel tense or ‘wound up’: 
   
I feel as if I am slowed down: 
 
Most of the time    Nearly all of the time  
A lot of the time  Very often  
Time to time, occasionally  Sometimes  
Not at all  Not at all  
   
I still enjoy the things I used to 
enjoy: 
 I get a sort of frightened feeling 
like ‘butterflies in the stomach’: 
 
Definitely as much  Not at all  
Not quite so much  Occasionally  
Only a little  Quite often  
Not at all  Very often  
    
I get a sort of frightened feeling like 
something awful is about to happen: 
I have lost interest in my 
appearance: 
 
Very definitely and quite badly  Definitely  
Yes, but not too badly  I don’t take as much care as I 
should 
 
A little, but it doesn’t worry me  I may not take quite as much care  
Not at all  I take just as much care as ever  
    
I can laugh and see the funny 
side of things: 
 I feel restless as if I have to be on 
the move: 
 
As much as I always could  Very much indeed  
Not quite so much now  Quite a lot  
Definitely not so much now  Not very much  
Not at all  Not at all  
    
Worrying thoughts go through 
my mind: 
 I look forward with enjoyment to 
things: 
A great deal of the time  As much as I ever did  
A lot of the time  Rather less than I used to  
From time to time but not too often  Definitely less than I used to  
Only occasionally  Hardly at all  
    
I feel cheerful:  I get sudden feelings of panic:  
Not at all  Very often indeed  
Not often  Quite often  
Sometimes  Not very often  
Most of the time  Not at all  
    
I can sit at ease and feel relaxed:  I can enjoy a good book or radio 
or TV programme:  
 
Definitely  Often  
Usually  Sometimes  
Not often  Not often  
Not at all  Very seldom  
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Below is a list of statements that other people with your illness have said are important.  
For each statement, please tick the box to indicate your response as it applies to the past 
7 days. 
Physical well-being 
Not a 
lot 
A little 
Some 
what 
Quite a 
bit 
Very 
much 
I have a lack of energy      
I have nausea       
Because of my physical condition,    
I have trouble meeting the needs of 
my family 
     
I have pain      
I am bothered by side effects of 
treatment 
     
I feel ill      
I am forced to spend time in bed      
Social/family well-being 
Not a 
lot 
A little 
Some 
what 
Quite a 
bit 
Very 
much 
I feel close to my friends      
I get emotional support from my 
family 
     
I get support from my friends      
My family has accepted my illness       
I am satisfied with family 
communication about my illness  
     
I feel close to my partner (or the   
person who is my main support) 
     
Regardless of your current level of sexual activity, please answer the following question. If 
you prefer not to answer it please mark this box       and go on to the next section 
I am satisfied with my sex life      
 
Continued on next page  
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Continued from previous page 
For each statement, please tick the box to indicate your response as it applies to the past 
7 days. 
Emotional well-being 
Not a 
lot 
A little 
Some 
what 
Quite a 
bit 
Very 
much 
I feel sad      
I am satisfied with how I am coping 
with my illness  
     
I am losing hope in the fight against 
my illness 
     
I feel nervous      
I worry about dying      
I worry that my condition will get 
worse 
     
Functional well-being 
Not a 
lot 
A little 
Some 
what 
Quite a 
bit 
Very 
much 
I am able to work (include work at 
home) 
     
My work (include work at home) is 
fulfilling 
     
I am able to enjoy life      
I have accepted my illness       
I am sleeping well       
I am enjoying the things I usually do     
for fun 
     
I am content with the quality of my life 
right now 
     
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Below is a list of symptoms that other people with your illness have said are important.  
For each symptom, please tick the box to indicate your response as it applies to the past 
7 days. 
 
Not a 
lot 
A little 
Some 
what 
Quite a 
bit 
Very 
much 
I have a lack of energy      
I have pain       
I feel ill      
I have cramps in my stomach area      
I feel fatigued      
I am bothered by constipation      
I have swelling in my stomach area      
I have control of my bowels      
I am sleeping well      
I worry that my condition will get 
worse 
     
I have nausea      
I am bothered by hair loss       
I am bothered by side effects of 
treatment  
     
I have been vomiting      
I am bothered by skin problems      
I am able to get around by myself      
I am able to enjoy life      
I am content with the quality of my life 
right now 
     
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The statements below are some specific responses you may have had after receiving 
your BRCA genetic test results. Please answer Sections 1 and 3, regardless of whether 
you received a positive (BRCA gene alteration) or negative (no BRCA gene alteration) 
result. Please indicate whether you have experienced each statement never, rarely, 
sometimes, or often in the past week, by ticking the corresponding box.  
Section 1.     
 Never Rarely Sometimes Often 
Feeling upset about my genetic test 
results 
    
Feeling sad about my genetic test results     
Feeling anxious or nervous about my 
genetic test results 
    
Feeling guilty about my genetic test 
results 
    
Feeling relieved about my genetic test 
results 
    
Feeling happy about my genetic test 
results 
    
Feeling a loss of control     
Having problems enjoying life because of 
my genetic test results 
    
Worrying about my risk of getting cancer 
again  
    
Being uncertain about what my genetic 
test results means about my cancer risk 
    
Being uncertain about what my genetic 
test results mean from my child(ren) 
and/or my family’s cancer risk 
    
Thinking about my genetic test results 
has affected my work or family life 
    
Feeling concerned about how my genetic 
test results will affect my insurance 
status  
    
Having difficulty talking about my genetic 
test results with family members 
    
Section 1 continues next page 
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Please indicate whether you have experienced each statement never, rarely, sometimes, 
or often in the past week, by ticking the corresponding box. 
Section 1. continued     
 Never Rarely Sometimes Often 
Feeling that my family has been 
supportive during the genetic testing 
process  
    
Feeling satisfied with family 
communication about my genetic test 
result 
    
Worrying that the genetic testing process 
has brought conflict within my family 
    
Feeling regret about getting my genetic 
test results 
    
Section 2. If you have children, regardless of your genetic test results, please answer the 
next two questions. Otherwise please go to Section 3. 
Worrying about the possibility of my 
child(ren) getting cancer 
    
Feeling guilty about possibly passing on 
the disease risk to my child(ren) 
    
Section 3.  
Feeling that the genetic test results have 
made it harder to cope with my cancer 
    
Feeling that the genetic test results have 
made it easier to cope with my cancer 
    
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Please think about the decision you made about BRCA genetic testing (e.g. if you 
chose to have genetic testing, or chose not to). Please indicate how much you agree or 
disagree with each statement by ticking the box that best indicates your level of 
agreement.   
 
Strongly 
agree 
Agree 
Neither 
agree or 
disagree 
Disagree 
Strongly 
disagree 
It was the right decision      
I regret the choice that was 
made  
     
I would go for the same 
choice if I had to do it over 
again 
     
The choice did me a lot of 
harm 
     
The decision was a wise 
one 
     
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Please think about your experiences of BRCA genetic testing. Please indicate how 
much you agree or disagree with each statement by ticking the box that best indicates 
your level of agreement.  
 
Strongly 
agree 
Agree 
Neither 
agree or 
disagree 
Disagree 
Strongly 
disagree 
Did you have enough time 
to make the decision about 
genetic testing? 
     
Did you have enough 
information to make the 
decision about genetic 
testing? 
     
Did you have enough 
support about your genetic 
testing decision? 
     
My genetic testing result 
had a significant impact on 
my medical treatment 
     
I am satisfied with my 
experience of genetic 
testing 
     
I plan to share my genetic 
test results with my family 
members 
     
 
My genetic test results (if unsure, please write ‘don’t know’): 
 
 
Any other comments:  
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You have reached the end of this questionnaire booklet. 
Thank you very much for completing this questionnaire! 
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Appendix VIII 
Interview schedule 
Ovarian cancer illness  
 Can you tell me how you were first diagnosed with ovarian cancer? 
 What have your experiences been since you were diagnosed?  
 What do you believe was the cause of your ovarian cancer? 
 How did you feel about your illness before this genetic testing process started? 
Genetic testing – self  
Recall 
- Can you tell me how you came to be offered genetic testing? 
- When genetic testing was first mentioned to you? 
- Who first mentioned it to you? 
- And can you remember what they [from prev. question] said about genetic testing?  
- What were your first thoughts about genetic testing? 
- Did you have any initial fears or doubts about genetic testing?  
Knowledge/understanding genetic testing 
- Had you heard about genetic testing before it was mentioned by 
[oncologist/registrar/HP]? 
- If yes, what did you know/understand about it? 
- What did you understand about genetic testing after your doctor first discussed it with 
you?  
- What were your expectations of genetic testing? 
- What were your hopes for genetic testing? 
- What did you expect your results from genetic testing to be? 
Tumour testing 
- You were offered tumour testing as part of research. Could you tell me in your own 
words what this involved? 
- What did you first understand about this approach/method of genetic testing?  
- What do you understand about it now? 
- How did you feel about taking part in research? 
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Decision making 
- Did you have enough information and discussion with your oncologist to make a 
decision about genetic testing?  
- What were your reasons for deciding to have genetic testing? 
- For you, what was the most important reason for having genetic testing? 
- What, in anything, influenced your decision to have genetic testing?  
- Was the decision to have genetic testing an easy one to make? 
Genetic testing outcomes 
Self – fact  
- What were your results of tumour testing? 
- How were your results given to you? 
- Did you receive any explanation about your results? 
- What has happened since you received your tumour test results? 
- Has there been any change to your treatment or treatment plans because of your 
results? 
Self – feeling 
While you were taking part in this study about tumour testing, you completed several 
questionnaires that looked at how you were feeling at different stages of the testing process, 
i.e. before testing, during testing and after you received your results.  
- Could you tell me how you felt at the first part, before you signed the consent form for 
genetic testing? 
- How did you feel while you were waiting to receive your results? 
- How did you feel after you received your results? 
- What was good about your experiences of genetic testing? 
- What was bad about your experiences of genetic testing? 
- At any point during the genetic process did you feel upset?  
- If there is anything you could change about your experience of tumour testing, what 
would it be? 
[Choose next questions based on genetic testing results] 
Tumour testing mutation negative 
- When your oncologist told you the results from tumour testing, that they were negative 
and so you don’t have a genetic mutation, how did you feel at the time? 
- How do you feel now?  
- For you, what are the positives of not having a genetic mutation? 
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- Are there any negatives of not having a genetic mutation?  
- What impact did your results have on how you feel about yourself? 
- What impact did your results have on how you feel about your illness? 
Tumour testing mutation positive 
- When your oncologist told you the results from tumour testing, that they found a 
genetic mutation but only in your tumour tissue, how did you feel at the time? 
- How do you feel now?  
- For you, what are the positives of having a genetic mutation only in your tumour 
tissue? 
- Are there any negatives of having a genetic mutation in tumour?  
- What impact did your results have on how you feel about yourself? 
- What impact did your results have on how you feel about your illness? 
Germline mutation positive 
- When your oncologist told you the results from tumour testing, that they had found a 
genetic mutation on tumour testing and in the blood test, how did you feel at the time? 
- How do you feel now?  
- For you, are there positives of having a genetic mutation? 
- Are there any negatives of having a genetic mutation?  
- What impact did your results have on how you feel about yourself? 
- What impact did your results have on how you feel about your illness? 
Family 
- What role did your family have (if any) in making the decision about genetic testing? 
- What was your family’s thoughts/feelings/expectations of genetic testing? 
- Did they have any fears or doubts about genetic testing? 
- What expectations did you have for genetic testing in terms of your children? 
- What expectations did you have for genetic testing in terms of your siblings/other 
family members? 
- Have you discussed your genetic testing results with your partner/children/siblings? 
- [If yes] What was their response? 
- How do you think they felt? 
- [If no] Could you tell me why? 
- Has your decision to have genetic testing, or your results of genetic testing, had any 
impact on your family relationships? 
Future of genetic testing and ovarian cancer 
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- Currently, tumour testing is not available to all women with ovarian cancer. Do you 
think it should be part of standard care? 
- What information would women need to have before making a decision whether or 
not to have genetic testing? 
- If we were introducing tumour testing for every woman with ovarian cancer, what 
would be important for us to know? 
Ovarian cancer illness  
- When we started this interview, I asked you about what you felt was the cause of your 
cancer, and how you felt about your illness. 
- Has genetic testing changed how you feel about your illness?  
- Has it changed your beliefs about the cause of ovarian cancer or why you developed 
ovarian cancer? 
Close  
- Is there anything else you’d like to tell me about your experiences of genetic testing?  
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